{"a7f51e6c3258dda74eb7c6cdbc71b9573e3c1dfc": [["SARS Geriatric Nursing Volume 24 Number 5There has recently been an outbreak of severe acute respiratory syndrome (SARS) worldwide, with China and Hong Kong being the worst affected.", [["SARS", "DISEASE", 0, 4], ["acute respiratory syndrome", "DISEASE", 87, 113], ["SARS", "DISEASE", 115, 119], ["severe acute respiratory syndrome", "PROBLEM", 80, 113], ["outbreak", "OBSERVATION_MODIFIER", 68, 76], ["severe", "OBSERVATION_MODIFIER", 80, 86], ["acute", "OBSERVATION_MODIFIER", 87, 92], ["respiratory syndrome", "OBSERVATION", 93, 113]]], ["The World Health Organization issued a global alert about the outbreak of SARS and instituted worldwide surveillance on March 13, 2003.", [["SARS", "DISEASE", 74, 78], ["SARS", "PROBLEM", 74, 78]]], ["1 SARS is an acute respiratory infection that is caused by a new member of the coronavirus family.", [["respiratory", "ANATOMY", 19, 30], ["SARS", "DISEASE", 2, 6], ["respiratory infection", "DISEASE", 19, 40], ["coronavirus", "ORGANISM", 79, 90], ["coronavirus family", "PROTEIN", 79, 97], ["coronavirus", "SPECIES", 79, 90], ["an acute respiratory infection", "PROBLEM", 10, 40], ["acute", "OBSERVATION_MODIFIER", 13, 18], ["respiratory", "ANATOMY", 19, 30], ["infection", "OBSERVATION", 31, 40]]], ["The main symptoms include fever of 38\u00b0C, malaise, chills, headache, and muscle pain.", [["muscle", "ANATOMY", 72, 78], ["fever", "DISEASE", 26, 31], ["38\u00b0C", "DISEASE", 35, 39], ["chills", "DISEASE", 50, 56], ["headache", "DISEASE", 58, 66], ["muscle pain", "DISEASE", 72, 83], ["muscle", "ORGAN", 72, 78], ["The main symptoms", "PROBLEM", 0, 17], ["fever", "PROBLEM", 26, 31], ["malaise", "PROBLEM", 41, 48], ["chills", "PROBLEM", 50, 56], ["headache", "PROBLEM", 58, 66], ["muscle pain", "PROBLEM", 72, 83], ["main", "OBSERVATION_MODIFIER", 4, 8], ["fever", "OBSERVATION", 26, 31], ["chills", "OBSERVATION", 50, 56], ["muscle", "ANATOMY", 72, 78], ["pain", "OBSERVATION", 79, 83]]], ["Chest X-rays show changes compatible with pneumonia.", [["pneumonia", "DISEASE", 42, 51], ["Chest X-rays", "TEST", 0, 12], ["pneumonia", "PROBLEM", 42, 51], ["compatible with", "UNCERTAINTY", 26, 41], ["pneumonia", "OBSERVATION", 42, 51]]], ["Other symptoms include coughing, diarrhea, and shortness of breath or difficulty in breathing.", [["coughing", "DISEASE", 23, 31], ["diarrhea", "DISEASE", 33, 41], ["shortness of breath", "DISEASE", 47, 66], ["Other symptoms", "PROBLEM", 0, 14], ["coughing", "PROBLEM", 23, 31], ["diarrhea", "PROBLEM", 33, 41], ["shortness of breath", "PROBLEM", 47, 66], ["difficulty in breathing", "PROBLEM", 70, 93], ["coughing", "OBSERVATION", 23, 31]]], ["2 There were 1750 reported SARS cases in Hong Kong at the time of this writing (June 7, 2003) .", [["SARS", "DISEASE", 27, 31]]], ["The total number of fatal cases to date is 286.", [["total", "OBSERVATION_MODIFIER", 4, 9]]], ["3 Figure 1 shows the age-gender specific incidence of SARS.", [["SARS", "DISEASE", 54, 58], ["SARS", "PROBLEM", 54, 58], ["SARS", "OBSERVATION", 54, 58]]], ["While SARS is by no means a disease of the elderly alone, a large number of cases are in the elderly, and men 75 or older show the highest incidence rate (10%).", [["SARS", "DISEASE", 6, 10], ["men", "ORGANISM", 106, 109], ["men", "SPECIES", 106, 109], ["large", "OBSERVATION_MODIFIER", 60, 65]]], ["3 Furthermore, the patient's age was strongly associated with SARS-related mortality, regardless of the time between onset of symptoms and admission to hospital.", [["SARS", "DISEASE", 62, 66], ["patient", "ORGANISM", 19, 26], ["patient", "SPECIES", 19, 26], ["SARS", "PROBLEM", 62, 66], ["symptoms", "PROBLEM", 126, 134]]], ["4 SARS is lethal for the elderly.", [["SARS", "DISEASE", 2, 6]]], ["Mortality for patients younger than 60 stands at 6.8%, but this increases dramatically to 55% for patients more than 60.", [["patients", "ORGANISM", 14, 22], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 14, 22], ["patients", "SPECIES", 98, 106]]], ["4 There are about 50,000 elderly persons living in 741 nursing homes in Hong Kong.", [["persons", "ORGANISM", 33, 40], ["persons", "SPECIES", 33, 40]]], ["5 In 54 of these nursing homes (7.2%) a resident has contracted SARS.", [["SARS", "DISEASE", 64, 68], ["contracted SARS", "PROBLEM", 53, 68]]], ["In addition, 11 staff members working in nursing homes have contracted SARS; two have died.", [["SARS", "DISEASE", 71, 75]]], ["5 With this in mind, the overall objective of this study was to explore the knowledge and understanding of SARS in the elderly and to elicit the prevention and precautionary measures taken by the elderly and by nursing homes to keep the disease under control and lessen the death toll of the elderly in particular.METHODSThis was a descriptive qualitative study.", [["SARS", "DISEASE", 107, 111], ["death", "DISEASE", 274, 279], ["this study", "TEST", 46, 56], ["precautionary measures", "TREATMENT", 160, 182], ["the disease under control", "PROBLEM", 233, 258], ["a descriptive qualitative study", "TEST", 330, 361]]], ["After gaining approval from the ethics committee of the university, residents and staff in a local nursing home were approached and invited to participate in the study.", [["the study", "TEST", 158, 167]]], ["Verbal consent was SARS evere acute respiratory syndrome (SARS) has affected many areas of the world recently and is becoming a global problem.", [["evere acute respiratory syndrome", "DISEASE", 24, 56], ["SARS", "DISEASE", 58, 62], ["SARS", "PROBLEM", 19, 23], ["acute respiratory syndrome", "PROBLEM", 30, 56], ["a global problem", "PROBLEM", 126, 142], ["acute", "OBSERVATION_MODIFIER", 30, 35], ["respiratory syndrome", "OBSERVATION", 36, 56], ["global", "OBSERVATION_MODIFIER", 128, 134], ["problem", "OBSERVATION", 135, 142]]], ["Hong Kong and China have been most severely affected by this new infectious disease.", [["infectious disease", "DISEASE", 65, 83], ["this new infectious disease", "PROBLEM", 56, 83], ["new", "OBSERVATION_MODIFIER", 61, 64], ["infectious", "OBSERVATION", 65, 75]]], ["The elderly population is highly vulnerable, and mortality in those older than 65 years is more than 50%.", [["highly", "OBSERVATION_MODIFIER", 26, 32], ["vulnerable", "OBSERVATION_MODIFIER", 33, 43]]], ["In our study, 27 health care workers and 40 elderly residents in a nursing home were interviewed to investigate their level of knowledge of SARS and its prevention.", [["SARS", "DISEASE", 140, 144], ["SARS", "PROBLEM", 140, 144]]], ["Most of the elderly residents knew little regarding SARS and prevention strategies, despite access to outside news by TV, radio, and visitors.", [["SARS", "DISEASE", 52, 56]]], ["Also, the worry and fear of an outbreak of SARS among staff working in the nursing home was considered to be high.", [["SARS", "DISEASE", 43, 47]]], ["Tailored education programs to promote awareness and prevention of SARS for the elderly are needed.", [["SARS", "DISEASE", 67, 71], ["Tailored education programs", "TREATMENT", 0, 27], ["SARS", "PROBLEM", 67, 71]]], ["Also, more in-service training, support, and counseling are strongly indicated for staff to promote disease prevention and improve quality of care.", [["disease prevention", "TREATMENT", 100, 118]]], ["(Geriatr Nurs 2003;24:266-9) obtained from all participants.", [["participants", "SPECIES", 47, 59]]], ["Inclusion criteria for the residents included being 60 or older, having resided in the nursing home for at least 3 months, and being cognitively intact based on Abbreviated Mental Test (Modified score of = 8).", [["Abbreviated Mental Test", "TEST", 161, 184], ["Modified score", "TEST", 186, 200]]], ["The response rate was 24.5% (40 of a total of 163) and 40% (27 out of a total of 68) in residents and staff, respectively.METHODSResidents were interviewed and asked to answer questions regarding their health status, knowledge of SARS, worries about contracting SARS, and knowledge on SARS prevention (Table 1) .", [["SARS", "DISEASE", 230, 234], ["SARS", "DISEASE", 262, 266], ["SARS", "DISEASE", 285, 289], ["The response rate", "TEST", 0, 17], ["SARS", "PROBLEM", 230, 234], ["SARS prevention", "TREATMENT", 285, 300]]], ["Staff were interviewed and invited to answer questions regarding their worries and fears about contracting SARS, the possibility of a SARS outbreak in their working area, and the precautionary measures that had been taken to control SARS (Table 2) .DATA ANALYSISInterviews were taped and transcribed.", [["SARS", "DISEASE", 107, 111], ["SARS", "DISEASE", 134, 138], ["SARS", "DISEASE", 233, 237], ["contracting SARS", "PROBLEM", 95, 111], ["a SARS outbreak", "PROBLEM", 132, 147], ["the precautionary measures", "TREATMENT", 175, 201], ["DATA ANALYSISInterviews", "TEST", 249, 272]]], ["Finally, the themes were further condensed into categories for comparison and discussion.SARS: The elderly perspectiveThere were 40 elderly (33 female and 7 male) residents who took part in this study.", [["SARS", "DISEASE", 89, 93], ["this study", "TEST", 190, 200]]], ["The majority (93%) of the participants had stayed in the nursing home for 3 years or more.", [["participants", "ORGANISM", 26, 38], ["participants", "SPECIES", 26, 38], ["majority", "OBSERVATION_MODIFIER", 4, 12]]], ["Their major underlying medical problems included hypertension (37.5%), diabetes mellitus (35%), history of stroke (30%), heart disease (37.5%), cataract (35%), and musculoskeletal problems (67.5%).", [["heart", "ANATOMY", 121, 126], ["musculoskeletal", "ANATOMY", 164, 179], ["hypertension", "DISEASE", 49, 61], ["diabetes mellitus", "DISEASE", 71, 88], ["stroke", "DISEASE", 107, 113], ["heart disease", "DISEASE", 121, 134], ["cataract", "DISEASE", 144, 152], ["musculoskeletal problems", "DISEASE", 164, 188], ["heart", "ORGAN", 121, 126], ["hypertension", "PROBLEM", 49, 61], ["diabetes mellitus", "PROBLEM", 71, 88], ["stroke", "PROBLEM", 107, 113], ["heart disease", "PROBLEM", 121, 134], ["cataract", "PROBLEM", 144, 152], ["musculoskeletal problems", "PROBLEM", 164, 188], ["hypertension", "OBSERVATION", 49, 61], ["stroke", "OBSERVATION", 107, 113], ["heart", "ANATOMY", 121, 126], ["disease", "OBSERVATION", 127, 134], ["cataract", "OBSERVATION", 144, 152], ["musculoskeletal", "ANATOMY", 164, 179]]], ["Half of the participants had not received any formal education but were able to read, write, and understand Chinese; 40% of the participants had primary education, 7.5% had received secondary education, and 2.5% had received tertiary education.", [["participants", "ORGANISM", 12, 24], ["participants", "ORGANISM", 128, 140], ["participants", "SPECIES", 12, 24], ["participants", "SPECIES", 128, 140], ["secondary education", "TREATMENT", 182, 201], ["tertiary education", "TREATMENT", 225, 243]]], ["Regarding occupation in the past, more than 50% of the participants were housewives, whereas others were mainly engaged in manufacturing and serving industries, including tailoring, textile, carpentry, butcher, chef, and market stall holder or street seller.SARS: The elderly perspectiveIn terms of knowledge of SARS, the questions were: 1.", [["SARS", "DISEASE", 258, 262], ["SARS", "DISEASE", 312, 316], ["participants", "ORGANISM", 55, 67], ["participants", "SPECIES", 55, 67]]], ["What is SARS?", [["SARS", "DISEASE", 8, 12]]], ["(Answer: It is a new type of pneumonia, also known as atypical pneumonia.) 2.", [["pneumonia", "DISEASE", 29, 38], ["pneumonia", "DISEASE", 63, 72], ["pneumonia", "PROBLEM", 29, 38], ["atypical pneumonia", "PROBLEM", 54, 72], ["pneumonia", "OBSERVATION", 29, 38], ["atypical", "OBSERVATION_MODIFIER", 54, 62], ["pneumonia", "OBSERVATION", 63, 72]]], ["What are the signs and symptoms of SARS (Answer:SARS: The elderly perspectiveFever and coughing are the most common symptoms of SARS.) 3.", [["SARS", "DISEASE", 35, 39], ["SARS", "DISEASE", 48, 52], ["coughing", "DISEASE", 87, 95], ["SARS", "DISEASE", 128, 132], ["symptoms", "PROBLEM", 23, 31], ["SARS", "PROBLEM", 35, 39], ["coughing", "PROBLEM", 87, 95]]], ["How is SARS spread?", [["SARS", "DISEASE", 7, 11], ["SARS spread", "PROBLEM", 7, 18]]], ["(Answer: It is infectious and is known to be transmitted by droplets, sneezing and spitting, and close personal contact.)", [["sneezing", "PROBLEM", 70, 78], ["spitting", "PROBLEM", 83, 91], ["infectious", "OBSERVATION", 15, 25]]], ["Answers of participants were categorized into good knowledge, little knowledge, and no knowledge about SARS, based on the number of correct responses.", [["SARS", "DISEASE", 103, 107], ["participants", "SPECIES", 11, 23], ["SARS", "PROBLEM", 103, 107]]], ["Among the 40 elderly residents who took part in this study, only 7 (17.5%) had what was categorized as good knowledge about SARS, whereas 16 (40%) had little knowledge, and 17 (42.5%) knew virtually nothing of SARS.", [["SARS", "DISEASE", 124, 128], ["SARS", "DISEASE", 210, 214], ["this study", "TEST", 48, 58], ["SARS", "PROBLEM", 124, 128]]], ["Around half of those whose knowledge was good worried about contracting SARS themselves compared with 66% of those with moderate knowledge about SARS.", [["SARS", "DISEASE", 72, 76], ["SARS", "DISEASE", 145, 149], ["SARS", "PROBLEM", 145, 149]]], ["In the least knowledgeable group, only 10% of the participants showed worries over SARS.", [["SARS", "DISEASE", 83, 87], ["participants", "ORGANISM", 50, 62], ["participants", "SPECIES", 50, 62], ["SARS", "PROBLEM", 83, 87]]], ["These results are shown in Figure 2 .SARS: The elderly perspectiveIn terms of SARS prevention, participants were questioned on the importance of wearing a surgical mask when going out, frequent handwashing with soapy water and washing hands before touching eyes and ears, maintaining good personal hygiene, eating well, avoiding crowded areas, and avoiding touching items in public areas, such as the elevator button.", [["eyes", "ANATOMY", 257, 261], ["ears", "ANATOMY", 266, 270], ["SARS", "DISEASE", 37, 41], ["SARS", "DISEASE", 78, 82], ["eyes", "ORGAN", 257, 261], ["ears", "ORGAN", 266, 270], ["participants", "SPECIES", 95, 107], ["a surgical mask", "TREATMENT", 153, 168], ["ears", "ANATOMY", 266, 270]]], ["Participants with good knowledge on SARS also had good knowledge on prevention.", [["SARS", "DISEASE", 36, 40], ["Participants", "SPECIES", 0, 12]]], ["They were able to name all of the above precautions.", [["the above precautions", "TREATMENT", 30, 51]]], ["Those with little knowledge on SARS were able to name 1 or 2 preventive measures, and the majority of those with no knowledge on SARS were able to name only 1.SARS: The staff perspectiveThere were 27 staff members (3 men and 24 women) who took part in the study; 2 were managers, 1 was a physiotherapist, 3 were registered nurses, 12 were health care assistants, and 9 were domestic staff.", [["SARS", "DISEASE", 31, 35], ["SARS", "DISEASE", 129, 133], ["SARS", "DISEASE", 159, 163], ["men", "ORGANISM", 217, 220], ["women", "ORGANISM", 228, 233], ["men", "SPECIES", 217, 220], ["women", "SPECIES", 228, 233], ["SARS", "PROBLEM", 31, 35], ["SARS", "PROBLEM", 129, 133]]], ["No incidence of SARS had been reported in this particular nursing home; however, 3 residents who had experienced fever recently had been taken to the hospital for further investigation and treatment.", [["SARS", "DISEASE", 16, 20], ["fever", "DISEASE", 113, 118], ["SARS", "PROBLEM", 16, 20], ["fever", "PROBLEM", 113, 118], ["further investigation", "TEST", 163, 184], ["treatment", "TREATMENT", 189, 198], ["SARS", "OBSERVATION", 16, 20]]], ["They were then confirmed to have health problems other than SARS.SARS: The staff perspectiveResults concerning the worries of staff regarding the contraction of SARS at work and fear of an outbreak of SARS in the nursing home are shown in Figure 3 .", [["SARS", "DISEASE", 60, 64], ["SARS", "DISEASE", 65, 69], ["SARS", "DISEASE", 161, 165], ["SARS", "DISEASE", 201, 205], ["health problems", "PROBLEM", 33, 48], ["SARS", "PROBLEM", 60, 64], ["SARS", "PROBLEM", 161, 165], ["SARS", "PROBLEM", 201, 205]]], ["The manager, physiotherapist, and domestic staff all stated that they were worried about contracting SARS at work.", [["SARS", "DISEASE", 101, 105]]], ["The majority of the staff expressed that residents in the nursing home were elderly with chronic illness and likely to have a poor immune system, predisposing them to infectious disease, including SARS.", [["chronic illness", "DISEASE", 89, 104], ["infectious disease", "DISEASE", 167, 185], ["SARS", "DISEASE", 197, 201], ["chronic illness", "PROBLEM", 89, 104], ["a poor immune system", "PROBLEM", 124, 144], ["infectious disease", "PROBLEM", 167, 185], ["SARS", "PROBLEM", 197, 201], ["majority", "OBSERVATION_MODIFIER", 4, 12]]], ["In light of the possibility of an outbreak, the physiotherapist, the majority of the domestic staff, and the health care assistants stated they felt fear and concern.", [["outbreak", "OBSERVATION", 34, 42]]], ["They expressed their concerns about visitors bringing the SARS virus into the nursing home.", [["SARS", "DISEASE", 58, 62], ["SARS virus", "SPECIES", 58, 68]]], ["In contrast, the manager and registered nurses were not worried about an outbreak because they recognized that conditions and hygiene in procedures in the nursing home environment were satisfactory and believed these to be less risky compared with the environment in a general hospital.SARS: The staff perspectiveTo strengthen precautionary measures to control the spread of SARS within the nursing home, nurses from Hong Kong Hospital Authority and outreach nurses were invited to give a health talk to residents and staff on knowledge and prevention of SARS.", [["SARS", "DISEASE", 286, 290], ["SARS", "DISEASE", 375, 379], ["SARS", "DISEASE", 555, 559], ["strengthen precautionary measures", "TREATMENT", 316, 349], ["SARS", "PROBLEM", 555, 559]]], ["Protective materials including surgical masks, gloves, face and eye shields, protective clothing, and caps were provided for the use of staff.", [["eye", "ANATOMY", 64, 67], ["eye", "ORGAN", 64, 67], ["Protective materials", "TREATMENT", 0, 20], ["surgical masks", "TREATMENT", 31, 45], ["gloves", "TREATMENT", 47, 53], ["face and eye shields", "TREATMENT", 55, 75], ["protective clothing", "TREATMENT", 77, 96], ["caps", "TREATMENT", 102, 106], ["surgical masks", "OBSERVATION", 31, 45], ["face", "ANATOMY", 55, 59], ["eye", "ANATOMY", 64, 67]]], ["Disinfection agents for handwashing and cleaning also were provided.", [["Disinfection agents", "TREATMENT", 0, 19], ["handwashing and cleaning", "TREATMENT", 24, 48]]], ["Also, when residents returned from the hospital after a follow-up appointment or on discharge from the hospital after medical treatment, they stayed in an isolated room in the nursing home for 14 days.", [["medical treatment", "TREATMENT", 118, 135]]], ["The resident under confinement had to wear a facemask and activities were restricted in the isolated room.", [["a facemask", "TREATMENT", 43, 53]]], ["Staff had to use strict isolation techniques in handling the isolated residents, including wearing a protective gown, gloves, and surgical mask.SARS: The staff perspectiveA further measure adopted was that letters were sent to all visitors regarding the outbreak of SARS, urging them to refrain from visiting the nursing home if they experienced any of the signs and symptoms.", [["SARS", "DISEASE", 144, 148], ["SARS", "DISEASE", 266, 270], ["strict isolation techniques", "TREATMENT", 17, 44], ["a protective gown", "TREATMENT", 99, 116], ["gloves", "TREATMENT", 118, 124], ["surgical mask", "TREATMENT", 130, 143], ["SARS", "PROBLEM", 266, 270], ["the signs and symptoms", "PROBLEM", 353, 375], ["surgical mask", "OBSERVATION", 130, 143]]], ["All visitors were required to wear surgical masks during their visits and to use disinfectants to clean their hands when they arrived at the nursing home.DISCUSSIONSARS is a new disease-one to which the elderly are particularly susceptible.", [["surgical masks", "TREATMENT", 35, 49], ["disinfectants", "TREATMENT", 81, 94], ["a new disease", "PROBLEM", 172, 185], ["new", "OBSERVATION_MODIFIER", 174, 177], ["disease", "OBSERVATION", 178, 185]]], ["The mortality rate in those older than 65 years of age is very high.", [["The mortality rate", "TEST", 0, 18], ["high", "OBSERVATION_MODIFIER", 63, 67]]], ["Knowledge of the disease and how to prevent it is crucial to keeping our elderly SARS free and to allay their concerns and fears about this disease.DISCUSSIONThe 40 nursing home residents who participated in this study were mentally alert, were able to read, and had access to televisions and radios to catch up with the latest news and current affairs in the outside world.", [["SARS", "DISEASE", 81, 85], ["the disease", "PROBLEM", 13, 24], ["this disease", "PROBLEM", 135, 147], ["this study", "TEST", 208, 218]]], ["In addition, health education regarding SARS and the importance of good personal hygiene in limiting the spread of SARS had been provided to residents via various sources and means, such as nurses giving health talks and pamphlets given to residents and relatives.", [["SARS", "DISEASE", 40, 44], ["SARS", "DISEASE", 115, 119], ["SARS", "PROBLEM", 40, 44]]], ["To our surprise, however, very few of the participants in the nursing home could be described as knowledgeable regarding SARS and its prevention.", [["SARS", "DISEASE", 121, 125], ["participants", "ORGANISM", 42, 54], ["participants", "SPECIES", 42, 54], ["SARS", "PROBLEM", 121, 125]]], ["Some of these residents were worried about contracting the disease themselves.", [["the disease themselves", "PROBLEM", 55, 77]]], ["However, the majority of the residents studied had either little or no knowledge about SARS.", [["SARS", "DISEASE", 87, 91], ["SARS", "PROBLEM", 87, 91]]], ["Not surprisingly perhaps, those with the least knowledge also had the least concerns about contracting the disease.", [["the disease", "PROBLEM", 103, 114], ["disease", "OBSERVATION", 107, 114]]], ["The lack of knowledge and concern may make them more vulnerable in terms of contracting SARS.", [["SARS", "DISEASE", 88, 92], ["contracting SARS", "PROBLEM", 76, 92]]], ["It is normal and justifiable to have concerns about contracting a potentially fatal disease, and these concerns can be useful to drive the implementation of precautionary measures that require active cooperation and participation of individuals.", [["a potentially fatal disease", "PROBLEM", 64, 91], ["precautionary measures", "TREATMENT", 157, 179], ["normal", "OBSERVATION", 6, 12], ["fatal", "OBSERVATION_MODIFIER", 78, 83], ["disease", "OBSERVATION", 84, 91]]], ["Care must be taken, however, to ensure that justifiable and constructive concerns must not be allowed to become destructive fears.", [["destructive fears", "PROBLEM", 112, 129], ["destructive", "OBSERVATION", 112, 123]]], ["The results of this study indicate that more tailored health education specifically targeted to inform and allay the fears of the elderly in the nursing home would be useful.", [["this study", "TEST", 15, 25]]], ["The majority of staff worried about contracting SARS at work and was concerned about an outbreak in the nursing home.", [["SARS", "DISEASE", 48, 52]]], ["These worries were caused largely by a tragic large-scale outbreak in a housing estate triggered by a single visitor with SARS and accounted for more than 300 SARS cases and more than 30 deaths.", [["SARS", "DISEASE", 122, 126], ["SARS", "DISEASE", 159, 163], ["deaths", "DISEASE", 187, 193], ["SARS", "PROBLEM", 122, 126]]], ["In addition, staff were very much aware that several medical staff and a health care assistant in a nursing home had died recently of SARS in Hong Kong.DISCUSSIONTo minimize the risk of an outbreak, the nursing home proactively implemented preventive measures including sending letters to visitors and shortening the visiting period.", [["SARS", "DISEASE", 134, 138], ["preventive measures", "TREATMENT", 240, 259]]], ["To further alleviate the worry and fear of the staff, especially the health care assistants and domestic staff, inservice workshops and seminars are indicated, and more channels for communication and support to all staff are recommended.DISCUSSIONThe SARS outbreak in Hong Kong has abated, and there have been very few new cases since June 1, 2003.", [["SARS", "DISEASE", 251, 255], ["very", "OBSERVATION_MODIFIER", 310, 314], ["few", "OBSERVATION_MODIFIER", 315, 318]]], ["All citizens, the elderly in particular, must continue to practice general preventive measures and guard against lapses in personal and environmental hygiene.", [["general preventive measures", "TREATMENT", 67, 94]]], ["Awareness of SARS should remain high because this disease is likely to remain a threat worldwide for some time to come.", [["SARS", "DISEASE", 13, 17], ["SARS", "PROBLEM", 13, 17], ["this disease", "PROBLEM", 45, 57]]], ["Our experience in Hong Kong shows SARS to be highly infectious and that infection in an elderly person is often fatal.", [["SARS", "DISEASE", 34, 38], ["infection", "DISEASE", 72, 81], ["person", "SPECIES", 96, 102], ["SARS", "PROBLEM", 34, 38], ["infection", "PROBLEM", 72, 81], ["highly", "OBSERVATION_MODIFIER", 45, 51], ["infectious", "OBSERVATION", 52, 62], ["infection", "OBSERVATION", 72, 81]]], ["Increasing awareness of SARS in the elderly and their caregivers and enhancing preventive measures are crucial to avoid new outbreaks.", [["SARS", "DISEASE", 24, 28], ["SARS", "PROBLEM", 24, 28], ["enhancing preventive measures", "TREATMENT", 69, 98]]], ["The worry and fear of an outbreak of SARS among staff working in the nursing home are still high.", [["SARS", "DISEASE", 37, 41]]], ["Tailored education for the residents of elderly care homes is also important because their active participation is needed in SARS prevention, and their fears and concerns of SARS, while often justified and possibly useful, must not be allowed to compromise their quality of life.", [["SARS", "DISEASE", 125, 129], ["SARS", "DISEASE", 174, 178], ["SARS", "PROBLEM", 174, 178]]], ["Are there any cases of SARS in this nursing home? 4.As the mortality rate of SARS for the elderly is so high, do you fear of an outbreak here? 5.What has been done to control the spread of SARS here?", [["SARS", "DISEASE", 23, 27], ["SARS", "DISEASE", 77, 81], ["SARS", "DISEASE", 189, 193], ["SARS", "PROBLEM", 23, 27], ["SARS", "PROBLEM", 77, 81], ["SARS", "PROBLEM", 189, 193]]]], "PMC7118485": [["Primer preparation ::: MATERIALS AND METHODSBased on previous studies [1, 5, 10, 14, 15], four pairs of specificprimers for one-step multiplex RT-PCR for the representative genes of the four viruseswere designed: RVA, BToV, BEV, and BCV, as shown in Table 1.", [["BCV", "ORGANISM", 233, 236], ["BToV", "SPECIES", 218, 222], ["BCV", "SPECIES", 233, 236], ["previous studies", "TEST", 53, 69], ["specificprimers", "TEST", 104, 119], ["RVA", "TEST", 213, 216], ["BEV", "TREATMENT", 224, 227], ["BCV", "ANATOMY", 233, 236]]], ["Each primer, set at 100 \u00b5M in Tris-ethylenediaminetetraacetic acid (EDTA) (TE) buffer (10 mM Tris-HCl at pH 8.0, 1 mM EDTA),was mixed at an equal volume and used as a primer mixture (final 10 \u00b5Mfor each primer).Sample collection ::: MATERIALS AND METHODSA total of 48 cattle farms that kept calves of Japanese Black or crossbred cattle(Holstein \u00d7 Japanese Black: F1) were selected for rectal feces sampling from September2016 to February 2017.", [["rectal feces", "ANATOMY", 385, 397], ["Tris-ethylenediaminetetraacetic acid", "CHEMICAL", 30, 66], ["EDTA", "CHEMICAL", 68, 72], ["Tris-HCl", "CHEMICAL", 93, 101], ["Tris-ethylenediaminetetraacetic acid", "CHEMICAL", 30, 66], ["EDTA", "CHEMICAL", 68, 72], ["Tris-HCl", "CHEMICAL", 93, 101], ["EDTA", "CHEMICAL", 118, 122], ["Tris-ethylenediaminetetraacetic acid", "SIMPLE_CHEMICAL", 30, 66], ["EDTA", "SIMPLE_CHEMICAL", 68, 72], ["Tris-HCl", "SIMPLE_CHEMICAL", 93, 101], ["cattle", "ORGANISM", 268, 274], ["calves", "ORGANISM", 291, 297], ["cattle", "ORGANISM", 329, 335], ["cattle", "SPECIES", 268, 274], ["calves", "SPECIES", 291, 297], ["cattle", "SPECIES", 329, 335], ["cattle", "SPECIES", 268, 274], ["cattle", "SPECIES", 329, 335], ["Each primer", "TEST", 0, 11], ["Tris-ethylenediaminetetraacetic acid (EDTA) (TE) buffer", "TREATMENT", 30, 85], ["Tris", "TEST", 93, 97], ["pH", "TEST", 105, 107], ["1 mM EDTA", "TREATMENT", 113, 122], ["a primer mixture", "TREATMENT", 165, 181], ["rectal feces sampling", "TEST", 385, 406], ["rectal", "ANATOMY", 385, 391]]], ["At farm A, located in Ibaraki Prefecture, 20 calves were numberedindividually and sampled every 5 to 10 days for up to 12 weeks (total 220 samples).", [["calves", "ORGANISM", 45, 51], ["calves", "SPECIES", 45, 51]]], ["Atfarm B, located in Chiba Prefecture, 10 calves were numbered individually and sampledevery week for up to five weeks (total 50 samples).", [["Atfarm B", "CHEMICAL", 0, 8], ["Atfarm B", "CELL", 0, 8], ["calves", "ORGANISM", 42, 48], ["calves", "SPECIES", 42, 48]]], ["At the rest of the 46 farms, locatedin Chiba Prefecture, one or two calves were randomly selected from each farm, and thereby88 calves aged 1\u201313 weeks were sampled once.", [["calves", "ORGANISM", 68, 74], ["calves", "ORGANISM", 128, 134], ["calves", "SPECIES", 68, 74], ["calves", "SPECIES", 128, 134]]], ["There was no invasive sampling of thecalves.Isolation of viral RNAs ::: MATERIALS AND METHODSOne gram of feces was suspended in 4 ml of phosphate buffered saline,mixed well using a vortex mixer, and centrifuged at 12,000 \u00d7 g for 3 min.Viral RNAs were extracted using ISOGEN-LS (Nippon Gene Co., Ltd., Tokyo, Japan), accordingto the manufacturer\u2019s instructions.", [["thecalves", "ANATOMY", 34, 43], ["feces", "ANATOMY", 105, 110], ["phosphate", "CHEMICAL", 136, 145], ["phosphate", "CHEMICAL", 136, 145], ["feces", "ORGANISM_SUBSTANCE", 105, 110], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 136, 161], ["viral RNAs", "RNA", 57, 67], ["Viral RNAs", "RNA", 235, 245], ["invasive sampling of thecalves", "PROBLEM", 13, 43], ["METHODSOne gram of feces", "TREATMENT", 86, 110], ["phosphate buffered saline", "TREATMENT", 136, 161], ["a vortex mixer", "TREATMENT", 179, 193], ["Viral RNAs", "PROBLEM", 235, 245], ["no", "UNCERTAINTY", 10, 12], ["invasive", "OBSERVATION_MODIFIER", 13, 21], ["thecalves", "ANATOMY", 34, 43], ["viral RNAs", "OBSERVATION", 57, 67]]], ["Just before use, 2 \u00b5l of RNA wasmixed with 1 \u00b5l of dimethyl sulfoxide (DMSO) (Wako Pure ChemicalIndustries, Co., Ltd., Osaka, Japan) together with 4.5 \u00b5l of redistilledwater (dH2O), and heated at 98\u00b0C for 5 min.One-step multiple RT-PCR ::: MATERIALS AND METHODSTo amplify viral RNAs, a PrimeScript\u2122 One Step RT-PCR Kit Ver.", [["dimethyl sulfoxide", "CHEMICAL", 51, 69], ["DMSO", "CHEMICAL", 71, 75], ["Ver", "CHEMICAL", 319, 322], ["dimethyl sulfoxide", "CHEMICAL", 51, 69], ["DMSO", "CHEMICAL", 71, 75], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 51, 69], ["DMSO", "SIMPLE_CHEMICAL", 71, 75], ["redistilledwater", "SIMPLE_CHEMICAL", 157, 173], ["viral RNAs", "RNA", 272, 282], ["RNA", "TREATMENT", 25, 28], ["dimethyl sulfoxide (DMSO", "TREATMENT", 51, 75], ["viral RNAs", "OBSERVATION", 272, 282]]], ["Briefly, 7.5\u00b5l of DMSO-treated viral RNA was mixed with 1 \u00b5l ofPrimeScript 1 step Enzyme Mix, 12.5 \u00b5l of 2 \u00d7 1-Step Buffer, 0.8\u00b5l of the primer mixture, and 3.2 \u00b5l of RNase-FreedH2O, totaling 25 \u00b5l and incubated at 50\u00b0C for 30 min, tomake cDNA stop the reaction thereafter at 95\u00b0C, for 10 min.", [["DMSO", "CHEMICAL", 18, 22], ["DMSO", "CHEMICAL", 18, 22], ["DMSO", "SIMPLE_CHEMICAL", 18, 22], ["RNase-FreedH2O", "SIMPLE_CHEMICAL", 167, 181], ["viral RNA", "RNA", 31, 40], ["RNase", "PROTEIN", 167, 172], ["FreedH2O", "PROTEIN", 173, 181], ["tomake cDNA", "DNA", 232, 243], ["DMSO", "TREATMENT", 18, 22], ["viral RNA", "TREATMENT", 31, 40], ["Enzyme Mix", "TEST", 82, 92], ["the primer mixture", "TEST", 133, 151], ["RNase", "TEST", 167, 172], ["FreedH2O", "TEST", 173, 181]]], ["Subsequently, the PCR reactionwas performed according to Fukuda et al. [5], with 35 cycles at 94\u00b0C for 45 sec, 52\u00b0C for 15 sec, and 72\u00b0C for 1 min, anda final incubation at 72\u00b0C for 10 min.", [["the PCR reactionwas", "TEST", 14, 33]]], ["The PCR products were visualized on 1.5% agarosegels stained with ethidium bromide.", [["ethidium bromide", "CHEMICAL", 66, 82], ["ethidium bromide", "CHEMICAL", 66, 82], ["agarosegels", "SIMPLE_CHEMICAL", 41, 52], ["ethidium bromide", "SIMPLE_CHEMICAL", 66, 82], ["PCR products", "DNA", 4, 16], ["The PCR products", "TREATMENT", 0, 16], ["ethidium bromide", "TREATMENT", 66, 82]]], ["These amplified products from one of each size,namely, 928 bp (RVA), 651 bp (BoTV), 483 bp (BEV), and 407 bp (BCV), were taken from theagarose gels, purified, and cloned into plasmid pCR\u00ae 2.1 vector, using a TACloning Kit (Thermo Fisher Scientific K. K., Tokyo, Japan).", [["BoTV", "DNA", 77, 81], ["BCV", "DNA", 110, 113], ["plasmid pCR\u00ae 2.1 vector", "DNA", 175, 198], ["bp", "TEST", 59, 61], ["bp", "TEST", 73, 75], ["bp", "TEST", 88, 90], ["BEV", "TEST", 92, 95], ["bp", "TEST", 106, 108], ["plasmid pCR", "TEST", 175, 186], ["size", "OBSERVATION_MODIFIER", 42, 46]]], ["Each recombinant plasmidcontaining each amplified product was sequenced with the BigDye Terminator v3.1 CycleSequencing Kit (Thermo Fisher Scientific K. K.) to confirm the virus specificity.One-step multiple RT-PCR ::: MATERIALS AND METHODSThe sensitivity of one-step multiplex RT-PCR (containing four primer sets) was comparedwith one-step single RT-PCR (containing one primer set), using the recombinant plasmids astemplates with a mixture of the four primer sets.", [["plasmids", "ANATOMY", 406, 414], ["recombinant plasmidcontaining each amplified product", "PROTEIN", 5, 57], ["recombinant plasmids", "DNA", 394, 414], ["Each recombinant plasmidcontaining each amplified product", "TREATMENT", 0, 57], ["the virus specificity", "TEST", 168, 189], ["METHODSThe sensitivity", "TEST", 233, 255], ["step multiplex RT-PCR", "TEST", 263, 284], ["the recombinant plasmids astemplates", "TREATMENT", 390, 426], ["plasmids", "OBSERVATION", 406, 414]]], ["For the multiplex RT-PCR, four plasmidswere used as templates, while single RT-PCR was based on only one plasmid for each virusas a template.", [["multiplex RT-PCR", "DNA", 8, 24], ["RT-PCR", "DNA", 76, 82], ["plasmid", "DNA", 105, 112], ["virusas", "DNA", 122, 129], ["the multiplex RT-PCR", "TREATMENT", 4, 24], ["single RT-PCR", "TREATMENT", 69, 82]]], ["The plasmid copy number was determined by the molecular weight of theplasmid, and the DNA concentration was determined with the Nano Drop ND-1000Spectrophotometer (Thermo Fisher Scientific K. K.).Confirmation of the amplified product specificity and sensitivity of one-stepmultiplex RT-PCR ::: RESULTSPreliminarily, samples from farm A were tested with one-step multiplex RT-PCR.", [["plasmid", "ANATOMY", 4, 11], ["samples", "ANATOMY", 316, 323], ["theplasmid", "SIMPLE_CHEMICAL", 66, 76], ["DNA", "CELLULAR_COMPONENT", 86, 89], ["theplasmid", "PROTEIN", 66, 76], ["the DNA concentration", "TEST", 82, 103], ["the amplified product specificity", "TEST", 212, 245], ["sensitivity", "TEST", 250, 261]]], ["Within 44samples, bands corresponding to RVA, BToV, BEV, and BCV were amplified.", [["BCV", "GENE_OR_GENE_PRODUCT", 61, 64], ["RVA, BToV, BEV, and BCV", "DNA", 41, 64], ["bands", "PROBLEM", 18, 23], ["RVA", "TEST", 41, 44], ["BToV", "TEST", 46, 50], ["BEV", "TEST", 52, 55], ["BCV", "ANATOMY", 61, 64]]], ["The amplifiedproducts could be easily distinguished from each other following agarose gelelectrophoresis (Fig. 1).", [["agarose", "SIMPLE_CHEMICAL", 78, 85], ["The amplifiedproducts", "TREATMENT", 0, 21], ["agarose gelelectrophoresis", "TEST", 78, 104]]], ["Each representative amplified product for each virus was cloned into the plasmid,sequenced, and then compared with the published sequences.", [["plasmid", "ANATOMY", 73, 80], ["plasmid", "DNA", 73, 80], ["each virus", "PROBLEM", 42, 52], ["the published sequences", "TEST", 115, 138]]], ["For RVA, the 928 bp product hadhomology at 96% with the RVA UK strain sequence of Accession No.", [["RVA UK strain sequence", "DNA", 56, 78], ["RVA", "PROBLEM", 4, 7], ["bp product hadhomology", "TEST", 17, 39]]], ["X53667.1; for BToV, the651 bp product had homology at 97% with the BToV Ishikawa/2010 Accession No.", [["X53667.1", "CHEMICAL", 0, 8], ["BToV", "PROTEIN", 14, 18]]], ["LC088094.1;for BEV, the 483 bp product had homology at 88% with the BEV strain Wye 8875 Accession No.AY724745.1; and for BCV, the 407 product had homology at 98% with the BCV E-AH65 AccessionNo.", [["LC088094.1", "CHEMICAL", 0, 10], ["AY724745.1", "CHEMICAL", 101, 111], ["AY724745.1", "CHEMICAL", 101, 111], ["BEV", "TEST", 15, 18], ["homology", "TEST", 43, 51], ["the BEV strain", "TEST", 64, 78], ["BCV", "TEST", 121, 124], ["homology", "TEST", 146, 154], ["the BCV E", "TEST", 167, 176]]], ["EF424615.1.Confirmation of the amplified product specificity and sensitivity of one-stepmultiplex RT-PCR ::: RESULTSUsing each of the four different recombinant plasmid DNAs containing each of our fourdifferent target viral genes as templates, the multiplex RT-PCR could amplify each of thespecific target genes (Fig. 1).", [["EF424615.1", "CHEMICAL", 0, 10], ["recombinant plasmid DNAs", "DNA", 149, 173], ["fourdifferent target viral genes", "DNA", 197, 229], ["thespecific target genes", "DNA", 287, 311], ["sensitivity", "TEST", 65, 76], ["the four different recombinant plasmid DNAs", "TREATMENT", 130, 173], ["our fourdifferent target viral genes", "TREATMENT", 193, 229], ["the multiplex RT-PCR", "TREATMENT", 244, 264], ["plasmid DNAs", "OBSERVATION", 161, 173], ["viral genes", "OBSERVATION", 218, 229]]], ["The detectionlimit of the multiplex RT-PCR was evaluated.", [["the multiplex RT-PCR", "TEST", 22, 42]]], ["As shown in Fig. 2, the single RT-PCR has 10\u2013100 times higher sensitivity than the multiplex RT-PCRfor detecting viral genes in plasmids, though the multiplex RT-PCR could detect106 to 104 copies of plasmids.", [["plasmids", "ANATOMY", 128, 136], ["plasmids", "ANATOMY", 199, 207], ["viral genes", "DNA", 113, 124], ["plasmids", "DNA", 128, 136], ["plasmids", "DNA", 199, 207], ["the single RT-PCR", "TEST", 20, 37], ["the multiplex RT", "TEST", 79, 95], ["viral genes in plasmids", "PROBLEM", 113, 136], ["the multiplex RT-PCR", "TEST", 145, 165], ["plasmids", "TREATMENT", 199, 207], ["viral genes", "OBSERVATION", 113, 124]]], ["Non-specific extra bands that didnot match any size of the targeted genes appeared in 5% of samples, and were all less than300 bp.Detection of viruses from field fecal samples ::: RESULTSThe four targeted viruses were detected in fecal samples.", [["samples", "ANATOMY", 92, 99], ["fecal samples", "ANATOMY", 162, 175], ["fecal samples", "ANATOMY", 230, 243], ["samples", "CANCER", 92, 99], ["fecal samples", "ORGANISM_SUBSTANCE", 230, 243], ["targeted genes", "DNA", 59, 73], ["Non-specific extra bands", "PROBLEM", 0, 24], ["bp", "TEST", 127, 129], ["four targeted viruses", "PROBLEM", 191, 212], ["fecal samples", "TEST", 230, 243], ["extra bands", "OBSERVATION", 13, 24], ["size", "OBSERVATION_MODIFIER", 47, 51], ["targeted", "OBSERVATION_MODIFIER", 59, 67], ["genes", "OBSERVATION", 68, 73], ["viruses", "OBSERVATION", 143, 150], ["viruses", "OBSERVATION", 205, 212]]], ["As shown in Fig. 3 and Tables 2 and 3, in some cases, two viruses were detected simultaneously in a givensample.Detection of viruses from field fecal samples ::: RESULTSTable 2 shows the virus detection pattern atfarm A. At that farm, 20 calves were numbered and individually sampled every 5 to 10 daysup to 12 weeks old.", [["fecal samples", "ANATOMY", 144, 157], ["3", "GENE_OR_GENE_PRODUCT", 36, 37], ["calves", "ORGANISM", 238, 244], ["calves", "SPECIES", 238, 244], ["calves", "SPECIES", 238, 244], ["two viruses", "PROBLEM", 54, 65], ["the virus detection", "TEST", 183, 202], ["viruses", "OBSERVATION", 58, 65], ["viruses", "OBSERVATION", 125, 132]]], ["Calves No. 12 and 16 died at the ages of two and four weeks,respectively.", [["Calves", "SPECIES", 0, 6]]], ["From a total of 220 samples at farm A, RVA was detected in eight calves, ofwhich seven were three weeks of age or less.", [["samples", "ANATOMY", 20, 27], ["calves", "ORGANISM", 65, 71], ["calves", "SPECIES", 65, 71]]], ["BEV was detected in 17 of 20 calves aged sixweeks or more.", [["BEV", "CANCER", 0, 3], ["calves", "ORGANISM", 29, 35], ["calves", "SPECIES", 29, 35], ["BEV", "SPECIES", 0, 3], ["BEV", "TEST", 0, 3]]], ["As shown in Table 2, BEV wasdetected up to five successive times in the same calves.", [["BEV", "ORGANISM", 21, 24], ["calves", "ORGANISM", 77, 83], ["calves", "SPECIES", 77, 83], ["calves", "ANATOMY", 77, 83]]], ["BCV was detected in 17 of 20calves.", [["BCV", "ORGANISM", 0, 3], ["BCV", "SPECIES", 0, 3], ["BCV", "TEST", 0, 3]]], ["This virus was also detected five successive times in the same calves.", [["calves", "ORGANISM", 63, 69], ["calves", "SPECIES", 63, 69], ["This virus", "PROBLEM", 0, 10], ["calves", "ANATOMY", 63, 69]]], ["BToV wasdetected in two calves aged over nine weeks.Detection of viruses from field fecal samples ::: RESULTSTable 3 shows the virus detection pattern at farm B. Ten calves were numbered andsampled weekly at the ages of one to five weeks.", [["fecal samples", "ANATOMY", 84, 97], ["calves", "ORGANISM", 24, 30], ["calves", "ORGANISM", 166, 172], ["calves", "SPECIES", 24, 30], ["calves", "SPECIES", 166, 172], ["BToV", "SPECIES", 0, 4], ["the virus detection pattern", "TEST", 123, 150], ["viruses", "OBSERVATION", 65, 72]]], ["RVA was detected in six calves, of whichfive were two to three weeks old.", [["calves", "ORGANISM", 24, 30], ["calves", "SPECIES", 24, 30], ["RVA", "PROBLEM", 0, 3]]], ["RVA was detected once in each calf up to five weeks old.BEV and BCV were also detected.Detection of viruses from field fecal samples ::: RESULTSIn Table 4, the results of 88 samples from the 46 farms were shown.", [["fecal samples", "ANATOMY", 119, 132], ["samples", "ANATOMY", 174, 181], ["calf", "ORGANISM_SUBDIVISION", 30, 34], ["BCV", "ORGANISM", 64, 67], ["calf", "SPECIES", 30, 34], ["BEV", "SPECIES", 56, 59], ["BCV", "SPECIES", 64, 67], ["RVA", "PROBLEM", 0, 3], ["BEV and BCV", "TEST", 56, 67], ["calf", "ANATOMY", 30, 34], ["BCV", "ANATOMY", 64, 67], ["viruses", "OBSERVATION", 100, 107]]], ["RVA was detected in13 samples, of which nine were aged three weeks or less.", [["samples", "ANATOMY", 22, 29], ["RVA", "PROBLEM", 0, 3]]], ["BEV was detected in threesamples, of which two were aged six weeks or more.", [["BEV", "CANCER", 0, 3], ["BEV", "SPECIES", 0, 3]]], ["BCV and BToV were each detected once atthe age of six weeks.DISCUSSIONNucleotide sequence analyses and comparisons of the obtained PCR products with theirreferenced viral strains demonstrated that one-step multiplex RT-PCR could amplify anddetect four target viral genes belonging to the four representative viruses.", [["BCV", "ORGANISM", 0, 3], ["BToV", "CANCER", 8, 12], ["PCR products", "DNA", 131, 143], ["viral genes", "DNA", 259, 270], ["BCV", "SPECIES", 0, 3], ["BCV", "TEST", 0, 3], ["DISCUSSIONNucleotide sequence analyses", "TEST", 60, 98], ["the obtained PCR products", "TEST", 118, 143], ["theirreferenced viral strains", "PROBLEM", 149, 178], ["step multiplex RT-PCR", "TEST", 201, 222]]], ["A detectionlimit test showed that at least 106 copies of templates were needed to detect thetarget viral genes using this method.", [["thetarget viral genes", "DNA", 89, 110], ["A detectionlimit test", "TEST", 0, 21], ["thetarget viral genes", "PROBLEM", 89, 110], ["this method", "TREATMENT", 117, 128]]], ["Fukada et al. showed that with theirmultiplex RT-PCR, the detection limit for bovine group B rotavirus was 106copies/ml, and that the sensitivity of one-step multiplex RT-PCR towardRVA was lessened compared to that toward BCV and BToV [5].", [["bovine", "ORGANISM", 78, 84], ["group B rotavirus", "ORGANISM", 85, 102], ["BCV", "ORGANISM", 222, 225], ["multiplex RT-PCR towardRVA", "DNA", 158, 184], ["bovine", "SPECIES", 78, 84], ["bovine", "SPECIES", 78, 84], ["B rotavirus", "SPECIES", 91, 102], ["BCV", "SPECIES", 222, 225], ["theirmultiplex RT-PCR", "PROBLEM", 31, 52], ["bovine group B rotavirus", "TREATMENT", 78, 102], ["the sensitivity", "TEST", 130, 145], ["PCR", "TEST", 171, 174]]], ["The specificity test showed that our method hadthe ability to detect four specific target viruses simultaneously.", [["The specificity test", "TEST", 0, 20]]], ["However, our data alsoshowed that the detection of RVA was less sensitive (10\u2013100 times) than that of BCV, BEV,and BToV.DISCUSSIONIn the field sampling, we randomly sampled rectal feces from calves under normalconditions.", [["rectal feces", "ANATOMY", 173, 185], ["BCV", "ORGANISM", 102, 105], ["rectal feces", "MULTI-TISSUE_STRUCTURE", 173, 185], ["calves", "ORGANISM", 191, 197], ["calves", "SPECIES", 191, 197], ["BCV", "SPECIES", 102, 105], ["our data", "TEST", 9, 17], ["RVA", "PROBLEM", 51, 54], ["BCV", "TEST", 102, 105], ["the field sampling", "TEST", 133, 151], ["RVA", "OBSERVATION", 51, 54], ["rectal", "ANATOMY", 173, 179], ["feces", "OBSERVATION", 180, 185]]], ["The screening of the 358 fecal samples proved positive for 27 RVA, 4 BToV, 55BEV, and 52 BCV.", [["fecal samples", "ANATOMY", 25, 38], ["fecal samples", "CANCER", 25, 38], ["BCV", "ORGANISM", 89, 92], ["BToV", "SPECIES", 69, 73], ["55BEV", "SPECIES", 75, 80], ["BCV", "SPECIES", 89, 92], ["The screening", "TEST", 0, 13], ["fecal samples", "TEST", 25, 38], ["RVA", "TEST", 62, 65]]], ["In the successive sampling at farm A, RVA was detected once in each calf,but not continuously.", [["calf", "ORGANISM_SUBDIVISION", 68, 72], ["calf", "SPECIES", 68, 72], ["RVA", "PROBLEM", 38, 41], ["calf", "ANATOMY", 68, 72]]], ["In comparison, BEV and BCV were detected in succession for up to fiveweeks in the same calves.DISCUSSIONAs reported by Cho and Yoon [2], the RVA-infectedcalves secreted large amounts of the virus in their feces for five to seven days.", [["feces", "ANATOMY", 205, 210], ["BEV", "ORGANISM", 15, 18], ["BCV", "ORGANISM", 23, 26], ["calves", "ORGANISM", 87, 93], ["feces", "ORGANISM_SUBDIVISION", 205, 210], ["calves", "SPECIES", 87, 93], ["BEV", "SPECIES", 15, 18], ["BCV", "SPECIES", 23, 26], ["BEV and BCV", "TEST", 15, 26], ["the RVA", "TEST", 137, 144], ["the virus", "PROBLEM", 186, 195], ["BCV", "ANATOMY", 23, 26], ["calves", "ANATOMY", 87, 93], ["virus", "OBSERVATION", 190, 195]]], ["Koopmanset al. [7] reported that BToV wasdetected in feces for four days.", [["feces", "ANATOMY", 53, 58], ["BToV", "ORGANISM", 33, 37], ["feces", "ORGANISM_SUBSTANCE", 53, 58]]], ["On the contrary, Chrouch et al. [4] reported that BCV was shed from infected calves for aperiod of 12 weeks.", [["BCV", "ORGANISM", 50, 53], ["calves", "ORGANISM", 77, 83], ["calves", "SPECIES", 77, 83], ["BCV", "SPECIES", 50, 53], ["BCV", "PROBLEM", 50, 53], ["BCV", "ANATOMY", 50, 53], ["infected", "OBSERVATION", 68, 76]]], ["They also reported that BEV was not recovered in calvesaged less than four weeks.DISCUSSIONOur present results revealed that RVA was the primary agent among the positive samplesobtained at the age of three weeks or below, while BEV was the primary among those obtainedat more than three weeks of age.", [["BEV", "SPECIES", 228, 231], ["RVA", "PROBLEM", 125, 128]]], ["Lay et al. reported that BEV was found infeces from 76% of cattle and suggested BEV as an indicator of fecal contamination [9].", [["fecal", "ANATOMY", 103, 108], ["BEV", "ORGANISM", 25, 28], ["cattle", "ORGANISM", 59, 65], ["fecal", "ORGANISM_SUBSTANCE", 103, 108], ["cattle", "SPECIES", 59, 65], ["BEV", "SPECIES", 25, 28], ["cattle", "SPECIES", 59, 65], ["BEV", "SPECIES", 80, 83], ["fecal contamination", "PROBLEM", 103, 122], ["et al", "OBSERVATION", 4, 9]]], ["Together with our findings, RVA and BEV can bereferred to as reliable viral pathogen indicators for evaluating biosecurity at bovinefarms.DISCUSSIONPED is a highly contagious viral disease; however, proper biosecurity procedures, such aschanging personal protective equipment (clothes and footwear), could prevent itstransmission [6].", [["viral disease", "DISEASE", 175, 188], ["itstransmission", "DISEASE", 314, 329], ["BEV", "ORGANISM", 36, 39], ["our findings", "TEST", 14, 26], ["RVA", "PROBLEM", 28, 31], ["biosecurity at bovinefarms", "TREATMENT", 111, 137], ["a highly contagious viral disease", "PROBLEM", 155, 188], ["contagious", "OBSERVATION_MODIFIER", 164, 174], ["viral disease", "OBSERVATION", 175, 188]]], ["In this report, taking a shower wasnot reported to be essential for controlling PED virus transmission.", [["PED virus", "ORGANISM", 80, 89]]], ["Normally, at bovinefarms, showering-in is not popular.", [["not", "UNCERTAINTY", 42, 45], ["popular", "OBSERVATION", 46, 53]]], ["It is possible to increase the level of biosecurity atbovine farms through the farm HACCP approach by changing boots and clothing, the appropriateuse of disinfectants, or limiting access to the farms.", [["biosecurity atbovine farms", "TREATMENT", 40, 66], ["changing boots", "TREATMENT", 102, 116], ["clothing", "TREATMENT", 121, 129], ["disinfectants", "TREATMENT", 153, 166]]], ["In such cases, the presence anddetection of the prevalent indicator viruses will be decreased.", [["the prevalent indicator viruses", "PROBLEM", 44, 75], ["viruses", "OBSERVATION", 68, 75]]]], "PMC4615573": [], "11914635e8fc7c041e815263d5e20ca4ad9166bb": [["IntroductionAvian respiratory tract infections are associated with massive economic losses particularly under poor intensive rearing conditions in winter seasons.", [["respiratory tract", "ANATOMY", 18, 35], ["respiratory tract infections", "DISEASE", 18, 46], ["IntroductionAvian respiratory tract", "ORGANISM_SUBDIVISION", 0, 35], ["IntroductionAvian respiratory tract infections", "PROBLEM", 0, 46], ["massive economic losses", "PROBLEM", 67, 90], ["respiratory tract", "ANATOMY", 18, 35], ["infections", "OBSERVATION", 36, 46], ["massive", "OBSERVATION_MODIFIER", 67, 74], ["economic losses", "OBSERVATION", 75, 90]]], ["Several pathogens, adverse environmental conditions and poor managemental factors are involved [1] [2] [3] .", [["[1] [2] [3]", "SIMPLE_CHEMICAL", 95, 106], ["Several pathogens", "PROBLEM", 0, 17], ["adverse environmental conditions", "PROBLEM", 19, 51], ["poor managemental factors", "PROBLEM", 56, 81], ["pathogens", "OBSERVATION", 8, 17]]], ["Pathogens include avian influenza virus (AIV), Newcastle disease virus (NDV), infectious bronchitis virus (IBV), avian pneumovirus (APV), Mycoplasma gallisepticum (MG), and avian pathogenic E. coli (APEC).", [["avian influenza virus (AIV)", "DISEASE", 18, 45], ["Newcastle disease", "DISEASE", 47, 64], ["infectious bronchitis virus", "DISEASE", 78, 105], ["avian pneumovirus", "DISEASE", 113, 130], ["APV", "CHEMICAL", 132, 135], ["Mycoplasma gallisepticum (MG)", "DISEASE", 138, 167], ["avian pathogenic E. coli", "DISEASE", 173, 197], ["avian influenza virus", "ORGANISM", 18, 39], ["AIV", "ORGANISM", 41, 44], ["Newcastle disease virus", "ORGANISM", 47, 70], ["NDV", "ORGANISM", 72, 75], ["infectious bronchitis virus", "ORGANISM", 78, 105], ["IBV", "ORGANISM", 107, 110], ["avian pneumovirus (APV)", "ORGANISM", 113, 136], ["Mycoplasma gallisepticum", "ORGANISM", 138, 162], ["MG", "CANCER", 164, 166], ["avian pathogenic E. coli", "ORGANISM", 173, 197], ["APEC", "ORGANISM", 199, 203], ["avian influenza virus", "SPECIES", 18, 39], ["Newcastle disease virus", "SPECIES", 47, 70], ["NDV", "SPECIES", 72, 75], ["infectious bronchitis virus", "SPECIES", 78, 105], ["avian pneumovirus", "SPECIES", 113, 130], ["Mycoplasma gallisepticum", "SPECIES", 138, 162], ["avian", "SPECIES", 173, 178], ["E. coli", "SPECIES", 190, 197], ["avian influenza virus", "SPECIES", 18, 39], ["AIV", "SPECIES", 41, 44], ["Newcastle disease virus", "SPECIES", 47, 70], ["NDV", "SPECIES", 72, 75], ["infectious bronchitis virus", "SPECIES", 78, 105], ["IBV", "SPECIES", 107, 110], ["APV", "SPECIES", 132, 135], ["Mycoplasma gallisepticum", "SPECIES", 138, 162], ["E. coli", "SPECIES", 190, 197], ["APEC", "SPECIES", 199, 203], ["Pathogens", "PROBLEM", 0, 9], ["avian influenza virus", "PROBLEM", 18, 39], ["Newcastle disease virus (NDV)", "PROBLEM", 47, 76], ["infectious bronchitis virus", "PROBLEM", 78, 105], ["avian pneumovirus", "PROBLEM", 113, 130], ["Mycoplasma gallisepticum", "PROBLEM", 138, 162], ["avian pathogenic E. coli", "PROBLEM", 173, 197], ["influenza virus", "OBSERVATION", 24, 39], ["infectious", "OBSERVATION_MODIFIER", 78, 88], ["bronchitis", "OBSERVATION", 89, 99], ["E. coli", "OBSERVATION", 190, 197]]], ["Avian respiratory tract infections can be caused by single pathogens or in combination with each other in form of preceding, concurrent or secondary infections [3] [4] [5] .", [["respiratory tract", "ANATOMY", 6, 23], ["Avian respiratory tract infections", "DISEASE", 0, 34], ["infections", "DISEASE", 149, 159], ["Avian respiratory tract", "ORGANISM", 0, 23], ["Avian", "SPECIES", 0, 5], ["Avian respiratory tract infections", "PROBLEM", 0, 34], ["single pathogens", "PROBLEM", 52, 68], ["secondary infections", "PROBLEM", 139, 159], ["respiratory tract", "ANATOMY", 6, 23], ["infections", "OBSERVATION", 24, 34], ["pathogens", "OBSERVATION", 59, 68]]], ["Change in the ecosystem of the respiratory microbiome [6] , mechanical damage of the epithelium, loss of ciliated cells and the impairment of innate immune responses are a consequence of primary respiratory infections and associated with enhanced disease and economical losses during superinfections [7] .IntroductionIn Egypt, respiratory diseases outbreaks caused significant economic losses in commercial poultry production during recent years [8] .", [["respiratory", "ANATOMY", 31, 42], ["epithelium", "ANATOMY", 85, 95], ["ciliated cells", "ANATOMY", 105, 119], ["respiratory", "ANATOMY", 195, 206], ["respiratory", "ANATOMY", 327, 338], ["primary respiratory infections", "DISEASE", 187, 217], ["superinfections", "DISEASE", 284, 299], ["respiratory diseases", "DISEASE", 327, 347], ["epithelium", "TISSUE", 85, 95], ["ciliated cells", "CELL", 105, 119], ["ciliated cells", "CELL_TYPE", 105, 119], ["mechanical damage of the epithelium", "PROBLEM", 60, 95], ["loss of ciliated cells", "PROBLEM", 97, 119], ["innate immune responses", "TREATMENT", 142, 165], ["primary respiratory infections", "PROBLEM", 187, 217], ["enhanced disease", "PROBLEM", 238, 254], ["economical losses during superinfections", "PROBLEM", 259, 299], ["respiratory diseases outbreaks", "PROBLEM", 327, 357], ["significant economic losses", "PROBLEM", 365, 392], ["ecosystem", "OBSERVATION_MODIFIER", 14, 23], ["respiratory", "ANATOMY", 31, 42], ["damage", "OBSERVATION", 71, 77], ["epithelium", "ANATOMY_MODIFIER", 85, 95], ["loss", "OBSERVATION_MODIFIER", 97, 101], ["ciliated cells", "OBSERVATION", 105, 119], ["primary", "OBSERVATION_MODIFIER", 187, 194], ["respiratory infections", "OBSERVATION", 195, 217], ["respiratory diseases", "OBSERVATION", 327, 347], ["significant", "OBSERVATION_MODIFIER", 365, 376], ["economic", "OBSERVATION_MODIFIER", 377, 385], ["losses", "OBSERVATION_MODIFIER", 386, 392]]], ["Laboratory investigations revealed that IBV represents the most common pathogen detected during these outbreaks [8] [9] [10] .", [["IBV", "ORGANISM", 40, 43], ["IBV", "SPECIES", 40, 43], ["Laboratory investigations", "TEST", 0, 25], ["IBV", "PROBLEM", 40, 43], ["the most common pathogen", "PROBLEM", 55, 79], ["IBV", "OBSERVATION", 40, 43]]], ["IB is a highly contagious disease affecting the respiratory, renal and reproductive tract of chickens.", [["respiratory", "ANATOMY", 48, 59], ["renal", "ANATOMY", 61, 66], ["reproductive tract", "ANATOMY", 71, 89], ["respiratory, renal and reproductive tract", "DISEASE", 48, 89], ["respiratory", "ORGAN", 48, 59], ["renal", "ORGAN", 61, 66], ["reproductive tract", "ORGANISM_SUBDIVISION", 71, 89], ["chickens", "ORGANISM", 93, 101], ["chickens", "SPECIES", 93, 101], ["chickens", "SPECIES", 93, 101], ["a highly contagious disease", "PROBLEM", 6, 33], ["highly", "OBSERVATION_MODIFIER", 8, 14], ["contagious", "OBSERVATION_MODIFIER", 15, 25], ["disease", "OBSERVATION", 26, 33], ["respiratory", "ANATOMY", 48, 59], ["renal", "ANATOMY", 61, 66], ["reproductive", "OBSERVATION_MODIFIER", 71, 83], ["tract", "OBSERVATION_MODIFIER", 84, 89], ["chickens", "OBSERVATION", 93, 101]]], ["The disease caused by single-stranded, enveloped RNA virus belongs to the genus of Gamma coronavirus [11] .", [["Gamma coronavirus", "ORGANISM", 83, 100], ["Gamma coronavirus", "SPECIES", 83, 100], ["Gamma coronavirus", "SPECIES", 83, 100], ["The disease", "PROBLEM", 0, 11], ["single-stranded, enveloped RNA virus", "PROBLEM", 22, 58], ["Gamma coronavirus", "PROBLEM", 83, 100], ["disease", "OBSERVATION", 4, 11], ["Gamma coronavirus", "OBSERVATION", 83, 100]]], ["The spike (S) glycoprotein represents the major structural and immunogenic domain, and plays a pivotal role in tissue tropism and carry the receptor-binding site [12] .", [["tissue", "ANATOMY", 111, 117], ["spike (S) glycoprotein", "GENE_OR_GENE_PRODUCT", 4, 26], ["tissue", "TISSUE", 111, 117], ["spike (S) glycoprotein", "PROTEIN", 4, 26], ["major structural and immunogenic domain", "PROTEIN", 42, 81], ["The spike (S) glycoprotein", "PROBLEM", 0, 26], ["the major structural and immunogenic domain", "PROBLEM", 38, 81], ["tissue tropism", "PROBLEM", 111, 125]]], ["The S glycoprotein is cleaved post transitionary into S1 (globular head) and S2 (stalk) domain [13] .", [["head", "ANATOMY", 67, 71], ["S glycoprotein", "GENE_OR_GENE_PRODUCT", 4, 18], ["globular head)", "GENE_OR_GENE_PRODUCT", 58, 72], ["S glycoprotein", "PROTEIN", 4, 18], ["S1", "PROTEIN", 54, 56], ["globular head) and S2 (stalk) domain", "PROTEIN", 58, 94], ["The S glycoprotein", "TREATMENT", 0, 18], ["S1", "ANATOMY_MODIFIER", 54, 56], ["globular", "ANATOMY_MODIFIER", 58, 66], ["head", "ANATOMY", 67, 71], ["S2", "ANATOMY", 77, 79]]], ["The S1 domain possesses three hypervariable regions (HVR 1, 2 and 3) responsible for the high genetic and antigenic variability of IBV [14] .", [["HVR 1", "GENE_OR_GENE_PRODUCT", 53, 58], ["IBV", "ORGANISM", 131, 134], ["S1 domain", "PROTEIN", 4, 13], ["hypervariable regions", "PROTEIN", 30, 51], ["IBV", "SPECIES", 131, 134], ["HVR", "TEST", 53, 56], ["the high genetic and antigenic variability of IBV", "PROBLEM", 85, 134], ["S1", "ANATOMY", 4, 6], ["three", "OBSERVATION_MODIFIER", 24, 29], ["hypervariable", "OBSERVATION_MODIFIER", 30, 43]]], ["Despite massive vaccination strategies used in Egypt, IBV extensively circulates in all over Egypt in vaccinated and non-vaccinated chickens with continuous viral evolution [9, 15, 16] .", [["IBV", "ORGANISM", 54, 57], ["chickens", "ORGANISM", 132, 140], ["chickens", "SPECIES", 132, 140], ["IBV", "SPECIES", 54, 57], ["chickens", "SPECIES", 132, 140], ["massive vaccination strategies", "TREATMENT", 8, 38], ["IBV", "TREATMENT", 54, 57], ["massive", "OBSERVATION_MODIFIER", 8, 15], ["vaccination", "OBSERVATION", 16, 27]]], ["Complications between APEC and IBV infections are widely observed under field conditions and are reproduced under experimental conditions resulting in enhanced severe colibacillosis [7] and enhanced pathogenicity post IBV infection.IntroductionUnder field conditions, commercial broiler farms with inadequate biosecurity measures and with the presence of colibacillosis in early age bird are associated with more severe IBV infections in late age birds (>20 days old).", [["infections", "DISEASE", 35, 45], ["colibacillosis", "DISEASE", 167, 181], ["IBV infection", "DISEASE", 218, 231], ["colibacillosis", "DISEASE", 355, 369], ["IBV infections", "DISEASE", 420, 434], ["APEC", "ORGANISM", 22, 26], ["IBV", "ORGANISM", 31, 34], ["IBV", "ORGANISM", 218, 221], ["IBV", "ORGANISM", 420, 423], ["IBV", "SPECIES", 31, 34], ["IBV", "SPECIES", 218, 221], ["IBV", "SPECIES", 420, 423], ["Complications between APEC", "PROBLEM", 0, 26], ["IBV infections", "PROBLEM", 31, 45], ["enhanced severe colibacillosis", "PROBLEM", 151, 181], ["enhanced pathogenicity", "PROBLEM", 190, 212], ["IBV infection", "PROBLEM", 218, 231], ["commercial broiler farms", "TREATMENT", 268, 292], ["inadequate biosecurity measures", "TREATMENT", 298, 329], ["colibacillosis", "PROBLEM", 355, 369], ["more severe IBV infections", "PROBLEM", 408, 434], ["IBV", "OBSERVATION_MODIFIER", 31, 34], ["infections", "OBSERVATION", 35, 45], ["enhanced", "OBSERVATION_MODIFIER", 151, 159], ["severe", "OBSERVATION_MODIFIER", 160, 166], ["colibacillosis", "OBSERVATION", 167, 181], ["pathogenicity", "OBSERVATION_MODIFIER", 199, 212], ["post IBV", "OBSERVATION_MODIFIER", 213, 221], ["infection", "OBSERVATION", 222, 231], ["colibacillosis", "OBSERVATION", 355, 369], ["severe", "OBSERVATION_MODIFIER", 413, 419], ["IBV", "OBSERVATION_MODIFIER", 420, 423], ["infections", "OBSERVATION", 424, 434]]], ["Despite the wide spread use of antibiotics and vaccination against IBV, complications as a consequence of mixed infections of avian bacterial pathogens including APEC and IBV became a general phenomenon associated with significant economic losses.IntroductionIn the present study samples were collected from broiler farms with birds with respiratory manifestations.", [["samples", "ANATOMY", 280, 287], ["respiratory", "ANATOMY", 338, 349], ["infections", "DISEASE", 112, 122], ["avian bacterial pathogens", "DISEASE", 126, 151], ["respiratory manifestations", "DISEASE", 338, 364], ["IBV", "ORGANISM", 67, 70], ["avian bacterial pathogens", "ORGANISM", 126, 151], ["APEC", "ORGANISM", 162, 166], ["IBV", "ORGANISM", 171, 174], ["IBV", "SPECIES", 67, 70], ["APEC", "SPECIES", 162, 166], ["IBV", "SPECIES", 171, 174], ["antibiotics", "TREATMENT", 31, 42], ["vaccination", "TREATMENT", 47, 58], ["IBV", "PROBLEM", 67, 70], ["complications", "PROBLEM", 72, 85], ["mixed infections", "PROBLEM", 106, 122], ["avian bacterial pathogens", "PROBLEM", 126, 151], ["APEC", "PROBLEM", 162, 166], ["IBV", "PROBLEM", 171, 174], ["a general phenomenon", "PROBLEM", 182, 202], ["significant economic losses", "PROBLEM", 219, 246], ["the present study samples", "TEST", 262, 287], ["respiratory manifestations", "PROBLEM", 338, 364], ["mixed", "OBSERVATION_MODIFIER", 106, 111], ["infections", "OBSERVATION", 112, 122], ["general phenomenon", "OBSERVATION", 184, 202], ["significant", "OBSERVATION_MODIFIER", 219, 230], ["economic losses", "OBSERVATION", 231, 246], ["respiratory manifestations", "OBSERVATION", 338, 364]]], ["All samples were tested for the presence of IBV and APEC.", [["samples", "ANATOMY", 4, 11], ["IBV", "ORGANISM", 44, 47], ["IBV", "SPECIES", 44, 47], ["All samples", "TEST", 0, 11], ["IBV", "PROBLEM", 44, 47], ["APEC", "PROBLEM", 52, 56], ["IBV", "OBSERVATION", 44, 47]]], ["Recovered IBV isolates were genetically characterized by partial spike protein sequencing.", [["IBV", "ORGANISM", 10, 13], ["IBV", "SPECIES", 10, 13], ["IBV isolates", "PROBLEM", 10, 22], ["partial spike protein sequencing", "PROBLEM", 57, 89], ["partial", "OBSERVATION_MODIFIER", 57, 64], ["spike", "OBSERVATION_MODIFIER", 65, 70]]], ["Recovered APEC were characterized by serotyping and antibiotic profiling.", [["APEC", "PROBLEM", 10, 14], ["serotyping", "PROBLEM", 37, 47], ["antibiotic profiling", "TREATMENT", 52, 72]]], ["Bacteriophages were isolated from water samples collected from the same farms and enriched against APEC O78.", [["samples", "ANATOMY", 40, 47], ["water samples", "ORGANISM_SUBSTANCE", 34, 47], ["APEC", "ORGANISM", 99, 103], ["APEC", "SPECIES", 99, 103], ["Bacteriophages", "PROBLEM", 0, 14], ["water samples", "TEST", 34, 47]]], ["In vivo study was conducted to evaluate the efficacy of bacteriophages in reducing the pathogenicity of single and mixed infections with APEC and IBV.Sampling and sample preparationOne hundred recently succumbed chickens suspected of being IBV infected were collected from forty broiler farms.", [["sample", "ANATOMY", 163, 169], ["infections", "DISEASE", 121, 131], ["IBV infected", "DISEASE", 240, 252], ["APEC", "ORGANISM", 137, 141], ["IBV", "ORGANISM", 146, 149], ["chickens", "ORGANISM", 212, 220], ["IBV", "ORGANISM", 240, 243], ["chickens", "SPECIES", 212, 220], ["APEC", "SPECIES", 137, 141], ["IBV", "SPECIES", 146, 149], ["chickens", "SPECIES", 212, 220], ["IBV", "SPECIES", 240, 243], ["vivo study", "TEST", 3, 13], ["bacteriophages", "TREATMENT", 56, 70], ["single and mixed infections", "PROBLEM", 104, 131], ["APEC", "TREATMENT", 137, 141], ["IBV", "TREATMENT", 146, 149], ["Sampling", "TEST", 150, 158], ["sample preparation", "TEST", 163, 181], ["IBV infected", "PROBLEM", 240, 252], ["bacteriophages", "OBSERVATION", 56, 70], ["mixed", "OBSERVATION_MODIFIER", 115, 120], ["infections", "OBSERVATION", 121, 131], ["succumbed chickens", "OBSERVATION", 202, 220], ["IBV", "OBSERVATION_MODIFIER", 240, 243], ["infected", "OBSERVATION", 244, 252]]], ["The study was conducted between late 2017 and early 2018 and samples collected in northern Egypt (Dakahila and Damietta governorates).", [["samples", "ANATOMY", 61, 68], ["The study", "TEST", 0, 9], ["samples", "TEST", 61, 68], ["Dakahila and Damietta governorates", "TREATMENT", 98, 132]]], ["Lung, trachea, kidney, and liver samples were aseptically collected.", [["Lung", "ANATOMY", 0, 4], ["trachea", "ANATOMY", 6, 13], ["kidney", "ANATOMY", 15, 21], ["liver samples", "ANATOMY", 27, 40], ["Lung", "ORGAN", 0, 4], ["trachea", "MULTI-TISSUE_STRUCTURE", 6, 13], ["kidney", "ORGAN", 15, 21], ["liver samples", "CANCER", 27, 40], ["Lung, trachea, kidney, and liver samples", "TEST", 0, 40], ["trachea", "ANATOMY", 6, 13], ["kidney", "ANATOMY", 15, 21], ["liver", "ANATOMY", 27, 32]]], ["On the same day of sampling, half of the organs were cultured for bacteriological investigation in buffered peptone water at 37\u00baC for 24 h.", [["organs", "ANATOMY", 41, 47], ["organs", "ORGAN", 41, 47], ["sampling", "TEST", 19, 27], ["bacteriological investigation", "TEST", 66, 95], ["buffered peptone water", "TREATMENT", 99, 121], ["organs", "ANATOMY", 41, 47]]], ["For IBV screening, lung and trachea samples were homogenized with an equal mass of phosphate buffer saline and then centrifuged at 7,000 \u00d7 g for 5 min.", [["lung", "ANATOMY", 19, 23], ["trachea samples", "ANATOMY", 28, 43], ["phosphate", "CHEMICAL", 83, 92], ["phosphate", "CHEMICAL", 83, 92], ["IBV", "ORGANISM", 4, 7], ["lung", "ORGAN", 19, 23], ["trachea samples", "CANCER", 28, 43], ["phosphate", "SIMPLE_CHEMICAL", 83, 92], ["saline", "SIMPLE_CHEMICAL", 100, 106], ["IBV", "SPECIES", 4, 7], ["IBV screening", "TEST", 4, 17], ["lung and trachea samples", "TEST", 19, 43], ["phosphate buffer saline", "TREATMENT", 83, 106], ["lung", "ANATOMY", 19, 23], ["trachea", "ANATOMY", 28, 35], ["mass", "OBSERVATION", 75, 79]]], ["Supernatant was collected and stored at \u221280\u00baC until further investigation.IBV and E.coli detection and characterizationViral RNA was extracted using the QIAamp viral RNA mini kit (QIAGEN) in accordance with the manufacturer instructions.", [["Supernatant", "ANATOMY", 0, 11], ["Supernatant", "ORGANISM_SUBSTANCE", 0, 11], ["IBV", "ORGANISM", 74, 77], ["Viral", "ORGANISM", 119, 124], ["Viral RNA", "RNA", 119, 128], ["IBV", "SPECIES", 74, 77], ["IBV", "SPECIES", 74, 77], ["E.coli", "SPECIES", 82, 88], ["further investigation", "TEST", 52, 73], ["IBV", "PROBLEM", 74, 77], ["E.coli detection", "TEST", 82, 98], ["characterization", "TEST", 103, 119], ["Viral RNA", "PROBLEM", 119, 128], ["the QIAamp viral RNA mini kit", "TREATMENT", 149, 178], ["E.coli", "OBSERVATION", 82, 88], ["RNA", "OBSERVATION", 125, 128]]], ["One-step RT-PCR was performed for IBV screening as previously described [17] .", [["IBV", "ORGANISM", 34, 37], ["IBV", "SPECIES", 34, 37], ["One-step RT-PCR", "TEST", 0, 15], ["IBV screening", "TEST", 34, 47]]], ["Genotyping with forward and reverse primers for amplification of HVR1, amplicon purification and sequencing was performed as previously described [17] .", [["HVR1", "DNA", 65, 69], ["forward and reverse primers", "TREATMENT", 16, 43], ["amplification of HVR1", "TREATMENT", 48, 69], ["amplicon purification", "TREATMENT", 71, 92], ["sequencing", "TEST", 97, 107]]], ["Obtained sequences in this study aligned with sequences represent all infectious bronchitis virus genotypes proposed by [18] .", [["bronchitis", "DISEASE", 81, 91], ["infectious bronchitis virus", "ORGANISM", 70, 97], ["infectious bronchitis virus", "SPECIES", 70, 97], ["this study", "TEST", 22, 32], ["sequences", "TEST", 46, 55], ["all infectious bronchitis virus genotypes", "PROBLEM", 66, 107], ["infectious", "OBSERVATION_MODIFIER", 70, 80]]], ["All samples used in the phylogenetic analysis were downloaded from GenBank (http://www.ncbi.nlm.nih.gov).", [["samples", "ANATOMY", 4, 11], ["All samples", "TEST", 0, 11], ["the phylogenetic analysis", "TEST", 20, 45]]], ["The sequences were aligned using multiple alignment MAFFT version 7 (https://mafft.cbrc.jp/alignment/server/).", [["multiple alignment MAFFT version", "TEST", 33, 65]]], ["The tree was constructed with the MEGA 6 software [19] using the nucleotide substitution of the Hasegawa-Kishino-Yano model with the gamma-distributed rate (with four rate categories) with bootstrap value based on 1000 replicates [20] .", [["nucleotide", "CHEMICAL", 65, 75], ["nucleotide", "CHEMICAL", 65, 75], ["the nucleotide substitution", "TREATMENT", 61, 88], ["the Hasegawa", "TEST", 92, 104], ["the gamma-distributed rate", "TREATMENT", 129, 155], ["four rate categories", "TREATMENT", 162, 182], ["bootstrap value", "TEST", 189, 204], ["tree", "ANATOMY_MODIFIER", 4, 8]]], ["Then, the tree was viewed and edited using the FigTree v1.4.2 software (http://tree.bio.ed.ac. uk/software/figtree/).IBV and E.coli detection and characterizationFor the bacteriological investigation, E.coli isolation and confirmation was performed in accordance with [21] .", [["IBV", "ORGANISM", 117, 120], ["IBV", "SPECIES", 117, 120], ["IBV", "SPECIES", 117, 120], ["E.coli", "SPECIES", 125, 131], ["E.coli", "SPECIES", 201, 207], ["IBV", "PROBLEM", 117, 120], ["E.coli detection", "TEST", 125, 141], ["the bacteriological investigation", "TEST", 166, 199], ["E.coli isolation", "TREATMENT", 201, 217], ["confirmation", "TEST", 222, 234], ["E.coli", "OBSERVATION", 125, 131]]], ["Confirmed, positive E.coli strains were subjected to serotyping using all available O (O1 to O181) antisera in accordance with [22] , cross-reacting antigens were used to ensure the removal of cross-reactivity.", [["cross-reacting antigens", "PROTEIN", 134, 157], ["E.coli", "SPECIES", 20, 26], ["positive E.coli strains", "PROBLEM", 11, 34], ["serotyping", "TEST", 53, 63], ["cross-reacting antigens", "TREATMENT", 134, 157], ["the removal of cross-reactivity", "TREATMENT", 178, 209], ["positive", "OBSERVATION_MODIFIER", 11, 19], ["E.coli strains", "OBSERVATION", 20, 34]]], ["All confirmed strains were tested against antibiotics commonly used in Egyptian farms by disc diffusion, with testing procedures and interpretations of the results performed in accordance with reference laboratory protocols.", [["disc", "ANATOMY", 89, 93], ["strains", "PROBLEM", 14, 21], ["antibiotics", "TREATMENT", 42, 53], ["disc diffusion", "TEST", 89, 103], ["testing procedures", "TEST", 110, 128], ["strains", "OBSERVATION", 14, 21], ["disc", "ANATOMY", 89, 93]]], ["One of the field isolates E.coli (serotype O78) was tested for purity using API 20E (bioM\u00e9rieux, Inc.) and counted in colony-forming units (CFU).Bacteriophage isolation, enrichment, and titrationOver the surveillance period, sewage water samples were collected from poultry farms and used for the isolation of bacteriophages specific to APEC O78.", [["colony", "ANATOMY", 118, 124], ["samples", "ANATOMY", 238, 245], ["API 20E", "CHEMICAL", 76, 83], ["O78", "CHEMICAL", 342, 345], ["E.coli", "ORGANISM", 26, 32], ["serotype O78", "ORGANISM", 34, 46], ["APEC", "ORGANISM", 337, 341], ["APEC O78", "SPECIES", 337, 345], ["E.coli (serotype O78", "TREATMENT", 26, 46], ["API", "TEST", 76, 79], ["Bacteriophage isolation", "TREATMENT", 145, 168], ["sewage water samples", "TEST", 225, 245], ["the isolation of bacteriophages", "TREATMENT", 293, 324], ["E.coli", "OBSERVATION", 26, 32], ["enrichment", "OBSERVATION_MODIFIER", 170, 180]]], ["Samples were centrifuged at 10,000 rpm for 10 min and then filtered through a 0.22 \u03bcm filter (Millipore).", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["a 0.22 \u03bcm filter (Millipore", "TREATMENT", 76, 103]]], ["Bacteriophage purification and enrichment was performed in accordance with [23] .", [["Bacteriophage purification", "TREATMENT", 0, 26]]], ["Briefly, filtered samples were mixed with Luria Bertani (LB) broth (Sigma), early-log grown APEC O78 added and samples incubated overnight at 37\u00baC with shaking set to 120 rpm/min.", [["samples", "ANATOMY", 18, 25], ["samples", "ANATOMY", 111, 118], ["O78", "CHEMICAL", 97, 100], ["APEC", "ORGANISM", 92, 96], ["O78", "SIMPLE_CHEMICAL", 97, 100], ["Luria Bertani", "SPECIES", 42, 55], ["APEC", "SPECIES", 92, 96], ["filtered samples", "TEST", 9, 25], ["shaking", "PROBLEM", 152, 159]]], ["Then, samples were centrifuged at 10,000 rpm for 10 min and filtered through a 0.22 \u03bcm filter.", [["samples", "ANATOMY", 6, 13], ["samples", "TEST", 6, 13], ["a 0.22 \u03bcm filter", "TREATMENT", 77, 93]]], ["The presence of bacteriophages was initially tested by the spot test method based on the double layer plaque technique in accordance with [24] .", [["bacteriophages", "PROBLEM", 16, 30], ["the spot test method", "TEST", 55, 75], ["the double layer plaque technique", "TREATMENT", 85, 118], ["bacteriophages", "OBSERVATION", 16, 30], ["layer", "OBSERVATION_MODIFIER", 96, 101], ["plaque", "OBSERVATION", 102, 108]]], ["For this, 100 \u00b5l of APEC O78 were cultured on LB agar for 8 h, then 10 \u00b5l of the prepared bacteriophage suspension spotted onto it, and plates incubated at 37\u00baC overnight.", [["APEC", "ORGANISM", 20, 24], ["O78", "CELL", 25, 28], ["APEC O78", "CELL_LINE", 20, 28], ["APEC", "SPECIES", 20, 24], ["APEC O78", "TREATMENT", 20, 28], ["the prepared bacteriophage suspension", "TREATMENT", 77, 114]]], ["The appearance of a clear zone in the plate indicated the presence of the lytic phage.", [["the lytic phage", "PROBLEM", 70, 85], ["clear", "OBSERVATION", 20, 25], ["zone", "OBSERVATION_MODIFIER", 26, 30], ["plate", "ANATOMY_MODIFIER", 38, 43], ["lytic", "OBSERVATION_MODIFIER", 74, 79], ["phage", "OBSERVATION", 80, 85]]], ["Plaque assay was used for the titration of bacteriophages as previously described [25] .Bacteriophage isolation, enrichment, and titrationIn vivo evaluation of bacteriophage efficacy in the reduction of E.coli and/or IB pathogenicityEthics statementAnimal experimental designs and procedures were reviewed and approved by RLQP in accordance with guidelines of the ministry of agriculture and land reclamation and ministry of environment of Egypt.Virus and bacteriaPure E.coli O78 isolate recovered in the present study were titrated by colony-forming units (CFU).", [["Plaque", "ANATOMY", 0, 6], ["colony", "ANATOMY", 536, 542], ["E.coli", "GENE_OR_GENE_PRODUCT", 203, 209], ["Virus", "ORGANISM", 446, 451], ["bacteriaPure E.coli", "ORGANISM", 456, 475], ["O78", "ORGANISM", 476, 479], ["bacteriaPure E.coli O78", "SPECIES", 456, 479], ["E.coli", "SPECIES", 203, 209], ["Plaque assay", "TEST", 0, 12], ["the titration of bacteriophages", "TREATMENT", 26, 57], ["Bacteriophage isolation", "TREATMENT", 88, 111], ["vivo evaluation", "TEST", 141, 156], ["bacteriophage efficacy", "TREATMENT", 160, 182], ["E.coli", "PROBLEM", 203, 209], ["IB pathogenicity", "PROBLEM", 217, 233], ["land reclamation", "TREATMENT", 392, 408], ["Virus", "PROBLEM", 446, 451], ["bacteriaPure E.coli", "TREATMENT", 456, 475], ["bacteriophage efficacy", "OBSERVATION", 160, 182], ["E.coli", "OBSERVATION", 203, 209], ["IB", "OBSERVATION_MODIFIER", 217, 219], ["pathogenicity", "OBSERVATION", 220, 233], ["bacteriaPure E.coli", "OBSERVATION", 456, 475]]], ["Birds were challenged with 10 8 CFU diluted in 100 \u00b5l sterile PBS.", [["Birds", "ORGANISM", 0, 5]]], ["The IBV strain IBV-EG/1212B-2012 (accession number: JQ839287) belonging to Egy/Var II [15] was used for the intratracheal challenge with 10 6 EID 50 in 100 \u00b5l per bird.", [["IBV-EG/1212B-2012", "CHEMICAL", 15, 32], ["Egy/Var II", "CHEMICAL", 75, 85], ["IBV strain", "ORGANISM", 4, 14], ["IBV-EG/1212B-2012", "ORGANISM", 15, 32], ["IBV strain IBV-EG/1212B-2012", "SPECIES", 4, 32], ["The IBV strain IBV", "TREATMENT", 0, 18], ["the intratracheal challenge", "TREATMENT", 104, 131], ["intratracheal", "ANATOMY", 108, 121]]], ["Previously described primers and probes were used to create a standard curve for absolute quantification of IBV shedding [26] .Experimental designA total of 70 healthy one-day old chicks were purchased from a local poultry hatchery and housed in isolators with ad libitum access to feed and water.", [["IBV", "ORGANISM", 108, 111], ["chicks", "ORGANISM", 180, 186], ["chicks", "SPECIES", 180, 186], ["IBV", "SPECIES", 108, 111], ["Previously described primers and probes", "PROBLEM", 0, 39], ["a standard curve", "TREATMENT", 60, 76], ["IBV shedding", "TREATMENT", 108, 120]]], ["One day later, chicks were monitored for the presence of IBV or APEC O78 as previously described and then randomly divided into seven groups.", [["chicks", "ORGANISM", 15, 21], ["IBV", "ORGANISM", 57, 60], ["chicks", "SPECIES", 15, 21], ["IBV", "SPECIES", 57, 60], ["APEC O78", "SPECIES", 64, 72], ["IBV", "PROBLEM", 57, 60], ["APEC", "PROBLEM", 64, 68], ["IBV", "OBSERVATION", 57, 60]]], ["Groups 1, 2, and 3 were treated with bacteriophages by intratracheal inoculation with 10 8 PFU at 1, 5, 8 and 13 days; whilst groups 4, 5, 6 and 7 were not treated with bacteriophages.", [["bacteriophages", "TREATMENT", 37, 51], ["intratracheal inoculation", "TREATMENT", 55, 80], ["bacteriophages", "TREATMENT", 169, 183], ["intratracheal", "ANATOMY", 55, 68]]], ["Groups 2 and 5 were challenged intratracheally with 10 6 EID 50 of IBV.", [["5", "ORGANISM", 13, 14], ["IBV", "ORGANISM", 67, 70], ["IBV", "SPECIES", 67, 70], ["IBV", "TREATMENT", 67, 70]]], ["Group 7 was kept as a negative control and received PBS.", [["PBS", "TREATMENT", 52, 55]]], ["Three birds per time point were humanely culled at 4, 9 and 15 days postinfection (dpi).", [["birds", "ORGANISM", 6, 11]]], ["The carcasses were weighed and dissected and trachea and lung samples collected aseptically for the detection and titration of APEC O78, bacteriophages and IBV as previously described.Experimental designClinical signs scoring and sampling All birds were observed twice daily and clinical signs recorded in accordance with [27] .", [["trachea", "ANATOMY", 45, 52], ["lung samples", "ANATOMY", 57, 69], ["trachea", "MULTI-TISSUE_STRUCTURE", 45, 52], ["lung samples", "CANCER", 57, 69], ["APEC", "ORGANISM", 127, 131], ["O78", "GENE_OR_GENE_PRODUCT", 132, 135], ["IBV", "ORGANISM", 156, 159], ["birds", "ORGANISM", 243, 248], ["APEC O78", "SPECIES", 127, 135], ["IBV", "SPECIES", 156, 159], ["trachea and lung samples", "TEST", 45, 69], ["the detection", "TEST", 96, 109], ["APEC O78", "TREATMENT", 127, 135], ["bacteriophages", "TREATMENT", 137, 151], ["IBV", "PROBLEM", 156, 159], ["Experimental designClinical signs scoring", "PROBLEM", 184, 225], ["clinical signs", "TEST", 279, 293], ["trachea", "ANATOMY", 45, 52], ["lung", "ANATOMY", 57, 61], ["IBV", "OBSERVATION", 156, 159]]], ["Briefly, no signs were recorded as 0, mild signs included mild gasping, coughing or depression and were recorded as 1, and severe gasping, coughing or depression with ruffled feathers was considered as severe signs and recorded as 2.", [["coughing", "DISEASE", 72, 80], ["depression", "DISEASE", 84, 94], ["coughing", "DISEASE", 139, 147], ["depression", "DISEASE", 151, 161], ["signs", "PROBLEM", 12, 17], ["mild signs", "PROBLEM", 38, 48], ["mild gasping", "PROBLEM", 58, 70], ["coughing", "PROBLEM", 72, 80], ["depression", "PROBLEM", 84, 94], ["severe gasping", "PROBLEM", 123, 137], ["coughing", "PROBLEM", 139, 147], ["depression", "PROBLEM", 151, 161], ["ruffled feathers", "PROBLEM", 167, 183], ["severe signs", "PROBLEM", 202, 214], ["mild", "OBSERVATION_MODIFIER", 58, 62], ["gasping", "OBSERVATION", 63, 70], ["severe", "OBSERVATION_MODIFIER", 123, 129], ["gasping", "OBSERVATION", 130, 137]]], ["Birds with severe signs unable to move were recorded as 3 and humanely culled and samples collected.", [["samples", "ANATOMY", 82, 89], ["severe signs", "PROBLEM", 11, 23], ["severe", "OBSERVATION_MODIFIER", 11, 17]]], ["Birds which unexpectedly succumbed to disease were also recorded as 3 and samples collected.Statistical analysisStatistical significances of viral and bacterial shedding between different groups were evaluated using Student's t-test in Microsoft Excel based on the mean of shedding quantities in three tested birds sampled from each group at each time point.ResultsHistory, clinical findings, and prevalence of APEC and IBV in the examined flocks Forty broiler flocks, aged between 30 and 40 days and suffering from respiratory affections, from the Dakahlia and Damietta governorate were examined.", [["samples", "ANATOMY", 74, 81], ["respiratory", "ANATOMY", 516, 527], ["APEC", "DISEASE", 411, 415], ["respiratory affections", "DISEASE", 516, 538], ["APEC", "ORGANISM", 411, 415], ["IBV", "ORGANISM", 420, 423], ["IBV", "SPECIES", 420, 423], ["disease", "PROBLEM", 38, 45], ["viral and bacterial shedding", "PROBLEM", 141, 169], ["Student's t-test", "TEST", 216, 232], ["APEC", "PROBLEM", 411, 415], ["IBV", "TREATMENT", 420, 423], ["Forty broiler flocks", "PROBLEM", 447, 467], ["respiratory affections", "PROBLEM", 516, 538], ["the Dakahlia and Damietta governorate", "TREATMENT", 545, 582], ["viral", "OBSERVATION_MODIFIER", 141, 146], ["bacterial", "OBSERVATION_MODIFIER", 151, 160], ["broiler flocks", "OBSERVATION", 453, 467], ["respiratory affections", "OBSERVATION", 516, 538]]], ["Unwell birds showed respiratory manifestations visible as nasal discharge, sneezing, gasping and swollen head.", [["respiratory", "ANATOMY", 20, 31], ["nasal", "ANATOMY", 58, 63], ["swollen head", "ANATOMY", 97, 109], ["nasal", "ORGANISM_SUBDIVISION", 58, 63], ["head", "ORGANISM_SUBDIVISION", 105, 109], ["Unwell birds", "TEST", 0, 12], ["respiratory manifestations", "PROBLEM", 20, 46], ["nasal discharge", "PROBLEM", 58, 73], ["sneezing", "PROBLEM", 75, 83], ["gasping and swollen head", "PROBLEM", 85, 109], ["respiratory manifestations", "OBSERVATION", 20, 46], ["nasal", "ANATOMY", 58, 63], ["sneezing", "OBSERVATION", 75, 83], ["swollen", "OBSERVATION", 97, 104], ["head", "ANATOMY", 105, 109]]], ["In all farms examined unwell birds were isolated and subjected to intense antibiotic treatments.", [["birds", "ORGANISM", 29, 34], ["intense antibiotic treatments", "TREATMENT", 66, 95]]], ["However, clear differences in activity and feed intake remained.", [["clear", "OBSERVATION_MODIFIER", 9, 14], ["differences", "OBSERVATION_MODIFIER", 15, 26], ["activity", "OBSERVATION_MODIFIER", 30, 38]]], ["Screening of collected samples focused on the detection of IBV and E.coli.ResultsEight farms were positive for E.coli (20% of all farms examined), five farms from the Dakahlia and three farms from the Damietta governate.", [["samples", "ANATOMY", 23, 30], ["IBV", "ORGANISM", 59, 62], ["E.coli", "GENE_OR_GENE_PRODUCT", 67, 73], ["IBV", "SPECIES", 59, 62], ["E.coli", "SPECIES", 67, 73], ["E.coli", "SPECIES", 111, 117], ["collected samples", "TEST", 13, 30], ["the detection", "TEST", 42, 55], ["IBV", "PROBLEM", 59, 62], ["E.coli", "PROBLEM", 67, 73], ["Eight farms", "TEST", 81, 92], ["E.coli", "PROBLEM", 111, 117], ["the Dakahlia", "PROBLEM", 163, 175], ["E.coli", "OBSERVATION", 67, 73]]], ["Serotyping of the isolated strains revealed the presence of the O26, O78, O86, O114, O119 serogroups, with the O125 serogroup detected on three farms.", [["the isolated strains", "PROBLEM", 14, 34], ["O26", "OBSERVATION_MODIFIER", 64, 67]]], ["Disc diffusion tests showed the following resistance rates: 100% to penicillin, 75% to gentamycin and streptomycin, 62.5% to ciprofloxacin, 50% to cefotaxime and 25% to doxycycline.", [["penicillin", "CHEMICAL", 68, 78], ["gentamycin", "CHEMICAL", 87, 97], ["streptomycin", "CHEMICAL", 102, 114], ["ciprofloxacin", "CHEMICAL", 125, 138], ["cefotaxime", "CHEMICAL", 147, 157], ["doxycycline", "CHEMICAL", 169, 180], ["penicillin", "CHEMICAL", 68, 78], ["gentamycin", "CHEMICAL", 87, 97], ["streptomycin", "CHEMICAL", 102, 114], ["ciprofloxacin", "CHEMICAL", 125, 138], ["cefotaxime", "CHEMICAL", 147, 157], ["doxycycline", "CHEMICAL", 169, 180], ["penicillin", "SIMPLE_CHEMICAL", 68, 78], ["gentamycin", "SIMPLE_CHEMICAL", 87, 97], ["streptomycin", "SIMPLE_CHEMICAL", 102, 114], ["ciprofloxacin", "SIMPLE_CHEMICAL", 125, 138], ["cefotaxime", "SIMPLE_CHEMICAL", 147, 157], ["doxycycline", "SIMPLE_CHEMICAL", 169, 180], ["Disc diffusion tests", "TEST", 0, 20], ["resistance rates", "TEST", 42, 58], ["penicillin", "TREATMENT", 68, 78], ["gentamycin", "TREATMENT", 87, 97], ["streptomycin", "TREATMENT", 102, 114], ["ciprofloxacin", "TREATMENT", 125, 138], ["cefotaxime", "TREATMENT", 147, 157], ["doxycycline", "TREATMENT", 169, 180]]], ["75% of all isolated strains were multidrug-resistant (MDR).ResultsTwelve farms were positive for IBV (30% of all farms examined) determined by real-time PCR, with ten farms from the Dakahlia and two farms from the Damietta governate.", [["IBV", "ORGANISM", 97, 100], ["IBV", "SPECIES", 97, 100], ["all isolated strains", "PROBLEM", 7, 27], ["Twelve farms", "TEST", 66, 78], ["IBV", "PROBLEM", 97, 100], ["the Dakahlia", "PROBLEM", 178, 190]]], ["Postmortem examination of the recently succumbed birds revealed the presence of caseous plug at the tracheal bifurcation, caseous trachitis, and fibrinous pericarditis, perihepatitis and air sacculitis.", [["tracheal bifurcation", "ANATOMY", 100, 120], ["caseous trachitis", "ANATOMY", 122, 139], ["perihepatitis", "ANATOMY", 169, 182], ["air sacculitis", "ANATOMY", 187, 201], ["trachitis", "DISEASE", 130, 139], ["fibrinous pericarditis", "DISEASE", 145, 167], ["perihepatitis", "DISEASE", 169, 182], ["air sacculitis", "DISEASE", 187, 201], ["birds", "ORGANISM", 49, 54], ["caseous plug", "PATHOLOGICAL_FORMATION", 80, 92], ["tracheal bifurcation", "MULTI-TISSUE_STRUCTURE", 100, 120], ["Postmortem examination", "TEST", 0, 22], ["caseous plug at the tracheal bifurcation", "PROBLEM", 80, 120], ["caseous trachitis", "PROBLEM", 122, 139], ["fibrinous pericarditis", "PROBLEM", 145, 167], ["perihepatitis", "PROBLEM", 169, 182], ["air sacculitis", "PROBLEM", 187, 201], ["caseous", "OBSERVATION_MODIFIER", 80, 87], ["plug", "OBSERVATION", 88, 92], ["tracheal", "ANATOMY", 100, 108], ["bifurcation", "ANATOMY_MODIFIER", 109, 120], ["caseous", "OBSERVATION_MODIFIER", 122, 129], ["trachitis", "OBSERVATION", 130, 139], ["fibrinous", "OBSERVATION_MODIFIER", 145, 154], ["pericarditis", "OBSERVATION", 155, 167], ["air sacculitis", "OBSERVATION", 187, 201]]], ["For virus isolation, specific pathogen free embryonated chicken eggs were inoculated.", [["eggs", "ANATOMY", 64, 68], ["chicken", "ORGANISM", 56, 63], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 64, 68], ["chicken", "SPECIES", 56, 63], ["chicken", "SPECIES", 56, 63], ["virus isolation", "TREATMENT", 4, 19], ["specific pathogen free embryonated chicken eggs", "PROBLEM", 21, 68]]], ["Schematic outline of the experimental design RNA was extracted from the allantoic fluid and the partial S1 gene of each isolate sequenced.", [["allantoic fluid", "ANATOMY", 72, 87], ["allantoic fluid", "ORGANISM_SUBSTANCE", 72, 87], ["S1", "GENE_OR_GENE_PRODUCT", 104, 106], ["partial S1 gene", "DNA", 96, 111], ["the experimental design RNA", "PROBLEM", 21, 48], ["the allantoic fluid", "TEST", 68, 87], ["allantoic fluid", "OBSERVATION", 72, 87]]], ["Results obtained revealed that the tested samples clustered within the Egyptian variant group of GI-23 genotype subgroups ( Figure 2In vivo evaluation of bacteriophage treatmentClinical signs observed including gasping, coughing or depression started to appear from three days postchallenge with APEC or a mixed APEC and IBV infection.", [["samples", "ANATOMY", 42, 49], ["coughing", "DISEASE", 220, 228], ["depression", "DISEASE", 232, 242], ["APEC", "CHEMICAL", 296, 300], ["IBV infection", "DISEASE", 321, 334], ["APEC", "ORGANISM", 312, 316], ["IBV", "ORGANISM", 321, 324], ["APEC", "SPECIES", 312, 316], ["IBV", "SPECIES", 321, 324], ["the tested samples", "TEST", 31, 49], ["GI", "TEST", 97, 99], ["vivo evaluation", "TEST", 135, 150], ["bacteriophage treatment", "TREATMENT", 154, 177], ["Clinical signs", "PROBLEM", 177, 191], ["gasping", "PROBLEM", 211, 218], ["coughing", "PROBLEM", 220, 228], ["depression", "PROBLEM", 232, 242], ["APEC", "PROBLEM", 296, 300], ["a mixed APEC", "PROBLEM", 304, 316], ["IBV infection", "PROBLEM", 321, 334], ["IBV", "OBSERVATION_MODIFIER", 321, 324], ["infection", "OBSERVATION", 325, 334]]], ["Bacteriophage treatment delayed the onset of the clinical signs to 6 days post-challenge (dpc) and in addition markedly reduced their severity in both groups (Figure 3) .", [["Bacteriophage treatment", "TREATMENT", 0, 23], ["markedly", "OBSERVATION_MODIFIER", 111, 119], ["reduced", "OBSERVATION_MODIFIER", 120, 127]]], ["Regarding IBV infection, clinical signs were observed from four-days postchallenge, with bacteriophage treatment leading to a reduction of their severity, but not delaying their onset (Figure 3) .In vivo evaluation of bacteriophage treatmentBacteriophage treatment was not associated with mortality in single APEC or mixed APEC and IBV infected groups.", [["IBV infection", "DISEASE", 10, 23], ["IBV infected", "DISEASE", 332, 344], ["IBV", "ORGANISM", 10, 13], ["IBV", "ORGANISM", 332, 335], ["IBV", "SPECIES", 10, 13], ["APEC", "SPECIES", 309, 313], ["APEC", "SPECIES", 323, 327], ["IBV", "SPECIES", 332, 335], ["IBV infection", "PROBLEM", 10, 23], ["clinical signs", "TEST", 25, 39], ["bacteriophage treatment", "TREATMENT", 89, 112], ["vivo evaluation", "TEST", 199, 214], ["bacteriophage treatmentBacteriophage treatment", "TREATMENT", 218, 264], ["single APEC", "PROBLEM", 302, 313], ["mixed APEC and IBV infected groups", "PROBLEM", 317, 351], ["infection", "OBSERVATION", 14, 23], ["mixed APEC", "OBSERVATION", 317, 327], ["IBV", "OBSERVATION_MODIFIER", 332, 335], ["infected", "OBSERVATION", 336, 344]]], ["In contrast, birds challenged with APEC alone and mixed APEC and IBV infection without bacteriophage treatment showed a 16% and 29% mortality rate at 8 and 7 days post-infection respectively (Figure 4 ).", [["APEC", "CHEMICAL", 35, 39], ["APEC", "CHEMICAL", 56, 60], ["IBV infection", "DISEASE", 65, 78], ["birds", "ORGANISM", 13, 18], ["APEC", "ORGANISM", 35, 39], ["APEC", "ORGANISM", 56, 60], ["IBV", "ORGANISM", 65, 68], ["APEC", "SPECIES", 35, 39], ["APEC", "SPECIES", 56, 60], ["IBV", "SPECIES", 65, 68], ["APEC", "PROBLEM", 35, 39], ["mixed APEC", "PROBLEM", 50, 60], ["IBV infection", "PROBLEM", 65, 78], ["bacteriophage treatment", "TREATMENT", 87, 110], ["mortality rate", "TEST", 132, 146], ["IBV", "OBSERVATION_MODIFIER", 65, 68], ["infection", "OBSERVATION", 69, 78]]], ["Bacteriophage treatment in combination with single IBV infection did not reduce the mortality of 26% (Figure 4 ).", [["IBV infection", "DISEASE", 51, 64], ["IBV", "ORGANISM", 51, 54], ["IBV", "SPECIES", 51, 54], ["Bacteriophage treatment", "TREATMENT", 0, 23], ["single IBV infection", "PROBLEM", 44, 64], ["infection", "OBSERVATION", 55, 64]]], ["[18] with samples from the present study indicated by black circles.", [["samples from the present study", "TEST", 10, 40], ["black circles", "OBSERVATION", 54, 67]]], ["The tree was constructed using the nucleotide substitution of the Hasegawa-Kishino-Yano model with the gammadistributed rate (with four rate categories) with bootstrap value based on 1000 replicates Bacteriophage treatment significantly reduced APEC shedding after single APEC or mixed APEC and IBV challenge, with a gradual decrease of bacterial loads in lung tissues over time.", [["lung tissues", "ANATOMY", 356, 368], ["nucleotide", "CHEMICAL", 35, 45], ["APEC", "CHEMICAL", 272, 276], ["nucleotide", "CHEMICAL", 35, 45], ["APEC", "ORGANISM", 245, 249], ["IBV", "ORGANISM", 295, 298], ["lung tissues", "TISSUE", 356, 368], ["APEC", "SPECIES", 245, 249], ["APEC", "SPECIES", 272, 276], ["APEC", "SPECIES", 286, 290], ["IBV", "SPECIES", 295, 298], ["the nucleotide substitution", "TREATMENT", 31, 58], ["the Hasegawa", "TREATMENT", 62, 74], ["the gammadistributed rate", "TREATMENT", 99, 124], ["four rate categories", "TREATMENT", 131, 151], ["bootstrap value", "TEST", 158, 173], ["Bacteriophage treatment", "TREATMENT", 199, 222], ["single APEC", "TREATMENT", 265, 276], ["mixed APEC", "TREATMENT", 280, 290], ["IBV challenge", "TREATMENT", 295, 308], ["bacterial loads in lung tissues", "PROBLEM", 337, 368], ["gradual", "OBSERVATION_MODIFIER", 317, 324], ["decrease", "OBSERVATION_MODIFIER", 325, 333], ["bacterial loads", "OBSERVATION", 337, 352], ["lung", "ANATOMY", 356, 360]]], ["In contrast, a nontreated and challenged group showed a significantly higher APEC load with a gradual increase over time especially at 9 and 15 dpc ( Figure 5 ).", [["a significantly higher APEC load", "PROBLEM", 54, 86], ["APEC load", "OBSERVATION", 77, 86], ["gradual", "OBSERVATION_MODIFIER", 94, 101], ["increase", "OBSERVATION_MODIFIER", 102, 110]]], ["Interestingly, bacteriophage treatment significantly reduced IBV shedding in the mixed infected group but not in the IBV alone infected group comparing to the mixed infected group without bacteriophage treatment.", [["IBV", "ORGANISM", 61, 64], ["IBV", "ORGANISM", 117, 120], ["IBV", "SPECIES", 61, 64], ["IBV", "SPECIES", 117, 120], ["bacteriophage treatment", "TREATMENT", 15, 38], ["IBV", "PROBLEM", 61, 64], ["bacteriophage treatment", "TREATMENT", 188, 211], ["bacteriophage", "OBSERVATION_MODIFIER", 15, 28], ["reduced", "OBSERVATION_MODIFIER", 53, 60], ["IBV", "OBSERVATION", 61, 64], ["mixed", "OBSERVATION_MODIFIER", 81, 86], ["infected", "OBSERVATION", 87, 95], ["infected", "OBSERVATION", 127, 135], ["mixed", "OBSERVATION_MODIFIER", 159, 164], ["infected", "OBSERVATION", 165, 173]]], ["The bacteriophage treated group infected with IBV showed relatively comparable results to the infected non-treated group.", [["IBV", "ORGANISM", 46, 49], ["IBV", "SPECIES", 46, 49], ["The bacteriophage", "TREATMENT", 0, 17], ["IBV", "PROBLEM", 46, 49], ["infected", "OBSERVATION", 94, 102]]], ["Groups with single IBV infection and mixed APEC and IBV infection with bacteriophage treatment showed a reduction, but not statistically significant, of IBV comparing to single IBV infection without bacteriophage treatment, with the reduction only becoming statistically significant at 15 dpc ( Figure 6 ).DiscussionInfectious bronchitis in particular complicated by mixed viral and/or bacterial infections is associated with catastrophic economic losses for the global poultry industry, and a significant threat for food security.", [["IBV infection", "DISEASE", 19, 32], ["IBV infection", "DISEASE", 52, 65], ["IBV infection", "DISEASE", 177, 190], ["bronchitis", "DISEASE", 327, 337], ["viral and/or bacterial infections", "DISEASE", 373, 406], ["IBV", "ORGANISM", 19, 22], ["APEC", "ORGANISM", 43, 47], ["IBV", "ORGANISM", 52, 55], ["IBV", "ORGANISM", 153, 156], ["IBV", "ORGANISM", 177, 180], ["IBV", "SPECIES", 19, 22], ["APEC", "SPECIES", 43, 47], ["IBV", "SPECIES", 52, 55], ["IBV", "SPECIES", 153, 156], ["IBV", "SPECIES", 177, 180], ["single IBV infection", "PROBLEM", 12, 32], ["mixed APEC", "PROBLEM", 37, 47], ["IBV infection", "PROBLEM", 52, 65], ["bacteriophage treatment", "TREATMENT", 71, 94], ["IBV", "PROBLEM", 153, 156], ["single IBV infection", "PROBLEM", 170, 190], ["bacteriophage treatment", "TREATMENT", 199, 222], ["DiscussionInfectious bronchitis", "PROBLEM", 306, 337], ["mixed viral", "PROBLEM", 367, 378], ["bacterial infections", "PROBLEM", 386, 406], ["catastrophic economic losses", "PROBLEM", 426, 454], ["infection", "OBSERVATION", 23, 32], ["mixed APEC", "OBSERVATION", 37, 47], ["IBV", "OBSERVATION_MODIFIER", 52, 55], ["infection", "OBSERVATION", 56, 65], ["reduction", "OBSERVATION_MODIFIER", 104, 113], ["IBV", "OBSERVATION", 153, 156], ["infection", "OBSERVATION", 181, 190], ["bronchitis", "OBSERVATION", 327, 337], ["mixed", "OBSERVATION_MODIFIER", 367, 372], ["viral", "OBSERVATION", 373, 378], ["bacterial", "OBSERVATION_MODIFIER", 386, 395], ["infections", "OBSERVATION", 396, 406], ["catastrophic", "OBSERVATION_MODIFIER", 426, 438]]], ["Under field conditions complications caused by mixed IBV and APEC infections are linked with with accentuating respiratory signs in addition to airsacculitis, pericarditis and possible perihepatitis [28] .", [["respiratory", "ANATOMY", 111, 122], ["infections", "DISEASE", 66, 76], ["airsacculitis", "DISEASE", 144, 157], ["pericarditis", "DISEASE", 159, 171], ["perihepatitis", "DISEASE", 185, 198], ["IBV", "ORGANISM", 53, 56], ["APEC", "ORGANISM", 61, 65], ["IBV", "SPECIES", 53, 56], ["APEC", "SPECIES", 61, 65], ["mixed IBV", "PROBLEM", 47, 56], ["APEC infections", "PROBLEM", 61, 76], ["accentuating respiratory signs", "PROBLEM", 98, 128], ["airsacculitis", "PROBLEM", 144, 157], ["pericarditis", "PROBLEM", 159, 171], ["perihepatitis", "PROBLEM", 185, 198], ["mixed", "OBSERVATION_MODIFIER", 47, 52], ["IBV", "OBSERVATION", 53, 56], ["APEC infections", "OBSERVATION", 61, 76], ["respiratory signs", "OBSERVATION", 111, 128], ["pericarditis", "OBSERVATION", 159, 171], ["possible", "UNCERTAINTY", 176, 184]]], ["Under experimentally controlled conditions, mixed IBV and APEC infections can induce more pronounced clinical lesions in the air sacs that persist for a longer time [29] .", [["lesions", "ANATOMY", 110, 117], ["air sacs", "ANATOMY", 125, 133], ["infections", "DISEASE", 63, 73], ["IBV", "ORGANISM", 50, 53], ["APEC", "ORGANISM", 58, 62], ["lesions", "PATHOLOGICAL_FORMATION", 110, 117], ["air sacs", "MULTI-TISSUE_STRUCTURE", 125, 133], ["IBV", "SPECIES", 50, 53], ["APEC", "SPECIES", 58, 62], ["experimentally controlled conditions", "PROBLEM", 6, 42], ["mixed IBV", "PROBLEM", 44, 53], ["APEC infections", "PROBLEM", 58, 73], ["pronounced clinical lesions in the air sacs", "PROBLEM", 90, 133], ["mixed IBV", "OBSERVATION", 44, 53], ["more pronounced", "OBSERVATION_MODIFIER", 85, 100], ["lesions", "OBSERVATION", 110, 117], ["air sacs", "OBSERVATION", 125, 133]]], ["In the present study samples were collected from birds with respiratory manifestations from a total of forty farms, and subjected to characterization based on currently circulating IBV and APEC strains.", [["samples", "ANATOMY", 21, 28], ["respiratory", "ANATOMY", 60, 71], ["birds", "ORGANISM", 49, 54], ["IBV", "ORGANISM", 181, 184], ["APEC", "ORGANISM", 189, 193], ["IBV", "SPECIES", 181, 184], ["respiratory manifestations", "PROBLEM", 60, 86], ["circulating IBV", "TREATMENT", 169, 184], ["APEC strains", "PROBLEM", 189, 201]]], ["In addition, the efficacy of bacteriophage treatment in reducing APEC replication in the avian respiratory tract was studied in vivo, as well as their effect in reducing IBV pathogenicity after mixed APEC and IBV infections.DiscussionOut of forty farms, IBV was detected on 12 farms (30% of all farms examined).", [["respiratory tract", "ANATOMY", 95, 112], ["APEC", "CHEMICAL", 65, 69], ["IBV infections", "DISEASE", 209, 223], ["APEC", "ORGANISM", 65, 69], ["avian", "ORGANISM", 89, 94], ["respiratory tract", "ORGANISM_SUBDIVISION", 95, 112], ["IBV", "ORGANISM", 170, 173], ["APEC", "ORGANISM", 200, 204], ["IBV", "ORGANISM", 209, 212], ["IBV", "ORGANISM", 254, 257], ["APEC", "SPECIES", 65, 69], ["IBV", "SPECIES", 170, 173], ["APEC", "SPECIES", 200, 204], ["IBV", "SPECIES", 209, 212], ["IBV", "SPECIES", 254, 257], ["bacteriophage treatment", "TREATMENT", 29, 52], ["reducing APEC replication", "TREATMENT", 56, 81], ["the avian respiratory tract", "PROBLEM", 85, 112], ["reducing IBV pathogenicity", "PROBLEM", 161, 187], ["mixed APEC", "PROBLEM", 194, 204], ["IBV infections", "PROBLEM", 209, 223], ["IBV", "TREATMENT", 254, 257], ["bacteriophage", "OBSERVATION", 29, 42], ["APEC replication", "OBSERVATION", 65, 81], ["respiratory tract", "ANATOMY", 95, 112], ["IBV infections", "OBSERVATION", 209, 223]]], ["The high incidence of IBV in Egyptian poultry flocks suffering from respiratory manifestations (39-75.6%) has been recorded in several previous studies [8, 10, 30, 31] .", [["respiratory", "ANATOMY", 68, 79], ["IBV", "DISEASE", 22, 25], ["respiratory manifestations", "DISEASE", 68, 94], ["IBV", "ORGANISM", 22, 25], ["IBV", "SPECIES", 22, 25], ["IBV", "PROBLEM", 22, 25], ["respiratory manifestations", "PROBLEM", 68, 94], ["high", "OBSERVATION_MODIFIER", 4, 8], ["IBV", "OBSERVATION", 22, 25], ["Egyptian poultry flocks", "OBSERVATION", 29, 52], ["respiratory manifestations", "OBSERVATION", 68, 94]]], ["The range in the incidence rate is apparently due to the differences in the age of birds, with a higher incidence in 20-30 days old birds [8] .", [["birds", "ORGANISM", 83, 88], ["range", "OBSERVATION_MODIFIER", 4, 9]]], ["Based on partial spike protein gene sequencing, all positive IBV samples were clustered within the Egyptian variant IBV that belongs to the GI-23 genotype [18] .", [["samples", "ANATOMY", 65, 72], ["IBV", "ORGANISM", 61, 64], ["IBV", "ORGANISM", 116, 119], ["GI-23", "ORGANISM", 140, 145], ["IBV", "SPECIES", 61, 64], ["IBV", "SPECIES", 116, 119], ["partial spike protein gene sequencing", "PROBLEM", 9, 46], ["all positive IBV samples", "PROBLEM", 48, 72], ["the GI", "TEST", 136, 142], ["GI", "ANATOMY", 140, 142]]], ["All recent molecular characterization of IBV circulating in Egypt revealed the circulation of two distinct genotypes, the GI-1 vicinal strains genotype and the GI-23 local variant genotype .", [["IBV", "ORGANISM", 41, 44], ["GI-1", "GENE_OR_GENE_PRODUCT", 122, 126], ["GI-23", "ORGANISM", 160, 165], ["IBV", "SPECIES", 41, 44], ["IBV", "PROBLEM", 41, 44], ["two distinct genotypes", "PROBLEM", 94, 116], ["the GI", "TEST", 118, 124], ["the GI", "TEST", 156, 162], ["IBV", "OBSERVATION", 41, 44], ["distinct", "OBSERVATION_MODIFIER", 98, 106], ["GI", "ANATOMY", 122, 124], ["GI", "ANATOMY", 160, 162], ["local variant", "OBSERVATION", 166, 179]]], ["Average percentage of mortality in different groups (birds per group at each time point).", [["mortality", "OBSERVATION_MODIFIER", 22, 31]]], ["The highest and earliest mortality was associated with mixed infections without bacteriophage treatment.", [["infections", "DISEASE", 61, 71], ["mixed infections", "PROBLEM", 55, 71], ["bacteriophage treatment", "TREATMENT", 80, 103], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["mixed", "OBSERVATION_MODIFIER", 55, 60], ["infections", "OBSERVATION", 61, 71]]], ["In contrast, no deaths occurred in bacteriophage treated groups with mixed infection.", [["deaths", "DISEASE", 16, 22], ["infection", "DISEASE", 75, 84], ["deaths", "PROBLEM", 16, 22], ["mixed infection", "PROBLEM", 69, 84], ["no", "UNCERTAINTY", 13, 15], ["mixed", "OBSERVATION_MODIFIER", 69, 74], ["infection", "OBSERVATION", 75, 84]]], ["Figure 5 . the E.coli bacterial counts.", [["the E.coli bacterial counts", "TEST", 11, 38], ["E.coli", "ANATOMY", 15, 21], ["bacterial counts", "OBSERVATION", 22, 38]]], ["Samples were collected at 4, 9 and 15 dpc and are represented by the mean log10 CFU/ml of samples collected and tested from three birds.", [["Samples", "ANATOMY", 0, 7], ["samples", "ANATOMY", 90, 97], ["Samples", "TEST", 0, 7], ["samples", "TEST", 90, 97]]], ["Ttests were performed. * p < 0.05, * * p < 0.01, p < 0.01, and ns for non-significant.", [["Ttests", "TEST", 0, 6], ["ns", "TREATMENT", 63, 65]]], ["The asterisks over columns represent a significant difference compared to the IBV infected group.", [["IBV infected", "DISEASE", 78, 90], ["IBV", "ORGANISM", 78, 81], ["IBV", "SPECIES", 78, 81], ["The asterisks over columns", "PROBLEM", 0, 26], ["a significant difference", "PROBLEM", 37, 61], ["significant", "OBSERVATION_MODIFIER", 39, 50], ["difference", "OBSERVATION", 51, 61], ["infected", "OBSERVATION", 82, 90]]], ["Asterisks over lines represent a significant difference between mixed infection groups with and without bacteriophage treatments.", [["infection", "DISEASE", 70, 79], ["Asterisks over lines", "PROBLEM", 0, 20], ["mixed infection groups", "PROBLEM", 64, 86], ["bacteriophage treatments", "TREATMENT", 104, 128], ["significant", "OBSERVATION_MODIFIER", 33, 44], ["difference", "OBSERVATION_MODIFIER", 45, 55], ["mixed", "OBSERVATION_MODIFIER", 64, 69], ["infection", "OBSERVATION", 70, 79], ["without", "UNCERTAINTY", 96, 103]]], ["Significantly lower viral titers were observed in the mixed infection group treated with bacteriophages.Discussionto thank the broilers farm's owners for their cooperation and patience during samples collection.Disclosure statementAll Authors declare that they have no conflict of interest.Notes on contributorsMaram Tawakol: Graduated 2004 from Mansoura university with PhD in bacteriology, immunology and mycology in parallel with work as microbiologist and head of biotechnology unit in the reference laboratory for veterinary quality control on poultry production animal health research institute (RLQP), Gamasa, Dakahlia, Egypt.Notes on contributorsNehal Nabil: Graduated 2004 from Mansoura university with PhD in bacteriology, immunology and mycology in parallel with work as microbiologist and quality manager in the RLQP, animal health research institute, Gamasa, Dakahlia, Egypt.", [["samples", "ANATOMY", 192, 199], ["head", "ANATOMY", 460, 464], ["infection", "DISEASE", 60, 69], ["broilers", "ORGANISM", 127, 135], ["head", "ORGANISM_SUBDIVISION", 460, 464], ["broilers", "SPECIES", 127, 135], ["Significantly lower viral titers", "PROBLEM", 0, 32], ["the mixed infection group", "PROBLEM", 50, 75], ["bacteriophages", "TREATMENT", 89, 103], ["samples collection", "TEST", 192, 210], ["lower", "OBSERVATION_MODIFIER", 14, 19], ["viral titers", "OBSERVATION", 20, 32], ["mixed", "OBSERVATION_MODIFIER", 54, 59], ["infection", "OBSERVATION", 60, 69]]]], "d8c2466863d8ff87bc1aaf5218ce6f3f7fb29c3b": [["INTRODUCTIONThe social environment, both in early life and in adulthood, has a profound and often long-lasting impact on health and mortality in humans and other social mammals (1) (2) (3) (4) (5) .", [["humans", "ORGANISM", 145, 151], ["2) (3) (4)", "SIMPLE_CHEMICAL", 182, 192], ["humans", "SPECIES", 145, 151], ["humans", "SPECIES", 145, 151]]], ["This relationship is thought to arise in part through changes in gene regulation, which mediate the genomic response to physiological signals of social stress (e.g., glucocorticoids, adrenaline, noradrenaline; (6, 7) ).", [["adrenaline", "CHEMICAL", 183, 193], ["noradrenaline", "CHEMICAL", 195, 208], ["adrenaline", "CHEMICAL", 183, 193], ["noradrenaline", "CHEMICAL", 195, 208], ["adrenaline", "SIMPLE_CHEMICAL", 183, 193], ["noradrenaline", "SIMPLE_CHEMICAL", 195, 208], ["6, 7)", "SIMPLE_CHEMICAL", 211, 216], ["social stress", "PROBLEM", 145, 158], ["glucocorticoids", "TREATMENT", 166, 181], ["adrenaline", "TREATMENT", 183, 193], ["noradrenaline", "TREATMENT", 195, 208], ["thought to arise", "UNCERTAINTY", 21, 37]]], ["Gene expression signatures of social status and social adversity have now been reported in multiple studies, encompassing clinical and population-based samples in humans, and studies of both experimental and natural populations in other social animals (6, (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (see also (20) (21) (22) (23) (24) (25) for evidence in social insects and other social vertebrates).", [["humans", "ORGANISM", 163, 169], ["(8) (9) (10) (11) (12) (13) (14) (15) (16) (17", "SIMPLE_CHEMICAL", 256, 302], ["humans", "SPECIES", 163, 169], ["humans", "SPECIES", 163, 169], ["multiple studies", "TEST", 91, 107]]], ["Because this work has concentrated most extensively on peripheral white blood cells, it provides a direct window into how social experiences are reflected in the regulation of the immune system (26) (27) (28) .INTRODUCTIONSeveral broad patterns have emerged from these studies.", [["peripheral white blood cells", "ANATOMY", 55, 83], ["peripheral white blood cells", "CELL", 55, 83], ["peripheral white blood cells", "CELL_TYPE", 55, 83], ["peripheral white blood cells", "TEST", 55, 83], ["these studies", "TEST", 263, 276]]], ["First, high social adversity, including social isolation, early life insults, and low social status in adulthood, tends to predict higher expression of genes in pro-inflammatory pathways.", [["high social adversity", "DISEASE", 7, 28], ["social isolation", "TREATMENT", 40, 56], ["early life insults", "PROBLEM", 58, 76]]], ["This observation dovetails with associations between chronic social stress and elevated levels of protein biomarkers of inflammation, including those produced by peripheral blood cells (e.g., interleukin-6; (13, 29, 30) ).", [["peripheral blood cells", "ANATOMY", 162, 184], ["inflammation", "DISEASE", 120, 132], ["peripheral blood cells", "CELL", 162, 184], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 192, 205], ["peripheral blood cells", "CELL_TYPE", 162, 184], ["interleukin", "PROTEIN", 192, 203], ["This observation dovetails", "TREATMENT", 0, 26], ["chronic social stress", "PROBLEM", 53, 74], ["elevated levels of protein biomarkers", "PROBLEM", 79, 116], ["inflammation", "PROBLEM", 120, 132], ["peripheral blood cells", "TEST", 162, 184], ["interleukin", "TEST", 192, 203], ["inflammation", "OBSERVATION", 120, 132], ["peripheral", "ANATOMY_MODIFIER", 162, 172], ["blood cells", "ANATOMY", 173, 184]]], ["Second, high social adversity tends to predict lower expression of genes that function in the innate immune defense against virus, especially genes involved in type I interferon (IFN) signaling.", [["type I interferon", "GENE_OR_GENE_PRODUCT", 160, 177], ["IFN", "GENE_OR_GENE_PRODUCT", 179, 182], ["type I interferon", "PROTEIN", 160, 177], ["IFN", "PROTEIN", 179, 182], ["virus", "PROBLEM", 124, 129], ["type I interferon (IFN) signaling", "PROBLEM", 160, 193]]], ["In most cases, this pattern has been shown based on data in unstimulated cells (6) ; however, in bacterial lipopolysaccharide (LPS)-stimulated cells, induction of type I IFN-associated gene expression responses are also attenuated in low status (compared to high status) rhesus macaques (18) .", [["cells", "ANATOMY", 73, 78], ["cells", "ANATOMY", 143, 148], ["lipopolysaccharide", "CHEMICAL", 107, 125], ["LPS", "CHEMICAL", 127, 130], ["cells", "CELL", 73, 78], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 107, 125], ["LPS", "SIMPLE_CHEMICAL", 127, 130], ["cells", "CELL", 143, 148], ["type I IFN", "GENE_OR_GENE_PRODUCT", 163, 173], ["rhesus", "ORGANISM", 271, 277], ["macaques", "ORGANISM", 278, 286], ["unstimulated cells", "CELL_TYPE", 60, 78], ["bacterial lipopolysaccharide (LPS)-stimulated cells", "CELL_LINE", 97, 148], ["type I IFN", "PROTEIN", 163, 173], ["rhesus macaques", "SPECIES", 271, 286], ["rhesus macaques", "SPECIES", 271, 286], ["unstimulated cells", "TEST", 60, 78], ["bacterial lipopolysaccharide (LPS)", "TREATMENT", 97, 131], ["stimulated cells", "PROBLEM", 132, 148], ["type I IFN", "PROBLEM", 163, 173], ["gene expression responses", "PROBLEM", 185, 210]]], ["Third, these findings are explained in part by socially patterned differences in the use of immune defense-modulating transcription factors.", [["transcription factors", "PROTEIN", 118, 139], ["immune defense", "TREATMENT", 92, 106], ["modulating transcription factors", "PROBLEM", 107, 139]]], ["For example, genes that are more highly expressed in low status female rhesus macaques are enriched near accessible binding sites for the transcription factor complex nuclear factor kappa-B (NF-\u03baB), a master regulator of inflammation.", [["inflammation", "DISEASE", 221, 233], ["female", "ORGANISM", 64, 70], ["rhesus macaques", "ORGANISM", 71, 86], ["nuclear factor kappa-B", "GENE_OR_GENE_PRODUCT", 167, 189], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 191, 196], ["binding sites", "DNA", 116, 129], ["transcription factor complex", "PROTEIN", 138, 166], ["nuclear factor kappa-B", "PROTEIN", 167, 189], ["NF-\u03baB", "PROTEIN", 191, 196], ["rhesus macaques", "SPECIES", 71, 86], ["rhesus macaques", "SPECIES", 71, 86], ["kappa", "TEST", 182, 187], ["inflammation", "PROBLEM", 221, 233], ["inflammation", "OBSERVATION", 221, 233]]], ["In contrast, genes that are more highly expressed in high status females fall near accessible binding sites for interferon regulatory factors, which coordinate type I IFN-mediated responses (18, 31) .INTRODUCTIONThese observations have led some authors to propose social environment-mediated trade-offs between antibacterial defense, associated with NF-\u03baB-driven pro-inflammatory signaling, and antiviral defense, associated with the type I IFN response (6, 32) .", [["interferon regulatory factors", "GENE_OR_GENE_PRODUCT", 112, 141], ["type I IFN", "GENE_OR_GENE_PRODUCT", 160, 170], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 350, 355], ["type I IFN", "GENE_OR_GENE_PRODUCT", 434, 444], ["binding sites", "DNA", 94, 107], ["interferon regulatory factors", "PROTEIN", 112, 141], ["type I IFN", "PROTEIN", 160, 170], ["NF-\u03baB", "PROTEIN", 350, 355], ["IFN", "PROTEIN", 441, 444], ["interferon regulatory factors", "TREATMENT", 112, 141], ["NF", "PROBLEM", 350, 352], ["pro-inflammatory signaling", "PROBLEM", 363, 389], ["antiviral defense", "PROBLEM", 395, 412], ["the type I IFN response", "PROBLEM", 430, 453], ["antiviral defense", "OBSERVATION", 395, 412]]], ["Such a model argues that high social adversity shifts investment in the immune system towards resistance against bacterial pathogens and wound healing (possibly in anticipation of physical insults), at the cost of increased susceptibility to viral pathogens.", [["immune system", "ANATOMY", 72, 85], ["wound", "ANATOMY", 137, 142], ["immune system", "ANATOMICAL_SYSTEM", 72, 85], ["wound", "PATHOLOGICAL_FORMATION", 137, 142], ["bacterial pathogens", "PROBLEM", 113, 132], ["wound healing", "PROBLEM", 137, 150], ["physical insults", "PROBLEM", 180, 196], ["increased susceptibility to viral pathogens", "PROBLEM", 214, 257], ["wound healing", "OBSERVATION", 137, 150], ["viral pathogens", "OBSERVATION", 242, 257]]], ["This in turn accounts for both social gradients in conditions linked to chronic inflammation, such as cardiovascular disease, and social gradients in viral infections.", [["cardiovascular", "ANATOMY", 102, 116], ["inflammation", "DISEASE", 80, 92], ["cardiovascular disease", "DISEASE", 102, 124], ["viral infections", "DISEASE", 150, 166], ["chronic inflammation", "PROBLEM", 72, 92], ["cardiovascular disease", "PROBLEM", 102, 124], ["viral infections", "PROBLEM", 150, 166], ["social gradients", "OBSERVATION", 31, 47], ["chronic", "OBSERVATION_MODIFIER", 72, 79], ["inflammation", "OBSERVATION", 80, 92], ["viral infections", "OBSERVATION", 150, 166]]], ["Consistent with this hypothesis, psychosocial stress predicts reactivation rates of latent herpesvirus in mice and humans (33, 34) and rates of respiratory virus infection for experimentally exposed human subjects (35, 36) .", [["respiratory virus infection", "DISEASE", 144, 171], ["herpesvirus", "ORGANISM", 91, 102], ["mice", "ORGANISM", 106, 110], ["humans", "ORGANISM", 115, 121], ["respiratory virus", "ORGANISM", 144, 161], ["human", "ORGANISM", 199, 204], ["mice", "SPECIES", 106, 110], ["humans", "SPECIES", 115, 121], ["human", "SPECIES", 199, 204], ["mice", "SPECIES", 106, 110], ["humans", "SPECIES", 115, 121], ["human", "SPECIES", 199, 204], ["this hypothesis", "PROBLEM", 16, 31], ["psychosocial stress", "PROBLEM", 33, 52], ["latent herpesvirus", "PROBLEM", 84, 102], ["respiratory virus infection", "PROBLEM", 144, 171], ["respiratory virus", "OBSERVATION", 144, 161]]], ["Similarly, low status cynomolgus macaques males housed in a controlled environment experience both increased susceptibility to experimentally administered adenovirus and elevated rates of coronary artery stenosis (35, 37, 38) .INTRODUCTIONNevertheless, it remains unclear whether social patterning of viral susceptibility is directly related to social patterning of gene expression in peripheral blood cells.", [["coronary artery", "ANATOMY", 188, 203], ["peripheral blood cells", "ANATOMY", 385, 407], ["coronary artery stenosis", "DISEASE", 188, 212], ["cynomolgus", "ORGANISM", 22, 32], ["macaques", "ORGANISM", 33, 41], ["adenovirus", "ORGANISM", 155, 165], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 188, 203], ["peripheral blood cells", "CELL", 385, 407], ["peripheral blood cells", "CELL_TYPE", 385, 407], ["cynomolgus macaques", "SPECIES", 22, 41], ["cynomolgus macaques", "SPECIES", 22, 41], ["low status cynomolgus macaques males", "PROBLEM", 11, 47], ["increased susceptibility", "PROBLEM", 99, 123], ["adenovirus", "TREATMENT", 155, 165], ["coronary artery stenosis", "PROBLEM", 188, 212], ["viral susceptibility", "PROBLEM", 301, 321], ["gene expression in peripheral blood cells", "PROBLEM", 366, 407], ["low", "OBSERVATION_MODIFIER", 11, 14], ["increased", "OBSERVATION_MODIFIER", 99, 108], ["coronary artery", "ANATOMY", 188, 203], ["stenosis", "OBSERVATION", 204, 212], ["viral susceptibility", "OBSERVATION", 301, 321], ["peripheral", "ANATOMY_MODIFIER", 385, 395], ["blood cells", "ANATOMY", 396, 407]]], ["In particular, increased susceptibility to virus has been suggested to occur because the trade-offs induced by social adversity lead to insufficient production of antiviral gene transcripts (32) .", [["antiviral gene transcripts", "RNA", 163, 189], ["increased susceptibility to virus", "PROBLEM", 15, 48], ["antiviral gene transcripts", "TREATMENT", 163, 189], ["increased", "OBSERVATION_MODIFIER", 15, 24], ["susceptibility", "OBSERVATION", 25, 39]]], ["This logic is largely based on lower expression levels for key antiviral genes (e.g., MX1, OAS family genes, interferon regulatory factors) measured at baseline.", [["MX1", "GENE_OR_GENE_PRODUCT", 86, 89], ["OAS", "GENE_OR_GENE_PRODUCT", 91, 94], ["interferon regulatory factors", "GENE_OR_GENE_PRODUCT", 109, 138], ["antiviral genes", "DNA", 63, 78], ["MX1", "DNA", 86, 89], ["OAS family genes", "DNA", 91, 107], ["interferon regulatory factors", "PROTEIN", 109, 138], ["lower expression levels", "PROBLEM", 31, 54], ["key antiviral genes", "PROBLEM", 59, 78], ["interferon regulatory factors", "TREATMENT", 109, 138], ["antiviral genes", "OBSERVATION", 63, 78]]], ["However, exposure to immune stimulants can radically change the transcriptional landscape of immune cells, and social environmental effects on gene expression have been shown to specifically depend on the cellular environment.", [["immune cells", "ANATOMY", 93, 105], ["cellular", "ANATOMY", 205, 213], ["immune cells", "CELL", 93, 105], ["cellular", "CELL", 205, 213], ["immune cells", "CELL_TYPE", 93, 105], ["immune stimulants", "TREATMENT", 21, 38], ["immune cells", "PROBLEM", 93, 105], ["immune cells", "OBSERVATION", 93, 105]]], ["For example, in rhesus macaque females, social status has more pronounced effects on gene expression after exposure to LPS, but weaker effects on gene expression after exposure to glucocorticoids (18, 31) .", [["LPS", "CHEMICAL", 119, 122], ["glucocorticoids", "CHEMICAL", 180, 195], ["rhesus", "ORGANISM", 16, 22], ["macaque", "ORGANISM", 23, 30], ["LPS", "SIMPLE_CHEMICAL", 119, 122], ["rhesus macaque", "SPECIES", 16, 30], ["rhesus macaque", "SPECIES", 16, 30], ["LPS", "TREATMENT", 119, 122], ["weaker effects", "PROBLEM", 128, 142], ["glucocorticoids", "TREATMENT", 180, 195], ["glucocorticoids", "ANATOMY", 180, 195]]], ["Because no study to date has evaluated the effects of social adversity on gene expression after both bacterial and viral challenge, it is therefore unclear whether chronic social stress in fact attenuates the gene regulatory response to virus, consistent with a trade-offs model.", [["study", "TEST", 11, 16], ["both bacterial and viral challenge", "PROBLEM", 96, 130], ["chronic social stress", "PROBLEM", 164, 185]]], ["In addition, although increased expression of inflammation-related genes and decreased expression of type I IFN-related genes have been associated with social adversity in both adulthood and early life (9, 13, 18, 39) but see (40), we do not yet understand how the timing of social experiences affects the response to either pathogen type.INTRODUCTIONTo address these gaps, we turned to an animal model for social subordination-induced chronic stress: dominance rank in female rhesus macaques.", [["type I IFN", "GENE_OR_GENE_PRODUCT", 101, 111], ["rhesus", "ORGANISM", 477, 483], ["macaques", "ORGANISM", 484, 492], ["type I IFN-related genes", "DNA", 101, 125], ["rhesus macaques", "SPECIES", 477, 492], ["rhesus macaques", "SPECIES", 477, 492], ["inflammation", "PROBLEM", 46, 58], ["type I IFN", "PROBLEM", 101, 111], ["increased", "OBSERVATION_MODIFIER", 22, 31], ["inflammation", "OBSERVATION", 46, 58], ["decreased", "OBSERVATION_MODIFIER", 77, 86]]], ["This model takes advantage of the highly hierarchical social structure of female macaques, in which low rank predicts increased harassment and reduced social control, and combines it with the ability to manipulate rank via controlled introduction into newly formed social groups (earlier introduced females are higher ranking) (41, 42) .", [["macaques", "ORGANISM", 81, 89], ["macaques", "SPECIES", 81, 89], ["highly", "OBSERVATION_MODIFIER", 34, 40], ["hierarchical", "OBSERVATION_MODIFIER", 41, 53], ["social structure", "OBSERVATION", 54, 70]]], ["Using this study design, we previously showed that social status effects on blood cell gene expression are pervasive, cell typespecific, and dependent on the cellular environment: most relevant to this study, they can be substantially altered by bacterial stimulation (18) .", [["blood cell", "ANATOMY", 76, 86], ["cell", "ANATOMY", 118, 122], ["cellular", "ANATOMY", 158, 166], ["blood cell", "CELL", 76, 86], ["cell", "CELL", 118, 122], ["cellular", "CELL", 158, 166], ["this study", "TEST", 6, 16], ["this study", "TEST", 197, 207]]], ["Because pre-and post-rearrangement social status are completely uncorrelated, this approach provides an ideal setting to investigate the relative contributions of past versus present social environment to immune gene regulation.INTRODUCTIONTo do so here, we measured genome-wide gene expression levels in 45 adult female rhesus macaques: members of nine, five-member social groups that had undergone two serial rank manipulations spaced ~1 year apart (18, 43, 44) .", [["rhesus", "ORGANISM", 321, 327], ["macaques", "ORGANISM", 328, 336], ["rhesus macaques", "SPECIES", 321, 336], ["rhesus macaques", "SPECIES", 321, 336], ["immune gene regulation", "TREATMENT", 205, 227]]], ["We generated genome-wide expression profiles in blood at baseline, and in blood samples stimulated with bacterial and viral ligands.", [["blood", "ANATOMY", 48, 53], ["blood samples", "ANATOMY", 74, 87], ["blood", "ORGANISM_SUBSTANCE", 48, 53], ["blood samples", "ORGANISM_SUBSTANCE", 74, 87], ["blood samples", "TEST", 74, 87], ["bacterial and viral ligands", "PROBLEM", 104, 131], ["viral ligands", "OBSERVATION", 118, 131]]], ["Finally, we took advantage of historical dominance rank data from the same females to evaluate whether, and for what genes and pathways, immune gene regulation in adulthood is influenced by biological embedding-when social experience leads to systematic, stable biological changes with the potential to influence health (45, 46) .", [["immune gene regulation", "PROBLEM", 137, 159]]], ["Together, our analyses provide new insight into how social subordination-induced chronic stress -both past and present -differentially affects the molecular response to distinct pathogen types.Pathogen exposure-and pathogen type-dependent effects of social status on gene expressionWe experimentally manipulated the dominance ranks of 45 adult female rhesus macaques by sequentially introducing them into newly constructed social groups of five females each (Fig. 1A , n=9 social groups, SI Appendix, Dataset S1), as described in (18) .", [["rhesus", "ORGANISM", 351, 357], ["macaques", "ORGANISM", 358, 366], ["rhesus macaques", "SPECIES", 351, 366], ["rhesus macaques", "SPECIES", 351, 366], ["chronic stress", "PROBLEM", 81, 95], ["Pathogen exposure", "PROBLEM", 193, 210], ["chronic", "OBSERVATION_MODIFIER", 81, 88], ["distinct", "OBSERVATION_MODIFIER", 169, 177], ["pathogen types", "OBSERVATION", 178, 192], ["Appendix", "ANATOMY", 491, 499]]], ["We then rearranged group composition by performing a second series of sequential introductions, in this case designed so that females from the same or adjacent ranks in Phase I were co-housed in their new groups.", [["sequential introductions", "TREATMENT", 70, 94]]], ["As expected from this experimental paradigm (42) , earlier introduction predicted higher social status in both phases, as measured by a continuous Elo rating score (Pearson's r between order of introduction and Elo score: Phase I: \u22120.57, p = 4.1 x 10 -5 ; Phase II: -0.68, p =3.3 x 10 -7 ).", [["Phase I", "TEST", 222, 229], ["p", "TEST", 238, 239], ["Phase II", "TEST", 256, 264], ["p", "TEST", 273, 274]]], ["Importantly, once dominance ranks were established, they remained highly stable throughout each study phase, and individual Elo scores were completely uncorrelated between phases (r=0.06, p=0.68, SI Appendix, Fig. S1 ).Fig.", [["individual Elo scores", "TEST", 113, 134], ["p", "TEST", 188, 189], ["stable", "OBSERVATION_MODIFIER", 73, 79], ["Appendix", "ANATOMY", 199, 207]]], ["(A)Schematic representation of group formation in Phase I, mid-study rearrangement, and reorganization into new hierarchies in Phase II.", [["Phase II", "PROTEIN", 127, 135], ["mid-study rearrangement", "TEST", 59, 82], ["new", "OBSERVATION_MODIFIER", 108, 111]]], ["(B) Principal components analysis of gene expression data across all three conditions.", [["gene expression data", "TEST", 37, 57]]], ["The combination of PC1, PC4 and PC5 separates unstimulated negative controls (NC, blue) from samples stimulated with either LPS (green) or Gard (yellow).", [["samples", "ANATOMY", 93, 100], ["LPS", "CHEMICAL", 124, 127], ["PC1", "GENE_OR_GENE_PRODUCT", 19, 22], ["PC4", "GENE_OR_GENE_PRODUCT", 24, 27], ["PC5", "GENE_OR_GENE_PRODUCT", 32, 35], ["LPS", "SIMPLE_CHEMICAL", 124, 127], ["PC1", "PROTEIN", 19, 22], ["PC4", "PROTEIN", 24, 27], ["PC5", "PROTEIN", 32, 35], ["PC1", "TEST", 19, 22], ["PC4", "TREATMENT", 24, 27], ["PC5", "TREATMENT", 32, 35], ["NC, blue", "TREATMENT", 78, 86]]], ["(C) Number of rank-associated genes (FDR<5%) that are more highly expressed in high ranking females (top bars) or low ranking females (bottom bars), within each condition.Fig.", [["FDR", "DNA", 37, 40]]], ["(A)To characterize the effects of social status on the immune response to bacterial versus viral challenge, including the contribution of social history, we obtained blood samples from each study subject in Phase II of the study.", [["blood samples", "ANATOMY", 166, 179], ["blood samples", "ORGANISM_SUBSTANCE", 166, 179], ["bacterial versus viral challenge", "PROBLEM", 74, 106], ["blood samples", "TEST", 166, 179], ["each study", "TEST", 185, 195], ["the study", "TEST", 219, 228]]], ["We generated three gene expression profiles per animal, from: (i) a control (untreated) sample, with blood cultured in cell culture media only (negative control, NC); (ii) a sample cultured in cell culture media spiked with LPS, a Tolllike receptor 4 (TLR4) agonist that mimics infection by Gram-negative bacteria; and (iii) a sample cultured in cell culture media spiked with Gardiquimod (Gard), a Toll-like receptor 7 (TLR7) agonist that mimics infection by a single-stranded RNA virus.", [["sample", "ANATOMY", 88, 94], ["blood", "ANATOMY", 101, 106], ["cell", "ANATOMY", 119, 123], ["sample", "ANATOMY", 174, 180], ["cell", "ANATOMY", 193, 197], ["sample", "ANATOMY", 327, 333], ["cell", "ANATOMY", 346, 350], ["LPS", "CHEMICAL", 224, 227], ["infection", "DISEASE", 278, 287], ["Gardiquimod", "CHEMICAL", 377, 388], ["infection", "DISEASE", 447, 456], ["Gardiquimod", "CHEMICAL", 377, 388], ["blood", "ORGANISM_SUBSTANCE", 101, 106], ["cell", "CELL", 119, 123], ["cell", "CELL", 193, 197], ["LPS", "SIMPLE_CHEMICAL", 224, 227], ["Tolllike receptor 4", "GENE_OR_GENE_PRODUCT", 231, 250], ["TLR4", "GENE_OR_GENE_PRODUCT", 252, 256], ["cell", "CELL", 346, 350], ["Gardiquimod", "SIMPLE_CHEMICAL", 377, 388], ["Toll-like receptor 7", "GENE_OR_GENE_PRODUCT", 399, 419], ["TLR7", "GENE_OR_GENE_PRODUCT", 421, 425], ["TLR4", "PROTEIN", 252, 256], ["TLR7", "PROTEIN", 421, 425], ["blood cultured", "TEST", 101, 115], ["cell culture media", "TEST", 119, 137], ["a sample cultured", "TEST", 172, 189], ["cell culture media", "TEST", 193, 211], ["LPS", "PROBLEM", 224, 227], ["a Tolllike receptor 4 (TLR4) agonist", "TREATMENT", 229, 265], ["mimics infection", "PROBLEM", 271, 287], ["Gram-negative bacteria", "PROBLEM", 291, 313], ["a sample", "TEST", 325, 333], ["cell culture media", "TEST", 346, 364], ["a Toll-like receptor 7 (TLR7) agonist", "TREATMENT", 397, 434], ["mimics infection", "PROBLEM", 440, 456], ["a single-stranded RNA virus", "PROBLEM", 460, 487], ["infection", "OBSERVATION", 278, 287], ["negative bacteria", "OBSERVATION_MODIFIER", 296, 313], ["infection", "OBSERVATION", 447, 456]]], ["We incubated samples from each individual for 4 hours in parallel, lysed the white blood cell fraction, and generated RNA-sequencing data from the matched non-stimulated and stimulated conditions.", [["samples", "ANATOMY", 13, 20], ["white blood cell", "ANATOMY", 77, 93], ["blood cell", "CELL", 83, 93], ["white blood cell fraction", "CELL_TYPE", 77, 102], ["the white blood cell fraction", "TEST", 73, 102], ["sequencing data", "TEST", 122, 137]]], ["To confirm successful immune stimulation, we performed a principal component analysis (PCA) on the correlation matrix of normalized gene expression levels for all conditions, after controlling for relatedness, age, and the potential confounding effects of batch and tissue composition ( Fig. 1B ; SI Appendix, Material and Methods).", [["tissue", "ANATOMY", 266, 272], ["tissue", "TISSUE", 266, 272], ["successful immune stimulation", "TREATMENT", 11, 40], ["a principal component analysis", "TEST", 55, 85], ["batch and tissue composition", "TREATMENT", 256, 284], ["Appendix", "ANATOMY", 300, 308]]], ["We observed distinct clusters corresponding to the control, LPS-stimulated, and Gard-stimulated samples, with treatment effects most clearly reflected along PC1 (r=0.61, p=6.5 x 10 -10 for the separation between control versus LPS samples) and PC4 (r=0.76, p=1.7 x 10 -17 for the separation between control versus Gard samples).", [["samples", "ANATOMY", 96, 103], ["samples", "ANATOMY", 319, 326], ["LPS", "CHEMICAL", 60, 63], ["LPS", "SIMPLE_CHEMICAL", 60, 63], ["PC4", "PROTEIN", 244, 247], ["distinct clusters", "PROBLEM", 12, 29], ["LPS", "TEST", 60, 63], ["treatment effects", "TREATMENT", 110, 127], ["PC1", "TEST", 157, 160], ["p", "TEST", 170, 171], ["LPS samples", "TEST", 227, 238], ["PC4", "TEST", 244, 247], ["p", "TEST", 257, 258], ["Gard samples", "TEST", 314, 326], ["distinct", "OBSERVATION_MODIFIER", 12, 20], ["clusters", "OBSERVATION", 21, 29]]], ["As expected, genes up-regulated after stimulation were significantly enriched for immunological and inflammatory processes canonically associated with bacterial and viral defense (see SI Appendix, Dataset S2).Fig.", [["immunological and inflammatory processes", "PROBLEM", 82, 122], ["bacterial and viral defense", "PROBLEM", 151, 178], ["inflammatory", "OBSERVATION", 100, 112], ["viral defense", "OBSERVATION", 165, 178]]], ["(A)Consistent with previous findings (18, 19, 34) , we also observed a strong signature of dominance rank.", [["Consistent with", "UNCERTAINTY", 3, 18]]], ["Specifically, dominance rank (Elo score) was significantly correlated with PC3 of the full gene expression matrix within all three conditions (Pearson's r = 0.75 (NC); r = 0.75 (LPS), r = 0.69 (Gard), p<6.0 x 10 -7 for all conditions; SI Appendix, Fig. S2 ).", [["PC3", "ANATOMY", 75, 78], ["PC3", "CANCER", 75, 78], ["matrix", "CELLULAR_COMPONENT", 107, 113], ["S2", "PROTEIN", 253, 255], ["Pearson's r", "TEST", 143, 154], ["NC", "TEST", 163, 165], ["r", "TEST", 168, 169], ["LPS", "TEST", 178, 181], ["r", "TEST", 184, 185], ["Gard", "TEST", 194, 198], ["p", "TEST", 201, 202], ["dominance", "OBSERVATION_MODIFIER", 14, 23], ["rank", "OBSERVATION_MODIFIER", 24, 28], ["Appendix", "ANATOMY", 238, 246]]], ["This observation translated to gene-level analyses, where dominance rank drove the expression of 3,675, 5,322 and 2,694 genes (FDR<5%) in the control, LPS, and Gard conditions, respectively (Fig. 1C , SI Appendix, Dataset S3).", [["3,675, 5,322 and 2,694 genes", "DNA", 97, 125], ["This observation", "TEST", 0, 16], ["gene-level analyses", "TEST", 31, 50], ["FDR", "TEST", 127, 130], ["LPS", "TEST", 151, 154], ["Gard conditions", "TEST", 160, 175], ["Appendix", "ANATOMY", 204, 212]]], ["Strikingly, the number of rank-associated genes in the LPS condition was 1.5 -2x higher than in the Gard or control conditions.", [["rank-associated genes", "DNA", 26, 47], ["the LPS condition", "TEST", 51, 68]]], ["Thus, although rank effects are amplified after activation of the bacterial-sensing TLR4 pathway, this pattern does not appear to be a universal feature of immune activation.", [["TLR4", "GENE_OR_GENE_PRODUCT", 84, 88], ["TLR4", "PROTEIN", 84, 88], ["the bacterial-sensing TLR4 pathway", "TREATMENT", 62, 96], ["immune activation", "PROBLEM", 156, 173], ["immune activation", "OBSERVATION", 156, 173]]], ["Indeed, the number of genes for which the intensity of the response (i.e., gene expression in LPS/Gard conditions, relative to paired control samples) depended on dominance rank was almost fivefold lower in the viral Gard condition than for the bacterial LPS-stimulated samples (851 vs 4,111; FDR < 0.05; Fig. 2A ).", [["samples", "ANATOMY", 142, 149], ["samples", "ANATOMY", 270, 277], ["LPS", "CHEMICAL", 255, 258], ["LPS", "SIMPLE_CHEMICAL", 255, 258], ["Gard conditions", "PROBLEM", 98, 113], ["the bacterial LPS", "TEST", 241, 258], ["stimulated samples", "TEST", 259, 277], ["vs", "TEST", 283, 285], ["FDR", "TEST", 293, 296]]], ["Further, while 73% of rank effects on the LPS response were directionally biased towards larger responses in low status females, neither low nor high status systematically predicted stronger responses to Gard.", [["LPS", "SIMPLE_CHEMICAL", 42, 45]]], ["Instead, rank effects on the response to Gard were almost perfectly balanced: 49.5% of rank-dependent genes exhibited a stronger response in low status animals, while 51.5% exhibited a stronger response in high status animals (Fig. 2B) .Fig.", [["rank-dependent genes", "DNA", 87, 107]]], ["Contrasting effects of dominance rank in cells challenged with a bacterial versus viral mimic.", [["cells", "ANATOMY", 41, 46], ["cells", "CELL", 41, 46], ["dominance rank in cells", "PROBLEM", 23, 46], ["a bacterial versus viral mimic", "PROBLEM", 63, 93], ["dominance", "OBSERVATION_MODIFIER", 23, 32], ["rank", "OBSERVATION_MODIFIER", 33, 37], ["cells", "OBSERVATION", 41, 46]]], ["(A)More genes show a rank-dependent response (stimulated condition compared to paired control sample) after challenge with LPS than with Gard.", [["LPS", "CHEMICAL", 123, 126], ["LPS", "SIMPLE_CHEMICAL", 123, 126]]], ["LPS challenge also leads to asymmetric responses, in which the response is more commonly stronger in low-ranking females (left bar) than in high-ranking females (right bar); no such asymmetry is observed after Gard challenge.", [["left bar", "ANATOMY", 122, 130], ["LPS", "CHEMICAL", 0, 3], ["LPS", "SIMPLE_CHEMICAL", 0, 3], ["LPS challenge", "TEST", 0, 13], ["such asymmetry", "PROBLEM", 177, 191], ["asymmetric", "OBSERVATION_MODIFIER", 28, 38], ["responses", "OBSERVATION_MODIFIER", 39, 48], ["left", "ANATOMY_MODIFIER", 122, 126], ["right", "ANATOMY_MODIFIER", 162, 167], ["asymmetry", "OBSERVATION", 182, 191]]], ["(B) Distribution of effect sizes among genes for which the absolute magnitude of the response to LPS (green) and Gard (yellow) depends on dominance rank.", [["LPS", "CHEMICAL", 97, 100], ["effect sizes", "PROBLEM", 20, 32], ["LPS", "TEST", 97, 100], ["effect", "OBSERVATION_MODIFIER", 20, 26], ["sizes", "OBSERVATION_MODIFIER", 27, 32]]], ["After LPS stimulation, most genes respond more strongly in low status females, but rank effects on the response to Gard are more balanced.", [["LPS", "CHEMICAL", 6, 9], ["LPS", "SIMPLE_CHEMICAL", 6, 9], ["LPS stimulation", "TREATMENT", 6, 21]]], ["(C) Polarization of rank effects in the union of the top ten Gene Ontology categories, per condition, that were most significantly enriched among genes up-regulated by LPS/Gard stimulation.", [["LPS", "CHEMICAL", 168, 171], ["LPS", "SIMPLE_CHEMICAL", 168, 171], ["rank effects", "OBSERVATION", 20, 32]]], ["For each category, darker squares correspond to stronger statistical support for enrichment in the LPS response (green) and Gard response (yellow), respectively, for genes upregulated relative to controls.", [["LPS", "CHEMICAL", 99, 102], ["LPS", "SIMPLE_CHEMICAL", 99, 102], ["darker squares", "PROBLEM", 19, 33], ["stronger statistical support", "TREATMENT", 48, 76], ["the LPS response", "TEST", 95, 111]]], ["Horizontal violin plots are colored based on the proportion of rank-associated genes in each category that are more highly expressed in high-ranking individuals, separately for the LPS and Gard conditions.", [["LPS", "SIMPLE_CHEMICAL", 181, 184], ["Horizontal violin plots", "PROBLEM", 0, 23], ["the LPS", "TEST", 177, 184], ["colored", "OBSERVATION", 28, 35]]], ["Positive x-axis values: genes that are more highly expressed in highranking females; negative x-axis values: genes that are more highly expressed in low-ranking females.", [["Positive x-axis values", "TEST", 0, 22], ["x-axis values", "OBSERVATION", 9, 22]]], ["The gray shaded box highlights gene categories for which the distributions of rank effects significantly differ between LPS and Gard conditions (Wilcoxon test: Benjamini-Hochberg FDR-corrected p<9x10 -3 ).", [["gray shaded box", "DNA", 4, 19], ["gene categories", "PROBLEM", 31, 46], ["rank effects", "PROBLEM", 78, 90], ["LPS", "TEST", 120, 123], ["Gard conditions", "TEST", 128, 143], ["Wilcoxon test", "TEST", 145, 158], ["Benjamini", "TEST", 160, 169]]], ["(D) Rank effects on gene expression in the LPS (x-axis) versus Gard (y-axis) conditions, for genes in the Gene Ontology category \"type I interferon signaling pathway\" that were rank-associated in the LPS condition, Gard condition, or both.", [["LPS", "SIMPLE_CHEMICAL", 43, 46], ["type I interferon", "GENE_OR_GENE_PRODUCT", 130, 147], ["interferon", "PROTEIN", 137, 147], ["gene expression", "PROBLEM", 20, 35], ["the LPS", "TEST", 39, 46], ["Gard (y-axis) conditions", "PROBLEM", 63, 87]]], ["Labeled genes in the lower right quadrant are cases in which rank effects are directionally reversed in LPS versus Gard-stimulated samples.", [["lower right quadrant", "ANATOMY", 21, 41], ["samples", "ANATOMY", 131, 138], ["LPS", "CHEMICAL", 104, 107], ["LPS", "SIMPLE_CHEMICAL", 104, 107], ["Gard-stimulated samples", "TEST", 115, 138], ["lower", "ANATOMY_MODIFIER", 21, 26], ["right", "ANATOMY_MODIFIER", 27, 32], ["quadrant", "ANATOMY", 33, 41]]], ["They include key master regulators of the response to virus such as STAT1, which is more highly expressed in high status females in control and LPS conditions, but more highly expressed in low status females in the Gard condition (STAT1 plot y-axis: normalized, log-transformed gene expression).", [["STAT1", "GENE_OR_GENE_PRODUCT", 68, 73], ["STAT1", "GENE_OR_GENE_PRODUCT", 231, 236], ["STAT1", "PROTEIN", 68, 73], ["STAT1", "PROTEIN", 231, 236], ["virus", "PROBLEM", 54, 59], ["LPS conditions", "PROBLEM", 144, 158], ["STAT1 plot y-axis", "TEST", 231, 248]]], ["In (C) and (D), all genes affected by rank at an FDR of 20% or less are plotted (the overall pattern is qualitatively unchanged at a more stringent FDR threshold).Fig.", [["an FDR", "TEST", 46, 52]]], ["Contrasting effects of dominance rank in cells challenged with a bacterial versus viral mimic.", [["cells", "ANATOMY", 41, 46], ["cells", "CELL", 41, 46], ["dominance rank in cells", "PROBLEM", 23, 46], ["a bacterial versus viral mimic", "PROBLEM", 63, 93], ["dominance", "OBSERVATION_MODIFIER", 23, 32], ["rank", "OBSERVATION_MODIFIER", 33, 37], ["cells", "OBSERVATION", 41, 46]]], ["(A)To investigate the hypothesis that social status-induced stress mediates trade-offs between antibacterial and antiviral responses, we restricted our analysis to genes belonging to the Gene Ontology categories that were most enriched among genes up-regulated by LPS, Gard, or both.", [["LPS", "SIMPLE_CHEMICAL", 264, 267], ["Gene Ontology categories", "DNA", 187, 211], ["antibacterial", "TREATMENT", 95, 108], ["antiviral responses", "TREATMENT", 113, 132]]], ["As we showed in previous analyses (18) , genes involved in immune defense, inflammation and cytokine signaling are biased towards higher expression in low-ranking females, in LPS condition samples (Fig. 2C) .", [["inflammation", "DISEASE", 75, 87], ["cytokine", "PROTEIN", 92, 100], ["immune defense", "PROBLEM", 59, 73], ["inflammation", "PROBLEM", 75, 87], ["cytokine signaling", "PROBLEM", 92, 110], ["inflammation", "OBSERVATION", 75, 87]]], ["In contrast, genes involved in viral defenseassociated type I IFN signaling are biased towards higher expression in high-ranking females, in the same condition (Fig. 2C) .", [["type I IFN", "GENE_OR_GENE_PRODUCT", 55, 65], ["IFN", "PROTEIN", 62, 65], ["viral defenseassociated type I IFN signaling", "PROBLEM", 31, 75], ["high", "OBSERVATION_MODIFIER", 116, 120]]], ["A trade-offs model would predict a similar dichotomy after challenge with a viral mimic.", [["A trade-offs model", "TREATMENT", 0, 18]]], ["Surprisingly, this is not what we observed: in the Gard condition, low status predicted increased expression of both proinflammatory/cytokine signaling-associated and type I IFN-associated genes.", [["type I IFN", "GENE_OR_GENE_PRODUCT", 167, 177], ["cytokine", "PROTEIN", 133, 141], ["type I IFN-associated genes", "DNA", 167, 194], ["low status", "PROBLEM", 67, 77], ["both proinflammatory/cytokine signaling", "PROBLEM", 112, 151], ["type I IFN-associated genes", "PROBLEM", 167, 194], ["both", "OBSERVATION_MODIFIER", 112, 116], ["proinflammatory", "OBSERVATION_MODIFIER", 117, 132], ["cytokine signaling", "OBSERVATION", 133, 151]]], ["For example, for rank-associated genes in the Gene Ontology category \"type I interferon signaling\" 57% of genes measured in the LPS condition were more highly expressed in high status females.", [["type I interferon", "GENE_OR_GENE_PRODUCT", 70, 87], ["LPS", "GENE_OR_GENE_PRODUCT", 128, 131], ["interferon", "PROTEIN", 77, 87], ["type I interferon signaling", "PROBLEM", 70, 97]]], ["Consequently, status-related effects for type I IFN genes differ significantly between LPS and Gard conditions (Wilcoxon test, p=6.4 x 10 -4 ).", [["type I IFN", "GENE_OR_GENE_PRODUCT", 41, 51], ["type I IFN genes", "DNA", 41, 57], ["type I IFN genes", "PROBLEM", 41, 57], ["LPS", "TEST", 87, 90], ["Gard conditions", "TEST", 95, 110], ["Wilcoxon test", "TEST", 112, 125], ["p", "TEST", 127, 128]]], ["This pattern holds for key viral defense genes such as OAS2 and OAS3, which are involved in inhibition of viral replication; the IFN-inducible genes IFIT2, IFIT3, MX1 and MX2; and STAT1, a master regulator of interferon-mediated defense (Fig. 2D) .", [["OAS2", "GENE_OR_GENE_PRODUCT", 55, 59], ["OAS3", "GENE_OR_GENE_PRODUCT", 64, 68], ["IFN", "GENE_OR_GENE_PRODUCT", 129, 132], ["IFIT2", "GENE_OR_GENE_PRODUCT", 149, 154], ["IFIT3", "GENE_OR_GENE_PRODUCT", 156, 161], ["MX1", "GENE_OR_GENE_PRODUCT", 163, 166], ["MX2", "GENE_OR_GENE_PRODUCT", 171, 174], ["STAT1", "GENE_OR_GENE_PRODUCT", 180, 185], ["interferon", "GENE_OR_GENE_PRODUCT", 209, 219], ["viral defense genes", "DNA", 27, 46], ["OAS2", "DNA", 55, 59], ["OAS3", "DNA", 64, 68], ["IFN-inducible genes", "DNA", 129, 148], ["IFIT2", "DNA", 149, 154], ["IFIT3", "DNA", 156, 161], ["MX1", "DNA", 163, 166], ["MX2", "DNA", 171, 174], ["STAT1", "PROTEIN", 180, 185], ["interferon", "PROTEIN", 209, 219], ["key viral defense genes", "PROBLEM", 23, 46], ["viral replication", "TREATMENT", 106, 123], ["viral replication", "OBSERVATION", 106, 123]]], ["It also extends to measures of the response to immune challenge (i.e., the change in gene expression levels between control and challenged cells): genes involved in type I IFN signaling tend to be more strongly up-regulated in high status females after LPS challenge, but more strongly up-regulated in low status females after Gard challenge (SI Appendix, Fig. S3 )Fig. 2.", [["cells", "ANATOMY", 139, 144], ["LPS", "CHEMICAL", 253, 256], ["cells", "CELL", 139, 144], ["type I IFN", "GENE_OR_GENE_PRODUCT", 165, 175], ["LPS", "SIMPLE_CHEMICAL", 253, 256], ["challenged cells", "CELL_TYPE", 128, 144], ["IFN", "PROTEIN", 172, 175], ["immune challenge", "TREATMENT", 47, 63], ["gene expression levels between control", "TREATMENT", 85, 123], ["type I IFN signaling", "PROBLEM", 165, 185], ["LPS challenge", "TREATMENT", 253, 266], ["Gard challenge", "TREATMENT", 327, 341], ["Appendix", "ANATOMY", 346, 354]]], ["Contrasting effects of dominance rank in cells challenged with a bacterial versus viral mimic.", [["cells", "ANATOMY", 41, 46], ["cells", "CELL", 41, 46], ["dominance rank in cells", "PROBLEM", 23, 46], ["a bacterial versus viral mimic", "PROBLEM", 63, 93], ["dominance", "OBSERVATION_MODIFIER", 23, 32], ["rank", "OBSERVATION_MODIFIER", 33, 37], ["cells", "OBSERVATION", 41, 46]]], ["(A)Previous studies suggest that social environmental effects on gene expression arise through socially structured differences in immune defense-associated transcription factor (TF) binding (e.g., (10, 13, 18) ).", [["TF", "GENE_OR_GENE_PRODUCT", 178, 180], ["transcription factor", "PROTEIN", 156, 176], ["TF", "PROTEIN", 178, 180], ["Previous studies", "TEST", 3, 19]]], ["We therefore investigated the TFs that might account for rank effects on gene expression during the immune response to bacteria (LPS condition) or .", [["TFs", "ANATOMY", 30, 33], ["TFs", "CELL", 30, 33], ["TFs", "DNA", 30, 33], ["the TFs", "TREATMENT", 26, 33], ["rank effects", "PROBLEM", 57, 69], ["gene expression", "PROBLEM", 73, 88], ["bacteria (LPS condition", "PROBLEM", 119, 142]]], ["CC-BY-NC-ND 4.0 International license is made available under a The copyright holder for this preprint (which was not peer-reviewed) is the author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["It . https://doi.org/10.1101/552356 doi: bioRxiv preprint virus (Gard condition).", [["bioRxiv preprint virus", "ORGANISM", 41, 63], ["bioRxiv preprint virus", "TREATMENT", 41, 63]]], ["To do so, we identified predicted TF binding sites in gene promoter regions that are also accessible to TF binding (i.e., in open chromatin regions identified using previously collected ATAC-seq data from rhesus macaque peripheral blood mononuclear cells (18) ).", [["TF", "ANATOMY", 104, 106], ["chromatin", "ANATOMY", 130, 139], ["peripheral blood mononuclear cells", "ANATOMY", 220, 254], ["TF", "GENE_OR_GENE_PRODUCT", 34, 36], ["TF", "GENE_OR_GENE_PRODUCT", 104, 106], ["chromatin", "CELLULAR_COMPONENT", 130, 139], ["macaque", "ORGANISM", 212, 219], ["peripheral blood mononuclear cells", "CELL", 220, 254], ["TF binding sites", "DNA", 34, 50], ["gene promoter regions", "DNA", 54, 75], ["TF", "PROTEIN", 104, 106], ["open chromatin regions", "DNA", 125, 147], ["ATAC", "PROTEIN", 186, 190], ["rhesus macaque peripheral blood mononuclear cells", "CELL_TYPE", 205, 254], ["rhesus macaque", "SPECIES", 205, 219], ["rhesus macaque", "SPECIES", 205, 219], ["open chromatin regions", "TREATMENT", 125, 147], ["previously collected ATAC", "TEST", 165, 190], ["TF binding", "OBSERVATION", 34, 44]]], ["As previously reported (18) , genes that were more highly expressed in low status animals were enriched for NF-\u03baB binding sites in the LPS condition.", [["NF-\u03ba", "GENE_OR_GENE_PRODUCT", 108, 112], ["B", "GENE_OR_GENE_PRODUCT", 112, 113], ["LPS", "SIMPLE_CHEMICAL", 135, 138], ["NF-\u03ba", "PROTEIN", 108, 112], ["B binding sites", "DNA", 112, 127], ["B binding sites", "PROBLEM", 112, 127], ["binding sites", "OBSERVATION", 114, 127]]], ["In contrast, genes that were more highly expressed in high status animals were enriched for predicted TF binding sites for interferon regulatory factors (IRF1, IRF2, and IRF7) and STAT1-the masterregulators of anti-viral responses (Fig. 3) .", [["TF", "GENE_OR_GENE_PRODUCT", 102, 104], ["interferon regulatory factors", "GENE_OR_GENE_PRODUCT", 123, 152], ["IRF1", "GENE_OR_GENE_PRODUCT", 154, 158], ["IRF2", "GENE_OR_GENE_PRODUCT", 160, 164], ["IRF7", "GENE_OR_GENE_PRODUCT", 170, 174], ["STAT1", "GENE_OR_GENE_PRODUCT", 180, 185], ["TF binding sites", "DNA", 102, 118], ["interferon regulatory factors", "PROTEIN", 123, 152], ["IRF1", "PROTEIN", 154, 158], ["IRF2", "PROTEIN", 160, 164], ["IRF7", "PROTEIN", 170, 174], ["STAT1", "PROTEIN", 180, 185], ["predicted TF binding sites", "PROBLEM", 92, 118], ["interferon regulatory factors", "TREATMENT", 123, 152], ["IRF1", "TEST", 154, 158], ["IRF2", "TEST", 160, 164], ["IRF7", "TEST", 170, 174], ["STAT1", "TEST", 180, 185]]], ["Strikingly, that dichotomy disappeared when samples were stimulated with a viral mimic.", [["samples", "ANATOMY", 44, 51]]], ["In the Gard condition, the promoter regions of genes that were more highly expressed in low status animals were enriched for TF binding sites for virtually all immune-associated TFs, including NF-\u03baB, several IRFs, and STAT1 (Fig. 3) .", [["TFs", "ANATOMY", 178, 181], ["TF", "GENE_OR_GENE_PRODUCT", 125, 127], ["TFs", "CELL", 178, 181], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 193, 198], ["IRFs", "GENE_OR_GENE_PRODUCT", 208, 212], ["STAT1", "GENE_OR_GENE_PRODUCT", 218, 223], ["promoter regions", "DNA", 27, 43], ["TF binding sites", "DNA", 125, 141], ["NF-\u03baB", "PROTEIN", 193, 198], ["IRFs", "PROTEIN", 208, 212], ["STAT1", "PROTEIN", 218, 223], ["TF binding sites", "PROBLEM", 125, 141], ["NF", "TEST", 193, 195], ["several", "OBSERVATION_MODIFIER", 200, 207], ["IRFs", "OBSERVATION", 208, 212]]], ["These results corroborate our enrichment analyses for the gene expression data alone (Fig. 2C) , and suggest that differences in TF activity account for the distinct patterns of social status-associated gene expression after LPS versus Gard stimulation.Fig.", [["LPS", "CHEMICAL", 225, 228], ["TF", "GENE_OR_GENE_PRODUCT", 129, 131], ["LPS", "SIMPLE_CHEMICAL", 225, 228], ["TF", "PROTEIN", 129, 131], ["LPS", "TREATMENT", 225, 228], ["Gard stimulation", "TREATMENT", 236, 252], ["TF activity", "OBSERVATION", 129, 140]]], ["Transcription factor binding sites enriched near rank-associated genes differ between LPS and Gard-challenged cells.In the LPS condition, (A) Predicted NF-\u03baB and NF-\u03baB subunit (RelA/RelB/p50/p65) binding sites are enriched in the promoter regions of genes that are upregulated by LPS and more highly expressed in low-ranking females, while (B) predicted interferon regulatory factor (IRF) and STAT1 binding sites dominate the enriched categories for genes that are upregulated by LPS but more highly expressed in high-Fig.", [["cells", "ANATOMY", 110, 115], ["LPS", "CHEMICAL", 86, 89], ["LPS", "CHEMICAL", 280, 283], ["LPS", "CHEMICAL", 480, 483], ["LPS", "SIMPLE_CHEMICAL", 86, 89], ["cells", "CELL", 110, 115], ["LPS", "SIMPLE_CHEMICAL", 123, 126], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 152, 157], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 162, 167], ["RelA", "GENE_OR_GENE_PRODUCT", 177, 181], ["RelB", "GENE_OR_GENE_PRODUCT", 182, 186], ["p50", "GENE_OR_GENE_PRODUCT", 187, 190], ["p65", "GENE_OR_GENE_PRODUCT", 191, 194], ["LPS", "GENE_OR_GENE_PRODUCT", 280, 283], ["interferon regulatory factor", "GENE_OR_GENE_PRODUCT", 354, 382], ["IRF", "GENE_OR_GENE_PRODUCT", 384, 387], ["STAT1", "GENE_OR_GENE_PRODUCT", 393, 398], ["LPS", "GENE_OR_GENE_PRODUCT", 480, 483], ["Transcription factor binding sites", "DNA", 0, 34], ["Gard-challenged cells", "CELL_LINE", 94, 115], ["NF-\u03baB", "PROTEIN", 152, 157], ["NF-\u03baB subunit (RelA/RelB/p50/p65) binding sites", "DNA", 162, 209], ["promoter regions", "DNA", 230, 246], ["interferon regulatory factor (IRF) and STAT1 binding sites", "DNA", 354, 412], ["Transcription factor binding sites", "PROBLEM", 0, 34], ["NF", "TEST", 152, 154], ["NF", "TEST", 162, 164], ["RelA/RelB/p50/p65", "TREATMENT", 177, 194], ["binding sites", "PROBLEM", 196, 209], ["interferon regulatory factor (IRF)", "PROBLEM", 354, 388], ["STAT1 binding sites", "PROBLEM", 393, 412], ["challenged cells", "OBSERVATION", 99, 115]]], ["Transcription factor binding sites enriched near rank-associated genes differ between LPS and Gard-challenged cells.The copyright holder for this preprint (which was not peer-reviewed) is the author/funder.", [["cells", "ANATOMY", 110, 115], ["LPS", "CHEMICAL", 86, 89], ["LPS", "SIMPLE_CHEMICAL", 86, 89], ["cells", "CELL", 110, 115], ["Transcription factor binding sites", "DNA", 0, 34], ["Gard-challenged cells", "CELL_LINE", 94, 115], ["Transcription factor binding sites", "PROBLEM", 0, 34], ["The copyright holder", "TREATMENT", 116, 136], ["challenged cells", "OBSERVATION", 99, 115]]], ["This polarization disappears in the Gard condition, where (C) Predicted NF-\u03baB, NF-\u03baB subunit, IRF, and STAT1 binding sites are all enriched in the promoter regions of genes that are upregulated by Gard and more highly expressed in low-ranking individuals, with (D) no clear signature of immune-related TF binding site enrichment among genes that are upregulated by Gard but more highly expressed in high-ranking individuals.", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 72, 77], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 79, 84], ["IRF", "GENE_OR_GENE_PRODUCT", 94, 97], ["STAT1", "GENE_OR_GENE_PRODUCT", 103, 108], ["TF", "GENE_OR_GENE_PRODUCT", 302, 304], ["NF-\u03baB, NF-\u03baB subunit, IRF, and STAT1 binding sites", "DNA", 72, 122], ["promoter regions", "DNA", 147, 163], ["Gard", "DNA", 197, 201], ["TF binding site", "DNA", 302, 317], ["Gard", "DNA", 365, 369], ["NF", "TEST", 72, 74], ["NF", "TEST", 79, 81], ["IRF", "PROBLEM", 94, 97], ["STAT1 binding sites", "PROBLEM", 103, 122], ["immune-related TF binding site", "PROBLEM", 287, 317], ["IRF", "OBSERVATION", 94, 97], ["TF binding", "OBSERVATION", 302, 312]]], ["Promoter regions are defined as the 5 kb upstream of each gene transcription start site; in each category, enrichment analyses included all rank-associated genes that passed an FDR cutoff of 20%.", [["Promoter regions", "DNA", 0, 16], ["5 kb upstream", "DNA", 36, 49], ["gene transcription start site", "DNA", 58, 87], ["each gene transcription", "TREATMENT", 53, 76], ["enrichment analyses", "TEST", 107, 126], ["an FDR cutoff", "TEST", 174, 187]]], ["Error bars show the 95% confidence interval for the log2(odds ratio), and those TFs shown in yellow indicate significant enrichment at an FDR threshold of 10% (p<1.3 x 10 -3 ).Social history effects on immune gene regulationAlthough the gene expression data were generated in Phase II, we also collected behavioral data that allowed us to quantify rank in Phase I, prior to the mid-study rank rearrangement (samples were collected 9.01\u00b10.60 s.d. months after Phase I groups were dissolved and 7.65\u00b10.50 s.d. months after each animal was introduced into her Phase II group).", [["samples", "ANATOMY", 408, 415], ["Phase I", "PROTEIN", 356, 363], ["the log2(odds ratio", "TEST", 48, 67], ["those TFs", "TEST", 74, 83], ["significant enrichment", "PROBLEM", 109, 131], ["an FDR threshold", "TEST", 135, 151], ["immune gene regulation", "TREATMENT", 202, 224], ["the gene expression data", "TEST", 233, 257], ["behavioral data", "TEST", 304, 319], ["Phase I groups", "TREATMENT", 459, 473], ["significant", "OBSERVATION_MODIFIER", 109, 120], ["enrichment", "OBSERVATION", 121, 131]]], ["We took advantage of this study design to investigate whether past social status affected immune cell gene expression independently from social status at the time of sampling (\"current rank\"), in support of biological embedding.", [["immune cell", "ANATOMY", 90, 101], ["immune cell", "CELL", 90, 101], ["this study", "TEST", 21, 31]]], ["Strikingly, we identified a strong global signature of past social status on gene expression levels as well: past Elo score was correlated with PC2 within each condition (control: Pearson's r = -0.76, p=2.4 x 10 -9 ; LPS: r = -0.58, p=8.0 x 10 -5 ; Gard: r = -0.44, p=3.8 x 10 -3 ; SI Appendix, Fig. S2 ) .Social history effects on immune gene regulationOn the level of individual genes, social history effects were detectable in all three conditions, but were by far more apparent in the unstimulated, control condition than in the LPS or Gard conditions (Fig. 4A) .", [["PC2", "GENE_OR_GENE_PRODUCT", 144, 147], ["PC2", "PROTEIN", 144, 147], ["Pearson's r", "TEST", 180, 191], ["p", "TEST", 201, 202], ["LPS", "TEST", 217, 220], ["r", "TEST", 222, 223], ["p", "TEST", 233, 234], ["Gard", "TEST", 249, 253], ["r", "TEST", 255, 256], ["p", "TEST", 266, 267], ["strong", "OBSERVATION_MODIFIER", 28, 34], ["Appendix", "ANATOMY", 285, 293], ["Fig. S2", "ANATOMY", 295, 302]]], ["For example, at an FDR of 10%, we identified 3,735 past rank-associated genes in the control condition, compared to 1,712 and 141 in the LPS and Gard conditions, respectively (Fig. 4A) .", [["an FDR", "TEST", 16, 22], ["the LPS", "TEST", 133, 140], ["Gard conditions", "TEST", 145, 160]]], ["This pattern is highly robust across statistical thresholds (SI Appendix, Fig. S4 ).", [["highly", "OBSERVATION_MODIFIER", 16, 22], ["robust", "OBSERVATION_MODIFIER", 23, 29], ["Appendix", "ANATOMY", 64, 72]]], ["For example, in the unstimulated controls, genes that were more highly expressed in high status animals at the time of sampling were strongly enriched for viral transcription (FDR-corrected p=2.8 x 10 -11 ) and viral gene expression (FDR-corrected p=5.5 x 10 -11 ).", [["viral gene", "DNA", 211, 221], ["viral transcription", "TEST", 155, 174], ["FDR", "TEST", 176, 179], ["viral gene expression", "PROBLEM", 211, 232], ["FDR", "TEST", 234, 237]]], ["Similarly, genes that were more highly expressed in females with a past history of high status were uniquely enriched in categories involved in the epigenetic regulation of gene expression, including chromatin organization (FDRcorrected p=4.8 x 10 -11 ), and histone modification (FDR-corrected p=3.6 x 10 -7 ) (SI Appendix, Fig. S5, Dataset S2) .Social history effects on immune gene regulationTo investigate the relative contribution of social history versus current rank at a more granular scale, we developed a gene-specific measure of plasticity (\u0398) in each condition.", [["chromatin", "ANATOMY", 200, 209], ["chromatin", "CELLULAR_COMPONENT", 200, 209], ["histone", "GENE_OR_GENE_PRODUCT", 259, 266], ["chromatin", "DNA", 200, 209], ["histone", "PROTEIN", 259, 266], ["S5", "PROTEIN", 330, 332], ["high status", "PROBLEM", 83, 94], ["gene expression", "PROBLEM", 173, 188], ["chromatin organization", "PROBLEM", 200, 222], ["histone modification", "PROBLEM", 259, 279], ["FDR", "TEST", 281, 284], ["immune gene regulation", "TREATMENT", 373, 395], ["gene expression", "OBSERVATION", 173, 188], ["Appendix", "ANATOMY", 315, 323]]], ["\u0398 values range from 0 to 1, where values close to 1 imply a high degree of plasticity and little evidence of memory, and values close to 0 imply a high degree of memory and little plasticity in response to changes in social status.", [["a high degree of memory", "PROBLEM", 145, 168], ["high degree", "OBSERVATION_MODIFIER", 60, 71], ["little evidence of", "UNCERTAINTY", 90, 108], ["memory", "OBSERVATION", 109, 115], ["high degree", "OBSERVATION_MODIFIER", 147, 158]]], ["Overall, we identified a much greater contribution of social history to gene expression levels in the unstimulated control samples than in either of the stimulated conditions (control: median \u0398 for the top 1000 rank-associated genes in NC = 0.52; LPS = 0.87; Gard = 0.74; Wilcoxon test p<2.2 x 10 -16 for all pairwise comparisons; Fig 4B; see also SI Appendix, Fig. S6 for comparisons using different numbers of rank-associated genes).", [["samples", "ANATOMY", 123, 130], ["S6", "GENE_OR_GENE_PRODUCT", 366, 368], ["S6", "PROTEIN", 366, 368], ["gene expression levels", "PROBLEM", 72, 94], ["NC", "TEST", 236, 238], ["LPS", "TEST", 247, 250], ["Gard", "TEST", 259, 263], ["Wilcoxon test p", "TEST", 272, 287], ["all pairwise comparisons", "TEST", 305, 329], ["Fig 4B", "TEST", 331, 337], ["Appendix", "ANATOMY", 351, 359]]], ["In agreement with this observation, social status effects on the response to LPS and Gard (i.e., the interaction between Elo score and control versus stimulated treatment) were dominated by the effects of current rank.", [["LPS", "CHEMICAL", 77, 80], ["this observation", "TEST", 18, 34], ["LPS", "TREATMENT", 77, 80], ["Elo score", "TEST", 121, 130], ["stimulated treatment", "TREATMENT", 150, 170]]], ["We identified 4,111 and 851 genes for which the response to LPS and Gard, respectively, depended on dominance rank at the time of sampling (FDR<5%), but no cases in which these responses depended on past rank.", [["LPS", "CHEMICAL", 60, 63], ["LPS", "TEST", 60, 63], ["Gard", "TEST", 68, 72], ["sampling", "TEST", 130, 138], ["FDR", "TEST", 140, 143]]], ["Thus, although there is a strong signature of social history on gene expression levels in an unperturbed state, this signature gives way to the effects of current social conditions when cells enter an immune-challenged state.Social history effects on immune gene regulationFinally, females with the same social status in Phase II could come from different social histories: some climbed the social hierarchy, some fell, and others maintained a consistent position.", [["cells", "ANATOMY", 186, 191], ["cells", "CELL", 186, 191], ["gene expression levels", "PROBLEM", 64, 86], ["immune gene regulation", "TREATMENT", 251, 273]]], ["In the control condition, where the effects of social history are most pronounced, we identified 1,079 genes in which past and current rank interacted to influence gene expression (FDR<5%).", [["1,079 genes", "DNA", 97, 108], ["FDR", "TEST", 181, 184]]], ["Interaction effects were strongly directionally biased: specifically, for 88% of these genes, a history of past low status predicted reduced sensitivity to current dominance rank ( Fig. 4C and 4D) .", [["past low status", "PROBLEM", 107, 122], ["reduced sensitivity", "PROBLEM", 133, 152]]], ["Thus, females who fell in rank were strongly affected by their current, lower rank in Phase II, whereas females who achieved higher status in Phase II were proportionally more affected by their lower status in Phase I. Fig. S6 ).", [["S6", "GENE_OR_GENE_PRODUCT", 224, 226], ["S6", "PROTEIN", 224, 226]]], ["Plasticity scores are systematically lower in the unstimulated control samples (NC) than in the LPS or Gard conditions, indicating that immune stimulation proportionally weakens social history effects, relative to current rank effects.", [["samples", "ANATOMY", 71, 78], ["LPS", "SIMPLE_CHEMICAL", 96, 99], ["Plasticity scores", "TEST", 0, 17], ["immune stimulation", "PROBLEM", 136, 154], ["lower", "OBSERVATION_MODIFIER", 37, 42]]], ["(D) In an example of a current rank x past rank interaction, current rank effects (x-axis) on expression of the transcription factor FOSL1, which is implicated in regulation of the type I IFN response (47) , are strongest in females who were previously high rank and weakest in females who were previously low rank (interaction=0.54, FDR-corrected p=0.01).", [["FOSL1", "GENE_OR_GENE_PRODUCT", 133, 138], ["type I IFN", "GENE_OR_GENE_PRODUCT", 181, 191], ["transcription factor", "PROTEIN", 112, 132], ["FOSL1", "PROTEIN", 133, 138], ["IFN", "PROTEIN", 188, 191], ["FDR", "TEST", 334, 337]]], ["(E) Predicted current rank effects, based on model fits for each gene on the full data set (see SI Appendix, Materials and Methods), for low past rank and high past rank females (based on the mean Elo scores for the lowest ranking and highest ranking females in Phase I groups, respectively).", [["the mean Elo scores", "TEST", 188, 207]]], ["Distributions show estimated effect sizes across 1,079 genes for which we identified a significant current rank-past rank interaction effect in the control condition.", [["1,079 genes", "DNA", 49, 60], ["estimated effect sizes", "PROBLEM", 19, 41], ["effect", "OBSERVATION_MODIFIER", 29, 35], ["sizes", "OBSERVATION_MODIFIER", 36, 41], ["significant", "OBSERVATION_MODIFIER", 87, 98]]], ["Current rank effects were systematically larger in females who were previously high-ranking than in females who were previously low-ranking (Wilcoxon test p<2.2x10 -16 ).Social history effects on immune gene regulation.", [["Wilcoxon test p", "TEST", 141, 156], ["immune gene regulation", "TREATMENT", 196, 218], ["larger", "OBSERVATION_MODIFIER", 41, 47]]], ["CC-BY-NC-ND 4.0 International license is made available under a The copyright holder for this preprint (which was not peer-reviewed) is the author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["It . https://doi.org/10.1101/552356 doi: bioRxiv preprintDISCUSSIONConvergent evidence from humans, wild animal populations, and experimental animal models indicates that social interactions are reflected in the regulation and activity of the immune system (6, 7, 11, (26) (27) (28) 48) .", [["humans", "ORGANISM", 92, 98], ["humans", "SPECIES", 92, 98], ["humans", "SPECIES", 92, 98]]], ["Our findings join those of others to suggest that social adversity is particularly relevant to the inflammatory response, one of the first lines of defense in the innate immune system (49) .", [["social adversity", "DISEASE", 50, 66], ["immune system", "ANATOMICAL_SYSTEM", 170, 183], ["inflammatory", "OBSERVATION", 99, 111]]], ["Because biomarkers of inflammation in turn predict disease and mortality outcomes (50), these findings suggest that social regulation of immune gene expression may partly mediate social gradients in health.", [["inflammation", "DISEASE", 22, 34], ["inflammation", "PROBLEM", 22, 34], ["predict disease", "PROBLEM", 43, 58], ["immune gene expression", "TREATMENT", 137, 159], ["inflammation", "OBSERVATION", 22, 34]]], ["However, contrary to current predictions based on data collected in unstimulated conditions, low status females did not mount attenuated gene regulatory responses to viral challenge (6, 32) .", [["low status females", "PROBLEM", 93, 111], ["viral challenge", "TEST", 166, 181]]], ["Instead, they show a stronger up-regulation of genes involved in the regulation of type I IFN when comparing Gard to control samples.", [["samples", "ANATOMY", 125, 132], ["type I IFN", "GENE_OR_GENE_PRODUCT", 83, 93], ["type I IFN", "PROTEIN", 83, 93]]], ["Further, for these genes, the status-dependent polarization of gene expression patterns observed following exposure to a bacteriaassociated challenge disappears following exposure to a virus-associated challenge.DISCUSSIONThese results suggest that baseline patterns of immune gene expression provide limited insight into the gene regulatory response to actual immune stimuli.", [["gene expression patterns", "PROBLEM", 63, 87], ["a bacteriaassociated challenge", "TREATMENT", 119, 149], ["a virus", "TREATMENT", 183, 190], ["immune gene expression", "TREATMENT", 270, 292]]], ["Thus, while the gene expression signature of social stress may be somewhat conserved across different types of social adversity, and potentially across species, it does not appear to be highly conserved across pathogen environments.", [["social stress", "PROBLEM", 45, 58]]], ["Our findings are consistent with previous reports that social status interacts with LPS and glucocorticoid exposure (18, 31) , and that genetic effects on gene expression can also be altered by local cellular conditions (i.e., gene-environment interactions, e.g., (51) (52) (53) (54) ).", [["cellular", "ANATOMY", 200, 208], ["LPS", "CHEMICAL", 84, 87], ["LPS", "SIMPLE_CHEMICAL", 84, 87], ["glucocorticoid", "SIMPLE_CHEMICAL", 92, 106], ["cellular", "CELL", 200, 208], ["LPS", "PROBLEM", 84, 87], ["glucocorticoid exposure", "PROBLEM", 92, 115], ["consistent with", "UNCERTAINTY", 17, 32]]], ["However, while prior work has primarily shown environment or genotype-dependent differences in the presence or magnitude of effects, here we observed a more striking pattern: directional shifts in the effects of social status, specifically for genes involved in the antiviral response.", [["directional shifts", "OBSERVATION_MODIFIER", 175, 193]]], ["This reversal of effects suggests that social status-sensitive regulatory elements involved in the response to LPS are, at least to some degree, distinct from social status-sensitive regulatory elements involved in the response to Gard -a hypothesis that requires further experimental validation.DISCUSSIONOur findings also highlight a novel way in which social environmental effects on gene regulation depend on context.", [["LPS", "CHEMICAL", 111, 114], ["LPS", "GENE_OR_GENE_PRODUCT", 111, 114], ["regulatory elements", "DNA", 63, 82], ["regulatory elements", "DNA", 183, 202], ["sensitive regulatory elements", "PROBLEM", 53, 82], ["Gard -a hypothesis", "PROBLEM", 231, 249], ["further experimental validation", "TREATMENT", 264, 295]]], ["Specifically, we identified thousands of genes for which gene expression levels in peripheral blood cells depend not only on current social status, but also on the effects of past social status.", [["peripheral blood cells", "ANATOMY", 83, 105], ["peripheral blood cells", "CELL", 83, 105], ["peripheral blood cells", "CELL_TYPE", 83, 105], ["gene expression levels", "TEST", 57, 79], ["peripheral blood cells", "TEST", 83, 105]]], ["Social history effects were themselves dependent on other factors, however, with much more extensive effects in unstimulated cells than immunechallenged cells, and in females with a history of low status than for females with a history of high status.", [["cells", "ANATOMY", 125, 130], ["cells", "ANATOMY", 153, 158], ["cells", "CELL", 125, 130], ["immunechallenged cells", "CELL", 136, 158], ["unstimulated cells", "CELL_TYPE", 112, 130], ["immunechallenged cells", "CELL_TYPE", 136, 158], ["unstimulated cells than immunechallenged cells", "PROBLEM", 112, 158], ["low status", "PROBLEM", 193, 203], ["high status", "PROBLEM", 239, 250]]], ["These observations are consistent with several possibilities.", [["These observations", "TEST", 0, 18], ["consistent with", "UNCERTAINTY", 23, 38]]], ["First, a history of high social status (i.e., low social adversity) could confer increased plasticity in response to environmental change (e.g., subsequent losses of status).", [["increased plasticity", "PROBLEM", 81, 101]]], ["Second, historical exposure to social subordination-induced stress could blunt responses to future high-quality environments.", [["blunt responses", "PROBLEM", 73, 88]]], ["Given that the effects of current rank dominate after immune stimulation, external environmental challenges might hasten this process.", [["immune stimulation", "TREATMENT", 54, 72], ["external environmental challenges", "TREATMENT", 74, 107]]], ["Longitudinal, repeated measures of gene expression will be needed to differentiate between these possibilities.DISCUSSIONRegardless of the explanation, our observations clearly highlight the importance of social history to immune gene expression patterns measured many months later.", [["gene expression", "TREATMENT", 35, 50]]], ["They therefore extend the concept of biological embedding to adulthood, in keeping with the observation that the molecular mechanisms thought to mediate the embedding process early in life (e.g., DNA methylation, histone marks) remain environmentally sensitive across the life course.", [["DNA", "CELLULAR_COMPONENT", 196, 199], ["histone", "GENE_OR_GENE_PRODUCT", 213, 220], ["DNA methylation, histone marks", "TREATMENT", 196, 226]]], ["The mechanism of memory in this case may differ from cases of biological embedding that persist over years or decades.", [["biological embedding", "PROBLEM", 62, 82], ["memory", "OBSERVATION", 17, 23]]], ["For example, memory T cells, which can represent up to 40% of total circulating T cells in adulthood (55) , can survive in the body for years, raising the possibility that slow turnover of some PBMC subsets could be responsible for the social history effects we observed.", [["memory T cells", "ANATOMY", 13, 27], ["T cells", "ANATOMY", 80, 87], ["body", "ANATOMY", 127, 131], ["PBMC", "ANATOMY", 194, 198], ["memory T cells", "CELL", 13, 27], ["T cells", "CELL", 80, 87], ["body", "ORGANISM_SUBDIVISION", 127, 131], ["PBMC", "CELL", 194, 198], ["memory T cells", "CELL_TYPE", 13, 27], ["circulating T cells", "CELL_TYPE", 68, 87], ["PBMC subsets", "CELL_TYPE", 194, 206], ["memory T cells", "PROBLEM", 13, 27], ["total circulating T cells", "PROBLEM", 62, 87], ["slow turnover of some PBMC subsets", "PROBLEM", 172, 206], ["raising the possibility", "UNCERTAINTY", 143, 166]]], ["However, recent evidence suggests that even shortlived cells in the innate immune system-which canonically has been thought to lack memory-can be epigenetically altered by environmental experience (56) .DISCUSSIONIndeed, there is very strong evidence that both early life social adversity and social adversity in adulthood shape health and fitness outcomes (2, 57, 58) .", [["cells", "ANATOMY", 55, 60], ["immune system", "ANATOMY", 75, 88], ["cells", "CELL", 55, 60], ["immune system", "ANATOMICAL_SYSTEM", 75, 88], ["shortlived cells", "CELL_TYPE", 44, 60], ["shortlived cells", "PROBLEM", 44, 60]]], ["If temporally separate exposures independently tap into the same gene regulatory mechanisms, then the genome can be viewed as a mosaic, in which some loci retain more of a long-term signature of social history than others.", [["genome", "CELLULAR_COMPONENT", 102, 108], ["tap", "TREATMENT", 47, 50]]], ["This perspective is consistent with studies of organism-level traits.", [["organism", "TEST", 47, 55], ["consistent with", "UNCERTAINTY", 20, 35]]], ["For example, in nonhuman primate models of social stress, behavioral signatures of status are highly plastic with changes in dominance rank, whereas the development of coronary artery plaques are explained by the combination of present and past social status (59, 60) .", [["coronary artery plaques", "ANATOMY", 168, 191], ["coronary artery plaques", "DISEASE", 168, 191], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 168, 183], ["social stress", "PROBLEM", 43, 56], ["coronary artery plaques", "PROBLEM", 168, 191], ["social stress", "OBSERVATION", 43, 56], ["coronary artery", "ANATOMY", 168, 183], ["plaques", "OBSERVATION", 184, 191]]], ["A key contribution of genomic approaches rests in their ability to compare levels of plasticity across thousands of traits simultaneously.", [["genomic approaches", "OBSERVATION", 22, 40]]], ["Such studies promise to reveal which pathways are more important for encoding memory versus sensing the current environment-an important step towards understanding the molecular mechanisms that affect resilience and recovery.DISCUSSIONFinally, our analyses suggest that there is no simple mapping between social environmental effects on immune cell gene expression and their effects on disease and mortality risk.", [["immune cell", "ANATOMY", 337, 348], ["immune cell", "CELL", 337, 348], ["Such studies", "TEST", 0, 12], ["immune cell gene expression", "TREATMENT", 337, 364], ["disease and mortality risk", "PROBLEM", 386, 412], ["immune cell", "OBSERVATION", 337, 348]]], ["Notably, although the type I IFN response is often discussed in opposition to pro-inflammatory, NF-\u03baB-mediated antibacterial responses, type I IFN signaling itself can also be pro-inflammatory (61) .", [["type I IFN", "GENE_OR_GENE_PRODUCT", 22, 32], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 96, 101], ["type I IFN", "GENE_OR_GENE_PRODUCT", 136, 146], ["IFN", "PROTEIN", 29, 32], ["NF-\u03baB", "PROTEIN", 96, 101], ["IFN", "PROTEIN", 143, 146], ["pro-inflammatory", "TEST", 78, 94], ["NF", "TEST", 96, 98], ["type I IFN signaling", "PROBLEM", 136, 156]]], ["High reactivity to both viral and bacterial ligands may therefore represent two distinct sources of elevated inflammation in low status individuals.", [["inflammation", "DISEASE", 109, 121], ["High reactivity", "PROBLEM", 0, 15], ["both viral and bacterial ligands", "PROBLEM", 19, 51], ["elevated inflammation in low status individuals", "PROBLEM", 100, 147], ["both", "OBSERVATION_MODIFIER", 19, 23], ["viral", "OBSERVATION", 24, 29], ["bacterial ligands", "OBSERVATION", 34, 51], ["elevated", "OBSERVATION_MODIFIER", 100, 108], ["inflammation", "OBSERVATION", 109, 121], ["low status", "OBSERVATION_MODIFIER", 125, 135]]], ["Alternatively, because Gardiquimod only models TLR7 stimulation by single-stranded RNA .", [["Gardiquimod", "CHEMICAL", 23, 34], ["Gardiquimod", "SIMPLE_CHEMICAL", 23, 34], ["TLR7", "GENE_OR_GENE_PRODUCT", 47, 51], ["TLR7", "PROTEIN", 47, 51], ["single-stranded RNA", "RNA", 67, 86], ["TLR7 stimulation", "TREATMENT", 47, 63], ["TLR7 stimulation", "OBSERVATION", 47, 63], ["stranded RNA", "OBSERVATION_MODIFIER", 74, 86]]], ["CC-BY-NC-ND 4.0 International license is made available under a The copyright holder for this preprint (which was not peer-reviewed) is the author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["It . https://doi.org/10.1101/552356 doi: bioRxiv preprint viruses, it remains possible that other types of viral challenges produce responses more consistent with social status-mediated trade-offs.", [["bioRxiv preprint viruses", "ORGANISM", 41, 65], ["bioRxiv preprint viruses", "TREATMENT", 41, 65], ["viral challenges", "PROBLEM", 107, 123], ["viral", "OBSERVATION", 107, 112]]], ["For instance, while many of the viruses that have been linked to social gradients are single-stranded RNA viruses (e.g., rhinovirus, respiratory syncytial virus, coronavirus), others are double-stranded DNA viruses (e.g., Epstein-Barr virus, cytomegalovirus, and other herpesviruses) that activate distinct immune pathways at the cell surface, in endosomes, and in the cytoplasm (e.g., TLR2, TLR9, and AIM2-dependent signaling, respectively) (62).Study PopulationThe primary set of study subjects were 45 adult female rhesus macaques (Macaca mulatta) housed in demographically uniform social groups of five each (n = 9 social groups) at the Yerkes National Primate Research Center (YNPRC) Field Station.", [["cell surface", "ANATOMY", 330, 342], ["endosomes", "ANATOMY", 347, 356], ["cytoplasm", "ANATOMY", 369, 378], ["respiratory syncytial virus", "DISEASE", 133, 160], ["rhinovirus", "ORGANISM", 121, 131], ["respiratory syncytial virus", "ORGANISM", 133, 160], ["coronavirus", "ORGANISM", 162, 173], ["DNA", "CELLULAR_COMPONENT", 203, 206], ["Epstein-Barr virus", "ORGANISM", 222, 240], ["cytomegalovirus", "ORGANISM", 242, 257], ["cell surface", "CELLULAR_COMPONENT", 330, 342], ["endosomes", "CELLULAR_COMPONENT", 347, 356], ["cytoplasm", "ORGANISM_SUBSTANCE", 369, 378], ["TLR2", "GENE_OR_GENE_PRODUCT", 386, 390], ["TLR9", "GENE_OR_GENE_PRODUCT", 392, 396], ["AIM2", "GENE_OR_GENE_PRODUCT", 402, 406], ["rhesus", "ORGANISM", 518, 524], ["macaques", "ORGANISM", 525, 533], ["Macaca mulatta", "ORGANISM", 535, 549], ["TLR2", "PROTEIN", 386, 390], ["TLR9", "PROTEIN", 392, 396], ["AIM2", "PROTEIN", 402, 406], ["respiratory syncytial virus", "SPECIES", 133, 160], ["Barr virus", "SPECIES", 230, 240], ["rhesus macaques", "SPECIES", 518, 533], ["Macaca mulatta", "SPECIES", 535, 549], ["respiratory syncytial virus", "SPECIES", 133, 160], ["Epstein-Barr virus", "SPECIES", 222, 240], ["rhesus macaques", "SPECIES", 518, 533], ["Macaca mulatta", "SPECIES", 535, 549], ["the viruses", "PROBLEM", 28, 39], ["stranded RNA viruses", "PROBLEM", 93, 113], ["rhinovirus", "PROBLEM", 121, 131], ["respiratory syncytial virus", "PROBLEM", 133, 160], ["coronavirus", "PROBLEM", 162, 173], ["double-stranded DNA viruses", "PROBLEM", 187, 214], ["Epstein-Barr virus", "PROBLEM", 222, 240], ["cytomegalovirus", "PROBLEM", 242, 257], ["other herpesviruses", "PROBLEM", 263, 282], ["TLR2", "TEST", 386, 390], ["TLR9", "TEST", 392, 396], ["AIM2", "TEST", 402, 406], ["viruses", "OBSERVATION", 32, 39], ["respiratory syncytial", "ANATOMY", 133, 154], ["surface", "OBSERVATION_MODIFIER", 335, 342], ["cytoplasm", "ANATOMY_MODIFIER", 369, 378]]], ["These animals were part of a larger, multi-year study investigating social status effects on behavior, physiology, and gene regulation in immune cells (18, 43, 44, 60) .", [["immune cells", "ANATOMY", 138, 150], ["immune cells", "CELL", 138, 150], ["immune cells", "CELL_TYPE", 138, 150], ["multi-year study", "TEST", 37, 53], ["immune cells", "TEST", 138, 150], ["larger", "OBSERVATION_MODIFIER", 29, 35]]], ["All study subjects were initially drawn from the YNPRC breeding colony, assigned to five-member social groups in January -June 2013, and behaviorally monitored to assess social status in February 2013 -March 2014 (Phase I).", [["colony", "ANATOMY", 64, 70], ["All study subjects", "TEST", 0, 18]]], ["Behavioral data on affiliative and agonistic interactions were collected in both phases using focal sampling (345 total hours of observation, 223.5 hours in Phase I and 121.5 hours in Phase II) (63) .", [["Behavioral data", "TEST", 0, 15], ["focal sampling", "TEST", 94, 108], ["focal", "OBSERVATION_MODIFIER", 94, 99]]], ["Based on these data, dominance rank values were assigned using Elo ratings, a continuous measure of rank in which higher scores correspond to higher status and ratings are updated following any interaction in which a winner or loser can be scored (64, 65) .", [["these data", "TEST", 9, 19], ["dominance rank values", "TEST", 21, 42], ["Elo ratings", "TEST", 63, 74]]], ["All blood samples for gene expression analysis were collected in Phase II, 7.65\u00b10.50 s.d. months after females were first introduced into their Phase II groups.", [["blood samples", "ANATOMY", 4, 17], ["blood samples", "ORGANISM_SUBSTANCE", 4, 17], ["All blood samples", "TEST", 0, 17], ["gene expression analysis", "TEST", 22, 46]]], ["These rank values were highly stable, with an Elo stability index from 0.995 -1.00 (n=9 groups), where 1 corresponds to a hierarchy in which higher-ranking females always win competitive encounters with lowerranking females, with no rank reversals (66) .", [["These rank values", "TEST", 0, 17], ["an Elo stability index", "TEST", 43, 65], ["stable", "OBSERVATION_MODIFIER", 30, 36]]], ["The copyright holder for this preprint (which was not peer-reviewed) is the author/funder.", [["The copyright holder", "TREATMENT", 0, 20]]], ["It . https://doi.org/10.1101/552356 doi: bioRxiv preprint Information on group membership, age, and dominance rank for all study subjects is provided in SI Appendix, Dataset S1.Blood Sample Collection and In Vitro ChallengesWe set out to test how dominance rank affects the immune response to bacterial versus viral stimulation and to investigate social history effects at both baseline and in response to pathogen stimulation.", [["Blood", "ANATOMY", 177, 182], ["Blood", "ORGANISM_SUBSTANCE", 177, 182], ["all study subjects", "TEST", 119, 137], ["Blood Sample Collection", "TEST", 177, 200], ["Vitro Challenges", "TREATMENT", 208, 224], ["bacterial", "PROBLEM", 293, 302], ["viral stimulation", "TREATMENT", 310, 327], ["pathogen stimulation", "TREATMENT", 406, 426], ["Appendix", "ANATOMY", 156, 164]]], ["To do so, we drew 1 mL of whole blood from each female into each of three TruCulture blood collection tubes (Myriad RBM) containing either: (i) cell culture media only (negative control: \"NC\"); (ii) cell culture media plus 1 \u00b5g/mL of E. coliderived lipopolysaccharide (0111:B4 strain: \"LPS\" condition); or (iii) cell culture media plus 1 \u00b5g/ml of the TLR7 agonist Gardiquimod (\"Gard\" condition), a synthetic ligand that mimics infection with a single-stranded RNA virus.", [["whole blood", "ANATOMY", 26, 37], ["blood", "ANATOMY", 85, 90], ["cell", "ANATOMY", 144, 148], ["cell", "ANATOMY", 199, 203], ["cell", "ANATOMY", 312, 316], ["lipopolysaccharide", "CHEMICAL", 249, 267], ["Gardiquimod", "CHEMICAL", 364, 375], ["infection", "DISEASE", 427, 436], ["Gardiquimod", "CHEMICAL", 364, 375], ["blood", "ORGANISM_SUBSTANCE", 32, 37], ["blood", "ORGANISM_SUBSTANCE", 85, 90], ["cell", "CELL", 144, 148], ["cell", "CELL", 199, 203], ["coliderived lipopolysaccharide", "SIMPLE_CHEMICAL", 237, 267], ["LPS", "SIMPLE_CHEMICAL", 286, 289], ["cell", "CELL", 312, 316], ["TLR7", "GENE_OR_GENE_PRODUCT", 351, 355], ["Gardiquimod", "SIMPLE_CHEMICAL", 364, 375], ["TLR7", "PROTEIN", 351, 355], ["E. coliderived", "SPECIES", 234, 248], ["E. coliderived lipopolysaccharide (0111:B4 strain", "SPECIES", 234, 283], ["three TruCulture blood collection tubes (Myriad RBM)", "TREATMENT", 68, 120], ["cell culture media", "TEST", 144, 162], ["cell culture media", "TREATMENT", 199, 217], ["cell culture media", "TREATMENT", 312, 330], ["a synthetic ligand", "TREATMENT", 396, 414], ["mimics infection", "PROBLEM", 420, 436], ["a single-stranded RNA virus", "PROBLEM", 442, 469], ["collection tubes", "OBSERVATION", 91, 107], ["infection", "OBSERVATION", 427, 436]]], ["Samples were incubated in parallel for 4 hours at 37\u00b0C. We then separated the serum and cellular fractions, lysed and discarded the red cells from the cell pellet with red blood cell lysis buffer (RBC lysis solution, 5 Prime Inc.), and lysed the remaining white blood cell fraction in Qiazol for storage at -80\u00b0C. We extracted total RNA from each sample using the Qiagen miRNAEASY kit.", [["Samples", "ANATOMY", 0, 7], ["serum", "ANATOMY", 78, 83], ["cellular fractions", "ANATOMY", 88, 106], ["red cells", "ANATOMY", 132, 141], ["cell pellet", "ANATOMY", 151, 162], ["red blood cell", "ANATOMY", 168, 182], ["RBC", "ANATOMY", 197, 200], ["white blood cell", "ANATOMY", 256, 272], ["sample", "ANATOMY", 347, 353], ["Qiazol", "CHEMICAL", 285, 291], ["Qiazol", "CHEMICAL", 285, 291], ["serum", "ORGANISM_SUBSTANCE", 78, 83], ["cellular fractions", "ORGANISM_SUBSTANCE", 88, 106], ["red cells", "CELL", 132, 141], ["cell", "CELL", 151, 155], ["red blood cell", "CELL", 168, 182], ["blood cell", "CELL", 262, 272], ["Qiazol", "SIMPLE_CHEMICAL", 285, 291], ["red cells", "CELL_TYPE", 132, 141], ["white blood cell fraction", "CELL_TYPE", 256, 281], ["Samples", "TEST", 0, 7], ["the red cells", "TEST", 128, 141], ["the cell pellet", "TEST", 147, 162], ["red blood cell lysis buffer", "TREATMENT", 168, 195], ["RBC lysis solution", "TREATMENT", 197, 215], ["Qiazol", "TREATMENT", 285, 291], ["the Qiagen miRNAEASY kit", "TREATMENT", 360, 384], ["cellular fractions", "OBSERVATION", 88, 106], ["red cells", "OBSERVATION", 132, 141], ["cell pellet", "OBSERVATION", 151, 162], ["blood cell lysis", "OBSERVATION", 172, 188], ["total RNA", "OBSERVATION_MODIFIER", 327, 336]]], ["Previous analyses of the NC and LPS samples are reported in (18) .", [["samples", "ANATOMY", 36, 43], ["Previous analyses", "TEST", 0, 17], ["the NC", "TREATMENT", 21, 27], ["LPS samples", "TEST", 32, 43], ["NC", "ANATOMY", 25, 27]]], ["Gard samples were also collected at the same time, but gene expression data for these samples were not generated until a later date (see below for discussion of possible associated batch effects).", [["Gard samples", "ANATOMY", 0, 12], ["Gard samples", "CANCER", 0, 12], ["Gard samples", "TEST", 0, 12], ["these samples", "TEST", 80, 93]]], ["Importantly, raw data for all three conditions were re-processed and re-normalized in parallel for this analysis.Blood Sample Collection and In Vitro ChallengesTo control for cellular compositional effects, we also drew an additional blood sample in the same draw to measure the proportional representation of ten white blood cell subsets: classical monocytes (CD14 + /CD16 -), CD14 + intermediate monocytes (CD14 + /CD16 + ), CD14non-classical monocytes (CD14 -/CD16 + ), helper T cells (CD3 + /CD4 + ), cytotoxic T cells (CD3 + /CD8 + ), double positive T cells (CD3 + /CD4 + /CD8 + ), CD8 -B cells (CD3 -/CD20 + /CD8 -), CD8 + B cells (CD3 -/CD20 + /CD8 + ), natural killer T lymphocytes (CD3 + /CD16 + ), and natural killer cells (CD3 -/CD16 + ).", [["Blood", "ANATOMY", 113, 118], ["cellular", "ANATOMY", 175, 183], ["blood sample", "ANATOMY", 234, 246], ["white blood cell", "ANATOMY", 314, 330], ["monocytes", "ANATOMY", 350, 359], ["CD14 + /CD16 -)", "ANATOMY", 361, 376], ["CD14 + intermediate monocytes", "ANATOMY", 378, 407], ["CD14 + /CD16 + )", "ANATOMY", 409, 425], ["monocytes", "ANATOMY", 445, 454], ["CD14 -/CD16 + )", "ANATOMY", 456, 471], ["helper T cells", "ANATOMY", 473, 487], ["CD3 + /CD4 + )", "ANATOMY", 489, 503], ["cytotoxic T cells", "ANATOMY", 505, 522], ["CD3 + /CD8 +", "ANATOMY", 524, 536], ["T cells", "ANATOMY", 556, 563], ["CD3 + /CD4 + /CD8 + )", "ANATOMY", 565, 586], ["CD8 -B cells", "ANATOMY", 588, 600], ["CD3 -/CD20 + /CD8 -)", "ANATOMY", 602, 622], ["CD8 + B cells", "ANATOMY", 624, 637], ["CD3 -/CD20 + /CD8 + )", "ANATOMY", 639, 660], ["natural killer T lymphocytes", "ANATOMY", 662, 690], ["CD3 + /CD16 + )", "ANATOMY", 692, 707], ["natural killer cells", "ANATOMY", 713, 733], ["CD3 -/CD16 +", "ANATOMY", 735, 747], ["Blood", "ORGANISM_SUBSTANCE", 113, 118], ["cellular", "CELL", 175, 183], ["blood", "ORGANISM_SUBSTANCE", 234, 239], ["blood cell subsets", "CELL", 320, 338], ["monocytes", "CELL", 350, 359], ["CD14", "GENE_OR_GENE_PRODUCT", 361, 365], ["CD16", "GENE_OR_GENE_PRODUCT", 369, 373], ["CD14", "GENE_OR_GENE_PRODUCT", 378, 382], ["CD14", "GENE_OR_GENE_PRODUCT", 409, 413], ["CD16", "GENE_OR_GENE_PRODUCT", 417, 421], ["CD14non", "GENE_OR_GENE_PRODUCT", 427, 434], ["monocytes", "CELL", 445, 454], ["CD14", "GENE_OR_GENE_PRODUCT", 456, 460], ["CD16", "GENE_OR_GENE_PRODUCT", 463, 467], ["CD3", "GENE_OR_GENE_PRODUCT", 489, 492], ["CD4", "GENE_OR_GENE_PRODUCT", 496, 499], ["CD3", "GENE_OR_GENE_PRODUCT", 524, 527], ["CD8", "GENE_OR_GENE_PRODUCT", 531, 534], ["CD3", "GENE_OR_GENE_PRODUCT", 565, 568], ["CD4", "GENE_OR_GENE_PRODUCT", 572, 575], ["CD8", "GENE_OR_GENE_PRODUCT", 579, 582], ["CD8", "GENE_OR_GENE_PRODUCT", 588, 591], ["CD3", "GENE_OR_GENE_PRODUCT", 602, 605], ["CD20", "GENE_OR_GENE_PRODUCT", 608, 612], ["CD8", "GENE_OR_GENE_PRODUCT", 616, 619], ["CD8", "GENE_OR_GENE_PRODUCT", 624, 627], ["CD3", "GENE_OR_GENE_PRODUCT", 639, 642], ["CD20", "GENE_OR_GENE_PRODUCT", 645, 649], ["CD8", "GENE_OR_GENE_PRODUCT", 653, 656], ["CD3", "GENE_OR_GENE_PRODUCT", 692, 695], ["CD16", "GENE_OR_GENE_PRODUCT", 699, 703], ["natural killer cells", "CELL", 713, 733], ["CD3", "GENE_OR_GENE_PRODUCT", 735, 738], ["CD16", "GENE_OR_GENE_PRODUCT", 741, 745], ["white blood cell subsets", "CELL_TYPE", 314, 338], ["classical monocytes", "CELL_TYPE", 340, 359], ["CD14", "PROTEIN", 361, 365], ["CD16", "PROTEIN", 369, 373], ["CD14", "PROTEIN", 378, 382], ["intermediate monocytes", "CELL_TYPE", 385, 407], ["CD14", "PROTEIN", 409, 413], ["CD16", "PROTEIN", 417, 421], ["CD14non", "PROTEIN", 427, 434], ["classical monocytes", "CELL_TYPE", 435, 454], ["CD14", "PROTEIN", 456, 460], ["CD16", "PROTEIN", 463, 467], ["helper T cells", "CELL_TYPE", 473, 487], ["CD3", "PROTEIN", 489, 492], ["CD4", "PROTEIN", 496, 499], ["cytotoxic T cells", "CELL_TYPE", 505, 522], ["CD3", "PROTEIN", 524, 527], ["CD8", "PROTEIN", 531, 534], ["double positive T cells", "CELL_TYPE", 540, 563], ["CD3", "PROTEIN", 565, 568], ["CD4", "PROTEIN", 572, 575], ["CD8", "PROTEIN", 579, 582], ["CD8", "PROTEIN", 588, 591], ["B cells", "CELL_TYPE", 593, 600], ["CD3", "PROTEIN", 602, 605], ["CD20", "PROTEIN", 608, 612], ["CD8", "PROTEIN", 616, 619], ["CD8", "PROTEIN", 624, 627], ["B cells", "CELL_TYPE", 630, 637], ["CD3", "PROTEIN", 639, 642], ["CD20", "PROTEIN", 645, 649], ["CD8", "PROTEIN", 653, 656], ["natural killer T lymphocytes", "CELL_TYPE", 662, 690], ["CD3", "PROTEIN", 692, 695], ["CD16", "PROTEIN", 699, 703], ["natural killer cells", "CELL_TYPE", 713, 733], ["CD3", "PROTEIN", 735, 738], ["CD16", "PROTEIN", 741, 745], ["this analysis", "TEST", 99, 112], ["Blood Sample Collection", "TEST", 113, 136], ["Vitro Challenges", "TREATMENT", 144, 160], ["an additional blood sample", "TEST", 220, 246], ["ten white blood cell subsets", "TEST", 310, 338], ["classical monocytes", "TEST", 340, 359], ["CD14", "TEST", 361, 365], ["CD16", "TEST", 369, 373], ["CD14", "TEST", 378, 382], ["monocytes", "TEST", 398, 407], ["CD14", "TEST", 409, 413], ["CD16", "TEST", 417, 421], ["CD14non", "TEST", 427, 434], ["classical monocytes", "TEST", 435, 454], ["CD14", "TEST", 456, 460], ["CD16", "TEST", 463, 467], ["helper T cells", "TEST", 473, 487], ["CD3", "TEST", 489, 492], ["CD4", "TEST", 496, 499], ["cytotoxic T cells", "TEST", 505, 522], ["CD3", "TEST", 524, 527], ["CD8", "TEST", 531, 534], ["double positive T cells", "PROBLEM", 540, 563], ["CD3", "TEST", 565, 568], ["CD4", "TEST", 572, 575], ["CD8", "TEST", 579, 582], ["CD8", "TEST", 588, 591], ["CD3", "TEST", 602, 605], ["CD20", "TEST", 608, 612], ["CD8", "TEST", 616, 619], ["CD8", "TEST", 624, 627], ["cells", "TEST", 632, 637], ["CD3", "TEST", 639, 642], ["CD20", "TEST", 645, 649], ["CD8", "TEST", 653, 656], ["lymphocytes", "TEST", 679, 690], ["CD3", "TEST", 692, 695], ["CD16", "TEST", 699, 703], ["natural killer cells", "TEST", 713, 733], ["CD16", "TEST", 741, 745], ["intermediate monocytes", "OBSERVATION", 385, 407], ["B cells", "ANATOMY", 593, 600], ["B cells", "ANATOMY", 630, 637], ["natural killer", "ANATOMY", 713, 727]]], ["The antibodyfluorophor combinations used for flow cytometry are provided in (18) , and estimated cell type proportions for each sample are provided in SI Appendix, Dataset S1.RNA-Seq library preparation, low-level data processing, and batch effect correctionEach RNA-sequencing library was prepared from 200 ng of total RNA using the NEBNext Poly(A) mRNA Magnetic Isolation Module and the NEBNext Ultra RNA Library Prep Kit (New England Biolabs), following the manufacturer's instructions and selecting for ~350 bp size fragments.", [["cell", "ANATOMY", 97, 101], ["sample", "ANATOMY", 128, 134], ["cell", "CELL", 97, 101], ["total RNA", "RNA", 314, 323], ["NEBNext Poly(A) mRNA", "RNA", 334, 354], ["350 bp size fragments", "DNA", 508, 529], ["The antibodyfluorophor combinations", "TREATMENT", 0, 35], ["flow cytometry", "TEST", 45, 59], ["each sample", "TEST", 123, 134], ["RNA", "TEST", 175, 178], ["Seq library preparation", "TREATMENT", 179, 202], ["total RNA", "TREATMENT", 314, 323], ["the NEBNext Poly(A) mRNA Magnetic Isolation Module", "TREATMENT", 330, 380], ["the NEBNext Ultra RNA", "TREATMENT", 385, 406], ["New England Biolabs)", "TREATMENT", 425, 445], ["~350 bp size fragments", "TREATMENT", 507, 529], ["SI Appendix", "ANATOMY", 151, 162], ["size", "OBSERVATION_MODIFIER", 515, 519], ["fragments", "OBSERVATION", 520, 529]]], ["Libraries were amplified via PCR for 13 cycles, barcoded, and pooled into sets of 10-12 samples for sequencing on an Illumina HiSeq 2500.", [["samples", "ANATOMY", 88, 95], ["Illumina HiSeq 2500", "DNA", 117, 136], ["Libraries", "TREATMENT", 0, 9], ["PCR", "TEST", 29, 32], ["barcoded", "TREATMENT", 48, 56], ["an Illumina HiSeq", "TREATMENT", 114, 131]]], ["Illumina adapters and low-quality score (<20) bases were removed from the raw reads using .", [["Illumina adapters", "TREATMENT", 0, 17], ["low", "OBSERVATION_MODIFIER", 22, 25]]], ["CC-BY-NC-ND 4.0 International license is made available under a The copyright holder for this preprint (which was not peer-reviewed) is the author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["It . https://doi.org/10.1101/552356 doi: bioRxiv preprint TrimGalore!", [["bioRxiv preprint TrimGalore", "TREATMENT", 41, 68]]], ["Trimmed reads were mapped to the rhesus macaque genome (MacaM v7) using the STAR 2-pass method (68) .", [["macaque", "ORGANISM", 40, 47], ["rhesus macaque genome", "DNA", 33, 54], ["MacaM v7", "DNA", 56, 64], ["STAR 2", "DNA", 76, 82], ["rhesus macaque", "SPECIES", 33, 47], ["rhesus macaque", "SPECIES", 33, 47]]], ["Following quality control, we retained RNA-seq for 125 samples: 42 NC samples, 40 LPS samples, and 43 Gard samples.RNA-Seq library preparation, low-level data processing, and batch effect correctionGene-level counts were obtained using STAR (69) .", [["samples", "ANATOMY", 55, 62], ["NC samples", "ANATOMY", 67, 77], ["samples", "ANATOMY", 86, 93], ["Gard samples", "ANATOMY", 102, 114], ["RNA", "TEST", 39, 42], ["NC samples", "TEST", 67, 77], ["LPS samples", "TEST", 82, 93], ["Gard samples", "TEST", 102, 114], ["RNA", "TEST", 115, 118], ["Seq library preparation", "TREATMENT", 119, 142], ["Gene-level counts", "TEST", 198, 215]]], ["Prior to RNA-seq data analysis, we first filtered out genes that were very lowly or not detectably expressed in our samples.", [["samples", "ANATOMY", 116, 123], ["RNA-seq data analysis", "TEST", 9, 30]]], ["Specifically, we removed genes that exhibited low median RPKM (\u2264 2) in all three conditions, which resulted in a final set of read counts for 9,088 genes.", [["9,088 genes", "DNA", 142, 153], ["low median RPKM", "PROBLEM", 46, 61], ["read counts", "TEST", 126, 137], ["low", "OBSERVATION_MODIFIER", 46, 49]]], ["We then normalized gene expression levels across samples using the TMM algorithm (weighted trimmed mean of M-values), implemented in the R package edgeR (70) .", [["the TMM algorithm", "TEST", 63, 80]]], ["Finally, we log-transformed the data using the voom function in R package limma (71, 72) .RNA-Seq library preparation, low-level data processing, and batch effect correctionGene expression levels can differ across social groups because of unknown environmental differences between groups.", [["RNA", "TEST", 90, 93], ["Seq library preparation", "TREATMENT", 94, 117], ["Gene expression levels", "PROBLEM", 173, 195]]], ["Additionally, samples from females living in the same social group were almost always collected at the same time (i.e., blood samples from all five members of the a group were drawn, cultured, shipped, and extracted in parallel).", [["samples", "ANATOMY", 14, 21], ["blood samples", "ANATOMY", 120, 133], ["blood samples", "MULTI-TISSUE_STRUCTURE", 120, 133], ["blood samples", "TEST", 120, 133]]], ["Hence, controlling for social group effects simultaneously controls for unmeasured variation between groups and most technical batch effects related to sample collection and processing.", [["sample", "ANATOMY", 152, 158], ["social group effects simultaneously controls", "TREATMENT", 23, 67], ["unmeasured variation between groups", "PROBLEM", 72, 107], ["most technical batch effects", "TREATMENT", 112, 140], ["sample collection", "PROBLEM", 152, 169]]], ["We also controlled for potential flow cell effects to take into account batch effects introduced at the sequencing stage.RNA-Seq library preparation, low-level data processing, and batch effect correctionTo correct for batch effects, we implemented a mixed model to estimate the effects of social group (i.e., collection batch) and flow cell on gene expression, while taking into account dominance rank and other biological covariates of interest.", [["cell", "ANATOMY", 38, 42], ["cell", "ANATOMY", 337, 341], ["cell", "CELL", 38, 42], ["cell", "CELL", 337, 341], ["potential flow cell effects", "PROBLEM", 23, 50], ["RNA", "TEST", 121, 124], ["Seq library preparation", "TREATMENT", 125, 148], ["social group (i.e., collection batch", "TREATMENT", 290, 326], ["flow cell effects", "OBSERVATION", 33, 50], ["flow cell", "OBSERVATION", 332, 341]]], ["To model past rank, we used Elo score evaluated a mean of 3.64 \u00b1 1.06 s.d. months after females were introduced into their Phase I groups.", [["Elo score", "TEST", 28, 37]]], ["Within each condition, we also quantile normalized past Elo scores to match the distribution of Elo scores for current rank, standardized the two Elo score variables and the two tissue composition variables to mean=0 and standard deviation=1, and mean-centered age.", [["tissue", "ANATOMY", 178, 184], ["tissue", "TISSUE", 178, 184], ["Elo scores", "PROBLEM", 96, 106]]], ["For each gene and each condition (NC, LPS, Gard) separately, we fit the following model:RNA-Seq library preparation, low-level data processing, and batch effect correctionEq.", [["Seq library preparation", "TREATMENT", 92, 115], ["low-level data processing", "TREATMENT", 117, 142]]], ["(1):RNA-Seq library preparation, low-level data processing, and batch effect correction= + ' + ) + + + -+ / + 1 \u00d7 ( = 2) + : : + ,RNA-Seq library preparation, low-level data processing, and batch effect correctionwhere the normalized expression level, y, is modeled as a function of an intercept, , and the fixed effects of past rank, p ( ' is its coefficient); rank at the time of sampling, r ( ) is its coefficient); age at the time of sampling, a ( + is its coefficient); the top two principal components of the normalized cell type proportions data, t and v (with coefficientsand sequenced on two flow cells; for LPS and NC conditions, all samples were sequenced on the same flow cell.", [["cell", "ANATOMY", 526, 530], ["cells", "ANATOMY", 606, 611], ["samples", "ANATOMY", 644, 651], ["cell", "ANATOMY", 684, 688], ["cell", "CELL", 526, 530], ["cells", "CELL", 606, 611], ["cell", "CELL", 684, 688], ["flow cells", "CELL_TYPE", 601, 611], ["RNA", "TEST", 4, 7], ["Seq library preparation", "TREATMENT", 8, 31], ["batch effect", "TEST", 64, 76], ["correction", "TEST", 77, 87], ["RNA", "TEST", 130, 133], ["Seq library preparation", "TEST", 134, 157], ["low-level data processing", "PROBLEM", 159, 184], ["batch effect", "PROBLEM", 190, 202], ["the normalized expression level", "PROBLEM", 219, 250], ["sampling", "TEST", 438, 446], ["two flow cells", "TREATMENT", 597, 611], ["LPS", "TEST", 617, 620], ["NC conditions", "TREATMENT", 625, 638], ["all samples", "TEST", 640, 651], ["normalized cell type", "OBSERVATION", 515, 535]]], ["Finally, we modeled a random effect, : , of social group membership, which captures most sources of batch effects. : is an incidence matrix that assign samples to social groups. denotes model error.RNA-Seq library preparation, low-level data processing, and batch effect correctionWe fit each model using the lme function in the R package lme4 (73) .", [["an incidence matrix", "PROBLEM", 120, 139], ["model error", "PROBLEM", 186, 197], ["RNA", "TEST", 198, 201], ["Seq library preparation", "TREATMENT", 202, 225], ["model error", "OBSERVATION", 186, 197]]], ["To obtain batchcorrected values, we then subtracted the sample-specific estimate of the random effects of social group and flow cell from the original gene expression values.", [["cell", "ANATOMY", 128, 132], ["cell", "CELL", 128, 132], ["the sample", "TEST", 52, 62], ["flow cell", "OBSERVATION", 123, 132]]], ["We note that this procedure only corrects for batch effects within, but not across conditions.", [["this procedure", "TREATMENT", 13, 27], ["batch effects", "PROBLEM", 46, 59]]], ["The major source of batch effects across conditions arises from differences in the timing of library prep and sequencing for the Gard samples, relative to the NC and LPS samples (which were prepped and sequenced together).", [["Gard samples", "ANATOMY", 129, 141], ["samples", "ANATOMY", 170, 177], ["batch effects across conditions", "PROBLEM", 20, 51], ["library prep", "TREATMENT", 93, 105], ["the Gard samples", "TEST", 125, 141], ["the NC and LPS samples", "TREATMENT", 155, 177], ["batch effects", "OBSERVATION", 20, 33]]], ["Because condition is completely collinear with this source of batch effects, we cannot correct for it in our data analysis.", [["our data analysis", "TEST", 105, 122]]], ["Importantly, this issue does not impact our estimation of rank effects within NC, LPS, or Gard data sets, which are the effects of primary interest for this study.", [["LPS", "TEST", 82, 85], ["Gard data sets", "TEST", 90, 104], ["this study", "TEST", 152, 162]]], ["It could, however, impact the identity and magnitude of our estimates for genes that are differentially expressed in response to Gard stimulation (i.e., when we compare NC to Gard data collected from the same individuals).", [["NC", "TREATMENT", 169, 171], ["Gard data", "TEST", 175, 184]]], ["Reassuringly, gene set enrichment analysis shows that genes we identified as responsive to Gard are strongly enriched for pathways involved in antiviral responses (e.g., response to cytokine: FDRcorrected p=2.4x10 -6 ; type I interferon signaling pathway: FDR-corrected p=1.2x10 -5 ; cellular response to interferon gamma: FDR-corrected p=3.1x10 -5 ; SI Appendix, Dataset S2).", [["cellular", "ANATOMY", 284, 292], ["type I interferon", "GENE_OR_GENE_PRODUCT", 219, 236], ["cellular", "CELL", 284, 292], ["interferon gamma", "GENE_OR_GENE_PRODUCT", 305, 321], ["Gard", "DNA", 91, 95], ["cytokine", "PROTEIN", 182, 190], ["interferon", "PROTEIN", 226, 236], ["interferon gamma", "PROTEIN", 305, 321], ["gene set enrichment analysis", "TEST", 14, 42], ["type I interferon signaling pathway", "PROBLEM", 219, 254], ["FDR", "TEST", 256, 259], ["cellular response", "TEST", 284, 301], ["interferon gamma", "TEST", 305, 321], ["FDR", "TEST", 323, 326], ["p", "TEST", 337, 338], ["Appendix", "ANATOMY", 354, 362]]], ["This observation suggests that differences in expression between Gard and NC samples reflect a true biological response to the viral ligand and are not a technical artifact of our sequencing design.Statistical modeling of rank effectsTo investigate rank effects on gene expression levels upon bacterial versus viral stimulation, and to quantify social history effects on these responses, we modeled batchcorrected gene expression levels using the following nested mixed model, with predictor variables quantile normalized (rank data), transformed to a standard normal (rank and tissue composition data), or mean-centered (age data) as described above: where y represents the normalized gene expression levels corrected for social group and flow cell effects, and data from all three conditions are modeled jointly.", [["NC samples", "ANATOMY", 74, 84], ["tissue", "ANATOMY", 578, 584], ["cell", "ANATOMY", 745, 749], ["Gard", "CELL", 65, 69], ["NC samples", "CANCER", 74, 84], ["tissue", "TISSUE", 578, 584], ["cell", "CELL", 745, 749], ["This observation", "TEST", 0, 16], ["Gard and NC samples", "TEST", 65, 84], ["the viral ligand", "TEST", 123, 139], ["gene expression levels", "PROBLEM", 265, 287], ["bacterial versus viral stimulation", "TREATMENT", 293, 327], ["the normalized gene expression levels", "PROBLEM", 671, 708], ["social group and flow cell effects", "TREATMENT", 723, 757], ["viral ligand", "OBSERVATION", 127, 139], ["rank effects", "OBSERVATION", 222, 234], ["flow cell", "OBSERVATION", 740, 749]]], ["Here, gene expression levels are modeled as a function of an intercept, ; the effects of LPS stimulation ( ) and Gard stimulation ( ); and the fixed effects of past rank, p; rank at the time of sampling (\"current rank\"), r; age, a; and the top two principal components of the normalized cell type proportions data, t and v. Fixed effects are nested within condition (control = 0; LPS = 1; Gard = 2), and I is an indicator variable for evaluating whether each sample was collected in the given condition.", [["cell", "ANATOMY", 287, 291], ["LPS", "CHEMICAL", 89, 92], ["LPS", "SIMPLE_CHEMICAL", 89, 92], ["cell", "CELL", 287, 291], ["gene expression levels", "TEST", 6, 28], ["LPS stimulation", "TREATMENT", 89, 104], ["LPS", "TEST", 380, 383], ["Gard", "TEST", 389, 393], ["normalized cell", "OBSERVATION", 276, 291]]], ["Coefficients are consistent with Eq.", [["consistent with", "UNCERTAINTY", 17, 32]]], ["(1), but with an added superscript to denote estimates specific to a given treatment condition.", [["treatment condition", "TREATMENT", 75, 94]]], ["We also model an m by 1 vector u as a random effects term to control for kinship and other sources of genetic structure.", [["genetic structure", "OBSERVATION", 102, 119]]], ["Here, m is the number of unique females in the analysis (m=45) and the m by m matrix K contains estimates of pairwise relatedness derived from a 45 x 54,165 genotype matrix, as described in (18) .", [["pairwise relatedness", "PROBLEM", 109, 129]]], ["Z is an incidence matrix of 1's and 0's that maps samples to individuals in the random effects term.", [["maps samples", "TEST", 45, 57]]], ["Residual errors are represented by , S Q represents the environmental variance component (unstructured by genetic relatedness), I is the identity matrix, and MVN denotes the multivariate normal distribution.Statistical modeling of rank effectsTo specifically estimate the effects of dominance rank on the response to LPS and Gard, we reformulated Eq.", [["LPS", "CHEMICAL", 317, 320], ["matrix", "CELLULAR_COMPONENT", 146, 152], ["LPS", "SIMPLE_CHEMICAL", 317, 320], ["MVN", "PROTEIN", 158, 161], ["Residual errors", "PROBLEM", 0, 15], ["LPS", "TREATMENT", 317, 320], ["errors", "OBSERVATION", 9, 15], ["multivariate normal", "OBSERVATION", 174, 193], ["distribution", "OBSERVATION_MODIFIER", 194, 206], ["rank effects", "OBSERVATION", 231, 243]]], ["(2) to extract estimates for the interaction between rank and treatment condition, separately for past rank and current rank.Eq.", [["treatment condition", "TREATMENT", 62, 81]]], ["(3):= + T + Q + ' + ) + + + -+ / + ( \u00d7 T ) '\u00d7U V + ( \u00d7 Q ) '\u00d7U W + ( \u00d7 T ) )\u00d7U V + ( \u00d7 Q ) )\u00d7U W + ( \u00d7 T ) +\u00d7U V + ( \u00d7 Q ) +\u00d7U W + ( \u00d7 T ) -\u00d7U V + ( \u00d7 Q ) -\u00d7U W + ( \u00d7 T ) /\u00d7U V + ( \u00d7 Q ) /\u00d7U W + + ,Eq.", [["(3):= + T + Q + ' + ) + + + -+ / + ( \u00d7 T ) '\u00d7U V + ( \u00d7 Q ) '\u00d7U W + ( \u00d7 T ) )\u00d7U V +", "CHEMICAL", 0, 82], ["W", "CHEMICAL", 127, 128], ["W + +", "SIMPLE_CHEMICAL", 191, 196], ["T", "TEST", 8, 9], ["T", "TEST", 39, 40], ["V", "TEST", 47, 48], ["U W", "TEST", 61, 64], ["T", "TEST", 71, 72], ["U", "TEST", 77, 78], ["V", "TEST", 79, 80], ["U W", "TEST", 93, 96], ["T", "TEST", 103, 104], ["U", "TEST", 109, 110], ["V", "TEST", 111, 112], ["U W", "TEST", 125, 128], ["T", "TEST", 135, 136], ["U", "TEST", 141, 142], ["V", "TEST", 143, 144], ["U W", "TEST", 157, 160], ["T", "TEST", 167, 168], ["U V", "TEST", 173, 176], ["Q", "TEST", 183, 184], ["/\u00d7", "TEST", 187, 189], ["U", "TEST", 189, 190], ["Eq.", "PROBLEM", 198, 201]]], ["(3):where the notation is consistent with Eq.", [["consistent with", "UNCERTAINTY", 26, 41]]], ["(2), but we reparametrize the model to obtain directly each covariate's interaction with treatment condition (i.e., the effects of each covariate on treatment response).", [["treatment condition", "TREATMENT", 89, 108], ["treatment response", "TREATMENT", 149, 167]]], ["These interactions can be interpreted as the effect of past rank, current rank, age, and tissue composition on the gene expression response to LPS or Gard challenge.Eq.", [["tissue", "ANATOMY", 89, 95], ["LPS", "CHEMICAL", 143, 146], ["tissue", "TISSUE", 89, 95], ["LPS", "SIMPLE_CHEMICAL", 143, 146], ["LPS", "TREATMENT", 143, 146], ["Gard challenge", "TREATMENT", 150, 164]]], ["(3):Finally, to explicitly model interaction effects between past rank and current rank, we introduced an additional term for each condition into Eq. where notations are consistent with Eq.", [["an additional term for each condition", "TREATMENT", 103, 140], ["consistent with", "UNCERTAINTY", 170, 185]]], ["To assess significance after correcting for multiple hypothesis testing, we compared the distribution of p-values for each variable of interest to the distribution of p-values from permuted data.", [["multiple hypothesis testing", "TEST", 44, 71], ["p-values", "TEST", 105, 113]]], ["To generate permutations that preserved the structure of our data set (especially the strong correlation between Phase II social group membership and past rank in Phase I, which is a product of our experimental design: see Fig. 1A ), we followed a two-step permutation procedure.Eq.", [["Phase I", "PROTEIN", 163, 170], ["permutations", "TREATMENT", 12, 24], ["a two-step permutation procedure", "TREATMENT", 246, 278]]], ["(3):First, we blocked all explanatory variables (past rank, current rank, animal age, tissue composition variables) by social group in Phase II.", [["tissue", "ANATOMY", 86, 92], ["tissue", "TISSUE", 86, 92]]], ["This two-step procedure maintains the correlation between Phase II social group and past rank observed in the original data because all co-housed females remain assigned to a shared social group label following permutation.", [["This two-step procedure", "TREATMENT", 0, 23]]], ["However, it also randomizes the relationship between gene expression and the explanatory variables (see SI Appendix, Fig. S7 for a graphical depiction of this two-step strategy).Eq.", [["S7", "PROTEIN", 122, 124], ["a graphical depiction", "TEST", 129, 150], ["Appendix", "ANATOMY", 107, 115]]], ["(3):We performed permutations independently for each gene, conducted our complete set of statistical analyses (i.e., batch effect removal followed by differential expression analysis) on the permuted data, and treated the resulting p-value distributions as empirical null distributions to calculate false discovery rates, following a generalized version of the method described by Storey and Tibshirani (75) .Eq.", [["statistical analyses", "TEST", 89, 109], ["removal", "TREATMENT", 130, 137], ["differential expression analysis", "TEST", 150, 182], ["the resulting p-value distributions", "PROBLEM", 218, 253], ["empirical null distributions", "PROBLEM", 257, 285], ["the method", "TREATMENT", 357, 367]]], ["(3):To identify genes that significantly responded to Gard and LPS stimulation, which should not be affected by correlations between past rank and Phase II social group, we used the standard method for multiple testing correction implemented in the R package qvalue (76) .Quantification of gene-specific plasticityTo quantify the plasticity of rank effects for each gene in each condition, we first estimated the total variance in gene expression levels explained by both past rank and current rank, '\u222a) Q .", [["LPS", "CHEMICAL", 63, 66], ["LPS", "SIMPLE_CHEMICAL", 63, 66], ["Gard and LPS stimulation", "TREATMENT", 54, 78], ["the standard method", "TREATMENT", 178, 197], ["multiple testing correction", "TREATMENT", 202, 229], ["the total variance in gene expression levels", "TREATMENT", 409, 453]]], ["We define gene-specific plasticity, \u0398, as the ratio of square roots of these variances (i.e., a ratio of standard deviations): Eq.", [["specific plasticity", "OBSERVATION_MODIFIER", 15, 34]]], ["(6) = | ) | /\u00a0' Q + ) Q therefore has an elementary geometric interpretation, which can be interpreted as the absolute value of the sine of the angle, , created by the vector ( , ) = ( ' , ) )and the xaxis (see SI Appendix, Fig. S7 for a schematic representation).Quantification of gene-specific plasticityTo make the distributions of directly comparable across conditions, we focused our analyses on the top 1000 genes with the largest values of '\u222a) Q within each conditions (i.e., the genes most strongly affected by dominance rank, whether past, current, or both).", [["S7", "PROTEIN", 229, 231], ["an elementary geometric interpretation", "TEST", 38, 76], ["Appendix", "ANATOMY", 214, 222]]], ["We excluded the small set of genes for which past and current ranks were significant but directionally opposed (FDR=10%; <7.5% of all rank-associated genes in each condition).", [["FDR", "TEST", 112, 115], ["small", "OBSERVATION_MODIFIER", 16, 21]]], ["Importantly, the overall pattern--that social history effects are less apparent in immunechallenged conditions than in control conditions-is robust across a wide range of top rankassociated genes (SI Appendix, Fig. S6 ).Gene Ontology enrichment analysisFor all GO term enrichment analyses, we used the Cytoscape module ClueGO (77) (SI Appendix, Dataset S3).", [["top rankassociated genes", "DNA", 171, 195], ["immunechallenged conditions", "PROBLEM", 83, 110], ["enrichment analysis", "TEST", 234, 253], ["overall", "OBSERVATION_MODIFIER", 17, 24], ["pattern", "OBSERVATION_MODIFIER", 25, 32], ["less apparent", "OBSERVATION_MODIFIER", 66, 79], ["Appendix", "ANATOMY", 200, 208]]], ["In all cases, we performed one-tailed Fisher's Exact Tests for enrichment, and corrected for multiple tests using the Benjamini-Hochberg (B-H) method (78) .", [["multiple tests", "TEST", 93, 107]]], ["To reduce the multiple testing space and account for the nested nature of GO terms, we analyzed only terms that fell between levels 3 and 8 of the GO tree for Biological Processes, included at least 5 genes in our data set, and for which at least 5% of the total number of genes belonging to the GO term were present in the test gene set.", [["GO term", "DNA", 296, 303], ["test gene set", "DNA", 324, 337], ["the multiple testing space", "TEST", 10, 36], ["multiple", "OBSERVATION_MODIFIER", 14, 22]]], ["We report significant gene set enrichments for those GO categories that passed a 5% FDR for the response to LPS/Gard challenge and for current rank effects, and a 10% FDR for past rank effects.Transcription factor binding site enrichment analysis.To investigate whether binding sites for specific TFs were enriched in the promoter regions of rank-associated genes, we drew on chromatin accessibility data generated via ATAC-seq and reported previously in (18) .", [["TFs", "ANATOMY", 297, 300], ["chromatin", "ANATOMY", 376, 385], ["LPS", "CHEMICAL", 108, 111], ["TFs", "CELL", 297, 300], ["chromatin", "CELLULAR_COMPONENT", 376, 385], ["Transcription factor", "PROTEIN", 193, 213], ["binding sites", "DNA", 270, 283], ["TFs", "DNA", 297, 300], ["promoter regions", "DNA", 322, 338], ["rank", "DNA", 342, 346], ["chromatin", "DNA", 376, 385], ["ATAC-seq", "DNA", 419, 427], ["significant gene set enrichments", "PROBLEM", 10, 42], ["a 5% FDR", "TREATMENT", 79, 87], ["LPS/Gard challenge", "TREATMENT", 108, 126], ["a 10% FDR", "TREATMENT", 161, 170], ["enrichment analysis", "TEST", 227, 246], ["binding sites", "PROBLEM", 270, 283], ["specific TFs", "PROBLEM", 288, 300], ["chromatin accessibility data", "TEST", 376, 404], ["significant", "OBSERVATION_MODIFIER", 10, 21]]], ["In brief, these data were generated from 50,000 PBMCs obtained from three mid-ranking study subjects.", [["PBMCs", "ANATOMY", 48, 53], ["PBMCs", "CELL", 48, 53], ["PBMCs", "CELL_TYPE", 48, 53], ["these data", "TEST", 10, 20], ["PBMCs", "TEST", 48, 53]]], ["The resulting libraries were sequenced on an Illumina NextSeq 500 and the reads mapped to the macaque genome and used to identify open chromatin peaks following the pipeline described in (18) .Transcription factor binding site enrichment analysis.To identify likely TFBSs that overlapped with accessible chromatin upstream of rank-responsive genes (within 5 kb of the transcription start site), we scanned the macaque genome for matches to 1900 TRANSFAC and JASPAR-derived position weight matrices (PWMs: threshold log2 likelihood ratio(TFBS/background)=13) (79, 80) .", [["chromatin", "ANATOMY", 135, 144], ["chromatin", "ANATOMY", 304, 313], ["macaque", "ORGANISM", 94, 101], ["chromatin", "CELLULAR_COMPONENT", 135, 144], ["chromatin", "CELLULAR_COMPONENT", 304, 313], ["macaque", "ORGANISM", 410, 417], ["Illumina NextSeq 500", "DNA", 45, 65], ["macaque genome", "DNA", 94, 108], ["Transcription factor", "PROTEIN", 193, 213], ["TFBSs", "DNA", 266, 271], ["chromatin", "DNA", 304, 313], ["rank-responsive genes", "DNA", 326, 347], ["transcription start site", "DNA", 368, 392], ["macaque genome", "DNA", 410, 424], ["1900 TRANSFAC", "DNA", 440, 453], ["JASPAR-derived position weight matrices", "DNA", 458, 497], ["PWMs", "DNA", 499, 503], ["an Illumina NextSeq", "TEST", 42, 61], ["open chromatin peaks", "PROBLEM", 130, 150], ["enrichment analysis", "TEST", 227, 246], ["TFBSs", "PROBLEM", 266, 271], ["JASPAR", "TEST", 458, 464], ["likelihood ratio", "TEST", 520, 536], ["TFBS/background", "TEST", 537, 552], ["chromatin peaks", "OBSERVATION", 135, 150], ["responsive genes", "OBSERVATION", 331, 347]]], ["To reduce redundancy, we used bedtools (81) to perform hierarchical clustering of the PWMs based on the pair-wise Jaccard distances between their locations in the macaque genome.", [["macaque", "ORGANISM", 163, 170], ["PWMs", "DNA", 86, 90], ["macaque genome", "DNA", 163, 177], ["redundancy", "OBSERVATION", 10, 20], ["macaque genome", "OBSERVATION", 163, 177]]], ["We then defined independent TF clusters at a dissimilarity threshold of 0.2.", [["TF", "PROTEIN", 28, 30], ["a dissimilarity threshold", "TEST", 43, 68], ["TF clusters", "OBSERVATION", 28, 39]]], ["After filtering for clusters that rarely occurred in open chromatin regions upstream of genes, we obtained a final set of 460 motif clusters that we tested for enrichment near rank-associated genes.AUTHOR CONTRIBUTIONSJS, MEW, JT, and LBB designed the study.", [["chromatin", "ANATOMY", 58, 67], ["chromatin", "CELLULAR_COMPONENT", 58, 67], ["open chromatin regions", "DNA", 53, 75], ["clusters", "PROBLEM", 20, 28], ["the study", "TEST", 248, 257], ["genes", "ANATOMY", 88, 93], ["JT", "ANATOMY", 227, 229]]], ["NSM, NDS, TV, JK, and VM collected the data.", [["NSM", "PROBLEM", 0, 3], ["TV", "TEST", 10, 12], ["VM", "ANATOMY", 22, 24]]], ["JT, LBB, VM, and MEW provided funding support.", [["funding support", "TREATMENT", 30, 45], ["VM", "ANATOMY", 9, 11]]]], "ab55bffcfc1a2529e5a61f05ee72bfcadd8433bb": [["Specifically, Colombia is characterized by low levels of use of copyright and industrial property protection systems [2] .", [["low levels", "OBSERVATION_MODIFIER", 43, 53]]], ["According to the World Intellectual Property Organization [3, 4] , in 2017 Colombia ranked 48th out of 129 countries in terms of applications for patent registrations, 36th in terms of trademark applications and 69th in terms of industrial registrations.", [["trademark applications", "TREATMENT", 185, 207], ["patent", "OBSERVATION", 146, 152], ["industrial registrations", "OBSERVATION", 229, 253]]]], "cc88796879fc03bccb77873694bd657fa7b40685": [["A su vez, el informe de la Organizaci on Mundial de la Salud sobre discapacidad mostr o que m as de un bill on de la poblaci on mundial (15%) vive con alguna forma de discapacidad, de los cuales 2-4% experimenta dificultades significativas en el funcionamiento.3 Lo cual demuestra la importancia de establecer conexiones entre la discapacidad y las emergencias sanitarias, y la necesidad de tomar medidas para la inclusi on durante emergencias sanitaria.", [["cuales", "TEST", 188, 194]]]], "PMC7434559": [["IntroductionThere is a consistent tension between ensuring open government information and maintaining national security.", [["tension", "OBSERVATION_MODIFIER", 34, 41]]], ["This tension exists not only in the USA, as seen in responses to the September 11 attacks and the Snowden leaks, but also in other established democracies and developing economies [8, 27].", [["This tension", "PROBLEM", 0, 12], ["the September 11 attacks", "PROBLEM", 65, 89], ["the Snowden leaks", "PROBLEM", 94, 111], ["tension", "OBSERVATION", 5, 12], ["not only", "UNCERTAINTY", 20, 28], ["leaks", "OBSERVATION", 106, 111], ["democracies", "OBSERVATION", 143, 154], ["economies", "OBSERVATION_MODIFIER", 170, 179]]], ["The main concern of the general public and academics is that national security is too often an excuse to dodge demands for government transparency.", [["main", "OBSERVATION_MODIFIER", 4, 8]]], ["Instead, they tend to adopt a Procrustean approach of one-size-fits-all, which lacks recognition of the \u201cqualified right\u201d to particular government information [25].IntroductionWhy should the boundaries for determining state secrets be marked clearly and carefully?", [["a Procrustean approach", "TREATMENT", 28, 50], ["right", "ANATOMY_MODIFIER", 115, 120]]], ["When the boundaries for determining state secrets are blurred, government activity apart from the genuine purpose of national security can become a breeding ground for bureaucracy and corruption and lead to reduced government performance and accountability.", [["blurred", "PROBLEM", 54, 61]]], ["When this happens, secrecy is not conducive to societal stability and national security but is harmful instead [7, 25].1IntroductionThis study focuses on the disclosure of budgetary data, a particular kind of government information, and its tension with vaguely defined state secrecy requirements in the Chinese context.", [["This study", "TEST", 132, 142]]], ["Although China has enjoyed rapid growth and development for four decades, budget transparency remains low at all levels of government [9, 11].", [["budget transparency", "TEST", 74, 93], ["low", "OBSERVATION_MODIFIER", 102, 105]]], ["Although there are multiple reasons for low transparency, this study focuses on a particular hindrance to the disclosure of government information: the absence of legal clarification of state secrecy requirements and the resulting tension with budget transparency.IntroductionUsing publicly available Chinese budgetary data, this study was intended to reveal where and how the boundaries between budget transparency and state secrecy requirements are drawn in practice.", [["low transparency", "PROBLEM", 40, 56], ["this study", "TEST", 58, 68], ["the resulting tension with budget transparency", "PROBLEM", 217, 263], ["this study", "TEST", 325, 335], ["multiple", "OBSERVATION_MODIFIER", 19, 27], ["low transparency", "OBSERVATION_MODIFIER", 40, 56], ["tension", "OBSERVATION_MODIFIER", 231, 238]]], ["Our brief examination of published budgetary documents in jurisdictions at multiple levels revealed that all information about the State Security Bureau (\u56fd\u5bb6\u5b89\u5168\u5c40) was missing, indicating that the State Security Bureau is uniformly classified a secret-involving department.", [["Our brief examination", "TEST", 0, 21]]], ["Such variations highlight the absence of an unambiguous definition at the national level and the lack of coordination at subnational levels.IntroductionThird, because the Regulations of the People\u2019s Republic of China on Open Government Information (\u4e2d\u534e\u4eba\u6c11\u5171\u548c\u56fd\u653f\u5e9c\u4fe1\u606f\u516c\u5f00\u6761\u4f8b, the Regulations hereafter) and the Procedures acknowledge \u201cdisclosure by request (\u4f9d\u7533\u8bf7\u516c\u5f00)\u201d as a supplementary channel to \u201cproactive disclosure\u201d (\u4e3b\u52a8\u516c\u5f00), we filed a request to the Civil Air Defense Office, seeking budgetary data on the state assets for which they authorized commercial use.", [["People", "SPECIES", 190, 196], ["unambiguous definition", "OBSERVATION", 44, 66]]], ["The survey results will be discussed then, leading to our conclusion with policy implications in the final section.Legislations Toward Budget Transparency ::: Institutional BackgroundIn place of the earlier Regulations on State Budget Management (\u56fd\u5bb6\u9884\u7b97\u7ba1\u7406\u6761\u4f8b), the original Budget Law of the People\u2019s Republic of China (\u4e2d\u534e\u4eba\u6c11\u5171\u548c\u56fd\u9884\u7b97\u6cd5) came into effect on January 1, 1995.", [["People", "SPECIES", 289, 295]]], ["Throughout this version of the Budget Law, however, there was no reference to \u201copen/openness (\u516c\u5f00)\u201d or \u201ctransparent/transparency (\u900f\u660e)\u201d in the text.", [["transparency", "OBSERVATION", 115, 127]]], ["This webpage was not refreshed until the issuance of the Regulations started a new phase on May 1, 2008.", [["This webpage", "TREATMENT", 0, 12]]], ["This Regulations marked a milestone, by which the Chinese government recognized open government information as a principle of governance for the first time.Legislations Toward Budget Transparency ::: Institutional BackgroundAiming to \u201cenhance the transparency of government work\u201d (Article 1), the Regulations specifies that \u201cadministrative departments shall disclose government information promptly and accurately\u201d (Article 6).", [["Institutional BackgroundAiming", "TREATMENT", 200, 230], ["marked", "OBSERVATION_MODIFIER", 17, 23]]], ["In addition to legislating proactive disclosure by administrative departments, the Regulations authorizes citizens, legal persons, and other organizations to file requests for obtaining relevant government information (Article 13).", [["persons", "SPECIES", 122, 129]]], ["Although the principle of transparency was absent from the old Budget Law at the time, the Regulations laid a foundation for further pursuit of budget disclosure.Legislations Toward Budget Transparency ::: Institutional BackgroundIn 2013, the Communist Party of China (CPC) made a promise to adopt \u201can all-inclusive, standardized, and transparent budget system.\u201d", [["budget disclosure", "TREATMENT", 144, 161], ["China (CPC", "TREATMENT", 262, 272], ["transparency", "OBSERVATION_MODIFIER", 26, 38]]], ["In 2014, the original Budget Law was supplemented with stipulations that budgetary reports and final accounts must be made public in a timely manner.Legislations Toward Budget Transparency ::: Institutional BackgroundIn the new Budget Law effective on January 1, 2015, the pursuit of an \u201copen and transparent budget system\u201d (Article 1) was recognized in statutory law for the first time.", [["stipulations", "TREATMENT", 55, 67], ["an \u201copen and transparent budget system", "TREATMENT", 284, 322], ["new", "OBSERVATION_MODIFIER", 224, 227]]], ["This move required subnational governments to follow detailed guidelines on the scope, format, and timeliness of budget disclosures.", [["subnational governments", "TREATMENT", 19, 42], ["the scope", "TEST", 76, 85]]], ["Additional language such as \u201cpay attention to actual effects,\u201d \u201crespond to societal concerns,\u201d and \u201cfacilitate public scrutiny\u201d (Article 4) suggests that the Chinese government no longer considers budgetary documents to be private information used exclusively for internal control.", [["internal control", "TREATMENT", 264, 280]]], ["Indeed, budget transparency covers more than just budget disclosure and the extent to which additional information can be understood and used by citizens is a powerful indicator of effectiveness [13, 14, 26].", [["transparency", "OBSERVATION_MODIFIER", 15, 27]]], ["Prior to 2004, 1 year after the SARS outbreak, the annual budgetary report prepared by the central government and submitted to the National People\u2019s Congress was stamped \u201cState Secrets.\u201dLegislations Regarding State Secrecy ::: Institutional BackgroundAccording to the present State Secrecy Law of the People\u2019s Republic of China (\u4e2d\u534e\u4eba\u6c11\u5171\u548c\u56fd\u4fdd\u5b88\u56fd\u5bb6\u79d8\u5bc6\u6cd5), state secrets are \u201cmatters that have a vital bearing on state security and national interests and, as specified by legal procedure, are entrusted to a limited number of people for a given period of time\u201d (Article 2).", [["SARS", "DISEASE", 32, 36], ["people", "ORGANISM", 515, 521], ["People", "SPECIES", 140, 146], ["People", "SPECIES", 301, 307], ["people", "SPECIES", 515, 521]]], ["As a standard procedure, \u201cprior to disclosure, administrative departments shall review the information to be disclosed in accordance with the State Secrecy Law and any other laws or regulations that may apply\u201d (Article 14).", [["a standard procedure", "TREATMENT", 3, 23]]], ["Unfortunately, this question is answered neither in the Budget Law, in the Regulations, nor in the Procedures, creating confusion about the proper scope and extent of disclosure to which a particular department ought to adhere.", [["confusion", "DISEASE", 120, 129], ["creating confusion", "PROBLEM", 111, 129]]], ["This lack of clarity in present legislations is at the root of disputes over the boundaries between budget transparency and state secrecy.", [["clarity", "OBSERVATION", 13, 20], ["legislations", "OBSERVATION", 32, 44], ["budget transparency", "OBSERVATION", 100, 119]]], ["In fact, as will be shown later, there are wide variations across jurisdictions in the scope, extent, and format of budget disclosure by departments that claim to deal with state secrets.", [["wide variations", "PROBLEM", 43, 58], ["wide", "OBSERVATION_MODIFIER", 43, 47], ["variations", "OBSERVATION_MODIFIER", 48, 58]]], ["Such variations are likely because of the lack of clarity from both legislative and administrative branches.Three Departments That Potentially Involve State Secrets ::: Institutional BackgroundTo the best of our knowledge, no existing Chinese laws and regulations openly define government departments that work with state secrets.", [["both", "OBSERVATION_MODIFIER", 63, 67], ["legislative", "OBSERVATION", 68, 79], ["branches", "OBSERVATION_MODIFIER", 99, 107]]], ["We thus defined these three departments as potentially involving state secrets.Three Departments That Potentially Involve State Secrets ::: Institutional BackgroundUnder the direction of the CPC Committee and in charge of stability maintenance, the Political and Legal Affairs Commission oversees the People\u2019s Procuratorate, the People\u2019s Court, the Public Security Bureau, the Judicial Bureau, and the State Security Bureau.", [["People", "SPECIES", 301, 307], ["People", "SPECIES", 329, 335], ["stability", "OBSERVATION", 222, 231]]], ["The functions of the Civil Air Defense Office include managing funds, facilities, and supplies for civil air defense, planning and implementing corresponding construction projects, and developing air defense plans and conducting air raid drills.Three Departments That Potentially Involve State Secrets ::: Institutional BackgroundBecause we cannot know, according to any official classification, exactly which departments do involve state secrets, we chose the three above-mentioned departments for our survey, based on their basic functions and their statements on non-disclosure.", [["conducting air raid drills", "PROBLEM", 218, 244], ["air defense", "OBSERVATION", 196, 207], ["air raid drills", "OBSERVATION", 229, 244]]], ["The present study proceeds with a survey of the three departments across 36 municipalities in mainland China, with the goal of calling attention to the lack of budget transparency under the guise of state secrecy.Full/Partial Disclosure Versus Non-disclosure ::: Budget Transparency in the Three Municipal DepartmentsAccording to the Procedures, local-government departments other than the Department of Finance should release at least eight budget tables to report (1) the general state of revenues and expenditures, (2) the general state of revenues, (3) the general state of expenditures, (4) the general state of revenues and expenditures through fiscal grants, (5) the general public budget for expenditures, (6) the general public budget for basic expenditures, (7) the general public budget for the \u201cthree public expenses,\u201d and (8) the budget for governmental-fund expenditures.Full/Partial Disclosure Versus Non-disclosure ::: Budget Transparency in the Three Municipal DepartmentsDepartments that released all eight tables were marked as meeting \u201cfull disclosure\u201d requirements.", [["Transparency", "OBSERVATION_MODIFIER", 270, 282], ["Transparency", "OBSERVATION_MODIFIER", 942, 954]]], ["The Political and Legal Affairs Commission in most municipalities (23) met the requirement of eight tables, while nine municipalities refused to provide any budgetary information on this department.", [["Political", "OBSERVATION_MODIFIER", 4, 13]]], ["Regarding the Civil Air Defense Office, the municipalities of full disclosure and of non-disclosure amounted to nine and 21, respectively.Full/Partial Disclosure Versus Non-disclosure ::: Budget Transparency in the Three Municipal DepartmentsDespite differences among municipalities, a given government department should perform similar functions and engage in similar financial activities across jurisdictions.", [["Transparency", "OBSERVATION_MODIFIER", 195, 207]]], ["In fact, however, there were significant variations in budget disclosure by the same department across municipalities.", [["significant", "OBSERVATION_MODIFIER", 29, 40], ["variations", "OBSERVATION_MODIFIER", 41, 51]]], ["For example, while Hohhot, the capital of a frontier autonomous region, fully disclosed its budgets for the Political and Legal Affairs Commission and for the Civil Air Defense Office, Beijing, the national capital of China, and surrounding Tianjin and Taiyuan, chose to withhold all three departments\u2019 budgetary information from public oversight.Full/Partial Disclosure Versus Non-disclosure ::: Budget Transparency in the Three Municipal DepartmentsSurvey results in Table 2 indicate no nationwide consensus on which departments and which outlays should be handled as classified information.", [["capital", "OBSERVATION_MODIFIER", 31, 38], ["no", "UNCERTAINTY", 486, 488]]], ["Where the boundaries between required transparency and necessary secrecy are blurred, stances on both sides of the divide cannot both be justified.", [["blurred", "PROBLEM", 77, 84], ["transparency", "OBSERVATION_MODIFIER", 38, 50]]], ["First, apart from budget tables, the Procedures requires publicizing details on important departmental matters, including (1) basic functions, (2) organizational structure, (3) changes in budgetary revenues and expenditures, (4) arrangements of overhead expenses, (5) government procurement, (6) technical terms, (7) the stock of state-owned assets, (8) performance goals for key projects, and (9) performance evaluations for key projects.", [["organizational structure, (3) changes in budgetary revenues", "PROBLEM", 147, 206], ["performance evaluations", "TEST", 398, 421]]], ["As shown in Table 3, the most frequently omitted details concern changes in budgetary revenues and expenditures, the stock of state-owned assets, and performance evaluations for key projects.Variations in Disclosure ::: Budget Transparency in the Three Municipal DepartmentsSecond, according to the new Budget Law, after the approval by the People\u2019s Congress, each department\u2019s budget should be reviewed by the same-level Department of Finance within 20 weekdays.", [["People", "SPECIES", 341, 347], ["performance evaluations", "TEST", 150, 173]]], ["Within the subgroup of disclosure departments, the Political and Legal Affairs Commission of Chongqing and the Civil Air Defense Office of Urumqi failed to meet the time limit.Variations in Disclosure ::: Budget Transparency in the Three Municipal DepartmentsThird, the Procedures requires disclosed budgetary information to be posted and maintained on government websites.", [["Urumqi", "TREATMENT", 139, 145], ["Transparency", "OBSERVATION_MODIFIER", 212, 224]]], ["Since 2017, a unified portal for open budgetary information has been added to the website of the Department of Finance.", [["open budgetary information", "TREATMENT", 33, 59], ["portal", "ANATOMY", 22, 28]]], ["However, this portal was not the exclusive source for budgetary information.", [["portal", "MULTI-TISSUE_STRUCTURE", 14, 20], ["portal", "ANATOMY", 14, 20]]], ["Similarly, the State Secrecy Bureau of Guiyang published its budgetary documents under \u201copen management of CPC affairs.\u201d5Variations in Disclosure ::: Budget Transparency in the Three Municipal DepartmentsLast, let us briefly review some budgetary data on the \u201cthree public expenses\u201d and \u201cother expenses (\u5176\u4ed6\u652f\u51fa).\u201d", [["open management", "TREATMENT", 88, 103], ["CPC affairs", "TREATMENT", 107, 118]]], ["Both the Political and Legal Affairs Commission and the Secrecy Bureau of Fuzhou \u201ccompletely\u201d disclosed eight budget tables as the Procedures requires.", [["Political", "OBSERVATION_MODIFIER", 9, 18]]], ["In view of black boxes such as \u201cother expenses,\u201d the number of disclosed budget tables is not necessarily an informative indicator of budget transparency.An Attempt to Request Disclosure ::: Budget Transparency in the Three Municipal DepartmentsAccording to the Regulations on the State-Owned Assets for Civil Air Defense (\u4eba\u6c11\u9632\u7a7a\u56fd\u6709\u8d44\u4ea7\u7ba1\u7406\u89c4\u5b9a) issued in 1998, air defense assets may be of a business or non-business use (Article 10).", [["black boxes", "PROBLEM", 11, 22], ["black boxes", "OBSERVATION", 11, 22], ["budget transparency", "OBSERVATION", 134, 153], ["Transparency", "OBSERVATION_MODIFIER", 198, 210]]], ["Without further information, there are no obvious reasons why commercially used air defense assets and their associated lease revenues should be shielded under the state-secret privilege.", [["no obvious", "UNCERTAINTY", 39, 49]]], ["For example, a Civil Air Defense Officer in Chaoyang, Beijing, pocketed CNY 730,000 lease payments and was sentenced to 8 years in prison plus a CNY 100,000 fine [32].An Attempt to Request Disclosure ::: Budget Transparency in the Three Municipal DepartmentsThe Regulations states that academic research, as a \u201cspecial need (\u7279\u6b8a\u9700\u8981),\u201d may be justified in requesting disclosure of certain government information (Article 13).6 Because no Civil Air Defense Office in the sample released any information about commercially used air defense assets, we filed a real-name request to the Office in the 36 municipalities.", [["Transparency", "OBSERVATION_MODIFIER", 211, 223]]], ["The requested information included the sources, amounts, and proportion of business revenues generated from air defense assets.An Attempt to Request Disclosure ::: Budget Transparency in the Three Municipal DepartmentsTo implement our request, we first browsed around government websites and found that 30 of the 36 municipalities provided a webpage for submitting information requests, while three municipalities provided an email address for receiving online requests.", [["air defense", "OBSERVATION", 108, 119]]], ["The three General Offices did respond with the requested contact information.An Attempt to Request Disclosure ::: Budget Transparency in the Three Municipal DepartmentsAccording to the guidelines on information disclosure by request, an administrative department is expected to review the request upon arrival.", [["Transparency", "OBSERVATION_MODIFIER", 121, 133]]], ["Because of relocation, the EMS parcel to the Office of Chongqing was not signed at the first attempt and was finally delivered on November 21.", [["relocation", "OBSERVATION", 11, 21]]], ["The request to the Office of Beijing was filed electronically, and the response arrived by registered mail on November 27, 2017.An Attempt to Request Disclosure ::: Budget Transparency in the Three Municipal DepartmentsIn their responses, the Offices of Dalian and Shenzhen claimed that they had proactively released all the information appropriate for disclosure and that requested information was unavailable because of either state secrecy or having no corresponding budget.", [["Transparency", "OBSERVATION_MODIFIER", 172, 184]]], ["The remainder argued that any information disclosure would cause a leakage of state secrets.", [["a leakage of state secrets", "PROBLEM", 65, 91], ["leakage", "OBSERVATION", 67, 74]]], ["Taken together, none of the 36 Offices gave a straight answer regarding the sources, amounts, and proportion of business revenues generated from air defense assets.An Attempt to Request Disclosure ::: Budget Transparency in the Three Municipal DepartmentsIn addition, seven of the 20 responses did not provide any legal justifications for their decision of non-disclosure.", [["air defense", "OBSERVATION", 145, 156], ["Transparency", "OBSERVATION_MODIFIER", 208, 220]]], ["Under the Chinese unitary system, local governments are normally required to carry out specific matters in accordance with centrally determined standards, especially when sensitive issues are involved.", [["local governments", "TREATMENT", 34, 51]]], ["As an exception, however, the procedure to define secret-involving departments is highly decentralized: the discretion is given to the State Secrecy Commission/Bureau at each administrative level.", [["the procedure", "TREATMENT", 26, 39]]], ["More importantly, the stipulations regarding departments that involve state secrets and their disclosure of budgetary information ought to be in the form of laws or regulations and enacted by the National People\u2019s Congress or the State Council.DiscussionSecond, the absence of an unambiguous definition at the national level and the lack of coordination at subnational levels lead to the same department in different places developing idiosyncratic definitions of what constitutes secret information.", [["People", "SPECIES", 205, 211], ["idiosyncratic definitions", "OBSERVATION", 435, 460]]], ["As a result, 27 Political and Legal Affairs Commissions in the sample disclosed budget tables to some extent, while nine disclosed nothing, for example.", [["some extent", "OBSERVATION_MODIFIER", 97, 108]]], ["Furthermore, regarding the departments in the disclosure group, there were considerable variations in the scope and depth of transparency.", [["considerable variations in the scope", "PROBLEM", 75, 111], ["considerable", "OBSERVATION_MODIFIER", 75, 87], ["variations", "OBSERVATION_MODIFIER", 88, 98], ["depth", "OBSERVATION_MODIFIER", 116, 121], ["transparency", "OBSERVATION_MODIFIER", 125, 137]]], ["In our view, business revenues generated from air defense assets are \u201cseparable (\u533a\u5206\u5904\u7406)\u201d from state secrets and should be open to public scrutiny.", [["air defense", "OBSERVATION", 46, 57]]], ["The intent of Article 22, however, appears to be undermined by bureaucratic inertia and efforts to avoid hassles or even criminal charges.", [["bureaucratic inertia", "PROBLEM", 63, 83], ["appears to be", "UNCERTAINTY", 35, 48], ["bureaucratic inertia", "OBSERVATION", 63, 83]]], ["Because government employees in charge of responding to requests worry about controversy or punishment that could follow disclosure, they favor blanket statements at best and resist justifying why withholding particular information is reasonable and necessary.", [["blanket statements", "TREATMENT", 144, 162]]], ["In our study, 16 of 36 Civil Air Defense Offices chose to ignore the Procedures and our request, while 20 in fact refused to reveal their business revenues without justifying why business revenues should be considered state secrets.DiscussionFinally, there exist discrepancies in information disclosed via different channels.", [["our study", "TEST", 3, 12]]], ["Given the confusion over the boundaries between budget transparency and sate secrecy, we are unable to determine which of their contradictory moves is lawful.ConclusionBudgetary documents not only contain information that matters to citizens, but also are an important channel to pursue open government information.", [["confusion", "DISEASE", 10, 19], ["the confusion", "PROBLEM", 6, 19]]], ["This study surveys budget transparency in three government departments that potentially involve state secrets across 36 Chinese municipalities.", [["This study", "TEST", 0, 10]]], ["In addition, departments that chose disclosure varied considerably in the scope and depth of their transparency.", [["transparency", "OBSERVATION_MODIFIER", 99, 111]]], ["Even the \u201cthree public expenses\u201d that, by common sense, are less likely to involve state secrets but more likely to breed corruption, were often deemed classified information.", [["more likely", "UNCERTAINTY", 101, 112]]], ["As shown in the survey results, the blurred boundaries between budget transparency and state secrecy create confusion for both government employees and the general public.", [["confusion", "DISEASE", 108, 117], ["the blurred boundaries between budget transparency", "PROBLEM", 32, 82], ["confusion", "PROBLEM", 108, 117]]], ["Without any proper definition by law, even efforts to file requests for information cannot dispel such confusion.ConclusionOur findings and discussion have important implications for policy.", [["confusion", "DISEASE", 103, 112], ["confusion", "PROBLEM", 103, 112]]], ["The National People\u2019s Congress should consider passing an open government law or merging the two existing legislations into a unified state secrecy and open government law to establish a solid legal foundation for transparent government.7 Second, present laws and regulations need to be amended to narrowly define vague terms in use such as \u201cstate secrets\u201d and \u201cgovernment departments involving state secrets\u201d and to enable itemization of information as (in)appropriate for disclosure.", [["People", "SPECIES", 13, 19]]], ["Third, even for departments that involve state secrets, budgetary information about the \u201cthree public expenses,\u201d business revenues earned through common market transactions, and any other financial arrangements less likely to involve state secrets but more likely to breed corruption should be open to public oversight.8ConclusionThis study contributes to the existing literature in several ways.", [["This study", "TEST", 330, 340]]], ["This study presents tentative answers with survey evidence.", [["This study", "TEST", 0, 10]]], ["Second, this study focuses in particular on the budget disclosure of three departments that potentially involve state secrets, highlighting a hurdle for budget transparency because of vaguely defined secrecy.", [["this study", "TEST", 8, 18], ["secrecy", "OBSERVATION", 200, 207]]], ["Third, the new Budget Law and the Procedures are a milestone for budget disclosure in China.", [["budget disclosure", "TREATMENT", 65, 82], ["new", "OBSERVATION_MODIFIER", 11, 14]]], ["Closely following ongoing fiscal reforms in China, this study provides timely insight into the actual implementation of the Procedures.ConclusionNevertheless, this study is limited in its ability to explain the reasons for the differences in secrecy-related responses across municipalities.", [["this study", "TEST", 51, 61], ["the Procedures", "TREATMENT", 120, 134], ["this study", "TEST", 159, 169]]], ["It can offer no insight about political, economic, or geographic factors that might contribute to inter-municipal variations in budget disclosure.", [["inter-municipal variations", "PROBLEM", 98, 124]]], ["In fact, our interviews with staff members in the People\u2019s Congress and in the Department of Finance suggested that they were either not well informed about the work of the State Secrecy Commission/Bureau or unwilling or unable to share more key information.", [["People", "SPECIES", 50, 56]]]], "6bdb41aa63efed5063efbecbb615896b8ea4ae5e": [["IntroductionGene overlap occurs when two or more genes share the same region of a nucleotide sequence in a genome.", [["nucleotide", "CHEMICAL", 82, 92], ["nucleotide", "CHEMICAL", 82, 92], ["nucleotide sequence", "DNA", 82, 101], ["Gene overlap", "PROBLEM", 12, 24]]], ["This occurs frequently in viruses, especially those with RNA genomes, but has also been observed in bacteria and in eukaryotes including humans (Smith et al. 1977; Keese and Gibbs 1992; Veeramachaneni et al. 2004; Nakayama et al. 2007 ).", [["humans", "ORGANISM", 137, 143], ["RNA genomes", "DNA", 57, 68], ["humans", "SPECIES", 137, 143], ["humans", "SPECIES", 137, 143], ["viruses", "PROBLEM", 26, 33], ["RNA genomes", "PROBLEM", 57, 68], ["bacteria", "PROBLEM", 100, 108], ["viruses", "OBSERVATION", 26, 33], ["bacteria", "OBSERVATION", 100, 108]]], ["The high prevalence of gene overlap in viruses has been attributed to two complementary theories: gene \"compression\" and gene \"novelty.\"", [["gene overlap in viruses", "PROBLEM", 23, 46], ["gene \"compression\"", "PROBLEM", 98, 116], ["high", "OBSERVATION_MODIFIER", 4, 8], ["viruses", "OBSERVATION", 39, 46]]], ["Compression theory argues that the size of viral genomes is constrained by factors such as high mutation rates and the small capsid structure housing the genetic material.", [["viral genomes", "DNA", 43, 56], ["viral genomes", "PROBLEM", 43, 56], ["high mutation rates", "PROBLEM", 91, 110], ["size", "OBSERVATION_MODIFIER", 35, 39], ["viral genomes", "OBSERVATION", 43, 56], ["small", "OBSERVATION_MODIFIER", 119, 124], ["capsid structure", "OBSERVATION", 125, 141], ["genetic material", "OBSERVATION", 154, 170]]], ["This constrained genome size subsequently exerts selection pressure on genes to overlap to maximize genetic potential (Belshaw et al. 2007; Chirico et al. 2010) .", [["selection pressure on genes", "TREATMENT", 49, 76], ["size", "OBSERVATION_MODIFIER", 24, 28], ["selection", "OBSERVATION_MODIFIER", 49, 58], ["pressure", "OBSERVATION_MODIFIER", 59, 67]]], ["Gene novelty theory asserts that the constrained nature of viral genomes, combined with their limited noncoding regions, makes the generation of new genes difficult without major changes in genomic structure or input from the host genome.", [["viral genomes", "DNA", 59, 72], ["noncoding regions", "DNA", 102, 119], ["host genome", "DNA", 226, 237], ["viral genomes", "PROBLEM", 59, 72], ["major changes in genomic structure", "PROBLEM", 173, 207], ["viral genomes", "OBSERVATION", 59, 72], ["host genome", "OBSERVATION", 226, 237]]], ["Mutations in current genes that generate a new open reading frame (ORF) then allow the generation of new genes within an established older gene in a process called \"overprinting\" (Keese and Gibbs 1992; Sabath et al. 2012; Brandes and Linial 2016) .", [["open reading frame", "DNA", 47, 65], ["ORF", "DNA", 67, 70], ["Mutations in current genes", "PROBLEM", 0, 26], ["a new open reading frame", "PROBLEM", 41, 65]]], ["These theories are not mutually exclusive and both processes may be operating in virus genomes.", [["may be", "UNCERTAINTY", 61, 67], ["virus genomes", "OBSERVATION", 81, 94]]], ["Overlapping genes may also function as a mechanism for regulating gene expression and reduce the probability of mutation fixation in overlapping areas as the resident genes may have competing selection pressures (Krakauer 2000; Dreher and Miller 2006) .", [["resident genes", "DNA", 158, 172], ["regulating gene expression", "TREATMENT", 55, 81], ["mutation fixation", "TREATMENT", 112, 129]]], ["Due to these evolutionary constraints, overlapping genes frequently encode proteins with accessory functions that play important roles in pathogenicity or spread (Rancurel et al. 2009 ).IntroductionOverlapping genes were first detected following the discovery that the cumulative length of protein sequences in bacteriophage u174 exceeded the length of the genome (Barrell et al. 1976 ).", [["bacteriophage u174", "GENE_OR_GENE_PRODUCT", 311, 329], ["overlapping genes", "DNA", 39, 56], ["protein sequences", "DNA", 290, 307], ["bacteriophage u174", "DNA", 311, 329], ["these evolutionary constraints", "PROBLEM", 7, 37], ["accessory functions", "PROBLEM", 89, 108], ["the cumulative length of protein sequences in bacteriophage", "TREATMENT", 265, 324]]], ["Today, the detection of overlapping genes still largely relies on laboratory methods that isolate, sequence, and align individual proteins to reference genomes (Fellner et al. 2015) .", [["overlapping genes", "DNA", 24, 41], ["overlapping genes", "PROBLEM", 24, 41], ["laboratory methods", "TEST", 66, 84]]], ["These and other potential laboratory methods such as ribosome profiling (Irigoyen et al. 2016) are costly and time intensive, making large scale screening and identification of overlapping genes expensive.", [["overlapping genes", "DNA", 177, 194], ["large scale screening", "TEST", 133, 154]]], ["Necessarily, these factors have led to the development of bioinformatics and theoretical methods for the analysis of overlapping genes that rely on genome sequence analyses alone.", [["overlapping genes", "DNA", 117, 134], ["theoretical methods", "TREATMENT", 77, 96], ["the analysis", "TEST", 101, 113], ["genome sequence analyses", "TEST", 148, 172]]], ["For example, synonymous sites that exhibit a reduced nucleotide substitution rate are indicative of functional overlapping proteins; because these substitutions affect two proteins they are usually expected to be deleterious and hence are observed at a reduced rate (Firth and Brown 2005, 2006; Jagger et al. 2012) .", [["nucleotide", "CHEMICAL", 53, 63], ["nucleotide", "CHEMICAL", 53, 63], ["functional overlapping proteins", "PROTEIN", 100, 131], ["synonymous sites", "PROBLEM", 13, 29], ["a reduced nucleotide substitution rate", "PROBLEM", 43, 81], ["functional overlapping proteins", "PROBLEM", 100, 131], ["these substitutions affect two proteins", "PROBLEM", 141, 180], ["synonymous sites", "OBSERVATION", 13, 29], ["reduced", "OBSERVATION_MODIFIER", 45, 52], ["nucleotide substitution", "OBSERVATION", 53, 76], ["indicative of", "UNCERTAINTY", 86, 99], ["functional overlapping proteins", "OBSERVATION", 100, 131], ["deleterious", "OBSERVATION", 213, 224]]], ["A number of other properties of overlapping genes have been Article \u00df The Author(s) 2018.", [["overlapping genes", "DNA", 32, 49]]], ["For commercial re-use, please contact journals.permissions@oup.com Open Access used as effective bioinformatics makers, such as synonymous codon dissimilarity between newly generated overlapping genes and the remainder of the genome (Pavesi et al. 1997 (Pavesi et al. , 2013 , and the restriction that particular codon sequence orders place on alternative reading frames (Lebre and Gascuel 2017) .", [["overlapping genes", "DNA", 183, 200], ["codon sequence orders", "DNA", 313, 334], ["alternative reading frames", "DNA", 344, 370], ["Open Access", "TREATMENT", 67, 78], ["effective bioinformatics makers", "TREATMENT", 87, 118], ["synonymous codon dissimilarity", "PROBLEM", 128, 158], ["synonymous codon", "OBSERVATION", 128, 144], ["overlapping genes", "OBSERVATION", 183, 200]]], ["For example, the reverse complementary nucleotide sequence for two adjacent tyrosines (TAT/C and TAT/C) will be A/GTA and A/GTA, which always creates a stop codon (either a TAA or TAG after a reading frame shift of 1 nucleotide).", [["nucleotide", "CHEMICAL", 39, 49], ["TAA", "DISEASE", 173, 176], ["TAG", "CHEMICAL", 180, 183], ["nucleotide", "CHEMICAL", 39, 49], ["TAG", "CHEMICAL", 180, 183], ["nucleotide", "CHEMICAL", 217, 227], ["TAT/C", "GENE_OR_GENE_PRODUCT", 87, 92], ["TAT/C", "GENE_OR_GENE_PRODUCT", 97, 102], ["reverse complementary nucleotide sequence", "DNA", 17, 58], ["TAT", "PROTEIN", 87, 90], ["TAT", "PROTEIN", 97, 100], ["stop codon", "DNA", 152, 162], ["the reverse complementary nucleotide sequence", "PROBLEM", 13, 58], ["two adjacent tyrosines", "TREATMENT", 63, 85], ["TAT/C and TAT/C)", "TREATMENT", 87, 103], ["A/GTA", "TREATMENT", 112, 117], ["A/GTA", "TREATMENT", 122, 127], ["a TAA or TAG", "TREATMENT", 171, 183]]], ["Although these properties help in the development of bioinformatics techniques to discover unknown overlapping genes, they are restricted by their requirement for multiple genomic sequences or by their poor sensitivity.", [["overlapping genes", "DNA", 99, 116], ["genomic sequences", "DNA", 172, 189], ["bioinformatics techniques", "TREATMENT", 53, 78], ["multiple genomic sequences", "TEST", 163, 189]]], ["With the rapid rise of metagenomics to discover new viruses (Bekal et al. 2011; Ballinger et al. 2014; Shi et al. 2016 Shi et al. , 2018 , efficient and sensitive approaches of identifying overlapping genes that require genome sequence information alone will be essential.IntroductionHerein, we present a new statistical method for detecting overlapping genes in different reading frames that relies on only a single nucleotide sequence of a gene or genome.", [["overlapping genes", "DNA", 342, 359], ["new viruses", "PROBLEM", 48, 59], ["genome sequence information", "TREATMENT", 220, 247], ["rapid", "OBSERVATION_MODIFIER", 9, 14], ["rise", "OBSERVATION_MODIFIER", 15, 19]]], ["We apply this method to a large scale computational screening of all available (linear) RNA virus genomes.", [["RNA virus genomes", "DNA", 88, 105], ["this method", "TREATMENT", 9, 20], ["a large scale computational screening", "TEST", 24, 61], ["RNA virus genomes", "PROBLEM", 88, 105]]], ["The method estimates the theoretical expected length of ORFs before a stop codon is reached in all reading frames within an established gene.", [["ORFs", "DNA", 56, 60], ["a stop codon", "TREATMENT", 68, 80]]], ["If an ORF exists of much greater length than predicted by this expected length, then we surmise that there has been selection against the accumulation of stop codons that shorten the putative ORF.", [["ORF", "DNA", 6, 9], ["ORF", "DNA", 192, 195], ["an ORF", "TEST", 3, 9], ["the accumulation of stop codons", "PROBLEM", 134, 165], ["the putative ORF", "PROBLEM", 179, 195], ["putative ORF", "OBSERVATION", 183, 195]]], ["We conclude that this constitutes evidence that the ORF in question provides functional benefit to the virus.", [["ORF", "DNA", 52, 55], ["the ORF", "PROBLEM", 48, 55], ["the virus", "PROBLEM", 99, 108]]], ["Despite its simplicity, we show that this method is a powerful way to detect functional overlapping genes that can be readily applied to large scale computational screening of all known viruses and to viruses newly discovered through metagenomics.New ApproachesOur rationale is that overlapping ORFs with functional benefit will result in negative selection against nucleotide substitutions that introduce stop codons within that gene.", [["nucleotide", "CHEMICAL", 366, 376], ["nucleotide", "CHEMICAL", 366, 376], ["ORFs", "DNA", 295, 299], ["functional overlapping genes", "PROBLEM", 77, 105], ["computational screening", "TEST", 149, 172], ["all known viruses", "PROBLEM", 176, 193], ["viruses", "PROBLEM", 201, 208], ["overlapping ORFs", "PROBLEM", 283, 299], ["nucleotide substitutions", "TREATMENT", 366, 390], ["viruses", "OBSERVATION", 186, 193]]], ["Accordingly, the length of ORFs (as measured by the distance between bookend stop codons) is likely to be larger when they are functional than what would be expected by random chance alone where stop codons could be introduced without penalty.", [["ORFs", "DNA", 27, 31], ["bookend stop codons", "DNA", 69, 88], ["ORFs", "TEST", 27, 31], ["likely to be", "UNCERTAINTY", 93, 105], ["larger", "OBSERVATION_MODIFIER", 106, 112]]], ["Hence, the defining characteristic of our method for the detection of overlapping genes is identifying ORFs larger than expected by chance alone (fig. 1A ).", [["overlapping genes", "DNA", 70, 87], ["ORFs", "DNA", 103, 107], ["ORFs", "PROBLEM", 103, 107], ["larger", "OBSERVATION_MODIFIER", 108, 114]]], ["We developed three tests for estimating the distribution of expected ORF lengths.", [["three tests", "TEST", 13, 24], ["lengths", "OBSERVATION_MODIFIER", 73, 80]]], ["Briefly, in the first test, we estimate the expected length of ORFs by permuting codon positions in the original reading frame and then measuring ORF lengths in other reading frames.", [["ORFs", "DNA", 63, 67], ["codon positions", "DNA", 81, 96], ["original reading frame", "DNA", 104, 126], ["ORF lengths", "DNA", 146, 157], ["reading frames", "DNA", 167, 181]]], ["This process is repeated to generate an expected distribution of ORF lengths (codon permutation test, fig. 1B ).", [["ORF lengths", "DNA", 65, 76], ["ORF lengths", "PROBLEM", 65, 76], ["codon permutation test", "TEST", 78, 100]]], ["In the second test, instead of permuting codon positions, the codon order is unchanged and nucleotide substitutions that would introduce synonymous mutations in the original reading frame are randomly generated (synonymous mutation test, fig. 1C ), before measuring ORF lengths in the other reading frames.", [["nucleotide", "CHEMICAL", 91, 101], ["nucleotide", "CHEMICAL", 91, 101], ["codon positions", "DNA", 41, 56], ["original reading frame", "DNA", 165, 187], ["ORF lengths", "DNA", 266, 277], ["reading frames", "DNA", 291, 305], ["permuting codon positions", "TREATMENT", 31, 56], ["nucleotide substitutions", "PROBLEM", 91, 115], ["synonymous mutations", "PROBLEM", 137, 157], ["synonymous mutation test", "TEST", 212, 236], ["unchanged", "OBSERVATION_MODIFIER", 77, 86]]], ["In the third test, referred to as the combined test, the P values for both the codon permutation test and the synonymous mutation test must fall below some cut-off value.New ApproachesTo demonstrate the applicability of this method, we first considered Andean potato latent virus that contains a known overlapping gene.", [["potato latent virus", "ORGANISM", 260, 279], ["P", "DNA", 57, 58], ["overlapping gene", "DNA", 302, 318], ["potato latent virus", "SPECIES", 260, 279], ["Andean potato latent virus", "SPECIES", 253, 279], ["the combined test", "TEST", 34, 51], ["the P values", "TEST", 53, 65], ["the codon permutation test", "TEST", 75, 101], ["the synonymous mutation test", "TEST", 106, 134], ["this method", "TREATMENT", 220, 231], ["Andean potato latent virus", "PROBLEM", 253, 279], ["latent virus", "OBSERVATION", 267, 279]]], ["Andean potato latent virus is a positivesense single-stranded RNA virus (family Tymoviridae) in which the I870_gp1 gene, that encodes the putative The expected ORF length based on codon composition is calculated.", [["Andean", "ORGANISM", 0, 6], ["potato latent virus", "ORGANISM", 7, 26], ["I870_gp1", "GENE_OR_GENE_PRODUCT", 106, 114], ["I870_gp1 gene", "DNA", 106, 119], ["ORF length", "DNA", 160, 170], ["potato latent virus", "SPECIES", 7, 26], ["Andean potato latent virus", "SPECIES", 0, 26], ["Andean potato latent virus", "PROBLEM", 0, 26], ["The expected ORF length", "PROBLEM", 147, 170], ["codon composition", "TEST", 180, 197], ["latent virus", "OBSERVATION", 14, 26], ["length", "OBSERVATION_MODIFIER", 164, 170]]], ["ORFs longer than expected by random chance are identified.", [["ORFs", "DNA", 0, 4], ["ORFs", "PROBLEM", 0, 4]]], ["The expected ORF length is estimated by one of three tests.", [["ORF length", "DNA", 13, 23], ["The expected ORF length", "TEST", 0, 23], ["three tests", "TEST", 47, 58], ["ORF", "OBSERVATION_MODIFIER", 13, 16], ["length", "OBSERVATION_MODIFIER", 17, 23]]], ["For the codon permutation test (B) the codon sequence on the original frame is permuted and ORF lengths on alternative reading frames measured for each permutation.", [["codon sequence", "DNA", 39, 53], ["alternative reading frames", "DNA", 107, 133], ["the codon permutation test", "TEST", 4, 30], ["alternative reading frames", "TEST", 107, 133]]], ["For the synonymous mutation test (C), codons that preserve the original amino acid sequence are randomly generated and the length of ORFs on alternative reading frames subsequently measured (note that codon replacement is not restricted to the example mutations shown in the figure, all of which occur in the third nucleotide positions, and that codon replacement with the original codon is also possible).", [["amino acid", "CHEMICAL", 72, 82], ["amino acid", "CHEMICAL", 72, 82], ["nucleotide", "CHEMICAL", 315, 325], ["amino acid", "AMINO_ACID", 72, 82], ["ORFs", "DNA", 133, 137], ["alternative reading frames", "DNA", 141, 167], ["third nucleotide positions", "DNA", 309, 335], ["the synonymous mutation test", "TEST", 4, 32], ["the original amino acid sequence", "TEST", 59, 91], ["codon replacement", "TREATMENT", 201, 218], ["codon replacement", "TREATMENT", 346, 363]]], ["The third test requires both the codon permutation test and the synonymous mutation test P values to be below some cut-off value.New ApproachesSimple Method to Detect Candidate Overlapping Genes . doi:10.1093/molbev/msy155 MBE movement protein, is overlapping.", [["doi:10.1093", "GENE_OR_GENE_PRODUCT", 197, 208], ["molbev", "GENE_OR_GENE_PRODUCT", 209, 215], ["P", "DNA", 89, 90], ["Candidate Overlapping Genes", "DNA", 167, 194], ["doi:10.1093", "PROTEIN", 197, 208], ["molbev", "PROTEIN", 209, 215], ["msy155", "PROTEIN", 216, 222], ["The third test", "TEST", 0, 14], ["the codon permutation test", "TEST", 29, 55], ["the synonymous mutation test P values", "TEST", 60, 97], ["New ApproachesSimple Method", "TREATMENT", 129, 156]]], ["I870_gp1 is 665 codons long, is located on frame \u00fe2, and is largely contained within the larger (1832 codon) I870_gp2 gene that encodes the enzymes necessary for virus replication (methyltransferase, endopeptidase, helicase, and polymerase) ( fig. 2A ).", [["I870_gp1", "GENE_OR_GENE_PRODUCT", 0, 8], ["I870_gp2", "GENE_OR_GENE_PRODUCT", 109, 117], ["methyltransferase", "GENE_OR_GENE_PRODUCT", 181, 198], ["endopeptidase", "GENE_OR_GENE_PRODUCT", 200, 213], ["I870_gp1", "DNA", 0, 8], ["frame \u00fe2", "DNA", 43, 51], ["1832 codon) I870_gp2 gene", "DNA", 97, 122], ["methyltransferase", "PROTEIN", 181, 198], ["endopeptidase", "PROTEIN", 200, 213], ["helicase", "PROTEIN", 215, 223], ["polymerase", "PROTEIN", 229, 239], ["the enzymes", "TEST", 136, 147], ["virus replication (methyltransferase, endopeptidase, helicase", "TREATMENT", 162, 223], ["665 codons", "OBSERVATION", 12, 22], ["larger", "OBSERVATION_MODIFIER", 89, 95]]], ["We calculated the distribution of expected ORF lengths on frames \u00fe1 and \u00fe2 using the codon permutation test.", [["ORF lengths", "DNA", 43, 54], ["\u00fe1", "DNA", 65, 67], ["\u00fe2", "DNA", 72, 74], ["the codon permutation test", "TEST", 81, 107], ["lengths", "OBSERVATION_MODIFIER", 47, 54]]], ["The distributions of these lengths are shown with the shading in figure 2B and C. The actual ORF lengths on frames \u00fe1 and \u00fe2 on the unpermuted I870_gp2 gene are represented by black dots on top of the theoretical distribution.", [["\u00fe1", "GENE_OR_GENE_PRODUCT", 115, 117], ["\u00fe2", "GENE_OR_GENE_PRODUCT", 122, 124], ["I870_gp2", "GENE_OR_GENE_PRODUCT", 143, 151], ["\u00fe1", "DNA", 115, 117], ["\u00fe2", "DNA", 122, 124], ["unpermuted I870_gp2 gene", "DNA", 132, 156], ["lengths", "OBSERVATION_MODIFIER", 27, 34], ["lengths", "OBSERVATION_MODIFIER", 97, 104], ["black dots", "OBSERVATION", 176, 186], ["theoretical", "ANATOMY_MODIFIER", 201, 212]]], ["For frame \u00fe1, we observe 37 ORFs, all of which have lengths within expected ranges (P \u00bc 0.92).", [["frame \u00fe1", "DNA", 4, 12], ["ORFs", "DNA", 28, 32]]], ["A different picture is observed in frame 2\u00fe.", [["A different picture", "PROBLEM", 0, 19]]], ["Although there are 62 ORFs, 61 of which have lengths within the expected range, there is a single ORF whose length far exceeds the expected distribution of lengths (P < 0.0001); this is correctly identified as I870_gp2.", [["I870_gp2", "GENE_OR_GENE_PRODUCT", 210, 218], ["ORFs", "DNA", 22, 26], ["ORF", "DNA", 98, 101], ["I870_gp2", "DNA", 210, 218], ["ORFs", "TEST", 22, 26], ["a single ORF", "PROBLEM", 89, 101], ["62 ORFs", "OBSERVATION_MODIFIER", 19, 26], ["length", "OBSERVATION_MODIFIER", 108, 114], ["distribution", "OBSERVATION_MODIFIER", 140, 152], ["lengths", "OBSERVATION_MODIFIER", 156, 163]]], ["The synonymous mutation test produces similar results in this example.Sensitivity and False Discovery RateTo explore the possibility of using this method to screen for candidate overlapping ORFs, we calculated both the sensitivity and false discovery rate of the codon permutation test, the synonymous mutation test, and a combined test that requires an ORF to be larger than expected by both the codon permutation and synonymous mutation test.", [["ORFs", "DNA", 190, 194], ["ORF", "DNA", 354, 357], ["The synonymous mutation test", "TEST", 0, 28], ["Sensitivity", "TEST", 70, 81], ["overlapping ORFs", "PROBLEM", 178, 194], ["the sensitivity", "TEST", 215, 230], ["the codon permutation test", "TEST", 259, 285], ["the synonymous mutation test", "TEST", 287, 315], ["a combined test", "TEST", 321, 336], ["an ORF", "PROBLEM", 351, 357], ["the codon permutation", "TEST", 393, 414], ["synonymous mutation test", "TEST", 419, 443], ["synonymous mutation", "OBSERVATION", 4, 23]]], ["As there are too few coding regions within a single genome to estimate the sensitivity and false discovery rate with sufficient precision, we estimated the population sensitivity and false positive rate across a subset of viruses (linear RNA viruses) known to contain many overlapping genes (see Materials and Methods section).", [["coding regions", "DNA", 21, 35], ["overlapping genes", "DNA", 273, 290], ["the population sensitivity", "TEST", 152, 178], ["false positive rate", "PROBLEM", 183, 202], ["a subset of viruses", "PROBLEM", 210, 229], ["linear RNA viruses", "PROBLEM", 231, 249], ["few", "OBSERVATION_MODIFIER", 17, 20]]], ["Accordingly, whole genome sequences were downloaded from 2548 reference linear RNA viruses available on GenBank; this produced a total of 6408 coding regions that were used to estimate the sensitivity and false discovery rate of each test.Sensitivity and False Discovery RateThe codon permutation, synonymous mutation and combined test all rely on detecting overlapping ORFs that are larger than expected by random chance.", [["whole genome sequences", "DNA", 13, 35], ["6408 coding regions", "DNA", 138, 157], ["ORFs", "DNA", 370, 374], ["whole genome sequences", "TEST", 13, 35], ["linear RNA viruses", "PROBLEM", 72, 90], ["the sensitivity", "TEST", 185, 200], ["each test", "TEST", 229, 238], ["Sensitivity", "TEST", 239, 250], ["False Discovery Rate", "TEST", 255, 275], ["The codon permutation", "TREATMENT", 275, 296], ["synonymous mutation", "PROBLEM", 298, 317], ["combined test", "TEST", 322, 335], ["overlapping ORFs", "PROBLEM", 358, 374], ["ORFs", "OBSERVATION", 370, 374], ["larger", "OBSERVATION_MODIFIER", 384, 390]]], ["Consequently, the sensitivity of these tests will depend on how much of a gene is overlapping (denoted as overlap length).", [["these tests", "TEST", 33, 44]]], ["The sensitivity and false discovery rate will also be dependent on the P value cutoffs used to determine if an ORF is larger than expected by random chance, with higher P values providing higher sensitivity at a cost of greater false discovery.", [["ORF", "DNA", 111, 114], ["The sensitivity", "TEST", 0, 15], ["false discovery rate", "TEST", 20, 40], ["the P value cutoffs", "TEST", 67, 86], ["an ORF", "PROBLEM", 108, 114], ["higher P values", "PROBLEM", 162, 177], ["higher sensitivity", "PROBLEM", 188, 206], ["larger", "OBSERVATION_MODIFIER", 118, 124], ["false discovery", "OBSERVATION", 228, 243]]], ["To understand these dependencies, receiver operator characteristic (ROC) curves were generated across a range of P values, and across a range of overlapping gene lengths for all three tests ( fig. 3 ).", [["ROC) curves", "TEST", 68, 79], ["all three tests", "TEST", 174, 189]]], ["The number of true overlapping ORF's used in this sensitivity set ranged from 958 for overlapping ORF lengths greater than 0 nucleotides, to 199 for overlapping ORF lengths greater than 300 nucleotides.Sensitivity and False Discovery RateWe find that the three test (codon permutation, synonymous mutation, and combined) have similar sensitivities for P value cut-offs between 0.001 and 0.10, with the synonymous mutation generally having the highest sensitivity, followed by the codon permutation test and then the combined test ( fig. 3 , Table 1 ).", [["nucleotides", "CHEMICAL", 190, 201], ["ORF", "DNA", 31, 34], ["P", "DNA", 352, 353], ["true overlapping ORF's", "PROBLEM", 14, 36], ["this sensitivity set", "TEST", 45, 65], ["overlapping ORF lengths", "TEST", 86, 109], ["nucleotides", "TEST", 125, 136], ["overlapping ORF lengths", "TEST", 149, 172], ["Sensitivity", "TEST", 202, 213], ["the three test (codon permutation", "TEST", 251, 284], ["synonymous mutation", "PROBLEM", 286, 305], ["P value cut", "TEST", 352, 363], ["the synonymous mutation", "PROBLEM", 398, 421], ["the codon permutation test", "TEST", 476, 502], ["the combined test", "TEST", 512, 529], ["lengths", "OBSERVATION_MODIFIER", 102, 109]]], ["However, for all three tests we also find that sensitivities are generally insufficient when the overlapping length is below 50 nucleotides in length (<17 codons), but improve considerably as the overlapping length increases above 50 nucleotides.", [["nucleotides", "CHEMICAL", 128, 139], ["nucleotides", "CHEMICAL", 234, 245], ["all three tests", "TEST", 13, 28], ["sensitivities", "TEST", 47, 60], ["the overlapping length", "TEST", 93, 115], ["length", "TEST", 143, 149], ["length", "OBSERVATION_MODIFIER", 109, 115], ["length", "OBSERVATION_MODIFIER", 208, 214]]], ["Importantly, the three tests show The expected distribution of ORF lengths in frame 2\u00fe (shaded area) calculated by permutation test, and the actual ORF lengths on frame 1\u00fe (black dots).", [["ORF lengths", "DNA", 63, 74], ["ORF lengths", "DNA", 148, 159], ["the three tests", "TEST", 13, 28], ["ORF lengths", "PROBLEM", 63, 74], ["permutation test", "TEST", 115, 131], ["ORF lengths", "OBSERVATION", 63, 74]]], ["The known frameshifted gene, I870_gp1, was clearly identified using the permutation test as its length was much larger than that expected by chance alone (P < 0.0001).", [["I870_gp1", "GENE_OR_GENE_PRODUCT", 29, 37], ["frameshifted gene", "DNA", 10, 27], ["I870_gp1", "DNA", 29, 37], ["the permutation test", "TEST", 68, 88], ["larger", "OBSERVATION_MODIFIER", 112, 118]]], ["Schlub et al. . doi:10.1093/molbev/msy155 MBE considerable differences in false discovery rates, with the synonymous mutation tests showing the highest (worst) rates and the combined test with the lowest (best) rates.", [["the synonymous mutation tests", "TEST", 102, 131], ["the combined test", "TEST", 170, 187]]], ["As the highest and lowest sensitivity tests (synonymous mutation and combined, respectively) are also the tests with the corresponding highest and lowest false discovery rates, we used the standard measure of a diagnostic tool-the area under the curve-to compare which test gave the best sensitivity and false discovery rate combinations.", [["lowest sensitivity tests", "TEST", 19, 43], ["synonymous mutation", "PROBLEM", 45, 64], ["the tests", "TEST", 102, 111], ["a diagnostic tool", "TEST", 209, 226], ["the curve", "TEST", 242, 251]]], ["The area under the curve here will lie between 0 and 1, with a value of 0.5 indicating a screening tool of no benefit, and a value of 1 indicating a perfect screening tool with no error.", [["the curve", "TEST", 15, 24], ["a value", "TEST", 61, 68], ["a screening tool", "TEST", 87, 103], ["a value", "TEST", 123, 130], ["a perfect screening tool", "TEST", 147, 171]]], ["Accordingly, we find that the combined test consistently has the best sensitivity and false discovery rate combinations across all minimum overlap lengths, with an area under the curve increasing from 0.59 to 0.89 as the minimum overlap length increases from 50 to 300 nucleotides (table 1).", [["nucleotides", "CHEMICAL", 269, 280], ["the combined test", "TEST", 26, 43], ["the curve", "TEST", 175, 184], ["minimum", "OBSERVATION_MODIFIER", 131, 138], ["overlap", "OBSERVATION_MODIFIER", 139, 146], ["lengths", "OBSERVATION_MODIFIER", 147, 154], ["area", "OBSERVATION_MODIFIER", 164, 168], ["curve", "OBSERVATION_MODIFIER", 179, 184], ["length", "OBSERVATION_MODIFIER", 237, 243], ["increases", "OBSERVATION_MODIFIER", 244, 253]]], ["This demonstrates that the combined test is a successful screening tool with both high sensitivity and relatively low false discovery.Comparison to Synplot2Synplot2 is a commonly used bioinformatic approach to identify overlapping genes by detecting reduced variability at synonymous sites (Firth 2014) .", [["Synplot2Synplot2", "DNA", 148, 164], ["overlapping genes", "DNA", 219, 236], ["synonymous sites", "DNA", 273, 289], ["a successful screening tool", "TEST", 44, 71], ["both high sensitivity", "PROBLEM", 77, 98], ["bioinformatic approach", "TEST", 184, 206], ["reduced variability at synonymous sites", "PROBLEM", 250, 289], ["low", "OBSERVATION_MODIFIER", 114, 117], ["false discovery", "OBSERVATION", 118, 133], ["reduced", "OBSERVATION_MODIFIER", 250, 257], ["variability", "OBSERVATION_MODIFIER", 258, 269]]], ["Although powerful, this method is necessarily constrained by the requirement for multiple sequences of sufficient diversity to robustly detect overlapping genes.", [["overlapping genes", "DNA", 143, 160], ["this method", "TREATMENT", 19, 30]]], ["In contrast, our method requires only a single sequence, and can therefore be applied in many situations where Synplot2 would be inviable.", [["Synplot2", "GENE_OR_GENE_PRODUCT", 111, 119], ["Synplot2", "PROTEIN", 111, 119], ["a single sequence", "TEST", 38, 55], ["Synplot2", "TREATMENT", 111, 119]]], ["Quantitative comparisons of sensitivity and false discovery between the methods are difficult, as the factors associated with sensitivity in Synplot2 (sequence diversity, recombination, and window size) are not present in our method.", [["Synplot2", "DNA", 141, 149], ["sensitivity", "TEST", 28, 39], ["sensitivity in Synplot2 (sequence diversity", "PROBLEM", 126, 169], ["size", "OBSERVATION_MODIFIER", 197, 201]]], ["This validation consists of 21 gene overlaps with a minimum overlap length of 108 nucleotides.", [["nucleotides", "CHEMICAL", 82, 93], ["This validation", "TEST", 0, 15]]], ["We find that using a P value cut of value of 0.01, the codon permutation method, synonymous mutation method, and combined approach detects 12, 12, and 10 of the gene overlaps, respectively.", [["a P value cut of value", "TEST", 19, 41], ["the codon permutation method", "TREATMENT", 51, 79], ["combined approach detects", "TEST", 113, 138]]], ["For example, Figure 3 shows that the combined approach will have $50% sensitivity for overlaps of at least 100 nucleotides when a P value cut-off of 0.01 is used.Newly Discovered Overlapping ORFsWe next screened for previously undiscovered overlapping genes by using the combined test and a P value cut-off of 0.001.", [["nucleotides", "CHEMICAL", 111, 122], ["ORFsWe", "DNA", 191, 197], ["overlapping genes", "DNA", 240, 257], ["a P value cut-", "TEST", 128, 142], ["the combined test", "TEST", 267, 284], ["a P value cut-off", "TEST", 289, 306]]], ["We find evidence for 40 undocumented functional overlapping ORFs within all reference genomes of linear RNA viruses.", [["ORFs", "DNA", 60, 64], ["40 undocumented functional overlapping ORFs", "PROBLEM", 21, 64], ["linear RNA viruses", "PROBLEM", 97, 115], ["overlapping ORFs", "OBSERVATION", 48, 64], ["linear", "OBSERVATION_MODIFIER", 97, 103], ["RNA viruses", "OBSERVATION", 104, 115]]], ["Of these 40 ORFs, two had been previously described in Synplot2's RNA screening in 2014 (Firth 2014 MBE not annotated within GenBank, they were not necessarily undiscovered, as some existed within the NCBI protein databases.", [["ORFs", "DNA", 12, 16], ["Synplot2", "DNA", 55, 63], ["NCBI protein databases", "DNA", 201, 223], ["RNA screening", "TEST", 66, 79]]], ["To remove these already discovered or hypothesized overlapping ORFs, we performed a protein BLAST search of the 38 undocumented overlapping ORFs and found that nine had previously been discovered but were not annotated within the reference genome, thereby leaving 29 newly discovered functional overlapping ORFs from our method (table 3, supplementary materials S2 and S5, Supplementary Material online).", [["ORFs", "DNA", 63, 67], ["ORFs", "DNA", 140, 144], ["reference genome", "DNA", 230, 246], ["ORFs", "DNA", 307, 311], ["a protein BLAST search", "TEST", 82, 104], ["functional overlapping ORFs", "PROBLEM", 284, 311], ["our method", "TEST", 317, 327], ["supplementary materials S2", "TREATMENT", 338, 364]]], ["Of these newly discovered ORFs, we would expect approximately three to be false discoveries.", [["ORFs", "DNA", 26, 30], ["these newly discovered ORFs", "PROBLEM", 3, 30]]], ["To test if we can detect homologs of the 29 newly discovered overlaps in other species, we aligned their protein sequence against the NCBI nt database using tblastn (supplementary material S4, Supplementary Material online).", [["NCBI nt database", "DNA", 134, 150], ["tblastn (supplementary material S4", "TREATMENT", 157, 191]]], ["We filtered the results to only include alignments with a similarity of at least 90% and where the alignment was at least 90% the length of the ORF (Material Table 1 .", [["ORF", "DNA", 144, 147]]], ["Sensitivity, false discovery, and area under the curve for each test across a range of P value cut-offs and overlapping lengths.", [["Sensitivity", "TEST", 0, 11], ["the curve", "TEST", 45, 54], ["each test", "TEST", 59, 68], ["P value", "TEST", 87, 94], ["false discovery", "OBSERVATION", 13, 28], ["lengths", "OBSERVATION_MODIFIER", 120, 127]]], ["The 29 discovered ORFs ranged from 87 to 708 codons in length, with a median and interquartile range of 195.5 (157-279.2) codons; 13 were transcribed in the same direction (sense, frames \u00fe1 and \u00fe2) as the original gene with 17 coded in the opposite direction on complementary nucleotides (antisense frames \u00c0c0, \u00c0c1, and \u00c0c2, supplementary material S1, Supplementary Material online).", [["nucleotides", "CHEMICAL", 276, 287], ["ORFs", "DNA", 18, 22], ["\u00fe1", "DNA", 187, 189], ["\u00fe2", "DNA", 194, 196], ["complementary nucleotides", "DNA", 262, 287], ["antisense frames", "DNA", 289, 305], ["\u00c0c0", "DNA", 306, 309], ["\u00c0c1", "DNA", 311, 314], ["\u00c0c2", "DNA", 320, 323], ["supplementary material S1", "DNA", 325, 350], ["ORFs", "TEST", 18, 22], ["length", "TEST", 55, 61], ["codons", "TEST", 122, 128], ["\u00c0c1", "TEST", 311, 314]]], ["In addition, 18 of the ORFs were located completely within their reference coding region, eight lay on the boundary and four encompassed the entire coding region, suggesting that the reference coding region may lie completely within the larger discovered ORF.", [["ORFs", "DNA", 23, 27], ["reference coding region", "DNA", 65, 88], ["reference coding region", "DNA", 183, 206], ["ORF", "DNA", 255, 258], ["the ORFs", "PROBLEM", 19, 27], ["larger", "OBSERVATION_MODIFIER", 237, 243], ["ORF", "OBSERVATION", 255, 258]]], ["Of these discovered ORFs, a number are of particular interest and discussed in more detail below.Nhumirim VirusThe largest detected ORF was 708 codons long and located within Nhumirim virus, a positive-sense flavivirus recently isolated from mosquitoes in Brazil (Pauvolid-Correa et al. 2015) .", [["Nhumirim Virus", "ORGANISM", 97, 111], ["Nhumirim virus", "ORGANISM", 175, 189], ["ORFs", "DNA", 20, 24], ["ORF", "DNA", 132, 135], ["Nhumirim Virus", "SPECIES", 97, 111], ["Nhumirim virus", "SPECIES", 175, 189], ["Nhumirim Virus", "TREATMENT", 97, 111], ["Nhumirim virus", "PROBLEM", 175, 189], ["a positive-sense flavivirus", "PROBLEM", 191, 218], ["ORFs", "OBSERVATION", 20, 24], ["largest", "OBSERVATION_MODIFIER", 115, 122], ["708 codons", "OBSERVATION", 140, 150], ["Nhumirim virus", "OBSERVATION", 175, 189]]], ["Unexpectedly, this ORF is coded on a reverse complementary reading frame (\u00c0c1), which means that unlike the other proteins in this virus, transcription must occur from a negative-sense RNA template.", [["ORF", "DNA", 19, 22], ["reverse complementary reading frame", "DNA", 37, 72], ["\u00c0c1", "DNA", 74, 77], ["negative-sense RNA template", "RNA", 170, 197], ["the other proteins", "PROBLEM", 104, 122], ["this virus", "PROBLEM", 126, 136]]], ["This finding invites further investigation of the potential mechanisms by which transcription of reverse complementary reading frames might occur in positive-sense RNA viruses.", [["reverse complementary reading frames", "DNA", 97, 133], ["reverse complementary reading frames", "PROBLEM", 97, 133], ["positive-sense RNA viruses", "PROBLEM", 149, 175]]], ["In addition, the 26th codon in this ORF is a methionine (a common start codon) suggesting that a large component of the 708 codons may be transcribed.Bovine Respirovirus Virus 3A 173 codon long ORF was detected within the phosphoprotein P coding gene of Bovine respirovirus virus 3 (singlestranded negative-sense RNA virus, family Paramyxoviridae).", [["methionine", "CHEMICAL", 45, 55], ["methionine", "CHEMICAL", 45, 55], ["methionine", "SIMPLE_CHEMICAL", 45, 55], ["Bovine", "ORGANISM", 150, 156], ["Respirovirus Virus 3A", "ORGANISM", 157, 178], ["Bovine respirovirus virus 3", "ORGANISM", 254, 281], ["singlestranded negative-sense RNA virus", "ORGANISM", 283, 322], ["26th codon", "DNA", 17, 27], ["ORF", "DNA", 36, 39], ["common start codon", "DNA", 59, 77], ["708 codons", "DNA", 120, 130], ["Bovine Respirovirus Virus 3A 173 codon long ORF", "DNA", 150, 197], ["phosphoprotein P coding gene", "DNA", 222, 250], ["Bovine", "SPECIES", 150, 156], ["Bovine respirovirus virus", "SPECIES", 254, 279], ["Bovine Respirovirus Virus 3A", "SPECIES", 150, 178], ["Bovine respirovirus virus", "SPECIES", 254, 279], ["the 26th codon", "TREATMENT", 13, 27], ["a methionine", "TREATMENT", 43, 55], ["a common start codon", "TREATMENT", 57, 77], ["a large component of the 708 codons", "PROBLEM", 95, 130], ["Bovine Respirovirus Virus", "PROBLEM", 150, 175], ["codon long ORF", "PROBLEM", 183, 197], ["Bovine respirovirus virus", "PROBLEM", 254, 279], ["large", "OBSERVATION_MODIFIER", 97, 102], ["component", "OBSERVATION_MODIFIER", 103, 112], ["708 codons", "OBSERVATION", 120, 130]]], ["This \u00fe2 reading frame ORF was particularly interesting because although its protein alignment didn't match any Bovine respirovirus virus proteins, it did align with V proteins and RNA editing derivatives within the phosphoprotein P gene of (Galinski et al. 1992; Wells and Malur 2008) .", [["Bovine", "ORGANISM", 111, 117], ["respirovirus virus", "ORGANISM", 118, 136], ["V proteins", "GENE_OR_GENE_PRODUCT", 165, 175], ["\u00fe2 reading frame ORF", "DNA", 5, 25], ["Bovine respirovirus virus proteins", "PROTEIN", 111, 145], ["V proteins", "PROTEIN", 165, 175], ["phosphoprotein P gene", "DNA", 215, 236], ["Bovine", "SPECIES", 111, 117], ["Bovine respirovirus virus", "SPECIES", 111, 136], ["its protein alignment", "PROBLEM", 72, 93], ["any Bovine respirovirus virus proteins", "PROBLEM", 107, 145], ["V proteins", "PROBLEM", 165, 175], ["RNA editing derivatives", "PROBLEM", 180, 203], ["the phosphoprotein P gene", "TEST", 211, 236]]], ["These derivatives may play an important role in virus replication (Durbin et al. 1999) , virulence (Huang et al. 2003) , and/or the disruption of interferon expression (Roth et al. 2013) , and the discovery is in agreement with that claims all three reading frames in the P gene of Bovine respirovirus are expressed (Pelet et al. 1991 ).Tioman VirusThe method also detected two new ORFS of length 160 and 131 codons in phosphoprotein in another paramyxovirus, Tioman virus.", [["Bovine", "ORGANISM", 282, 288], ["respirovirus", "GENE_OR_GENE_PRODUCT", 289, 301], ["Tioman Virus", "ORGANISM", 337, 349], ["Tioman virus", "ORGANISM", 460, 472], ["interferon", "PROTEIN", 146, 156], ["P gene", "DNA", 272, 278], ["Bovine respirovirus", "DNA", 282, 301], ["ORFS of length 160 and 131 codons", "DNA", 382, 415], ["phosphoprotein", "PROTEIN", 419, 433], ["Bovine", "SPECIES", 282, 288], ["Bovine respirovirus", "SPECIES", 282, 301], ["Tioman Virus", "SPECIES", 337, 349], ["Tioman virus", "SPECIES", 460, 472], ["These derivatives", "TREATMENT", 0, 17], ["virus replication", "TREATMENT", 48, 65], ["virulence", "PROBLEM", 89, 98], ["interferon expression", "TREATMENT", 146, 167], ["Tioman Virus", "TREATMENT", 337, 349], ["length", "TEST", 390, 396], ["131 codons in phosphoprotein in another paramyxovirus", "PROBLEM", 405, 458], ["Tioman virus", "PROBLEM", 460, 472]]], ["Although one of these ORFs was in the same sense (\u00fe2 reading frame) the other was in the reverse complementary frame (\u00c0c2).Smallest ORFs DetectedThe three smallest ORFs detected were in Ligustrum necrotic ringspot virus, a positive-sense virus from the Betaflexiviridae, Okahandja mammarenavirus, a negative-sense virus from the Arenaviridae, and Simbu orthobunyavirus, a vector-borne negative-sense virus from the Peribunyaviridae.", [["Ligustrum necrotic ringspot virus", "ORGANISM", 186, 219], ["Okahandja mammarenavirus", "ORGANISM", 271, 295], ["Simbu orthobunyavirus", "ORGANISM", 347, 368], ["ORFs", "DNA", 22, 26], ["\u00fe2 reading frame", "DNA", 50, 66], ["reverse complementary frame", "DNA", 89, 116], ["\u00c0c2", "DNA", 118, 121], ["ORFs", "DNA", 132, 136], ["ORFs", "DNA", 164, 168], ["Ligustrum necrotic ringspot virus", "SPECIES", 186, 219], ["Okahandja mammarenavirus", "SPECIES", 271, 295], ["Simbu orthobunyavirus", "SPECIES", 347, 368], ["Ligustrum necrotic ringspot virus", "SPECIES", 186, 219], ["Okahandja mammarenavirus", "SPECIES", 271, 295], ["Simbu orthobunyavirus", "SPECIES", 347, 368], ["these ORFs", "TEST", 16, 26], ["Smallest ORFs", "PROBLEM", 123, 136], ["The three smallest ORFs", "PROBLEM", 145, 168], ["Ligustrum necrotic ringspot virus", "PROBLEM", 186, 219], ["a positive-sense virus", "PROBLEM", 221, 243], ["the Betaflexiviridae", "TEST", 249, 269], ["Okahandja mammarenavirus", "TEST", 271, 295], ["sense virus", "PROBLEM", 308, 319], ["the Arenaviridae", "TEST", 325, 341], ["sense virus", "PROBLEM", 394, 405], ["the Peribunyaviridae", "TREATMENT", 411, 431], ["ORFs", "OBSERVATION", 22, 26], ["ORFs", "OBSERVATION", 132, 136], ["smallest", "OBSERVATION_MODIFIER", 155, 163], ["ORFs", "OBSERVATION", 164, 168], ["necrotic", "OBSERVATION_MODIFIER", 196, 204], ["ringspot virus", "OBSERVATION", 205, 219]]], ["These ORFs had lengths 105, 91, and 87 codons, and were in frames \u00fe1, \u00fe2, and \u00c0c2, respectively.", [["ORFs", "DNA", 6, 10], ["\u00fe2", "DNA", 70, 72], ["\u00c0c2", "DNA", 78, 81], ["These ORFs", "TEST", 0, 10], ["lengths", "TEST", 15, 22]]], ["Interestingly, these were three of the four detected ORFs that completely encompass their relatively short reference genes, suggesting that the reference gene may be entirely located within the ORFs discovered by this method.DiscussionWe present a simple new method that uses a single genome sequence to detect candidates for overlapping genes.", [["ORFs", "DNA", 53, 57], ["reference gene", "DNA", 144, 158], ["ORFs", "DNA", 194, 198], ["overlapping genes", "DNA", 326, 343], ["this method", "TEST", 213, 224], ["a single genome sequence", "TREATMENT", 276, 300], ["overlapping genes", "PROBLEM", 326, 343], ["relatively", "OBSERVATION_MODIFIER", 90, 100], ["short", "OBSERVATION_MODIFIER", 101, 106], ["may be entirely", "UNCERTAINTY", 159, 174]]], ["The method assumes that functional ORFs are longer than expected by random chance as they experience selective pressure against mutations that introduce stop codons.", [["ORFs", "DNA", 35, 39], ["functional ORFs", "PROBLEM", 24, 39], ["selective pressure against mutations", "TREATMENT", 101, 137]]], ["We quantify this by using three ways to estimate the null distribution for ORFs lengths within each reading frame of a gene, and use the null to identify those ORFs significantly longer than predicted by random chance.", [["ORFs", "DNA", 75, 79], ["ORFs", "DNA", 160, 164]]], ["This approach has a number of advantages over current bioinformatics methods to detect overlapping genes.", [["overlapping genes", "DNA", 87, 104], ["overlapping genes", "OBSERVATION", 87, 104]]], ["In addition to being simple and quick, it only requires a single genome sequence.", [["single genome sequence", "DNA", 58, 80], ["a single genome sequence", "TREATMENT", 56, 80]]], ["This is in contrast to other bioinformatic methods that require multiple sequences to estimate and compare nucleotide or codon diversity.", [["nucleotide", "CHEMICAL", 107, 117], ["nucleotide", "CHEMICAL", 107, 117], ["multiple sequences", "TEST", 64, 82], ["nucleotide or codon diversity", "PROBLEM", 107, 136]]], ["This feature allows the method to be applied much more broadly in both metagenomics projects where genomes of new viruses are frequently only present in a single copy (Bekal et al. 2011; Ballinger et al. 2014; Shi et al. 2016) , and also in screening scenarios such as demonstrated herein.", [["the method", "TREATMENT", 20, 30], ["new viruses", "PROBLEM", 110, 121], ["new", "OBSERVATION_MODIFIER", 110, 113], ["viruses", "OBSERVATION", 114, 121]]], ["The method is best suited to refine regions of the genome that contain candidates for functional overlapping genes, after which these regions can be further tested for functionality with more resource intensive laboratory methods such as protein isolation, ribosomal profiling (Michel et al. 2012; Ingolia 2016) , and studying the effects of introduced knock out mutations (Chung et al. 2008) .DiscussionA second important feature of our method is the relatively high sensitivity to detect overlapping genes, whilst maintaining acceptable false discovery rates.", [["ribosomal", "ANATOMY", 257, 266], ["ribosomal", "CELLULAR_COMPONENT", 257, 266], ["overlapping genes", "DNA", 490, 507], ["functional overlapping genes", "PROBLEM", 86, 114], ["protein isolation", "TREATMENT", 238, 255]]], ["This is best achieved by using the combined test where newly detected ORFs must be larger than expected by both the codon permutation and synonymous mutation tests.", [["ORFs", "DNA", 70, 74], ["the combined test", "TEST", 31, 48], ["newly detected ORFs", "PROBLEM", 55, 74], ["the codon permutation", "TEST", 112, 133], ["synonymous mutation tests", "TEST", 138, 163], ["larger", "OBSERVATION_MODIFIER", 83, 89], ["synonymous mutation", "OBSERVATION", 138, 157]]], ["The combined test is advantageous as true positives are readily detected by both tests, so the constraint of requiring both tests to detect the ORF does not impact the sensitivity.", [["ORF", "DNA", 144, 147], ["The combined test", "TEST", 0, 17], ["both tests", "TEST", 76, 86], ["both tests", "TEST", 119, 129], ["the ORF", "PROBLEM", 140, 147]]], ["However, the combined test does substantially reduce the false positives rate, as false positives detected by one test are frequently excluded by the other.", [["the combined test", "TEST", 9, 26], ["the false positives rate", "PROBLEM", 53, 77], ["false positives", "PROBLEM", 82, 97], ["false positives", "OBSERVATION", 57, 72]]], ["There is also scope to further reduce false discovery by modifying our method, or by imposing post analysis constraints, for example by calculating ORF lengths from start codon to stop codon rather than between two stop codons.", [["ORF lengths", "DNA", 148, 159], ["start codon", "DNA", 165, 176], ["codon", "TREATMENT", 171, 176]]], ["This was not considered for the screening results here due to variation in alternative start codons among viruses, but would be an important optimization in more targeted screening.", [["the screening", "TEST", 28, 41], ["codons among viruses", "PROBLEM", 93, 113], ["targeted screening", "TEST", 162, 180]]], ["One caveat to this method (and other bioinformatics approaches) is that sensitivity depends on the size of overlap, with smaller regions of overlap being more difficult to detect.", [["size", "OBSERVATION_MODIFIER", 99, 103], ["smaller", "OBSERVATION_MODIFIER", 121, 128]]], ["Unlike other methods, however, we explicitly calculated the sensitivity for many lengths of overlap and find that a length of at least 50 nucleotides (17 codons) is required before the method becomes effective.", [["nucleotides", "CHEMICAL", 138, 149], ["nucleotides (17 codons)", "TREATMENT", 138, 161]]], ["As this length increases to 300 nucleotides (100 codons), the method becomes a very powerful diagnostic tool as measured by an area under the curve equal to 0.89.", [["nucleotides", "CHEMICAL", 32, 43]]], ["The estimate of this method's sensitivity and false discovery rates for an overlapping gene detection method is a strength, as although sensitivity can be calculated for other methods, false discovery estimation is often neglected and rarely reported due to a lack of negative controls.", [["this method's sensitivity", "TEST", 16, 41], ["false discovery estimation", "TEST", 185, 211]]], ["When it is reported, it is usually based on estimates of type 1 error rates of P values, rather than comparison to a negative control as we have done in here.DiscussionTo demonstrate the utility of our method's effectiveness for overlapping gene screening, we individually analyzed all reference linear RNA genomes available on GenBank.", [["reference linear RNA genomes", "DNA", 286, 314], ["P values", "TEST", 79, 87], ["overlapping gene screening", "TEST", 229, 255]]], ["This provided evidence for 29 undocumented overlapping ORFs of which we expect only 3 to be false positives, although all should be verified experimentally.", [["ORFs", "DNA", 55, 59], ["29 undocumented overlapping ORFs", "PROBLEM", 27, 59], ["false positives", "PROBLEM", 92, 107], ["positives", "OBSERVATION", 98, 107]]], ["One notable ORF identified here is the exceptionally long (708 codons) antisense ORF in Nhumirim virus, a single-stranded positive-sense RNA virus from the family Flaviviridae, which suggests that this virus may employ a novel method of transcription and clearly merits further investigation.", [["Nhumirim virus", "ORGANISM", 88, 102], ["ORF", "DNA", 12, 15], ["exceptionally long (708 codons", "DNA", 39, 69], ["antisense ORF", "DNA", 71, 84], ["Nhumirim virus", "SPECIES", 88, 102], ["the exceptionally long (708 codons) antisense ORF in Nhumirim virus", "PROBLEM", 35, 102], ["a single-stranded positive-sense RNA virus", "PROBLEM", 104, 146], ["Flaviviridae", "TREATMENT", 163, 175], ["this virus", "PROBLEM", 197, 207], ["further investigation", "TEST", 270, 291], ["notable", "OBSERVATION_MODIFIER", 4, 11], ["ORF", "OBSERVATION", 12, 15]]], ["We also identified several undiscovered ORFs in the phosphoprotein P within the Paramyxoviridae family, a region known to frequently contain overlapping genes in other reading frames due to RNA editing.", [["ORFs", "DNA", 40, 44], ["phosphoprotein P", "DNA", 52, 68], ["Paramyxoviridae family", "DNA", 80, 102], ["several undiscovered ORFs", "PROBLEM", 19, 44], ["RNA editing", "PROBLEM", 190, 201], ["ORFs", "OBSERVATION", 40, 44], ["RNA editing", "OBSERVATION", 190, 201]]], ["Within Bovine respirovirus virus 3, the ORF codon sequence discovered here aligned with many V proteins of other members of the Paramyxoviridae.", [["Bovine respirovirus virus 3", "ORGANISM", 7, 34], ["ORF codon sequence", "DNA", 40, 58], ["V proteins", "PROTEIN", 93, 103], ["Bovine respirovirus virus", "SPECIES", 7, 32], ["Bovine respirovirus virus", "SPECIES", 7, 32], ["Bovine respirovirus virus", "PROBLEM", 7, 32], ["the ORF codon sequence", "TEST", 36, 58], ["the Paramyxoviridae", "TREATMENT", 124, 143]]], ["As the V protein in these viruses also overlaps with the phosphoprotein P protein, this suggests that the V protein also exists in Bovine respirovirus virus 3.", [["V", "GENE_OR_GENE_PRODUCT", 7, 8], ["V", "GENE_OR_GENE_PRODUCT", 106, 107], ["Bovine respirovirus virus 3", "ORGANISM", 131, 158], ["V protein", "PROTEIN", 7, 16], ["phosphoprotein P protein", "PROTEIN", 57, 81], ["V protein", "PROTEIN", 106, 115], ["Bovine", "SPECIES", 131, 137], ["Bovine respirovirus virus", "SPECIES", 131, 156], ["the V protein", "TEST", 3, 16], ["the phosphoprotein P protein", "TEST", 53, 81], ["the V protein", "TEST", 102, 115], ["Bovine respirovirus virus", "PROBLEM", 131, 156], ["viruses", "OBSERVATION", 26, 33], ["Bovine respirovirus virus", "OBSERVATION", 131, 156]]], ["In other Paramyxoviridae, notably Tioman virus, we also identified antisense ORFs in the phosphoprotein.DiscussionThe detection of 17 antisense ORFs is notable.", [["Tioman virus", "ORGANISM", 34, 46], ["antisense ORFs", "DNA", 67, 81], ["phosphoprotein", "PROTEIN", 89, 103], ["17 antisense ORFs", "DNA", 131, 148], ["Tioman virus", "SPECIES", 34, 46], ["Tioman virus", "PROBLEM", 34, 46], ["antisense ORFs", "PROBLEM", 67, 81], ["The detection", "TEST", 114, 127], ["Tioman virus", "OBSERVATION", 34, 46], ["antisense ORFs", "OBSERVATION", 67, 81]]], ["Antisense overlaps have been shown to exist in a number viruses that use DNA as a replication intermediate including those in the Herpesviridae (Ward et al. 1996) , REP/ORF3 in Porcine Schlub et al. . doi:10.1093/molbev/msy155 MBE circovirus 2 (He et al. 2012 ) and HBZ/p12 and HBZ/p30 in Human T lymphotropic virus 1 (Arnold et al. 2006) .", [["DNA", "CELLULAR_COMPONENT", 73, 76], ["HBZ", "GENE_OR_GENE_PRODUCT", 266, 269], ["p12", "GENE_OR_GENE_PRODUCT", 270, 273], ["HBZ", "GENE_OR_GENE_PRODUCT", 278, 281], ["p30", "GENE_OR_GENE_PRODUCT", 282, 285], ["Human T lymphotropic virus 1", "ORGANISM", 289, 317], ["REP", "DNA", 165, 168], ["ORF3", "DNA", 169, 173], ["HBZ", "PROTEIN", 266, 269], ["p12", "PROTEIN", 270, 273], ["HBZ", "PROTEIN", 278, 281], ["p30", "PROTEIN", 282, 285], ["Porcine", "SPECIES", 177, 184], ["Human", "SPECIES", 289, 294], ["T lymphotropic virus", "SPECIES", 295, 315], [". doi:10.1093/molbev/msy155 MBE circovirus", "SPECIES", 199, 241], ["Human T lymphotropic virus 1", "SPECIES", 289, 317], ["Antisense overlaps", "PROBLEM", 0, 18], ["DNA", "TREATMENT", 73, 76], ["circovirus", "TEST", 231, 241], ["He et al.", "TEST", 245, 254], ["HBZ/p12", "TEST", 266, 273], ["HBZ", "TEST", 278, 281], ["Human T lymphotropic virus", "PROBLEM", 289, 315]]], ["They are also suspected to occur in many more viruses with DNA intermediaries, including a long suspected antisense protein (asp) in HIV-1 (Torresilla et al. 2015; Cassan et al. 2016 ).", [["DNA", "CELLULAR_COMPONENT", 59, 62], ["asp", "GENE_OR_GENE_PRODUCT", 125, 128], ["HIV-1", "ORGANISM", 133, 138], ["antisense protein", "PROTEIN", 106, 123], ["asp", "PROTEIN", 125, 128], ["HIV", "SPECIES", 133, 136], ["HIV-1", "SPECIES", 133, 138], ["a long suspected antisense protein (asp) in HIV", "PROBLEM", 89, 136]]], ["In addition, they have been infrequently suggested to occur in RNA viruses that do not use DNA intermediates, such as a more than 100 amino acid (a) overlapping antisense hypothetical protein in Rice black streaked dwarf virus (dsRNA) (Zhang et al. 2001 ), a 96 aa overlapping antisense hypothetical protein in Lymphocytic Choriomeningitis Mammarenavirus (-ssRNA) (Salvato et al. 1989) , and a possible 167 aa overlapping antisense ORF called \"NEG8\" in human influenza A virus (Clifford et al. 2009; Sabath et al. 2011) .", [["amino acid", "CHEMICAL", 134, 144], ["influenza A", "DISEASE", 459, 470], ["amino acid", "CHEMICAL", 134, 144], ["DNA", "CELLULAR_COMPONENT", 91, 94], ["amino acid", "AMINO_ACID", 134, 144], ["Rice black streaked dwarf virus", "ORGANISM", 195, 226], ["NEG8", "GENE_OR_GENE_PRODUCT", 444, 448], ["human influenza A virus", "ORGANISM", 453, 476], ["antisense hypothetical protein", "PROTEIN", 161, 191], ["96 aa overlapping antisense hypothetical protein", "PROTEIN", 259, 307], ["167 aa overlapping antisense ORF", "DNA", 403, 435], ["NEG8", "DNA", 444, 448], ["black streaked dwarf virus", "SPECIES", 200, 226], ["human", "SPECIES", 453, 458], ["influenza A virus", "SPECIES", 459, 476], ["Rice black streaked dwarf virus", "SPECIES", 195, 226], ["Lymphocytic Choriomeningitis Mammarenavirus", "SPECIES", 311, 354], ["human influenza A virus", "SPECIES", 453, 476], ["RNA viruses", "PROBLEM", 63, 74], ["DNA intermediates", "PROBLEM", 91, 108], ["overlapping antisense hypothetical protein in Rice black streaked dwarf virus (dsRNA)", "PROBLEM", 149, 234], ["Lymphocytic Choriomeningitis Mammarenavirus", "PROBLEM", 311, 354], ["dwarf virus", "OBSERVATION", 215, 226], ["Lymphocytic Choriomeningitis", "OBSERVATION", 311, 339]]], ["Our method can be used to investigate these further.", [["Our method", "TREATMENT", 0, 10]]], ["For example, in the case of NEG8 we find that a 167 codon ORF on in the NEG8 reading frame (\u00c0c2) is highly statistically unlikely by both the codon permutation and synonymous mutation methods, providing further evidence for a functional benefit of this ORF.", [["NEG8", "GENE_OR_GENE_PRODUCT", 28, 32], ["NEG8", "GENE_OR_GENE_PRODUCT", 72, 76], ["NEG8", "DNA", 28, 32], ["167 codon ORF", "DNA", 48, 61], ["NEG8 reading frame", "DNA", 72, 90], ["\u00c0c2", "DNA", 92, 95], ["ORF", "DNA", 253, 256], ["a 167 codon ORF", "PROBLEM", 46, 61], ["synonymous mutation methods", "PROBLEM", 164, 191], ["this ORF", "PROBLEM", 248, 256], ["highly statistically unlikely", "UNCERTAINTY", 100, 129], ["synonymous mutation", "OBSERVATION", 164, 183]]], ["Interestingly, however, a further frameshift of 1 nucleotide (frame \u00c0c1) would make ORFs of such lengths much more likely (P \u00bc 0.02 and 0.03 for codon permutation and synonymous mutation methods respectively), demonstrating the importance of the expected ORF lengths on every individual reading frame, rather than just the sense direction.", [["1 nucleotide", "DNA", 48, 60], ["frame \u00c0c1", "DNA", 62, 71], ["ORFs", "DNA", 84, 88], ["ORF", "DNA", 255, 258], ["reading frame", "DNA", 287, 300], ["a further frameshift of 1 nucleotide (frame \u00c0c1", "PROBLEM", 24, 71], ["ORFs of such lengths", "PROBLEM", 84, 104], ["codon permutation", "TREATMENT", 145, 162], ["synonymous mutation methods", "TEST", 167, 194], ["lengths", "OBSERVATION_MODIFIER", 259, 266]]], ["Furthermore, when applying our method to HIV-1, we find that the possible antisense ORF (asp) is not substantially longer than expected by chance alone (P \u00bc 0.06 and P \u00bc 0.04 for codon permutation and synonymous mutation methods, respectively) in that reading frame.DiscussionOur results do indicate that antisense ORFs are present at levels higher than currently expected.", [["HIV-1", "ORGANISM", 41, 46], ["antisense ORF", "DNA", 74, 87], ["asp", "DNA", 89, 92], ["reading frame", "DNA", 252, 265], ["antisense ORFs", "DNA", 305, 319], ["HIV-1", "SPECIES", 41, 46], ["HIV-1", "SPECIES", 41, 46], ["antisense ORF (asp)", "PROBLEM", 74, 93], ["codon permutation", "TREATMENT", 179, 196], ["synonymous mutation methods", "TREATMENT", 201, 228], ["antisense ORFs", "PROBLEM", 305, 319]]], ["This does not necessarily mean that a transcribed protein is functional, although its presence may be indicative of some functional benefit, such as regulating expression by diverting ribosomes (Pelechano and Steinmetz 2013; Beltran and Garcia de Herreros 2016) .", [["ribosomes", "ANATOMY", 184, 193], ["ribosomes", "CELLULAR_COMPONENT", 184, 193], ["a transcribed protein", "TEST", 36, 57], ["diverting ribosomes", "TREATMENT", 174, 193], ["may be indicative of", "UNCERTAINTY", 95, 115]]], ["Importantly, our method's high detection of antisense ORFs are in contrast to other bioinformatic screening methods which have been shown to have poor sensitivity to antisense ORFs by computer simulations.", [["antisense ORFs", "DNA", 44, 58], ["antisense ORFs", "DNA", 166, 180], ["antisense ORFs", "PROBLEM", 44, 58], ["bioinformatic screening methods", "TEST", 84, 115], ["poor sensitivity to antisense ORFs", "PROBLEM", 146, 180]]], ["This is because synonymous mutations in frame \u00fe0 impact the reverse complementary frame (specifically frame \u00c0c2) much less than other reading frames (Mir and Schober 2014) .", [["frame \u00fe0", "DNA", 40, 48], ["reverse complementary frame", "DNA", 60, 87], ["frame \u00c0c2", "DNA", 102, 111], ["reading frames", "DNA", 134, 148], ["Mir", "DNA", 150, 153], ["synonymous mutations", "PROBLEM", 16, 36], ["synonymous mutations", "OBSERVATION", 16, 36]]], ["Although this feature would impact the sensitivity of our synonymous mutation test, as it would for all current methods, the codon permutation test will not impacted by this, and could be used in isolation when specifically screening for antisense ORFs.DiscussionOverlapping genes play an important role in viral evolution (Simon-Loriere et al. 2013) , and are particularly prevalent in RNA viruses with small genomes.", [["antisense ORFs", "DNA", 238, 252], ["our synonymous mutation test", "TEST", 54, 82], ["the codon permutation test", "TEST", 121, 147], ["screening", "TEST", 224, 233], ["antisense ORFs", "PROBLEM", 238, 252], ["small genomes", "PROBLEM", 404, 417], ["RNA viruses", "OBSERVATION", 387, 398], ["small genomes", "OBSERVATION", 404, 417]]], ["However, the study of overlapping genes is limited by detection methods that either have high laboratory costs, or require enough sequences to make reliable substitution rate comparisons.", [["overlapping genes", "DNA", 22, 39], ["the study", "TEST", 9, 18], ["high laboratory costs", "PROBLEM", 89, 110], ["reliable substitution rate comparisons", "TEST", 148, 186]]], ["Our simple, but powerful, permutation and synonymous mutation method requires only a single genome sequence and is computationally quick to run.", [["genome sequence", "DNA", 92, 107], ["permutation and synonymous mutation method", "TREATMENT", 26, 68]]], ["These properties make it an ideal choice for identifying candidate ORFs in screening situations such as metagenomics viral discovery projects, or applied to large genome databases such as we have done here.Data CollectionWhole genome sequences were downloaded for all viruses available from the NCBI FTP site ftp://ftp.ncbi.nlm.nih.gov/ genomes/Viruses.", [["ORFs", "DNA", 67, 71], ["CollectionWhole genome sequences", "DNA", 211, 243], ["NCBI FTP site", "DNA", 295, 308], ["ORFs in screening situations", "PROBLEM", 67, 95], ["metagenomics viral discovery", "TREATMENT", 104, 132], ["Data CollectionWhole genome sequences", "TEST", 206, 243], ["all viruses", "PROBLEM", 264, 275]]], ["Of the 5757 viral genomes, 2548 were RNA viruses with linear genomes, and these were selected for analysis.", [["5757 viral genomes", "DNA", 7, 25], ["linear genomes", "DNA", 54, 68], ["RNA viruses with linear genomes", "PROBLEM", 37, 68], ["analysis", "TEST", 98, 106]]], ["All 6408 coding regions (annotated with a CDS in Genbank) were analyzed, excluding 291 regions annotated with a \"join\" indicating some form of midsequence frameshift in the established gene such as a ribosomal slippage (leaving 6117 coding regions analyzed).Reading Frame DefinitionsThe following notation is used to identify the different reading frames (supplementary material S1, Supplementary Material online): \u00fe0 is the original reading frame; \u00fe1 or \u00fe2 is a frameshift of 1 or 2 nucleotides, respectively (5 0 to 3 0 transcription); \u00c00, \u00c01, or \u00c02 a frameshift of 0, 1 or 2 nucleotides, respectively, after the coding sequence has been reversed (i.e. 3 0 to 5 0 transcription); \u00fec0, \u00fec1 or \u00fec2 is a frameshift of 0, 1 or 2 nucleotides, respectively, on the complement of the coding sequence (3 0 to 5 0 transcription); and \u00c0c0, \u00c0c1 or -c2 is a frameshift of 0, 1 or 2 nucleotides, respectively, on the complement and reversed coding sequence (5 0 to 3 0 transcription). \u00fe0, \u00fe1, \u00fe2, \u00fec0, \u00fec1, \u00fec2 are considered the only viable reading frames as transcription on these frames occur in the 5 0 to 3 0 direction.Tests to Identify Frameshifted GenesFor each coding region and for each viable alternative reading frame (\u00fe1,\u00fe2,\u00c0c0, \u00c0c1, \u00c0c2) we performed the following analysis (summarized in fig. 1A ).", [["ribosomal", "ANATOMY", 200, 209], ["nucleotides", "CHEMICAL", 484, 495], ["nucleotides", "CHEMICAL", 727, 738], ["nucleotides", "CHEMICAL", 872, 883], ["ribosomal", "CELLULAR_COMPONENT", 200, 209], ["\u00fec0", "GENE_OR_GENE_PRODUCT", 682, 685], ["\u00fec1", "GENE_OR_GENE_PRODUCT", 687, 690], ["\u00fec2", "GENE_OR_GENE_PRODUCT", 694, 697], ["\u00c0c0", "GENE_OR_GENE_PRODUCT", 827, 830], ["\u00c0c1", "GENE_OR_GENE_PRODUCT", 832, 835], ["-c2", "GENE_OR_GENE_PRODUCT", 839, 842], ["\u00fe0", "GENE_OR_GENE_PRODUCT", 974, 976], ["\u00fe1", "GENE_OR_GENE_PRODUCT", 978, 980], ["\u00fe2", "GENE_OR_GENE_PRODUCT", 982, 984], ["\u00fec0", "GENE_OR_GENE_PRODUCT", 986, 989], ["\u00fec1", "GENE_OR_GENE_PRODUCT", 991, 994], ["\u00fec2", "GENE_OR_GENE_PRODUCT", 996, 999], ["\u00c0c0", "GENE_OR_GENE_PRODUCT", 1225, 1228], ["6408 coding regions", "DNA", 4, 23], ["CDS", "DNA", 42, 45], ["291 regions", "DNA", 83, 94], ["midsequence frameshift", "DNA", 143, 165], ["ribosomal slippage", "DNA", 200, 218], ["6117 coding regions", "DNA", 228, 247], ["reading frames", "DNA", 340, 354], ["supplementary material S1", "DNA", 356, 381], ["original reading frame", "DNA", 425, 447], ["\u00fe2", "DNA", 455, 457], ["\u00c01", "DNA", 542, 544], ["\u00c02", "DNA", 549, 551], ["\u00fec0", "DNA", 682, 685], ["\u00fec1", "DNA", 687, 690], ["\u00fec2", "DNA", 694, 697], ["coding sequence", "DNA", 779, 794], ["\u00c0c0", "DNA", 827, 830], ["\u00c0c1", "DNA", 832, 835], ["c2", "DNA", 840, 842], ["complement and reversed coding sequence", "DNA", 906, 945], ["\u00fe0", "DNA", 974, 976], ["\u00fe1", "DNA", 978, 980], ["\u00fe2", "PROTEIN", 982, 984], ["\u00fec0", "PROTEIN", 986, 989], ["\u00fec1", "PROTEIN", 991, 994], ["\u00fec2", "PROTEIN", 996, 999], ["reading frames", "DNA", 1031, 1045], ["5 0 to 3 0 direction", "DNA", 1092, 1112], ["Frameshifted Genes", "DNA", 1131, 1149], ["coding region", "DNA", 1158, 1171], ["alternative reading frame", "DNA", 1192, 1217], ["\u00fe1", "DNA", 1219, 1221], ["\u00c0c0", "DNA", 1225, 1228], ["\u00c0c1", "DNA", 1230, 1233], ["\u00c0c2", "DNA", 1235, 1238], ["a CDS in Genbank", "TEST", 40, 56], ["midsequence frameshift", "PROBLEM", 143, 165], ["a ribosomal slippage", "TREATMENT", 198, 218], ["the coding sequence", "TEST", 611, 630], ["\u00fec0", "TEST", 682, 685], ["the coding sequence", "TEST", 775, 794], ["\u00c0c0", "TEST", 827, 830], ["Tests", "TEST", 1113, 1118], ["analysis", "TEST", 1267, 1275], ["midsequence frameshift", "OBSERVATION", 143, 165], ["ribosomal slippage", "OBSERVATION", 200, 218], ["frameshift", "OBSERVATION", 703, 713], ["c2", "ANATOMY", 840, 842]]], ["First, the length of ORFs between the stop codons \"TGA,\" \"TAG,\" and \"TAA\" on that specific alternative reading frame was calculated.", [["TAA", "DISEASE", 69, 72], ["ORFs", "DNA", 21, 25], ["stop codons \"TGA,\" \"TAG", "RNA", 38, 61], ["TAA", "DNA", 69, 72], ["alternative reading frame", "DNA", 91, 116], ["ORFs", "TREATMENT", 21, 25]]], ["Then, 20,000 new coding sequences were created by either randomly permuting the codons in frame \u00fe0 (codon permutation test; fig. 1B ), or for each amino acid in reading frame \u00fe0, randomly choosing a replacement codon (for which the original codon is a possible candidate) that encodes the same amino acid (synonymous mutation test; fig. 1C ).", [["amino acid", "CHEMICAL", 147, 157], ["amino acid", "CHEMICAL", 294, 304], ["amino acid", "CHEMICAL", 147, 157], ["amino acid", "CHEMICAL", 294, 304], ["amino acid", "AMINO_ACID", 147, 157], ["amino acid", "AMINO_ACID", 294, 304], ["20,000 new coding sequences", "DNA", 6, 33], ["frame \u00fe0", "DNA", 90, 98], ["reading frame", "DNA", 161, 174], ["replacement codon", "DNA", 199, 216], ["new coding sequences", "TEST", 13, 33], ["codon permutation test", "TEST", 100, 122], ["each amino acid", "TEST", 142, 157], ["a replacement codon", "TREATMENT", 197, 216], ["the same amino acid", "TEST", 285, 304], ["synonymous mutation test", "TEST", 306, 330], ["replacement codon", "OBSERVATION", 199, 216]]], ["For each of these 20,000 new coding sequences, the length of ORFs between stop codons in that alternative reading frame was calculated again.", [["20,000 new coding sequences", "DNA", 18, 45], ["ORFs", "DNA", 61, 65], ["alternative reading frame", "DNA", 94, 119], ["the length of ORFs", "TREATMENT", 47, 65], ["stop codons", "TREATMENT", 74, 85]]], ["The lengths of ORFs over all 20,000 randomly generated coding sequences were pooled to calculate a theoretical distribution of the length of ORFs on that specific alternative reading frame.", [["ORFs", "DNA", 15, 19], ["ORFs", "DNA", 141, 145], ["alternative reading frame", "DNA", 163, 188], ["ORFs", "TREATMENT", 15, 19], ["the length of ORFs", "PROBLEM", 127, 145], ["lengths", "OBSERVATION_MODIFIER", 4, 11]]], ["For each ORF length L in the original unpermuted coding sequence, the probability of observing a length as large or larger by random chance alone is calculated using this theoretical distribution as follows:Tests to Identify Frameshifted Geneswhere C is the empirical cumulative distribution function of the theoretical distribution of lengths calculated by permuting codons in the original coding sequence: that is, C(L) is the Simple Method to Detect Candidate Overlapping Genes . doi:10.1093/molbev/msy155 MBE probability of sampling an ORF length less than L on that specific reading frame.", [["ORF length L", "DNA", 9, 21], ["unpermuted coding sequence", "DNA", 38, 64], ["Overlapping Genes", "DNA", 463, 480], ["doi:10.1093", "DNA", 483, 494], ["ORF length", "DNA", 540, 550], ["specific reading frame", "DNA", 571, 593], ["Tests", "TEST", 207, 212], ["an ORF length", "TEST", 537, 550], ["length", "OBSERVATION_MODIFIER", 13, 19], ["large", "OBSERVATION_MODIFIER", 107, 112], ["larger", "OBSERVATION_MODIFIER", 116, 122]]], ["The value 1 \u00c0 C(L) has an interpretation similar to that of a P value testing whether or not the length L is sampled from the theoretical distribution of lengths calculated earlier.", [["P", "DNA", 62, 63], ["The value", "TEST", 0, 9], ["a P value testing", "TEST", 60, 77], ["lengths", "OBSERVATION_MODIFIER", 154, 161]]], ["To correct this \"P value\" for the total number of alternative reading frame ORFs, s, in the original coding sequence the following equation is used:Tests to Identify Frameshifted GenesThis adjustment is analogous to a Bonferroni adjustment of P values, here correcting for the number of ORFs within a reading frame.", [["P", "DNA", 17, 18], ["alternative reading frame ORFs", "DNA", 50, 80], ["Frameshifted Genes", "DNA", 166, 184], ["P", "DNA", 243, 244], ["ORFs", "DNA", 287, 291], ["reading frame", "DNA", 301, 314], ["Tests", "TEST", 148, 153], ["P values", "TEST", 243, 251], ["ORFs", "PROBLEM", 287, 291]]], ["Small P values for an ORF are interpreted as evidence that the ORF in question is larger than expected by random chance alone and therefore provides evidence that there has been negative selection against mutations that introduce stop codons in this ORF.", [["ORF", "DNA", 22, 25], ["ORF", "DNA", 63, 66], ["ORF", "DNA", 250, 253], ["Small P values", "TEST", 0, 14], ["an ORF", "TEST", 19, 25], ["the ORF", "PROBLEM", 59, 66], ["mutations", "PROBLEM", 205, 214], ["larger", "OBSERVATION_MODIFIER", 82, 88]]], ["From this, we can also infer that the ORF is of functional benefit to the virus.", [["ORF", "DNA", 38, 41], ["the ORF", "PROBLEM", 34, 41], ["the virus", "PROBLEM", 70, 79]]], ["The third test, denoted as the \"combined test,\" requires that the P value for both the codon permutation test and the synonymous mutation test be below some cut-off value.Tests to Identify Frameshifted GenesThe method was only applied to ORFs on alternative reading frames that exist totally or partially within the parent ORF.", [["P", "DNA", 66, 67], ["Frameshifted Genes", "DNA", 189, 207], ["ORFs", "DNA", 238, 242], ["alternative reading frames", "DNA", 246, 272], ["parent ORF", "DNA", 316, 326], ["The third test", "TEST", 0, 14], ["the P value", "TEST", 62, 73], ["the codon permutation test", "TEST", 83, 109], ["the synonymous mutation test", "TEST", 114, 142], ["Tests", "TEST", 171, 176], ["The method", "TREATMENT", 207, 217]]], ["When ORFs on alternative reading frames extended beyond the parent ORF boundaries, its length was truncated to the length contained with the parent ORF.Tests to Identify Frameshifted GenesThis analysis was performed using R (version 3.3.2; R_Core_Team 2016) and required the packages seqinrSensitivity and False Discovery RateThe sensitivity (true positive rate) is measured as the proportion of known overlapping genes within the downloaded reference genomes that are detected using our method.", [["ORFs", "DNA", 5, 9], ["alternative reading frames", "DNA", 13, 39], ["parent ORF boundaries", "DNA", 60, 81], ["parent ORF", "DNA", 141, 151], ["Frameshifted Genes", "DNA", 170, 188], ["overlapping genes", "DNA", 402, 419], ["downloaded reference genomes", "DNA", 431, 459], ["alternative reading frames", "TREATMENT", 13, 39], ["Tests", "TEST", 152, 157], ["This analysis", "TEST", 188, 201], ["the packages seqinrSensitivity", "TEST", 271, 301], ["The sensitivity", "TEST", 326, 341], ["known overlapping genes", "PROBLEM", 396, 419], ["length", "OBSERVATION_MODIFIER", 87, 93], ["overlapping genes", "OBSERVATION", 402, 419]]], ["An ORF identified with our method was considered a true positive if it was located on the same reading frame and overlapped with a gene already annotated in the reference genome.", [["ORF", "DNA", 3, 6], ["reading frame", "DNA", 95, 108], ["reference genome", "DNA", 161, 177], ["An ORF", "PROBLEM", 0, 6], ["our method", "TEST", 23, 33]]], ["As the sensitivity of our method will be dependent on the extent of overlap, we calculated the sensitivity for detecting previously annotated overlapping genes where the minimum nucleotide length of overlap is 1, 10, 20 50, 100, 150, 200, and 300 nucleotides.", [["nucleotide", "CHEMICAL", 178, 188], ["nucleotides", "CHEMICAL", 247, 258], ["overlapping genes", "DNA", 142, 159], ["1, 10, 20 50, 100, 150, 200, and 300 nucleotides", "DNA", 210, 258], ["our method", "TEST", 22, 32], ["the sensitivity", "TEST", 91, 106], ["the minimum nucleotide length of overlap", "TEST", 166, 206], ["length", "OBSERVATION_MODIFIER", 189, 195]]], ["The false discovery rate calculation is more complex as the absence of an annotated overlapping gene does not exclude its biological presence so that distinguishing between false positives and new discoveries is not possible without extensive laboratory work.", [["overlapping gene", "DNA", 84, 100], ["The false discovery rate calculation", "TEST", 0, 36], ["false positives", "PROBLEM", 173, 188], ["false", "OBSERVATION_MODIFIER", 4, 9], ["more complex", "OBSERVATION_MODIFIER", 40, 52], ["not possible", "UNCERTAINTY", 212, 224]]], ["To overcome this, we conservatively estimated the false discovery rate of our tests by using the nonviable 3 0 -5 0 reading frames (\u00c00, \u00c01, \u00c02, \u00fec0, \u00fec1, and \u00fec2, supplementary material S1, Supplementary Material online) as a negative control.", [["nonviable 3 0 -5 0 reading frames", "DNA", 97, 130], ["\u00c00", "DNA", 132, 134], ["\u00c01", "DNA", 136, 138], ["\u00c02", "DNA", 140, 142], ["\u00fec0", "DNA", 144, 147], ["\u00fec1", "DNA", 149, 152], ["\u00fec2", "DNA", 158, 161], ["supplementary material S1", "DNA", 163, 188], ["our tests", "TEST", 74, 83]]], ["That is, as detected ORFs on these frames cannot be transcribed into proteins and are therefore false positives, they serve as an estimate to what proportion of detected ORFs on viable reading frames are similarly not functional.Identifying Homologous SequencesA search for sequences homologous to the 29 newly discovered overlapping ORFs was performed by aligning their protein sequences to the NCBI nt database using tblastn (TBLASTN 2.6.0\u00fe).", [["ORFs", "DNA", 21, 25], ["ORFs", "DNA", 170, 174], ["ORFs", "DNA", 334, 338], ["protein sequences", "DNA", 371, 388], ["NCBI nt database", "DNA", 396, 412], ["false positives", "PROBLEM", 96, 111], ["tblastn (TBLASTN", "TREATMENT", 419, 435]]], ["The e-value threshold was set to 0.001 while all other settings were set to their default values.", [["The e-value threshold", "TEST", 0, 21]]], ["The results were stored in a SQLite3 database (3.24.0).", [["a SQLite3 database", "TEST", 27, 45]]], ["For homologous sequence detection the alignments were filtered to include only alignments with similarity !90% and length !90% of the corresponding ORF sequence.", [["ORF sequence", "DNA", 148, 160], ["homologous sequence detection", "TEST", 4, 33], ["the corresponding ORF sequence", "TEST", 130, 160]]], ["From each filtered alignment, the NCBI accession for the query (ORF) and subject were extracted and the corresponding taxid and lineage obtained using NCBI Entrez.", [["NCBI accession", "DNA", 34, 48], ["ORF", "DNA", 64, 67], ["NCBI Entrez", "DNA", 151, 162], ["the NCBI accession", "TREATMENT", 30, 48], ["alignment", "OBSERVATION_MODIFIER", 19, 28]]], ["A python tool taxmax.py was developed (https://gitlab.com/janpb/taxmax.git) to compare the NCBI lineage from each ORF and its aligned sequence.", [["NCBI lineage", "DNA", 91, 103], ["ORF", "DNA", 114, 117], ["A python tool taxmax.py", "TEST", 0, 23]]], ["The similarity between two lineages is described as a score between 0 and 1.", [["two", "OBSERVATION_MODIFIER", 23, 26], ["lineages", "OBSERVATION_MODIFIER", 27, 35]]], ["A score of 0 indicates no similarity between lineages while a score of 1 indicates both sequences have the same NCBI lineage.", [["NCBI lineage", "CELL_TYPE", 112, 124], ["A score", "TEST", 0, 7]]]], "12f5d1ea103b1a5f1b864eb28e430b1369960001": [["\u25a0 INTRODUCTIONThe global outbreak of Corona Virus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a severe threat to human health.", [["Corona Virus Disease", "DISEASE", 37, 57], ["COVID-19", "CHEMICAL", 64, 72], ["acute respiratory syndrome coronavirus", "DISEASE", 91, 129], ["SARS-CoV-2", "CHEMICAL", 133, 143], ["Corona Virus", "ORGANISM", 37, 49], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 84, 131], ["SARS-CoV-2", "ORGANISM", 133, 143], ["human", "ORGANISM", 170, 175], ["human", "SPECIES", 170, 175], ["Corona Virus Disease 2019 (COVID-19", "SPECIES", 37, 72], ["severe acute respiratory syndrome coronavirus", "SPECIES", 84, 129], ["SARS-CoV-2", "SPECIES", 133, 143], ["human", "SPECIES", 170, 175], ["Corona Virus Disease", "PROBLEM", 37, 57], ["COVID", "TEST", 64, 69], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 84, 129], ["a severe threat to human health", "PROBLEM", 151, 182], ["global", "OBSERVATION_MODIFIER", 18, 24], ["outbreak", "OBSERVATION_MODIFIER", 25, 33], ["Corona Virus Disease", "OBSERVATION", 37, 57], ["severe", "OBSERVATION_MODIFIER", 84, 90], ["acute", "OBSERVATION_MODIFIER", 91, 96], ["respiratory syndrome", "OBSERVATION", 97, 117], ["severe", "OBSERVATION_MODIFIER", 153, 159], ["threat", "OBSERVATION", 160, 166]]], ["1\u22125 Compared to its relatives (e.g., SARS-CoV and MERS-CoV), the new coronavirus exhibits a more significant person-toperson transmission tendency.", [["coronavirus", "DISEASE", 69, 80], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 37, 45], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 50, 58], ["coronavirus", "ORGANISM", 69, 80], ["person", "SPECIES", 109, 115], ["SARS-CoV", "SPECIES", 37, 45], ["MERS-CoV", "SPECIES", 50, 58], ["SARS", "TEST", 37, 41], ["CoV", "TEST", 42, 45], ["the new coronavirus", "PROBLEM", 61, 80], ["new", "OBSERVATION_MODIFIER", 65, 68], ["coronavirus", "OBSERVATION", 69, 80], ["significant", "OBSERVATION_MODIFIER", 97, 108]]], ["Most importantly, no drugs or vaccines have thus far been approved to treat infections of SARS-CoV-2, which seems to render this pandemic uncontrollable, with the number of infected cases worldwide exceeding ten million.", [["infections", "DISEASE", 76, 86], ["SARS", "DISEASE", 90, 94], ["SARS-CoV-2", "ORGANISM", 90, 100], ["SARS-CoV", "SPECIES", 90, 98], ["drugs", "TREATMENT", 21, 26], ["vaccines", "TREATMENT", 30, 38], ["infections of SARS", "PROBLEM", 76, 94], ["CoV", "TEST", 95, 98], ["infected", "OBSERVATION_MODIFIER", 173, 181]]], ["Under such circumstances, several existing antiviral drugs and drug candidates are actively evaluated for their therapeutic potential for this disease.", [["antiviral drugs", "TREATMENT", 43, 58], ["drug candidates", "TREATMENT", 63, 78], ["this disease", "PROBLEM", 138, 150], ["antiviral drugs", "OBSERVATION", 43, 58]]], ["6\u22128 Among them, remdesivir (GS-5734, 1; Figure 1 ) represents one of the most promising compounds.", [["remdesivir", "CHEMICAL", 16, 26], ["GS-5734", "CHEMICAL", 28, 35], ["remdesivir", "CHEMICAL", 16, 26], ["GS-5734", "CHEMICAL", 28, 35], ["remdesivir", "SIMPLE_CHEMICAL", 16, 26], ["GS", "TEST", 28, 30]]], ["8\u221210 Remdesivir is an investigational small-molecule drug originally developed to treat Ebola virus infections and later found to exhibit broad-spectrum activity against various RNA viruses.", [["Remdesivir", "CHEMICAL", 5, 15], ["Ebola virus infections", "DISEASE", 88, 110], ["Remdesivir", "CHEMICAL", 5, 15], ["Ebola virus", "ORGANISM", 88, 99], ["Ebola virus", "SPECIES", 88, 99], ["Ebola virus", "SPECIES", 88, 99], ["Remdesivir", "TREATMENT", 5, 15], ["an investigational small-molecule drug", "TREATMENT", 19, 57], ["Ebola virus infections", "PROBLEM", 88, 110], ["various RNA viruses", "PROBLEM", 170, 189], ["RNA viruses", "OBSERVATION", 178, 189]]], ["11 \u221217 In particular, a recent study (published on February 4, 2020) clearly demonstrated that remdesivir was effective against SARS-CoV-2 in vitro with an EC 50 of 0.77 \u03bcM in Vero E6 cells.", [["EC", "ANATOMY", 156, 158], ["Vero E6 cells", "ANATOMY", 176, 189], ["remdesivir", "CHEMICAL", 95, 105], ["SARS", "DISEASE", 128, 132], ["remdesivir", "CHEMICAL", 95, 105], ["remdesivir", "SIMPLE_CHEMICAL", 95, 105], ["SARS-CoV-2", "ORGANISM", 128, 138], ["EC", "CELL", 156, 158], ["Vero E6 cells", "CELL", 176, 189], ["Vero E6 cells", "CELL_LINE", 176, 189], ["SARS-CoV", "SPECIES", 128, 136], ["Vero E6", "SPECIES", 176, 183], ["a recent study", "TEST", 22, 36], ["SARS", "PROBLEM", 128, 132], ["CoV", "TEST", 133, 136], ["an EC", "TEST", 153, 158], ["E6 cells", "OBSERVATION", 181, 189]]], ["17 Of note, approximately 1 week prior to this report, Holshue et al. disclosed that the first COVID-19 patient in the USA had gradually recovered after receiving a compassionate administration of remdesivir.", [["remdesivir", "CHEMICAL", 197, 207], ["remdesivir", "CHEMICAL", 197, 207], ["patient", "ORGANISM", 104, 111], ["remdesivir", "SIMPLE_CHEMICAL", 197, 207], ["patient", "SPECIES", 104, 111], ["a compassionate administration of remdesivir", "TREATMENT", 163, 207]]], ["18 Subsequently, a number of clinical trials have been launched worldwide to evaluate the efficacy and safety of remdesivir, 19 and other compassionate use of this molecule has also been initiated, 20 in the hope that it would benefit the treatment of the epidemic COVID-19.", [["remdesivir", "CHEMICAL", 113, 123], ["remdesivir", "CHEMICAL", 113, 123], ["remdesivir", "SIMPLE_CHEMICAL", 113, 123], ["remdesivir", "TREATMENT", 113, 123], ["this molecule", "TREATMENT", 159, 172], ["the epidemic COVID", "TEST", 252, 270]]], ["Although the earliest clinical trials conducted in China did not yield positive results in terms of reducing the death rate of severely affected patients due to insufficient data, 21 preliminary data from a clinical trial led by the National Institute of Allergy and Infectious Diseases (NIAID) suggest a promising therapeutic effect of remdesivir.", [["death", "DISEASE", 113, 118], ["Allergy and Infectious Diseases", "DISEASE", 255, 286], ["remdesivir", "CHEMICAL", 337, 347], ["remdesivir", "CHEMICAL", 337, 347], ["patients", "ORGANISM", 145, 153], ["remdesivir", "SIMPLE_CHEMICAL", 337, 347], ["patients", "SPECIES", 145, 153], ["remdesivir", "TREATMENT", 337, 347]]], ["22 On May 1, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for remdesivir to treat COVID-19 patients.", [["remdesivir", "CHEMICAL", 106, 116], ["COVID", "DISEASE", 126, 131], ["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 135, 143], ["remdesivir", "TREATMENT", 106, 116], ["COVID", "TEST", 126, 131]]], ["22 Once further evidence supports the broad clinical use of remdesivir, the bulk supply of the active pharmaceutical ingredients required for the production of remdesivir would be an urgent concern.", [["remdesivir", "CHEMICAL", 60, 70], ["remdesivir", "CHEMICAL", 160, 170], ["remdesivir", "CHEMICAL", 60, 70], ["remdesivir", "CHEMICAL", 160, 170], ["remdesivir", "SIMPLE_CHEMICAL", 60, 70], ["remdesivir", "SIMPLE_CHEMICAL", 160, 170], ["remdesivir", "TREATMENT", 60, 70], ["the active pharmaceutical ingredients", "TREATMENT", 91, 128], ["remdesivir", "TREATMENT", 160, 170], ["active", "OBSERVATION_MODIFIER", 95, 101], ["pharmaceutical ingredients", "OBSERVATION", 102, 128]]], ["23 Structurally, remdesivir consists of three fragments: an adenine analogue (base), a pentose unit, and a phosphoramidate side chain.", [["adenine", "CHEMICAL", 60, 67], ["pentose", "CHEMICAL", 87, 94], ["phosphoramidate", "CHEMICAL", 107, 122], ["adenine", "CHEMICAL", 60, 67], ["pentose", "CHEMICAL", 87, 94], ["phosphoramidate", "CHEMICAL", 107, 122], ["adenine", "SIMPLE_CHEMICAL", 60, 67], ["pentose", "SIMPLE_CHEMICAL", 87, 94], ["phosphoramidate side chain", "PROTEIN", 107, 133], ["an adenine analogue (base", "TREATMENT", 57, 82], ["a pentose unit", "TREATMENT", 85, 99], ["a phosphoramidate side chain", "TREATMENT", 105, 133], ["fragments", "OBSERVATION_MODIFIER", 46, 55]]], ["A key challenge in the preparation of this C-nucleoside analogue is the coupling of the ribose and base moieties.", [["C-nucleoside", "CHEMICAL", 43, 55], ["ribose", "CHEMICAL", 88, 94], ["C-nucleoside", "CHEMICAL", 43, 55], ["ribose", "CHEMICAL", 88, 94], ["C-nucleoside", "SIMPLE_CHEMICAL", 43, 55], ["ribose", "SIMPLE_CHEMICAL", 88, 94], ["base moieties", "SIMPLE_CHEMICAL", 99, 112], ["this C-nucleoside analogue", "TREATMENT", 38, 64], ["the ribose and base moieties", "TREATMENT", 84, 112], ["base", "ANATOMY_MODIFIER", 99, 103]]], ["Previously, two-generation syntheses of remdesivir, including three different methods for accessing ribofuranoside 4, have been developed by chemists at Gilead Sciences (2 + 3 to 4; Figure 2 ).", [["remdesivir", "CHEMICAL", 40, 50], ["ribofuranoside", "CHEMICAL", 100, 114], ["remdesivir", "CHEMICAL", 40, 50], ["ribofuranoside", "CHEMICAL", 100, 114], ["remdesivir", "SIMPLE_CHEMICAL", 40, 50], ["ribofuranoside 4", "SIMPLE_CHEMICAL", 100, 116], ["remdesivir", "TREATMENT", 40, 50], ["accessing ribofuranoside", "TREATMENT", 90, 114]]], ["11,12,24\u221227 Temporary silyl protection of the free primary amine group in the base fragment 2 was required in the addition reaction between 2 and 3.", [["11,12,24\u221227", "CHEMICAL", 0, 11], ["silyl", "CHEMICAL", 22, 27], ["amine", "CHEMICAL", 59, 64], ["silyl", "CHEMICAL", 22, 27], ["primary amine", "CHEMICAL", 51, 64], ["silyl", "SIMPLE_CHEMICAL", 22, 27], ["amine", "SIMPLE_CHEMICAL", 59, 64], ["Temporary silyl protection", "TREATMENT", 12, 38], ["the free primary amine group in the base fragment", "TREATMENT", 42, 91], ["free", "OBSERVATION_MODIFIER", 46, 50], ["primary", "OBSERVATION_MODIFIER", 51, 58], ["amine group", "OBSERVATION", 59, 70], ["base", "ANATOMY_MODIFIER", 78, 82], ["fragment", "OBSERVATION_MODIFIER", 83, 91]]], ["Two silyl reagents (i.e., trimethylchlorosilane and 1,1,4,4-tetramethyl-1,4-dichloro disilethylene (5)) were employed to generate the corresponding protected intermediates 6 and 7, 28 respectively.", [["silyl", "CHEMICAL", 4, 9], ["trimethylchlorosilane", "CHEMICAL", 26, 47], ["1,1,4,4-tetramethyl-1,4-dichloro disilethylene", "CHEMICAL", 52, 98], ["silyl", "CHEMICAL", 4, 9], ["trimethylchlorosilane", "CHEMICAL", 26, 47], ["1,1,4,4-tetramethyl-1,4-dichloro disilethylene", "CHEMICAL", 52, 98], ["silyl reagents", "SIMPLE_CHEMICAL", 4, 18], ["trimethylchlorosilane", "SIMPLE_CHEMICAL", 26, 47], ["1,1,4,4-tetramethyl-1,4-dichloro disilethylene (5)", "SIMPLE_CHEMICAL", 52, 102], ["Two silyl reagents", "TREATMENT", 0, 18], ["trimethylchlorosilane", "TREATMENT", 26, 47], ["tetramethyl", "TREATMENT", 60, 71], ["dichloro disilethylene", "TREATMENT", 76, 98]]], ["In the first generation synthesis, subjection of bromide 2a and ribolactone 3 to the conditions of TMSCl and n-BuLi at \u221278\u00b0C furnished the desired C-glycosylation product 4 in a low yield of 25% (method A; Figure 2 ).", [["bromide 2a", "CHEMICAL", 49, 59], ["ribolactone", "CHEMICAL", 64, 75], ["TMSCl", "CHEMICAL", 99, 104], ["bromide", "CHEMICAL", 49, 56], ["ribolactone 3", "CHEMICAL", 64, 77], ["TMSCl", "CHEMICAL", 99, 104], ["n-BuLi", "CHEMICAL", 109, 115], ["C", "CHEMICAL", 147, 148], ["bromide 2a", "SIMPLE_CHEMICAL", 49, 59], ["ribolactone 3", "SIMPLE_CHEMICAL", 64, 77], ["TMSCl", "SIMPLE_CHEMICAL", 99, 104], ["n-BuLi", "SIMPLE_CHEMICAL", 109, 115], ["C", "SIMPLE_CHEMICAL", 123, 124], ["C-glycosylation product 4", "PROTEIN", 147, 172], ["bromide 2a", "TREATMENT", 49, 59], ["ribolactone", "TREATMENT", 64, 75], ["the desired C-glycosylation product", "TREATMENT", 135, 170]]], ["24, 25 Alternatively, the use of disilane 5 and NaH in this transformation could deliver 4 in a reported yield of 60% on 4.4 g scale (method B; Figure 2 ).", [["disilane 5", "CHEMICAL", 33, 43], ["NaH", "CHEMICAL", 48, 51], ["disilane", "CHEMICAL", 33, 41], ["NaH", "CHEMICAL", 48, 51], ["disilane 5", "SIMPLE_CHEMICAL", 33, 43], ["NaH", "SIMPLE_CHEMICAL", 48, 51], ["disilane", "TREATMENT", 33, 41]]], ["12, 26, 27 The authors of the original studies added that \"the ef f iciency of both conditions (in the first generation synthesis) was suboptimal as the yields were capricious and highly dependent on the cryogenic temperatures and the rate of n-BuLi addition required for the transformation\".", [["n-BuLi", "GENE_OR_GENE_PRODUCT", 243, 249], ["the original studies", "TEST", 26, 46], ["both conditions", "PROBLEM", 79, 94], ["the cryogenic temperatures", "PROBLEM", 200, 226]]], ["12 In the second generation synthesis (method C; Figure 3 ), iodide 2b was employed as the source of the base unit, with a combination of TMSCl, PhMgCl, and i-PrMgCl\u00b7 LiCl reagents, which resulted in a 40% yield of 4.", [["iodide 2b", "CHEMICAL", 61, 70], ["TMSCl", "CHEMICAL", 138, 143], ["PhMgCl", "CHEMICAL", 145, 151], ["i-PrMgCl\u00b7 LiCl", "CHEMICAL", 157, 171], ["iodide", "CHEMICAL", 61, 67], ["TMSCl", "CHEMICAL", 138, 143], ["PhMgCl", "CHEMICAL", 145, 151], ["i-PrMgCl\u00b7", "CHEMICAL", 157, 166], ["LiCl", "CHEMICAL", 167, 171], ["iodide 2b", "SIMPLE_CHEMICAL", 61, 70], ["TMSCl", "SIMPLE_CHEMICAL", 138, 143], ["PhMgCl", "SIMPLE_CHEMICAL", 145, 151], ["i-PrMgCl\u00b7 LiCl reagents", "SIMPLE_CHEMICAL", 157, 180], ["the second generation synthesis (method C", "TREATMENT", 6, 47], ["iodide 2b", "TREATMENT", 61, 70], ["TMSCl", "TREATMENT", 138, 143], ["PhMgCl", "TREATMENT", 145, 151], ["i-PrMgCl\u00b7 LiCl reagents", "TREATMENT", 157, 180]]], ["11, 12 We attempted to reproduce these documented procedures on a decagram scale 11, 25, 26 which resulted in the isolation of 4 with yields in the range 21\u221242% (see Table S1 in the Supporting Information).", [["a decagram scale", "TEST", 64, 80]]], ["Evidently, none of the three above approaches efficiently addressed this problematic synthetic step, and the aforementioned techniques are not suitable for scale-up preparation of remdesivir.", [["remdesivir", "CHEMICAL", 180, 190], ["remdesivir", "CHEMICAL", 180, 190], ["remdesivir", "SIMPLE_CHEMICAL", 180, 190], ["remdesivir", "TREATMENT", 180, 190]]], ["Until very recently, during the course of our manuscript preparation, the Gilead scientists reported an optimization of method C for the critical Cglycosylation step, in which NdCl 3 and n-Bu 4 NCl were employed to facilitate the addition of lactone 3 with TMSprotected amine 2b (Method D; Figure 2 ).", [["NdCl", "CHEMICAL", 176, 180], ["n-Bu 4 NCl", "CHEMICAL", 187, 197], ["lactone", "CHEMICAL", 242, 249], ["TMSprotected amine", "CHEMICAL", 257, 275], ["NdCl 3", "CHEMICAL", 176, 182], ["n-Bu 4 NCl", "CHEMICAL", 187, 197], ["lactone", "CHEMICAL", 242, 249], ["TMSprotected amine", "CHEMICAL", 257, 275], ["NdCl 3", "SIMPLE_CHEMICAL", 176, 182], ["n-Bu 4 NCl", "SIMPLE_CHEMICAL", 187, 197], ["lactone 3", "SIMPLE_CHEMICAL", 242, 251], ["TMSprotected amine 2b", "SIMPLE_CHEMICAL", 257, 278], ["method C", "TREATMENT", 120, 128], ["the critical Cglycosylation step", "TREATMENT", 133, 165], ["lactone", "TREATMENT", 242, 249], ["TMSprotected amine", "TREATMENT", 257, 275]]], ["29 The 282 kg scaleup synthesis of compound 4 with a 69% yield proved the reliability of this method.", [["this method", "TREATMENT", 89, 100]]], ["In this report, we describe an alternative improvement for the C-glycosylation step, which renders the synthesis of remdesivir simple and efficient, with the aim of meeting the demand for its large-scale synthesis.\u25a0 RESULTS AND DISCUSSIONEfficient protection of the free amine group in 2 would be essential for the successful addition reaction of base 2 to lactone 3.", [["remdesivir", "CHEMICAL", 116, 126], ["amine", "CHEMICAL", 271, 276], ["lactone", "CHEMICAL", 357, 364], ["C", "CHEMICAL", 63, 64], ["remdesivir", "CHEMICAL", 116, 126], ["amine", "CHEMICAL", 271, 276], ["lactone", "CHEMICAL", 357, 364], ["remdesivir", "SIMPLE_CHEMICAL", 116, 126], ["free amine", "SIMPLE_CHEMICAL", 266, 276], ["lactone 3", "SIMPLE_CHEMICAL", 357, 366], ["the C-glycosylation step", "TREATMENT", 59, 83], ["the demand", "TREATMENT", 173, 183], ["its large-scale synthesis", "TREATMENT", 188, 213], ["the free amine group", "TREATMENT", 262, 282], ["the successful addition reaction of base 2 to lactone", "TREATMENT", 311, 364]]], ["We envisioned that the addition of a secondary amine might be helpful for improving the reaction efficiency ( Figure 3 ).", [["amine", "CHEMICAL", 47, 52], ["secondary amine", "CHEMICAL", 37, 52], ["amine", "SIMPLE_CHEMICAL", 47, 52], ["a secondary amine", "TREATMENT", 35, 52], ["the reaction efficiency", "PROBLEM", 84, 107]]], ["First, the secondary amine could serve to activate disilane 5 through the formation of a disilyl substituted cyclic quaternary amine salt 8, 30 thereby promoting the exchange of the silyl groups between the inactive primary amine in 2 and the secondary amine to form cyclic disilazane 7.", [["amine", "CHEMICAL", 21, 26], ["disilane 5", "CHEMICAL", 51, 61], ["disilyl", "CHEMICAL", 89, 96], ["amine salt", "CHEMICAL", 127, 137], ["silyl", "CHEMICAL", 182, 187], ["amine", "CHEMICAL", 224, 229], ["amine", "CHEMICAL", 253, 258], ["cyclic disilazane", "CHEMICAL", 267, 284], ["amine", "CHEMICAL", 21, 26], ["disilane", "CHEMICAL", 51, 59], ["disilyl", "CHEMICAL", 89, 96], ["cyclic quaternary amine", "CHEMICAL", 109, 132], ["silyl", "CHEMICAL", 182, 187], ["primary amine", "CHEMICAL", 216, 229], ["secondary amine", "CHEMICAL", 243, 258], ["cyclic disilazane", "CHEMICAL", 267, 284], ["amine", "SIMPLE_CHEMICAL", 21, 26], ["disilane 5", "SIMPLE_CHEMICAL", 51, 61], ["disilyl substituted cyclic quaternary amine salt 8, 30", "SIMPLE_CHEMICAL", 89, 143], ["silyl", "SIMPLE_CHEMICAL", 182, 187], ["amine", "SIMPLE_CHEMICAL", 224, 229], ["amine", "SIMPLE_CHEMICAL", 253, 258], ["cyclic disilazane 7", "SIMPLE_CHEMICAL", 267, 286], ["a disilyl substituted cyclic quaternary amine salt", "TREATMENT", 87, 137], ["the silyl groups", "TREATMENT", 178, 194], ["the inactive primary amine", "TREATMENT", 203, 229], ["the secondary amine", "TREATMENT", 239, 258], ["cyclic disilazane", "TREATMENT", 267, 284]]], ["Second, a stabilized lithium intermediate 9 could be formed in the presence of the secondary amine after lithium\u2212halogen exchange with 7, which would subsequently facilitate the addition of the base motif to lactone 3 to yield the desired ribofuranoside 4.\u25a0 RESULTS AND DISCUSSIONWith the above working hypothesis in mind, we initiated our studies by performing the reactions with bromide 2a (1.0 g scale) and lactone 3 employing disilane 5 in the presence of n-BuLi with various secondary amines (Table 1) .", [["lithium", "CHEMICAL", 21, 28], ["amine", "CHEMICAL", 93, 98], ["lithium\u2212halogen", "CHEMICAL", 105, 120], ["lactone", "CHEMICAL", 208, 215], ["bromide 2a", "CHEMICAL", 381, 391], ["lactone", "CHEMICAL", 410, 417], ["disilane 5", "CHEMICAL", 430, 440], ["n-BuLi", "CHEMICAL", 460, 466], ["amines", "CHEMICAL", 490, 496], ["lithium", "CHEMICAL", 21, 28], ["secondary amine", "CHEMICAL", 83, 98], ["lithium\u2212halogen", "CHEMICAL", 105, 120], ["lactone", "CHEMICAL", 208, 215], ["ribofuranoside", "CHEMICAL", 239, 253], ["bromide", "CHEMICAL", 381, 388], ["lactone", "CHEMICAL", 410, 417], ["disilane", "CHEMICAL", 430, 438], ["n-BuLi", "CHEMICAL", 460, 466], ["secondary amines", "CHEMICAL", 480, 496], ["lithium", "SIMPLE_CHEMICAL", 21, 28], ["amine", "SIMPLE_CHEMICAL", 93, 98], ["lithium\u2212halogen", "SIMPLE_CHEMICAL", 105, 120], ["lactone 3", "SIMPLE_CHEMICAL", 208, 217], ["ribofuranoside 4", "SIMPLE_CHEMICAL", 239, 255], ["bromide 2a", "SIMPLE_CHEMICAL", 381, 391], ["lactone 3", "SIMPLE_CHEMICAL", 410, 419], ["disilane 5", "SIMPLE_CHEMICAL", 430, 440], ["n-BuLi", "SIMPLE_CHEMICAL", 460, 466], ["a stabilized lithium intermediate", "TREATMENT", 8, 41], ["lithium\u2212halogen exchange", "TREATMENT", 105, 129], ["lactone", "TREATMENT", 208, 215], ["the desired ribofuranoside", "TREATMENT", 227, 253], ["our studies", "TEST", 336, 347], ["bromide 2a", "TREATMENT", 381, 391], ["lactone", "TREATMENT", 410, 417]]], ["When secondary amines bearing two linear alkyl groups (such as diethylamine, dipropylamine, and dibutylamine) were used, the addition reactions proceeded to afford 4 in moderate yields (41\u221254%, entries 1\u22123).", [["amines", "CHEMICAL", 15, 21], ["alkyl", "CHEMICAL", 41, 46], ["diethylamine", "CHEMICAL", 63, 75], ["dipropylamine", "CHEMICAL", 77, 90], ["dibutylamine", "CHEMICAL", 96, 108], ["secondary amines", "CHEMICAL", 5, 21], ["diethylamine", "CHEMICAL", 63, 75], ["dipropylamine", "CHEMICAL", 77, 90], ["dibutylamine", "CHEMICAL", 96, 108], ["amines", "SIMPLE_CHEMICAL", 15, 21], ["diethylamine", "SIMPLE_CHEMICAL", 63, 75], ["dipropylamine", "SIMPLE_CHEMICAL", 77, 90], ["dibutylamine", "SIMPLE_CHEMICAL", 96, 108], ["secondary amines bearing two linear alkyl groups", "TREATMENT", 5, 53], ["diethylamine", "TREATMENT", 63, 75], ["dipropylamine", "TREATMENT", 77, 90], ["dibutylamine", "TREATMENT", 96, 108], ["linear", "OBSERVATION_MODIFIER", 34, 40], ["alkyl groups", "OBSERVATION", 41, 53]]], ["To our delight, bulkier alkyl substituents in the secondary amine were beneficial for improving the reaction efficiency.", [["alkyl substituents", "CHEMICAL", 24, 42], ["amine", "CHEMICAL", 60, 65], ["secondary amine", "CHEMICAL", 50, 65], ["bulkier alkyl substituents", "SIMPLE_CHEMICAL", 16, 42], ["secondary amine", "SIMPLE_CHEMICAL", 50, 65], ["bulkier alkyl substituents", "TREATMENT", 16, 42], ["the secondary amine", "TREATMENT", 46, 65], ["the reaction efficiency", "PROBLEM", 96, 119], ["alkyl substituents", "OBSERVATION", 24, 42], ["reaction efficiency", "OBSERVATION", 100, 119]]], ["As a result, conducting the reaction in the presence of diisopropylamine led to the generation of 4 in 74% yield (entry 4).", [["diisopropylamine", "CHEMICAL", 56, 72], ["diisopropylamine", "CHEMICAL", 56, 72], ["diisopropylamine", "SIMPLE_CHEMICAL", 56, 72], ["the reaction", "PROBLEM", 24, 36], ["diisopropylamine", "TREATMENT", 56, 72]]], ["Notably, similar results were obtained with other bulky secondary amines: diisobutylamine (71%, entry 5), dicyclohexylamine (70%, entry 6), and 2,2,6,6-tetramethylpiperidine (74%, entry 7).", [["amines", "CHEMICAL", 66, 72], ["diisobutylamine", "CHEMICAL", 74, 89], ["dicyclohexylamine", "CHEMICAL", 106, 123], ["2,2,6,6-tetramethylpiperidine", "CHEMICAL", 144, 173], ["secondary amines", "CHEMICAL", 56, 72], ["diisobutylamine", "CHEMICAL", 74, 89], ["dicyclohexylamine", "CHEMICAL", 106, 123], ["2,2,6,6-tetramethylpiperidine", "CHEMICAL", 144, 173], ["diisobutylamine", "SIMPLE_CHEMICAL", 74, 89], ["dicyclohexylamine", "SIMPLE_CHEMICAL", 106, 123], ["2,2,6,6-tetramethylpiperidine", "SIMPLE_CHEMICAL", 144, 173], ["diisobutylamine", "TREATMENT", 74, 89], ["dicyclohexylamine", "TREATMENT", 106, 123], ["tetramethylpiperidine", "TREATMENT", 152, 173]]], ["For the purposes of comparison, the use of tertiary amines was likewise evaluated.", [["amines", "CHEMICAL", 52, 58], ["tertiary amines", "CHEMICAL", 43, 58], ["tertiary amines", "SIMPLE_CHEMICAL", 43, 58], ["tertiary amines", "TREATMENT", 43, 58]]], ["For instance, we performed the addition reaction of 2a and 3 under the identical conditions of entry 4, except for the replacement of diisopropylamine with diisopropylethylamine, which resulted in a lower yield (49%, entry 8) of product 4.\u25a0 RESULTS AND DISCUSSIONBased on the above preliminary results, we then carried out scale-up experiments employing diisopropylamine as an additive (Table 2) .", [["diisopropylamine", "CHEMICAL", 134, 150], ["diisopropylethylamine", "CHEMICAL", 156, 177], ["diisopropylamine", "CHEMICAL", 354, 370], ["diisopropylamine", "CHEMICAL", 134, 150], ["diisopropylethylamine", "CHEMICAL", 156, 177], ["diisopropylamine", "CHEMICAL", 354, 370], ["diisopropylamine", "SIMPLE_CHEMICAL", 134, 150], ["diisopropylethylamine", "SIMPLE_CHEMICAL", 156, 177], ["diisopropylamine", "SIMPLE_CHEMICAL", 354, 370], ["the replacement of diisopropylamine", "TREATMENT", 115, 150], ["diisopropylethylamine", "TREATMENT", 156, 177], ["diisopropylamine", "TREATMENT", 354, 370]]], ["A 10-g-scale addition of 2a to lactone 3 was performed according to the conditions described in Table 1 , leading to the generation of adduct 4 in 75% yield (entry 1).", [["2a to lactone", "CHEMICAL", 25, 38], ["adduct 4", "CHEMICAL", 135, 143], ["lactone", "CHEMICAL", 31, 38], ["lactone 3", "SIMPLE_CHEMICAL", 31, 40], ["2a to lactone", "TREATMENT", 25, 38]]], ["To further improve the practicality of the addition process, we sought to reduce the amount of solvent and increase the reaction concentration.", [["the reaction concentration", "PROBLEM", 116, 142], ["amount", "OBSERVATION_MODIFIER", 85, 91], ["reaction concentration", "OBSERVATION", 120, 142]]], ["Specifically, a 74% yield was observed when conducting the reaction at the concentration of 0.20 mol/L (entry 2), comparable to that of 0.08 mol/L (entry 1), while the reaction at 0.25 mol/L led to a slightly diminished yield (70%, entry 3).", [["the reaction", "PROBLEM", 55, 67], ["the reaction", "PROBLEM", 164, 176], ["a slightly diminished yield", "PROBLEM", 198, 225], ["slightly", "OBSERVATION_MODIFIER", 200, 208], ["diminished", "OBSERVATION", 209, 219]]], ["Moreover, the effect of the equivalents of lactone 3 was investigated.", [["lactone", "CHEMICAL", 43, 50], ["lactone 3", "CHEMICAL", 43, 52], ["lactone 3", "SIMPLE_CHEMICAL", 43, 52], ["the equivalents of lactone", "TREATMENT", 24, 50]]], ["Lowering the loading of 3 delivered inferior results (i.e., 1.8 equiv, 62%, entry 4; 1.6 equiv, 59%, entry 5) compared to that obtained with 2.0 equiv of 3.", [["entry", "TEST", 76, 81]]], ["With the optimized reaction conditions (entry 2), a 180-g-scale experiment was conducted, which proceeded smoothly to provide 4 with a 62% yield and 99.3% purity after recrystallization without the need for column chromatographic operations (entry 6).\u25a0 CONCLUSIONIn summary, the crucial C-glycosylation step that ordinarily limits the overall efficiency of remdesivir synthesis has been significantly improved by the use of a cost-effective secondary amine, diisopropylamine.", [["remdesivir", "CHEMICAL", 357, 367], ["amine", "CHEMICAL", 451, 456], ["diisopropylamine", "CHEMICAL", 458, 474], ["C", "CHEMICAL", 287, 288], ["remdesivir", "CHEMICAL", 357, 367], ["secondary amine", "CHEMICAL", 441, 456], ["diisopropylamine", "CHEMICAL", 458, 474], ["remdesivir", "SIMPLE_CHEMICAL", 357, 367], ["amine", "SIMPLE_CHEMICAL", 451, 456], ["diisopropylamine", "SIMPLE_CHEMICAL", 458, 474], ["a 180-g-scale experiment", "TREATMENT", 50, 74], ["recrystallization", "TREATMENT", 168, 185], ["column chromatographic operations", "TREATMENT", 207, 240], ["remdesivir synthesis", "PROBLEM", 357, 377], ["a cost-effective secondary amine", "TREATMENT", 424, 456], ["diisopropylamine", "TREATMENT", 458, 474]]], ["Thus, subjecting the base unit 2a and ribolactone 3 to the optimal reaction conditions delivered up to a 75% yield of the anticipated ribofuranoside 4, which, to the best of our knowledge, represents the highest yield obtained for this critical transformation thus far.", [["ribolactone", "CHEMICAL", 38, 49], ["ribofuranoside", "CHEMICAL", 134, 148], ["ribolactone 3", "CHEMICAL", 38, 51], ["ribofuranoside", "CHEMICAL", 134, 148], ["ribolactone 3", "GENE_OR_GENE_PRODUCT", 38, 51], ["ribofuranoside 4", "SIMPLE_CHEMICAL", 134, 150], ["the base unit 2a", "TREATMENT", 17, 33], ["ribolactone", "TREATMENT", 38, 49], ["the anticipated ribofuranoside 4", "TREATMENT", 118, 150], ["this critical transformation", "PROBLEM", 231, 259]]], ["Furthermore, the procedure is amenable to hectogram scale synthesis without column chromatographic operations, and as such would be highly advantageous for the large-scale manufacture of the antiviral, remdesivir.\u25a0 EXPERIMENTAL DETAILSGeneral Information.", [["remdesivir", "CHEMICAL", 202, 212], ["remdesivir", "SIMPLE_CHEMICAL", 202, 212], ["the procedure", "TREATMENT", 13, 26], ["hectogram scale synthesis", "TREATMENT", 42, 67], ["column chromatographic operations", "TREATMENT", 76, 109], ["the large-scale manufacture", "TREATMENT", 156, 183], ["the antiviral", "TREATMENT", 187, 200], ["remdesivir", "TREATMENT", 202, 212]]], ["All reagents were purchased from commercial suppliers and were used without further purification.", [["All reagents", "TREATMENT", 0, 12], ["further purification", "TREATMENT", 76, 96]]], ["The product of the decagram scale synthesis was purified by flash column chromatography on silica gel (200\u2212 300 meshes) from the Anhui Liangchen Silicon Material Company in China.", [["silica gel", "CHEMICAL", 91, 101], ["silica gel", "CHEMICAL", 91, 101], ["the decagram scale synthesis", "TREATMENT", 15, 43], ["flash column chromatography", "PROBLEM", 60, 87], ["silica gel", "TREATMENT", 91, 101], ["the Anhui Liangchen Silicon Material", "TREATMENT", 125, 161]]], ["1 H NMR and 13 C NMR spectra were recorded on Varian INOVA-400/54, Agilent DD2\u2212600/54 and calibrated by using deuterated dimethyl sulfoxide (DMSOd 6 , 1 H NMR: \u03b4 = 2.50, 13 C NMR: \u03b4 = 39.5) unless otherwise noted.", [["DD2\u2212600/54", "CHEMICAL", 75, 85], ["deuterated dimethyl sulfoxide", "CHEMICAL", 110, 139], ["1 H", "CHEMICAL", 0, 3], ["C", "CHEMICAL", 15, 16], ["dimethyl sulfoxide", "CHEMICAL", 121, 139], ["DMSOd", "CHEMICAL", 141, 146], ["H", "CHEMICAL", 153, 154], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 121, 139], ["NMR spectra", "TEST", 17, 28], ["Varian INOVA", "TEST", 46, 58], ["deuterated dimethyl sulfoxide", "TREATMENT", 110, 139], ["NMR", "TEST", 155, 158], ["C NMR", "TEST", 173, 178], ["\u03b4", "TEST", 180, 181]]], ["High-resolution mass spectra (HRMS) were recorded on Agilent LC-MSD TOF ESI mass spectrometers.\u25a0 EXPERIMENTAL DETAILSGeneral Procedure for Synthesis of Compound 4 by Using Different Amines.", [["Amines", "SIMPLE_CHEMICAL", 182, 188], ["High-resolution mass spectra (HRMS)", "PROBLEM", 0, 35], ["Agilent LC", "TEST", 53, 63], ["EXPERIMENTAL DETAILSGeneral Procedure", "TREATMENT", 97, 134], ["Synthesis of Compound", "TREATMENT", 139, 160], ["resolution", "OBSERVATION_MODIFIER", 5, 15], ["mass", "OBSERVATION", 16, 20]]], ["To an oven-dried round-bottom flask equipped with a stir bar was added 7-bromopyrrolo[2,1f ][1,2,4]triazin-4-amine (2a, 1.00 g, 4.694 mmol, 1.0 equiv).", [["7-bromopyrrolo[2,1f ][1,2,4]triazin-4-amine", "CHEMICAL", 71, 114], ["7-bromopyrrolo[2,1f ][1,2,4]triazin-4-amine", "CHEMICAL", 71, 114], ["7-bromopyrrolo[2,1f ][1,2,4]triazin-4-amine", "SIMPLE_CHEMICAL", 71, 114], ["bottom flask", "TREATMENT", 23, 35], ["a stir bar", "TREATMENT", 50, 60], ["triazin", "TREATMENT", 99, 106]]], ["The flask was evacuated and backfilled with argon three times.", [["The flask", "TREATMENT", 0, 9], ["argon", "TREATMENT", 44, 49], ["flask", "OBSERVATION", 4, 9]]], ["Under the protection of argon, anhydrous THF (40 mL) was added and the mixture was stirred at room temperature for 5 min before a solution of 1,2-bis(chlorodimethylsilyl) ethane (5, 1.111 g, 5.163 mmol, 1.1 equiv) in anhydrous tetrahydrofuran (5 mL) was added.", [["anhydrous THF", "CHEMICAL", 31, 44], ["1,2-bis(chlorodimethylsilyl) ethane", "CHEMICAL", 142, 177], ["anhydrous tetrahydrofuran", "CHEMICAL", 217, 242], ["anhydrous THF", "CHEMICAL", 31, 44], ["1,2-bis(chlorodimethylsilyl) ethane", "CHEMICAL", 142, 177], ["anhydrous tetrahydrofuran", "CHEMICAL", 217, 242], ["argon", "SIMPLE_CHEMICAL", 24, 29], ["anhydrous THF", "SIMPLE_CHEMICAL", 31, 44], ["1,2-bis(chlorodimethylsilyl) ethane", "SIMPLE_CHEMICAL", 142, 177], ["anhydrous tetrahydrofuran", "SIMPLE_CHEMICAL", 217, 242], ["argon, anhydrous THF", "TREATMENT", 24, 44], ["a solution of 1,2-bis(chlorodimethylsilyl) ethane", "TREATMENT", 128, 177], ["anhydrous tetrahydrofuran", "TREATMENT", 217, 242]]], ["The resulting mixture was stirred for 10 min.", [["mixture", "OBSERVATION_MODIFIER", 14, 21]]], ["Then amine (5.163 mmol, 1.1 equiv) was added.", [["amine", "CHEMICAL", 5, 10], ["amine", "CHEMICAL", 5, 10], ["amine", "SIMPLE_CHEMICAL", 5, 10]]], ["At this point, n-BuLi (2.5 M in n-hexane, 8.1 mL, 20.18 mmol, 4.3 equiv) was added dropwise over 30 min through a syringe to the mixture and the reaction was allowed to stir at \u221278\u00b0C for additional 15 min.", [["BuLi", "CHEMICAL", 17, 21], ["n-hexane", "CHEMICAL", 32, 40], ["n-hexane", "CHEMICAL", 32, 40], ["n-BuLi", "SIMPLE_CHEMICAL", 15, 21], ["n-hexane", "SIMPLE_CHEMICAL", 32, 40], ["n-BuLi", "TREATMENT", 15, 21], ["n-hexane", "TREATMENT", 32, 40], ["a syringe to the mixture", "TREATMENT", 112, 136], ["the reaction", "PROBLEM", 141, 153]]], ["Next, a solution of lactone 3 (3.930 g, 9.388 mmol, 2.0 equiv) in anhydrous THF (5 mL) was added dropwise over 10 min under the argon atmosphere through a syringe.", [["lactone", "CHEMICAL", 20, 27], ["anhydrous THF", "CHEMICAL", 66, 79], ["lactone 3", "CHEMICAL", 20, 29], ["anhydrous THF", "CHEMICAL", 66, 79], ["lactone 3", "SIMPLE_CHEMICAL", 20, 29], ["anhydrous THF", "SIMPLE_CHEMICAL", 66, 79], ["a solution of lactone", "TREATMENT", 6, 27], ["anhydrous THF", "TREATMENT", 66, 79], ["a syringe", "TREATMENT", 153, 162]]], ["After the reaction was stirred at \u221278\u00b0C for 2 h, it was allowed to warm slowly to 0 to 10\u00b0C. The reaction was quenched by adding 1 M citric acid (50 mL) and stirred vigorously for 15 min.", [["citric acid", "CHEMICAL", 133, 144], ["citric acid", "CHEMICAL", 133, 144], ["citric acid", "SIMPLE_CHEMICAL", 133, 144], ["the reaction", "PROBLEM", 6, 18], ["The reaction", "PROBLEM", 93, 105], ["1 M citric acid", "TREATMENT", 129, 144]]], ["Then the layers were separated, and the aqueous layer was extracted with EtOAc (3 \u00d7 30 mL).", [["aqueous layer", "ANATOMY", 40, 53], ["EtOAc", "CHEMICAL", 73, 78], ["layers", "TISSUE", 9, 15], ["aqueous layer", "ORGANISM_SUBSTANCE", 40, 53], ["EtOAc", "SIMPLE_CHEMICAL", 73, 78], ["EtOAc", "TREATMENT", 73, 78], ["layers", "OBSERVATION_MODIFIER", 9, 15], ["aqueous", "OBSERVATION_MODIFIER", 40, 47], ["layer", "OBSERVATION_MODIFIER", 48, 53]]], ["The organic layers were combined and washed sequentially with water (1 \u00d7 50 mL), saturated aqueous NaHCO 3 (1 \u00d7 50 mL), and brine (1 \u00d7 50 mL).", [["NaHCO", "CHEMICAL", 99, 104], ["NaHCO 3", "CHEMICAL", 99, 106], ["The organic layers", "TREATMENT", 0, 18], ["saturated aqueous NaHCO", "TREATMENT", 81, 104], ["organic", "OBSERVATION_MODIFIER", 4, 11], ["layers", "OBSERVATION_MODIFIER", 12, 18]]], ["The organic phase was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure.", [["magnesium sulfate", "CHEMICAL", 43, 60], ["magnesium sulfate", "CHEMICAL", 43, 60], ["magnesium sulfate", "SIMPLE_CHEMICAL", 43, 60], ["anhydrous magnesium sulfate", "TREATMENT", 33, 60], ["organic phase", "OBSERVATION_MODIFIER", 4, 17], ["reduced pressure", "OBSERVATION", 95, 111]]], ["The residue was subjected to silica gel column chromatography (50% EtOAc in petroleum ether to 100% EtOAc to 10% MeOH in EtOAc) to give 4 as a white foam.\u25a0 EXPERIMENTAL DETAILSDecagram Scale Synthesis of Compound 4 under the Optimized Reaction Conditions.", [["silica gel", "CHEMICAL", 29, 39], ["petroleum ether", "CHEMICAL", 76, 91], ["MeOH", "CHEMICAL", 113, 117], ["silica gel", "CHEMICAL", 29, 39], ["EtOAc", "CHEMICAL", 67, 72], ["petroleum ether", "CHEMICAL", 76, 91], ["EtOAc", "CHEMICAL", 100, 105], ["MeOH", "CHEMICAL", 113, 117], ["EtOAc", "CHEMICAL", 121, 126], ["silica", "SIMPLE_CHEMICAL", 29, 35], ["MeOH", "SIMPLE_CHEMICAL", 113, 117], ["EtOAc", "SIMPLE_CHEMICAL", 121, 126], ["The residue", "PROBLEM", 0, 11], ["silica gel column chromatography", "TEST", 29, 61], ["a white foam", "TREATMENT", 141, 153]]], ["An oven-dried three-neck round-bottom flask equipped with a stir bar and an additional funnel was charged with 7-bromopyrrolo[2,1-f ] [1, 2, 4] triazin-4-amine (2a, 10.0 g, 46.94 mmol, 1.0 equiv).", [["7-bromopyrrolo[2,1-f ] [1, 2, 4] triazin-4-amine", "CHEMICAL", 111, 159], ["7-bromopyrrolo[2,1-f ] [1, 2, 4] triazin-4-amine", "CHEMICAL", 111, 159], ["7-bromopyrrolo[2,1-f ] [1, 2, 4] triazin-4-amine", "SIMPLE_CHEMICAL", 111, 159], ["An oven-dried three-neck round-bottom flask", "TREATMENT", 0, 43], ["a stir bar", "TREATMENT", 58, 68], ["an additional funnel", "TREATMENT", 73, 93], ["triazin", "TEST", 144, 151], ["neck", "ANATOMY", 20, 24]]], ["The above flask was evacuated and backfilled with argon three times.", [["The above flask", "TREATMENT", 0, 15], ["argon", "TREATMENT", 50, 55], ["above flask", "OBSERVATION", 4, 15]]], ["Under the protection of argon, anhydrous THF (80 mL) was added and the mixture was stirred at room temperature for 5 min before a solution of 1,2-bis(chlorodimethylsilyl) ethane (5, 11.1 g, 51.63 mmol, 1.1 equiv) in anhydrous tetrahydrofuran (20 mL) was added.", [["anhydrous THF", "CHEMICAL", 31, 44], ["1,2-bis(chlorodimethylsilyl) ethane", "CHEMICAL", 142, 177], ["anhydrous tetrahydrofuran", "CHEMICAL", 216, 241], ["anhydrous THF", "CHEMICAL", 31, 44], ["1,2-bis(chlorodimethylsilyl) ethane", "CHEMICAL", 142, 177], ["anhydrous tetrahydrofuran", "CHEMICAL", 216, 241], ["argon", "SIMPLE_CHEMICAL", 24, 29], ["anhydrous THF", "SIMPLE_CHEMICAL", 31, 44], ["1,2-bis(chlorodimethylsilyl) ethane", "SIMPLE_CHEMICAL", 142, 177], ["anhydrous tetrahydrofuran", "SIMPLE_CHEMICAL", 216, 241], ["argon, anhydrous THF", "TREATMENT", 24, 44], ["a solution of 1,2-bis(chlorodimethylsilyl) ethane", "TREATMENT", 128, 177], ["anhydrous tetrahydrofuran", "TREATMENT", 216, 241]]], ["The resulting mixture was stirred for 10 min.", [["mixture", "OBSERVATION_MODIFIER", 14, 21]]], ["Then diisopropylamine (7.3 mL, 51.63 mmol, 1.1 equiv) was added.", [["diisopropylamine", "CHEMICAL", 5, 21], ["diisopropylamine", "CHEMICAL", 5, 21], ["diisopropylamine", "SIMPLE_CHEMICAL", 5, 21], ["diisopropylamine", "TREATMENT", 5, 21]]], ["At this point, n-BuLi (2.5 M in n-hexane, 81 mL, 201.8 mmol, 4.3 equiv) was added dropwise over 45 min through the additional funnel to the mixture.", [["BuLi", "CHEMICAL", 17, 21], ["n-hexane", "CHEMICAL", 32, 40], ["n-hexane", "CHEMICAL", 32, 40], ["n-BuLi", "SIMPLE_CHEMICAL", 15, 21], ["n-hexane", "SIMPLE_CHEMICAL", 32, 40], ["n-BuLi", "TREATMENT", 15, 21]]], ["Note: the dropwise addition of n-BuLi is essential for this exothermic step.", [["n-BuLi", "CHEMICAL", 31, 37], ["n-BuLi", "CHEMICAL", 31, 37], ["n-BuLi", "SIMPLE_CHEMICAL", 31, 37], ["n-BuLi", "TREATMENT", 31, 37], ["this exothermic step", "PROBLEM", 55, 75]]], ["The addition time depends on the volume of n-BuLi, during which the reaction temperature should be kept below \u221278\u00b0C. In the decagram scale case, a 45 min period could guarantee the complete formation of lithium intermediate.", [["lithium", "CHEMICAL", 203, 210], ["n-BuLi", "CHEMICAL", 43, 49], ["lithium", "CHEMICAL", 203, 210], ["n-BuLi", "SIMPLE_CHEMICAL", 43, 49], ["lithium intermediate", "SIMPLE_CHEMICAL", 203, 223], ["the reaction temperature", "PROBLEM", 64, 88], ["lithium intermediate", "TREATMENT", 203, 223]]], ["After the additional funnel was rinsed by anhydrous THF, a solution of lactone 3 (39.3 g, 93.88 mmol, 2.0 equiv) in anhydrous THF (50 mL) was added dropwise over 20 min under the argon atmosphere, and the reaction was allowed to stir at \u221278\u00b0C for 2 h.", [["anhydrous THF", "CHEMICAL", 42, 55], ["lactone", "CHEMICAL", 71, 78], ["anhydrous THF", "CHEMICAL", 116, 129], ["anhydrous THF", "CHEMICAL", 42, 55], ["lactone 3", "CHEMICAL", 71, 80], ["anhydrous THF", "CHEMICAL", 116, 129], ["anhydrous THF", "SIMPLE_CHEMICAL", 42, 55], ["lactone 3", "SIMPLE_CHEMICAL", 71, 80], ["anhydrous THF", "SIMPLE_CHEMICAL", 116, 129], ["a solution of lactone", "TREATMENT", 57, 78], ["anhydrous THF", "TREATMENT", 116, 129], ["the argon atmosphere", "TREATMENT", 175, 195], ["the reaction", "PROBLEM", 201, 213]]], ["Then the cold bath was removed, and the mixture was slowly warmed to 0 to 10\u00b0C. The reaction was quenched by adding 1 M citric acid (200 mL) and stirred vigorously for 15 min.", [["citric acid", "CHEMICAL", 120, 131], ["citric acid", "CHEMICAL", 120, 131], ["citric acid", "SIMPLE_CHEMICAL", 120, 131], ["the cold bath", "TREATMENT", 5, 18], ["The reaction", "PROBLEM", 80, 92], ["1 M citric acid", "TREATMENT", 116, 131]]], ["Then the layers were separated, and the aqueous layer was extracted with EtOAc (3 \u00d7 200 mL).", [["aqueous layer", "ANATOMY", 40, 53], ["EtOAc", "CHEMICAL", 73, 78], ["layers", "TISSUE", 9, 15], ["aqueous layer", "ORGANISM_SUBSTANCE", 40, 53], ["EtOAc", "SIMPLE_CHEMICAL", 73, 78], ["EtOAc", "TREATMENT", 73, 78], ["layers", "OBSERVATION_MODIFIER", 9, 15], ["aqueous", "OBSERVATION_MODIFIER", 40, 47], ["layer", "OBSERVATION_MODIFIER", 48, 53]]], ["The organic layers were combined and washed sequentially with water (1 \u00d7 250 mL), saturated aqueous NaHCO 3 (1 \u00d7 250 mL), and brine (1 \u00d7 250 mL).", [["NaHCO", "CHEMICAL", 100, 105], ["NaHCO 3", "CHEMICAL", 100, 107], ["The organic layers", "TREATMENT", 0, 18], ["saturated aqueous NaHCO", "TREATMENT", 82, 105], ["organic", "OBSERVATION_MODIFIER", 4, 11], ["layers", "OBSERVATION_MODIFIER", 12, 18]]], ["The organic phase was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure.", [["magnesium sulfate", "CHEMICAL", 43, 60], ["magnesium sulfate", "CHEMICAL", 43, 60], ["magnesium sulfate", "SIMPLE_CHEMICAL", 43, 60], ["anhydrous magnesium sulfate", "TREATMENT", 33, 60], ["organic phase", "OBSERVATION_MODIFIER", 4, 17], ["reduced pressure", "OBSERVATION", 95, 111]]], ["The residue was subjected to silica gel column chromatography (50% EtOAc in petroleum ether to 100% EtOAc to 10% MeOH in EtOAc) to give the mixture of isomers 4 (19.2 g, 74%) as white foam.", [["silica gel", "CHEMICAL", 29, 39], ["petroleum ether", "CHEMICAL", 76, 91], ["MeOH", "CHEMICAL", 113, 117], ["silica gel", "CHEMICAL", 29, 39], ["EtOAc", "CHEMICAL", 67, 72], ["petroleum ether", "CHEMICAL", 76, 91], ["EtOAc", "CHEMICAL", 100, 105], ["MeOH", "CHEMICAL", 113, 117], ["EtOAc", "CHEMICAL", 121, 126], ["silica", "SIMPLE_CHEMICAL", 29, 35], ["MeOH", "SIMPLE_CHEMICAL", 113, 117], ["EtOAc", "SIMPLE_CHEMICAL", 121, 126], ["The residue", "PROBLEM", 0, 11], ["silica gel column chromatography", "TEST", 29, 61], ["white foam", "TEST", 178, 188]]], ["The analytical data were consistent with data previously reported in the literature.", [["The analytical data", "TEST", 0, 19]]], ["11 [1, 2, 4] triazin-4-amine (2a, 180.0 g, 0.845 mol, 1.0 equiv) and anhydrous THF (1.44 L) under an atmosphere of nitrogen at 20\u00b0C. The mixture was stirred for 10 min before a solution of 1,2bis(chlorodimethylsilyl) ethane (5, 200.0 g, 0.929 mol, 1.1 equiv) in anhydrous tetrahydrofuran (360 mL) was added at the same temperature.", [["11 [1, 2, 4] triazin-4-amine", "CHEMICAL", 0, 28], ["anhydrous THF", "CHEMICAL", 69, 82], ["nitrogen", "CHEMICAL", 115, 123], ["1,2bis(chlorodimethylsilyl) ethane", "CHEMICAL", 189, 223], ["anhydrous tetrahydrofuran", "CHEMICAL", 262, 287], ["11 [1, 2, 4] triazin-4-amine", "CHEMICAL", 0, 28], ["anhydrous THF", "CHEMICAL", 69, 82], ["nitrogen", "CHEMICAL", 115, 123], ["1,2bis(chlorodimethylsilyl) ethane", "CHEMICAL", 189, 223], ["anhydrous tetrahydrofuran", "CHEMICAL", 262, 287], ["11 [1, 2, 4] triazin-4-amine", "SIMPLE_CHEMICAL", 0, 28], ["anhydrous THF", "SIMPLE_CHEMICAL", 69, 82], ["1,2bis(chlorodimethylsilyl) ethane", "SIMPLE_CHEMICAL", 189, 223], ["anhydrous tetrahydrofuran", "SIMPLE_CHEMICAL", 262, 287], ["triazin", "TEST", 13, 20], ["anhydrous THF", "PROBLEM", 69, 82], ["an atmosphere of nitrogen", "TREATMENT", 98, 123], ["a solution of 1,2bis(chlorodimethylsilyl) ethane", "TREATMENT", 175, 223], ["anhydrous tetrahydrofuran", "TREATMENT", 262, 287]]], ["Then diisopropylamine (94.1 g, 131 mL, 0.929 mol, 1.1 equiv) was added.", [["diisopropylamine", "CHEMICAL", 5, 21], ["diisopropylamine", "CHEMICAL", 5, 21], ["diisopropylamine", "SIMPLE_CHEMICAL", 5, 21], ["diisopropylamine", "TREATMENT", 5, 21]]], ["After stirring for 10 min, the reaction was cooled to \u221285 to \u221278\u00b0C. At this point, n-BuLi (4, 2.5 M in nhexane, 1.45 L, 3.634 mol, 4.3 equiv) was added dropwise over 4 h while maintaining the reaction temperature below \u221278\u00b0C during the exothermic addition, and the resulting mixture was allowed to stir at \u221285 to \u221278\u00b0C for 30 min.", [["BuLi", "CHEMICAL", 85, 89], ["nhexane", "CHEMICAL", 103, 110], ["n-BuLi", "CHEMICAL", 83, 89], ["nhexane", "CHEMICAL", 103, 110], ["nhexane", "SIMPLE_CHEMICAL", 103, 110], ["C", "SIMPLE_CHEMICAL", 223, 224], ["the reaction", "PROBLEM", 27, 39], ["nhexane", "TEST", 103, 110], ["the reaction temperature", "TEST", 188, 212], ["stir", "TEST", 298, 302]]], ["Next, a solution of lactone 3 (707.2 g, 1.69 mol, 2.0 equiv) in anhydrous THF (900 mL) was added dropwise over 3 h while maintaining the temperature between \u221285 to \u221278\u00b0C. After the reaction was stirred at the same temperature for another 2 h, it was allowed to warm slowly to 0 to 10\u00b0C. The reaction was quenched by the addition of 1 M citric acid (3.6 L), and the temperature was maintained below 25\u00b0C while vigorously stirring for 10 min.", [["lactone", "CHEMICAL", 20, 27], ["anhydrous THF", "CHEMICAL", 64, 77], ["citric acid", "CHEMICAL", 336, 347], ["lactone 3", "CHEMICAL", 20, 29], ["anhydrous THF", "CHEMICAL", 64, 77], ["citric acid", "CHEMICAL", 336, 347], ["lactone 3", "SIMPLE_CHEMICAL", 20, 29], ["anhydrous THF", "SIMPLE_CHEMICAL", 64, 77], ["citric acid", "SIMPLE_CHEMICAL", 336, 347], ["a solution of lactone", "TREATMENT", 6, 27], ["anhydrous THF", "TREATMENT", 64, 77], ["the temperature", "TEST", 133, 148], ["the reaction", "PROBLEM", 177, 189], ["The reaction", "PROBLEM", 287, 299], ["1 M citric acid", "TREATMENT", 332, 347], ["the temperature", "TEST", 361, 376]]], ["Then the layers were separated, and the aqueous layer was extracted with EtOAc (3 \u00d7 3.6 L).", [["aqueous layer", "ANATOMY", 40, 53], ["EtOAc", "CHEMICAL", 73, 78], ["layers", "TISSUE", 9, 15], ["aqueous layer", "ORGANISM_SUBSTANCE", 40, 53], ["EtOAc", "SIMPLE_CHEMICAL", 73, 78], ["EtOAc", "TREATMENT", 73, 78], ["layers", "OBSERVATION_MODIFIER", 9, 15], ["aqueous", "OBSERVATION_MODIFIER", 40, 47], ["layer", "OBSERVATION_MODIFIER", 48, 53]]], ["The organic layers were combined and washed sequentially with water (1 \u00d7 3.6 L), saturated aqueous NaHCO 3 (1 \u00d7 3.6 L), and brine (1 \u00d7 3.6 L).", [["NaHCO", "CHEMICAL", 99, 104], ["NaHCO 3", "CHEMICAL", 99, 106], ["The organic layers", "TREATMENT", 0, 18], ["saturated aqueous NaHCO", "TREATMENT", 81, 104], ["organic", "OBSERVATION_MODIFIER", 4, 11], ["layers", "OBSERVATION_MODIFIER", 12, 18]]], ["The organic phase was then concentrated in vacuo at 30\u00b0C to remove the majority of organic solvents.", [["organic solvents", "TREATMENT", 83, 99], ["organic phase", "OBSERVATION_MODIFIER", 4, 17], ["organic solvents", "OBSERVATION", 83, 99]]], ["The residual solvents were removed by adding tert-butyl methyl ether (2 \u00d7 3.6 L) and evaporated at 30\u00b0C under reduced pressure.", [["tert-butyl methyl ether", "CHEMICAL", 45, 68], ["tert-butyl methyl ether", "CHEMICAL", 45, 68], ["tert-butyl methyl ether", "SIMPLE_CHEMICAL", 45, 68], ["The residual solvents", "TREATMENT", 0, 21], ["tert-butyl methyl ether", "TREATMENT", 45, 68], ["reduced pressure", "TREATMENT", 110, 126], ["residual solvents", "OBSERVATION", 4, 21], ["reduced", "OBSERVATION_MODIFIER", 110, 117], ["pressure", "OBSERVATION_MODIFIER", 118, 126]]], ["The mixture was finally concentrated in vacuo to a total batch volume of 540 mL, whereupon n-heptane (3600 mL) was added.", [["n-heptane", "CHEMICAL", 91, 100], ["n-heptane", "CHEMICAL", 91, 100], ["n-heptane", "SIMPLE_CHEMICAL", 91, 100], ["a total batch volume", "TREATMENT", 49, 69], ["n-heptane", "TREATMENT", 91, 100]]], ["The resulting mixture was heated to 50\u00b0C and stirred at this temperature for 30 min.", [["C", "SIMPLE_CHEMICAL", 39, 40]]], ["Then it was allowed to cool to 0\u00b0C. The resulting pale yellow solid was collected by filtration.", [["pale yellow solid", "CANCER", 50, 67], ["The resulting pale yellow solid", "PROBLEM", 36, 67], ["pale", "OBSERVATION_MODIFIER", 50, 54], ["yellow solid", "OBSERVATION", 55, 67]]], ["The filter cake was rinsed with n-heptane (540 mL) and dried under vacuum at 30\u00b0C to afford a pale yellow solid of product 4 (291.5 g, 62%).", [["n-heptane", "CHEMICAL", 32, 41], ["n-heptane", "CHEMICAL", 32, 41], ["n-heptane", "SIMPLE_CHEMICAL", 32, 41], ["The filter cake", "TREATMENT", 0, 15], ["n-heptane", "TREATMENT", 32, 41], ["vacuum", "TREATMENT", 67, 73], ["a pale yellow solid of product", "PROBLEM", 92, 122], ["filter cake", "OBSERVATION", 4, 15]]]]}